Tricyclic heterocycles as bet protein inhibitors

ABSTRACT

The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

FIELD OF THE INVENTION

The present invention relates to tricyclic heterocycles which areinhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and areuseful in the treatment of diseases such as cancer.

BACKGROUND OF THE INVENTION

The genomes of eukaryotic organisms are highly organized within thenucleus of the cell. DNA is packaged into chromatin by wrapping around acore of histone proteins to form a nucleosome. These nucleosomes arefurther compacted by aggregation and folding to form a highly condensedchromatin structure. A range of different states of condensation arepossible, and the tightness of this structure varies during the cellcycle, being most compact during the process of cell division. Chromatinstructure plays a critical role in regulating gene transcription byregulating protein access to the DNA. The chromatin structure iscontrolled by a series of post translational modifications to histoneproteins, mainly within the tails of histones H3 and H4 that extendbeyond the core nucleosome structure. These reversible modificationsinclude acetylation, methylation, phosphorylation, ubiquitination andSUMOylation. These epigenetic marks are written and erased by specificenzymes that modify specific residues within the histone tail, therebyforming an epigenetic code. Other nuclear proteins bind to these marksand effect outputs specified by this information through the regulationof chromatin structure and gene transcription. Increasing evidence linksgenetic changes to genes encoding epigenetic modifiers and regulatorsleading to aberrant histone marks in diseases such as neurodegenerativedisorders, metabolic diseases, inflammation and cancer.

Histone acetylation is typically associated with the activation of genetranscription, as the modification weakens the interaction between theDNA and the histone proteins, permitting greater access to DNA by thetranscriptional machinery. Specific proteins bind to acetylated lysineresidues within histones to “read” the epigenetic code. A highlyconserved protein module called the bromodomain binds to acetylatedlysine residues on histone and other proteins. There are more than 60bromodomain-containing proteins in the human genome.

The BET (Bromodomain and Extra-Terminal) family of bromodomaincontaining proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t)that share a conserved structural organization containing tandemN-terminal bromodomains capable of binding to acetylated lysine residuesof histones and other proteins. BRD2, BRD3 and BRD4 are ubiquitiouslyexpressed while BRDt is restricted to germ cells. BRD proteins playessential, but non-overlapping roles in regulating gene transcriptionand controlling cell growth. BET proteins are associated with largeprotein complexes including Mediator, PAFc and super elongation complexthat regulate many aspects of gene transcription. BRD2 and BRD4 proteinshave been shown to remain in complex with chromosomes during mitosis andare required to promote transcription of critical genes including cyclinD and c-Myc that initiate the cell cycle (Mochizuki J Biol. Chem. 2008283:9040-9048). BRD4 is essential for recruiting the proteintranslational elongation factor B complex to the promoters of induciblegenes resulting in the phosphorylation of RNA polymerase II andstimulating productive gene transcription and elongation (Jang et al.Mol. Cell 2005 19:523-534). In some instances, a kinase activity of BRD4may directly phosphorylate and activate RNA polymerase II (Devaiah etal. PNAS 2012 109:6927-6932). Cells lacking BRD4 show impairedprogression through cell cycle. BRD2 and BRD3 are reported to associatewith histones along actively transcribed genes and may be involved infacilitating transcriptional elongation (Leroy et al, Mol. Cell. 200830:51-60). In addition to acetylated histones, BET proteins have beenshown to bind selectively to acetylated transcription factors includingthe RelA subunit of NF-kB and GATA1 thereby directly regulating thetranscriptional activity of these proteins to control expression ofgenes involved in inflammation and hematopoietic differentiation (Huanget al, Mol. Cell. Biol. 2009 29:1375-1387; Lamonica Proc. Nat. Acad.Sci. 2011 108:E159-168).

A recurrent translocation involving NUT (nuclear protein in testes) withBRD3 or BRD4 to form a novel fusion oncogene, BRD-NUT, is found in ahighly malignant form of epithelial neoplasia (French et al, CancerResearch 2003 63:304-307; French et al, Journal of Clinical Oncology2004 22:4135-4139). Selective ablation of this oncogene restores normalcellular differentiation and reverses the tumorigenic phenotype(Filippakopoulos et al, Nature 2010 468:1068-1073). Genetic knockdown ofBRD2, BRD3 and BRD4 has been shown to impair the growth and viability ofa wide range of hematological and solid tumor cells (Zuber et al, Nature2011 478:524-528; Delmore et al, Cell 2011 146:904-917). Aside from arole in cancer, BET proteins regulate inflammatory responses tobacterial challenge, and a BRD2 hypomorph mouse model showeddramatically lower levels of inflammatory cytokines and protection fromobesity induced diabetes (Wang et al Biochem J. 2009 425:71-83; Belkinaet al. J. Immunol 2013). In addition, some viruses make use of these BETproteins to tether their genomes to the host cell chromatin, as part ofthe process of viral replication or use BET proteins to facilitate viralgene transcription and repression (You et al, Cell 2004 117:349-60; Zhuet al, Cell Reports 2012 2:807-816).

Accordingly, there is a need for compounds that modulate the activity ofthe BET family of proteins, including BRD2, BRD3, and BRD4, that can beused to treat BET protein-associated diseases such as cancer. Thecompounds of the invention help meet this need.

SUMMARY OF THE INVENTION

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein the variables areas defined below.

The present invention also provides a pharmaceutical compositioncomprising a compound of Formula I, or a pharmaceutically acceptablesalt thereof, and at least one pharmaceutically acceptable carrier.

The present invention also provides a method of inhibiting a BET proteincomprising contacting a compound of Formula I, or a pharmaceuticallyacceptable salt thereof, with the BET protein.

The present invention also provides a method of treating cancer andother diseases comprising administering to a patient a therapeuticallyeffective amount of a compound of Formula I, or a pharmaceuticallyacceptable salt thereof.

The present invention also provides a compound of Formula I, or apharmaceutically acceptable salt thereof, for use in therapy.

The present invention also provides use of a compound of Formula I, or apharmaceutically acceptable salt thereof, in the preparation of amedicament for use in therapy.

DETAILED DESCRIPTION

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein

X is N or CR⁴; Y is N or CR⁵;

L is C₁₋₆ alkylene, —(C₁₋₄ alkylene)_(n)-C(═O)—(C₁₋₄ alkylene)_(m)-,—(C₁₋₄ alkylene)_(n)-C(═O)NR⁶—(C₁₋₄ alkylene)_(m)-,alkylene)_(n)-NR⁶—(C₁₋₄ alkylene)_(m)-, alkylene)_(n)-NR⁶—C(═O)NR⁷—(C₁₋₄alkylene)_(m)-, alkylene)_(n)-C(═O)O—(C₁₋₄ alkylene)_(m)-,alkylene)_(n)-S(═O)—(C₁₋₄ alkylene)_(m)-, —(C₁₋₄alkylene)_(n)-S(═O)₂—(C₁₋₄ alkylene)_(m)-, —(C₁₋₄ alkylene)_(n)-O—(C₁₋₄alkylene)_(m)-, or —(C₁₋₄ alkylene)_(n)-S—(C₁₋₄ alkylene)_(m)- whereineach alkylene moiety of any of the aforementioned L groups is optionallysubstituted by 1, 2, or 3 substituents independently selected from F,Cl, OH, C₁₋₄ alkoxy, CF₃, and CN;

wherein when the L group includes a —O—, —S—, —NR⁶—, or —NR⁷— moiety,then the —O—, —S—, —NR⁶—, or —NR⁷— moiety of L is not bonded directly toN of the tricyclic core structure, but is connected to N via a C₁₋₄alkylene moiety of L;

Cy is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl, each of which is optionally substituted by 1,2, or 3 R^(Cy);

R¹ is H, C₁₋₆ alkyl, cyclopropyl, cyclobutyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, or C₁₋₆ hydroxyalkyl;

R² and R³ are each independently selected from H, halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a), SR^(a),C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d),C(═NR^(e))R^(b), C(═NR^(e))NR^(c)R^(d), NR^(c)C(═NR^(e))NR^(c)R^(d),NR^(c)S(O)R^(b), NR^(c)S(O)₂R^(b), NR^(c)S(O)₂NR^(c)R^(d), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), and S(O)₂NR^(c)R^(d); wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from halo, CN,NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), C(═NR^(e))NR^(c)R^(d), NR^(c)C(═NR^(e))NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d),NR^(c)S(O)R^(b), NR^(c)S(O)₂R^(b), NR^(c)S(O)₂NR^(c)R^(d), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), and S(O)₂NR^(c)R^(d);

R⁴ is H, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10 memberedheterocycloalkyl, C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,(5-10 membered heteroaryl)-C₁₋₄ alkyl, (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1),C(O)NR^(c1)R^(d1), C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1),NR^(c1)R^(d1), NR^(c1)C(O)R^(b1), NR^(c1)C(O)OR^(a1),NR^(c1)C(O)NR^(c1)R^(d1), C(═NR^(e1))R^(b1), C(═NR^(e1))NR^(c1)R^(d1),NR^(c1)C(═NR^(e1))NR^(c1)R^(d1), NR^(c1)S(O)R^(b1), NR^(c1)S(O)₂R^(b1),NR^(c1)S(O)₂NR^(c1)R^(d1), S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1),and S(O)₂NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄alkyl, (5-10 membered heteroaryl)-C₁₋₄ alkyl, and (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl are each optionally substituted with 1, 2,3, 4, or 5 substituents independently selected from R^(A);

R⁵ is H, halo, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ haloalkyl, OR^(a2),C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2), or S(O)₂NR^(c2)R^(d2);

R⁶ and R⁷ are each independently selected from H and C₁₋₄ alkyl;

each R^(Cy) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C₆₋₁₀aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, (5-10 memberedheteroaryl)-C₁₋₄ alkyl, (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl, CN,NO₂, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), C(═NR^(e3))R^(b3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, (5-10 memberedheteroaryl)-C₁₋₄ alkyl, and (4-10 membered heterocycloalkyl)-C₁₋₄ alkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3),NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3), NR^(c4)S(O)₂R^(b3),NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3),and S(O)₂NR^(c3)R^(d3);

each R^(A) is independently selected from Cy¹, halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4), SR^(a4),C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are eachoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from Cy¹, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4),C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4), C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4),NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4),S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4);

each Cy¹ is independently selected from C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each ofwhich is optionally substituted by 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b5),C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5),NR^(c5)R^(d5), NR^(c5)C(O)R^(b5), NR^(c5)C(O)OR^(a5),NR^(c5)C(O)NR^(c5)R^(d5), C(═NR^(e5))R^(b5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)S(O)R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5), S(O)₂R^(b5),and S(O)₂NR^(c5)R^(d5); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl are each optionally substituted with 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ haloalkyl, CN, NO₂,OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(C5)R^(d5), NR^(c5)S(O)R^(b5),NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5);

each R^(a), R^(b), R^(c), R^(d), R^(a1), R^(b1), R^(c1), R^(d1), R^(a2),R^(b2), R^(c2), R^(d2), R^(a3), R^(b3), R^(c3), R^(d3), R^(a4), R^(b4),R^(c4), R^(d4), R^(a5), R^(b5), R^(c5), and R^(d5) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10 memberedheterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀ cycloalky-C₁₋₆ alkyl,(5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10 memberedheterocycloalkyl)-C₁₋₆ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl is optionally substituted with 1,2, 3, 4, or 5 substituents independently selected from C₁₋₄ alkyl, C₁₋₄haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c) and R^(d) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c1) and R^(d)l together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR⁶S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c2) and R^(d2) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c3) and R^(d3) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c4) and R^(d4) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

or any R^(c5) and R^(d5) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6);

each R^(e), R^(e1), R^(e3), R^(e4), and R^(e5) is independently selectedfrom H, C₁₋₄ alkyl, CN, OR^(a6), SR^(b6), S(O)₂R^(b6), C(O)R^(b6),S(O)₂NR^(c6)R^(d6), and C(O)NR^(c6)R^(d6);

each R^(a6), R^(b6), R^(c6), and R^(d6) is independently selected fromH, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, whereinsaid C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, is optionallysubstituted with 1, 2, or 3 substituents independently selected from OH,CN, amino, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

or any R^(c6) and R^(d6) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from OH, CN, amino, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄alkylthio, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄ haloalkyl, andC₁₋₄ haloalkoxy;

each R^(e6) is independently selected from H, C₁₋₄ alkyl, and CN;

n is 0 or 1; and

m is 0 or 1.

In some embodiments, X is N.

In some embodiments, X is CR⁴.

In some embodiments, Y is N.

In some embodiments, Y is CR⁵.

In some embodiments, L is C₁₋₆ alkylene or —(C₁₋₄alkylene)n-S(═O)₂—(C₁₋₄ alkylene)_(m)-, wherein each alkylene moiety ofany of the aforementioned L groups is optionally substituted by 1, 2, or3 substituents independently selected from F, Cl, OH, C₁₋₄ alkoxy, CF₃,and CN.

In some embodiments, L is CH₂, S(═O)₂, —CH(CH₂OH)—, or —CH((CH₂)₃CH₃)—.

In some embodiments, L is CH₂ or S(═O)₂.

In some embodiments, L is S(═O)₂.

In some embodiments, L is —CH₂CH₂—.

In some embodiments, L is CH₂.

In some embodiments, Cy is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, or 5-10membered heteroaryl, each of which is optionally substituted by 1, 2, or3 R^(Cy).

In some embodiments, Cy is C₃₋₆ cycloalkyl optionally substituted by 1,2, or 3 R^(Cy).

In some embodiments, Cy is 5-10 membered heteroaryl optionallysubstituted by 1, 2, or 3 R^(Cy).

In some embodiments, Cy is 5-6 membered heteroaryl optionallysubstituted by 1, 2, or 3 R^(Cy).

In some embodiments, Cy is phenyl, cyclopentyl, quinolinyl, or pyridyl,each of which is optionally substituted by 1, 2, or 3 R^(Cy).

In some embodiments, Cy is phenyl or pyridyl, each of which isoptionally substituted by 1, 2, or 3 R^(Cy).

In some embodiments, Cy is phenyl optionally substituted by 1, 2, or 3R^(Cy).

In some embodiments, Cy is pyridyl optionally substituted by 1, 2, or 3R^(Cy).

In some embodiments, each R^(Cy) is independently selected from halo,C₁₋₆ alkyl, C₁₋₄ haloalkyl, (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl,CN, OR^(a3), C(O)NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), andNR^(c3)C(O)NR^(c3)R^(d3) wherein said C₁₋₆ alkyl and (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl are each optionally substituted with 1, 2,or 3 substituents independently selected from halo, C₁₋₆ alkyl, OR^(a3),and NR^(c3)R^(d3).

In some embodiments, each R^(Cy) is independently selected from halo,C₁₋₆ alkyl, (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl, CN, OR^(a3),C(O)NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), and NR^(c3)C(O)NR^(c3)R^(d3)wherein said C₁₋₆ alkyl and (4-10 membered heterocycloalkyl)-C₁₋₄ alkylare each optionally substituted with 1, 2, or 3 substituentsindependently selected from C₁₋₆ alkyl, OR^(a3), and NR^(c3)R^(d3).

In some embodiments, each R^(Cy) is independently selected from C₁₋₆alkyl substituted by NR^(c3)R^(d3).

In some embodiments, each R^(a3), R^(b3), R^(c3), and R^(d3) isindependently selected from methyl, ethyl, propyl, and butyl.

In some embodiments, each R^(Cy) is independently selected from fluoro,chloro, methyl, cyano, hydroxy, methoxy, aminocarbonyl,methylcarbonylamino, methylaminocarbonyl, ethylaminocarbonyl,azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl,piperazinylmethyl, morpholinomethyl, ureido, and ethylureido, whereinsaid methyl, azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl,piperazinylmethyl, and morpholinomethyl are each optionally substitutedwith 1, 2, or 3 substituents independently selected from fluoro, methyl,hydroxy, methoxy, methylamino, ethylamino, dimethylamino,hydroxycyclobutylamino, hydroxyethyl(methyl)amino, andhydroxyethylamino.

In some embodiments, each R^(Cy) is independently selected from fluoroand chloro.

In some embodiments, R¹ is H or C₁₋₆ alkyl.

In some embodiments, R¹ is C₁₋₆ alkyl.

In some embodiments, R¹ is methyl.

In some embodiments, R¹ is H.

In some embodiments, R² and R³ are both H.

In some embodiments, R² is H.

In some embodiments, R³ is H.

In some embodiments, R² is H, OR^(a), NR^(c)R^(d), NR^(c)C(O)R^(b),NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d), or NR^(c)S(O)₂R^(b).

In some embodiments, R² is H, —OH, —NHC(═O)OCH₃, —NHC(═O)CH₃—,NHC(═O)CH₂CH₃, —NHC(═O)CH₂CH₂CH₃, —NHC(═O)CH(CH₃)₂, —NHS(═O)₂CH₃, —OCH₃,—NHCH₃, —NHCH₂CH₃, —NHCH(CH₃)₂, —NHCH₂CH₂CH₃, —NH-(phenyl),—NH-(imidazolyl), —NH-(pyridyl), —NHCH₂CH₂NH₂, —NHCH₂CH₂CH₂NH₂,—NHC(═O)NH₂, —NHC(═O)NH(CH₃), —NHC(═O)N(CH₃)₂, —NHC(═O)NHCH(CH₃)₂,—NHC(═O)NHCH₂CH₃, —NHC(═O)O-(t-butyl), —NH-(hydroxycyclobutyl),—NHCH₂CH₂N(CH₃)₂, —NHCH₂CH₂CH₂N(CH₃)₂,—NH-(t-butyloxycarbonylazetidinyl),—NH-(t-butyloxycarbonylazetidinylmethyl),—NH-(t-butyloxycarbonylpiperidinylmethyl), —NH-(cyclobutylmethyl),—NH-(cyclohexyl), —NH-(cyclopropylmethyl),—NH-(8-azabicyclo[3,2,1]octan-3-yl), —NH-(dimethylpiperidinyl),—NH-(methylpiperidinyl), —NH-(piperidinyl), —NH-(methylpiperidinyl),—NH-(dimethylaminocyclohexyl), —NH-(methylaminocyclohexyl),—NH-(aminocyclohexyl), —NH-(acetylpiperidinyl), —NH-(cyanocyclohexyl),—NH-(t-butyloxycarbonylpiperidinyl), —NH-(2-propylpiperidinyl),—NH-(ethylpiperidinyl), —NH-(methylsulfonylpiperidinyl), —NHCH₂CH₂OH,—NHCH₂CH₂OCH₃, —NH-(morpholinoethyl), —NH-(benzimidazolyl),—NH-(benzoxazolyl), —NH-(methylpyrazolyl), —NH-(pyrimidinyl),—NH-(pyrazolyl), —NH-(pyrrolidinyl), —NH-(methylpyrrolidinyl),—NH-(t-butyloxycarbonylpyrrolidinyl), —NH-(tetrahydrofuranyl), or—NH-(tetrahydropyranyl).

In some embodiments, R^(a), R^(b), R^(c) and R^(d) are independentlyselected from H, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂CH₂CH₂CH₃,i-butyl, s-butyl, t-butyl, —CH₂CH₂NH₂, —CH₂CH₂CH₂NH₂, —CH₂CH₂N(CH₃)₂,—CH₂CH₂CH₂N(CH₃)₂, —CH₂CH₂OH, —CH₂CH₂OCH₃, phenyl, pyridyl, imidazolyl,azetidinyl, azetidinylmethyl-, piperidinyl, piperidinylmethyl-,methylpiperidinyl-, acetylpiperidinyl-, 2-propylpiperidinyl-,ethylpiperidinyl-, methylsulfonylpiperidinyl-, pyrrolidinyl-,methylpyrrolidinyl-, benzimidazolyl-, benzoxazolyl-, pyrazolyl-,pyrimidinyl-, tetrahydrofuranyl-, methylpyrazolyl-, tetrahydropyranyl-,cyclobutyl-, hydroxycyclobutyl-, cyclopropylmethyl-, cyclobutylmethyl-,cyclohexyl-, dimethylaminocyclohexyl-, methylaminocyclohexyl-,aminocyclohexyl-, cyanocyclohexyl-, and morpholinoethyl-.

In some embodiments, R^(a), R^(b), R^(c) and R^(d) are independentlyselected from H and C₁₋₆ alkyl.

In some embodiments, R⁴ is H, CN, C₁₋₆ alkyl, C₁₋₄ haloalkyl, 5-10membered heteroaryl, (5-10 membered heteroaryl)-C₁₋₄ alkyl, 4-10membered heterocycloalkyl, C(O)NR^(c1)R^(d1), C(O)OR^(a1), orNR^(c1)R^(d1); wherein said C₁₋₆ alkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl and (5-10 membered heteroaryl)-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from R^(A).

In some embodiments, R⁴ is H, C₁₋₆ alkyl, 5-10 membered heteroaryl,(5-10 membered heteroaryl)-C₁₋₄ alkyl, C(O)NR^(c1)R^(d1), C(O)OR^(a1),or NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, 5-10 membered heteroaryl, and(5-10 membered heteroaryl)-C₁₋₄ alkyl are each optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from R^(A).

In some embodiments, R⁴ is H, C₁₋₄ alkyl, 5 to 6-membered heteroaryl,(5-membered heteroaryl)-C₁₋₄ alkyl, C(O)NR^(c1)R^(d1), C(O)OR^(a1), orNR^(c1)R^(d1); wherein said C₁₋₆ alkyl, 5-10 membered heteroaryl, and(5-10 membered heteroaryl)-C₁₋₄ alkyl are each optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from R^(A).

In some embodiments, R⁴ is C₁₋₄ alkyl optionally substituted with 1, 2,or 3 substituents independently selected from R^(A).

In some embodiments, R⁴ is 5 to 6-membered heteroaryl optionallysubstituted with 1, 2, or 3 substituents independently selected fromR^(A).

In some embodiments, R⁴ is 5-membered heteroaryl optionally substitutedwith 1 or 2 substituents independently selected from R^(A).

In some embodiments, R⁴ is (5-membered heteroaryl)-C₁₋₄ alkyl optionallysubstituted with 1 or 2 substituents independently selected from R^(A).

In some embodiments, R⁴ is C(O)NR^(c1)R^(d1) In some embodiments, R⁴ is4 to 6-membered heterocycloalkyl optionally substituted with 1 or 2substituents independently selected from R^(A).

In some embodiments, R⁴ is H, C₁₋₄ alkyl, pyrazolyl, imidazolyl,thienyl, thiazolyl, pyridyl, imidazolylmethyl, C(O)NR^(c1)R^(d1),C(O)OR^(a1), or NR^(c1)R^(d1); wherein said C₁₋₄ alkyl, pyrazolyl,imidazolyl, thienyl, thiazolyl, pyridyl, and imidazolylmethyl, are eachoptionally substituted with 1, 2, or 3 substituents independentlyselected from R^(A).

In some embodiments, R⁴ is H, CN, methyl, ethyl, pyrazolyl, imidazolyl,thienyl, thiazolyl, pyridyl, imidazolylmethyl, oxadiazolyl, oxazolyl,dihydrooxazolyl, pyrrolidinyl, —C(═O)NH-(methyl), —C(═O)NH-(ethyl),—C(═O)—NH-(t-butyl), —C(═O)—NH-(s-butyl), —C(═O)NH-(pyridylmethyl),—C(═O)NH-(isopropyl), —C(═O)NH-(hydroxypropyl),—C(═O)NH-(azetidinylmethyl), —C(═O)NH-(morpholinoethyl),—C(═O)-(methylazetidinyl), —C(═O)NH-(hydroxyethyl), —C(═O)-(morpholino),—C(═O)NH-(dimethylaminoethyl), —C(═O)NH-(cyclopropylmethyl),—C(═O)NH-(cyclobutyl), —C(═O)NH-(cyanocyclobutyl), —C(═O)NH₂,—C(═O)N(CH₃)₂, —C(═O)NH-(2,2,2-trifluoro-1-methylethyl), or—C(═O)-(cyanoazetidinyl), wherein said methyl, ethyl, pyrazolyl,imidazolyl, thienyl, thiazolyl, pyridyl, imidazolylmethyl, oxadiazolyl,oxazolyl, dihydrooxazolyl, and pyrrolidinyl are each optionallysubstituted with 1, 2, or 3 substituents independently selected fromR^(A).

In some embodiments, R⁴ is pyrazolyl optionally substituted with R^(A).

In some embodiments, R⁴ is imidazolyl optionally substituted with R^(A).

In some embodiments, R⁴ is thienyl optionally substituted with R^(A).

In some embodiments, R⁴ is thiazolyl optionally substituted with R^(A).

In some embodiments, R⁴ is pyridyl optionally substituted with R^(A).

In some embodiments, R⁴ is imidazolylmethyl optionally substituted withR^(A).

In some embodiments, R⁴ is oxadiazolyl optionally substituted withR^(A).

In some embodiments, R⁴ is oxazolyl optionally substituted with R^(A).

In some embodiments, R⁴ is pyrrolidinyl optionally substituted withR^(A).

In some embodiments, R⁴ is dihydrooxazolyl optionally substituted withR^(A).

In some embodiments, each R^(A) is independently selected from Cy¹,C(O)R^(b4), and C₁₋₆ alkyl, wherein said C₁₋₆ alkyl is optionallysubstituted with 1, 2, or 3 substituents independently selected fromCy¹, CN, OR^(a4), C(O)NR^(c4)R^(d4), and NR^(c4)R^(d4).

In some embodiments, each R^(A) is independently selected from Cy¹ andC₁₋₆ alkyl, wherein said C₁₋₆ alkyl is optionally substituted with 1, 2,or 3 substituents independently selected from Cy¹, CN,C(O)NR^(c4)R^(d4), and NR^(c4)R^(d4).

In some embodiments, each R^(A) is C₁₋₄ alkyl optionally substitutedwith 1, 2, or 3 substituents independently selected from Cy¹, halo, C₁₋₃alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, CN, NO₂, OR^(a4),SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4),NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4),S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4).

In some embodiments, each R^(A) is ethyl optionally substituted with 1,2, or 3 substituents independently selected from Cy¹, halo, C₁₋₃ alkyl,C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, CN, NO₂, OR^(a4), SR^(a4),C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4),NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4),S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4).

In some embodiments, each R^(A) is Cy¹.

In some embodiments, each R^(A) is Cy¹ wherein Cy¹ is selected from 4-6membered heterocycloalkyl optionally substituted by 1, 2, or 3substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b)sC(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5),NR^(c5)R^(d5), NR^(c5)C(O)R^(b5), NR^(c5)C(O)OR^(a5),NR^(c5)C(O)NR^(c5)R^(d5), C(═NR^(e5))R^(b5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)S(O)R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5), S(O)₂R^(b5),and S(O)₂NR^(c5)R^(d5); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl are each optionally substituted with 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ haloalkyl, CN, NO₂,OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)S(O)R^(b5),NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5).

In some embodiments, each R^(A) is azetidinyl optionally substituted by1 or 2 substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(c5)R^(d5), C(═NR^(e5))R^(b5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)S(O)R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5),S(O)R^(b5), S(O)NR^(c5)R^(d5), S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are eachoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ haloalkyl, CN, NO₂, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)S(O)R^(b5),NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5).

In some embodiments, R^(c1) and R^(d1) are independently selected fromH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and 4-6 membered heterocycloalkyl, C₃₋₆cycloalky-C₁₋₆ alkyl, and (4-6 membered heterocycloalkyl)-C₁₋₆ alkyl,wherein said C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl,C₃₋₆ cycloalky-C₁₋₆ alkyl, and (4-6 membered heterocycloalkyl)-C₁₋₆alkyl is optionally substituted with 1, 2, or 3 substituentsindependently selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, CN,OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6), C(O)OR^(a6),OC(O)R^(b6), OC(O)NR^(C6)R^(d6), NR^(c6)R^(d6), NR^(c6)C(O)R^(b6),NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6).

In some embodiments, R^(c1) and R^(d1) together with the N atom to whichthey are attached form a 4-, 5-, or 6-membered heterocycloalkyl groupoptionally substituted with 1 or 2 substituents independently selectedfrom C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6).

In some embodiments, R⁵ is H.

In some embodiments, the compounds of the invention have Formula IIa:

In some embodiments, the compounds of the invention have Formula IIb:

In some embodiments, the compounds of the invention have Formula IIc:

In some embodiments, the compounds of the invention have Formula III:

In some embodiments, the compounds of the invention have Formula IVa,IVb, or IVc:

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, can also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention which are, for brevity, described in thecontext of a single embodiment, can also be provided separately or inany suitable subcombination.

As used herein, the phrase “optionally substituted” means unsubstitutedor substituted. As used herein, the term “substituted” means that ahydrogen atom is removed and replaced by a substituent. It is to beunderstood that substitution at a given atom is limited by valency.

Throughout the definitions, the term “C_(i-j)” indicates a range whichincludes the endpoints, wherein i and j are integers and indicate thenumber of carbons. Examples include C₁₋₄, C₁₋₆, and the like.

The term “p-membered” where p is an integer typically describes thenumber of ring-forming atoms in a moiety where the number ofring-forming atoms is p. For example, piperidinyl is an example of a6-membered heterocycloalkyl ring, pyrazolyl is an example of a5-membered heteroaryl ring, pyridyl is an example of a 6-memberedheteroaryl ring, and 1, 2, 3, 4-tetrahydro-naphthalene is an example ofa 10-membered cycloalkyl group.

In regard to linking group L in Formula I, the groups listed as choicesfor L are not intended to have directionality. For example, when L is—(C₁₋₄ alkylene)n-C(═O)NR⁶—(C₁₋₄ alkylene)_(m)-, it is meant to includeboth Cy-(C₁₋₄ alkylene)_(n)-C(═O)NR⁶—(C₁₋₄ alkylene)_(m)-N and Cy-(C₁₋₄alkylene)_(m)-NR⁶C(═O)—(C₁₋₄ alkylene)_(n)-N.

Additionally, the phrase “wherein when the L group includes a —O—, —S—,—NR⁶—, or —NR⁷— moiety, then the —O—, —S—, —NR⁶—, or —NR⁷— moiety of Lis not bonded directly to N of the tricyclic core structure, but isconnected to N via a C₁₋₄ alkylene moiety of L” is meant to excludeunstable linkages such as —O—N—, —S—N—, or —N—N— linkages by requiringthe presence of at least one carbon atom between the —O—, —S—, —NR⁶—, or—NR⁷— moiety of L and the N atom of the tricyclic core.

As used herein, the term “C_(i-j) alkyl,” employed alone or incombination with other terms, refers to a saturated hydrocarbon groupthat may be straight-chain or branched, having i to j carbons. In someembodiments, the alkyl group contains from 1 to 6 carbon atoms or from 1to 4 carbon atoms, or from 1 to 3 carbon atoms. Examples of alkylmoieties include, but are not limited to, chemical groups such asmethyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t-butyl.

As used herein, the term “C_(i-j) alkylene,” employed alone or incombination with other terms, refers to a divalent linking alkyl groupthat may be straight-chain or branched, having i to j carbons. In someembodiments, the alkylene group contains from 1 to 4 carbon atoms, orfrom 1 to 3 carbon atoms. Examples of alkylene moieties include, but arenot limited to, methylene, ethylene (e.g., 1,1-ethylene or1,2-ethylene), n-propylene, isopropylene, n-butylene, isobutylene,n-pentylene (e.g., 1,1-pentylene), etc.

As used herein, the term “C_(i-j) alkoxy,” employed alone or incombination with other terms, refers to a group of formula —O-alkyl,wherein the alkyl group has i to j carbons. Example alkoxy groupsinclude methoxy, ethoxy, and propoxy (e.g., n-propoxy and isopropoxy).In some embodiments, the alkyl group has 1 to 3 carbon atoms.

As used herein, “C_(i-j) alkenyl,” employed alone or in combination withother terms, refers to an unsaturated, straight-chained or branched,hydrocarbon group having one or more double carbon-carbon bonds andhaving i to j carbons. In some embodiments, the alkenyl moiety contains2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but arenot limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl,sec-butenyl, and the like.

As used herein, “C_(i-j) alkynyl,” employed alone or in combination withother terms, refers to an unsaturated hydrocarbon group having one ormore triple carbon-carbon bonds and having i to j carbons. Examplealkynyl groups include, but are not limited to, ethynyl, propyn-1-yl,propyn-2-yl, and the like. In some embodiments, the alkynyl moietycontains 2 to 6 or 2 to 4 carbon atoms.

As used herein, the term “C_(i-j) alkylamino,” employed alone or incombination with other terms, refers to a group of formula —NH(alkyl),wherein the alkyl group has i to j carbon atoms. In some embodiments,the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Example, C_(i-j)alkylamino groups include, but are not limited to, methylamino,ethylamino, propylamino, and butylamino.

As used herein, the term “di-C_(i-j)-alkylamino,” employed alone or incombination with other terms, refers to a group of formula —N(alkyl)₂,wherein each of the two alkyl groups has, independently, i to j carbonatoms. In some embodiments, each alkyl group independently has 1 to 6 or1 to 4 carbon atoms. Example, di-C_(i-j)-alkylamino groups include, butare not limited to, dimethylamino, diethylamino, and(methyl)(ethyl)amino.

As used herein, the term “C_(i-j) alkylthio,” employed alone or incombination with other terms, refers to a group of formula —S-alkyl,wherein the alkyl group has i to j carbon atoms. In some embodiments,the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Example, Ci-jalkylthio groups include, but are not limited to, methyl-S—, andethyl-S—.

As used herein, the term “amino,” employed alone or in combination withother terms, refers to a group of formula —NH₂.

As used herein, the term “aryl,” employed alone or in combination withother terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or4 fused rings) aromatic hydrocarbon, such as, but not limited to,phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and thelike. In some embodiments, aryl is C₆₋₁₀ aryl. In some embodiments, thearyl group is a naphthalene ring or phenyl ring. In some embodiments,the aryl group is phenyl.

As used herein, the term “carbonyl”, employed alone or in combinationwith other terms, refers to a —C(O)— group.

As used herein, the term “C_(i-j) cycloalkyl,” employed alone or incombination with other terms, refers to a non-aromatic cyclichydrocarbon moiety having i to j ring-forming carbon atoms, which mayoptionally contain one or more alkenylene groups as part of the ringstructure. Cycloalkyl groups can include mono- or polycyclic (e.g.,having 2, 3 or 4 fused rings) ring systems, including spirocyclic andbridged ring systems. Also included in the definition of cycloalkyl aremoieties that have one or more aromatic rings fused (i.e., having a bondin common with) to the cycloalkyl ring, for example, benzo derivativesof cyclopentane, cyclopentene, cyclohexane, and the like. One or morering-forming carbon atoms of a cycloalkyl group can be oxidized to formcarbonyl linkages. In some embodiments, cycloalkyl is C₃₋₇ cycloalkyl.In some embodiments, cycloalkyl is C₃₋₆ cycloalkyl. Examplary cycloalkylgroups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl,cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, and the like. In someembodiments, the cycloalkyl groups include cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl.

As used herein, “C_(i-j) haloalkoxy,” employed alone or in combinationwith other terms, refers to a group of formula —O-haloalkyl having i toj carbon atoms. An example haloalkoxy group is OCF₃. An additionalexample haloalkoxy group is OCHF₂. In some embodiments, the haloalkoxygroup is fluorinated only. In some embodiments, the alkyl group has 1 to6 or 1 to 4 or 1 to 3 carbon atoms.

As used herein, the term “halo,” employed alone or in combination withother terms, refers to a halogen atom selected from F, Cl, I or Br. Insome embodiments, “halo” refers to a halogen atom selected from F, Cl,or Br. In some embodiments, the halo substituent is F.

As used herein, the term “C_(i-j) haloalkyl,” employed alone or incombination with other terms, refers to an alkyl group having from onehalogen atom to 2s+1 halogen atoms which may be the same or different,where “s” is the number of carbon atoms in the alkyl group, wherein thealkyl group has i to j carbon atoms. In some embodiments, the haloalkylgroup is fluorinated only. In some embodiments, the haloalkyl group isfluoromethyl, difluoromethyl, or trifluoromethyl. In some embodiments,the haloalkyl group is trifluoromethyl. In some embodiments, the alkylgroup has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “heteroaryl,” employed alone or in combinationwith other terms, refers to a monocyclic or polycyclic (e.g., having 2,3 or 4 fused rings) aromatic heterocylic moiety, having one or moreheteroatom ring members selected from nitrogen, sulfur and oxygen. Insome embodiments, the heteroaryl group has 1, 2, 3, or 4 heteroatom ringmembers. In some embodiments, the heteroaryl group has 1, 2, or 3heteroatom ring members.

In some embodiments, the heteroaryl group has 1 or 2 heteroatom ringmembers. In some embodiments, the heteroaryl group has 1 heteroatom ringmember. In some embodiments, the heteroaryl group is 5- to 10-membered.In some embodiments, the heteroaryl group is 5- to 6-membered. When theheteroaryl group contains more than one heteroatom ring member, theheteroatoms may be the same or different. The nitrogen atoms in thering(s) of the heteroaryl group can be oxidized to form N-oxides.Example heteroaryl groups include, but are not limited to, pyridine,pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole,isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole,tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene,benzofuran, benzisoxazole, imidazo[1, 2-b]thiazole, purine, triazine,and the like. In some embodiments, the heteroaryl group is pyridine,quinoline, thiophene, imidazole, pyrazole, or thiazole.

A 5-membered heteroaryl is a heteroaryl group having five ring-formingatoms comprising wherein one or more of the ring-forming atoms areindependently selected from N, O, and S. In some embodiments, the5-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. Insome embodiments, the 5-membered heteroaryl group has 1 or 2 heteroatomring members. In some embodiments, the 5-membered heteroaryl group has 1heteroatom ring member. Example ring-forming atoms include CH, N, NH, O,and S. Example five-membered ring heteroaryls are thienyl, furyl,pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl,isoxazolyl, 1, 2, 3-triazolyl, tetrazolyl, 1, 2, 3-thiadiazolyl, 1, 2,3-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 4-thiadiazolyl, 1, 2,4-oxadiazolyl, 1, 3, 4-triazolyl, 1, 3, 4-thiadiazolyl, and 1, 3,4-oxadiazolyl. In some embodiments, the 5-membered heteroaryl group isthiophene, imidazole, pyrazole, or thiazole.

A 6-membered heteroaryl is a heteroaryl group having six ring-formingatoms wherein one or more of the ring-forming atoms is N. In someembodiments, the 6-membered heteroaryl group has 1, 2, or 3 heteroatomring members. In some embodiments, the 6-membered heteroaryl group has 1or 2 heteroatom ring members. In some embodiments, the 6-memberedheteroaryl group has 1 heteroatom ring member. Example ring-formingmembers include CH and N. Example six-membered ring heteroaryls arepyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl. In someembodiments, the 6-membered heteroaryl group is pyridine.

As used herein, the term “heterocycloalkyl,” employed alone or incombination with other terms, refers to non-aromatic heterocyclic ringsystem, which may optionally contain one or more unsaturations as partof the ring structure, and which has at least one heteroatom ring memberindependently selected from nitrogen, sulfur and oxygen. In someembodiments, the heterocycloalkyl group has 1, 2, 3, or 4 heteroatomring members. In some embodiments, the heterocycloalkyl group has 1, 2,or 3 heteroatom ring members. In some embodiments, the heterocycloalkylgroup has 1 or 2 heteroatom ring members. In some embodiments, theheterocycloalkyl group has 1 heteroatom ring member. When theheterocycloalkyl group contains more than one heteroatom in the ring,the heteroatoms may be the same or different. Example ring-formingmembers include CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂.Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2,3 or 4 fused rings) ring systems, including spiro systems and bridgedsystems. Also included in the definition of heterocycloalkyl aremoieties that have one or more aromatic rings fused (i.e., having a bondin common with) to the non-aromatic ring, for example, 1, 2, 3,4-tetrahydro-quinoline, dihydrobenzofuran and the like. The carbon atomsor heteroatoms in the ring(s) of the heterocycloalkyl group can beoxidized to form a carbonyl, sulfinyl, or sulfonyl group (or otheroxidized linkage) or a nitrogen atom can be quaternized. In someembodiments, heterocycloalkyl is 5- to 10-membered. In some embodiments,heterocycloalkyl is 5- to 6-membered. Examples of heterocycloalkylgroups include 1, 2, 3, 4-tetrahydroquinolinyl, dihydrobenzofuranyl,azetidinyl, azepanyl, pyrrolidinyl, piperidinyl, piperazinyl,morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl,oxetanyl, dihydrooxazolyl, and 8-azabicyclo[3.2.1]octanyl.

As used herein, the term “C_(i-j) hydroxyalkyl,” employed alone or incombination with other terms, refers to an alkyl group substituted by ahydroxy group. In some embodiments, the hydroxyalkyl group has 1 to 6 or1 to 4 carbon atoms.

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereoisomers, are intended unless otherwise indicated. Compounds ofthe present invention that contain asymmetrically substituted carbonatoms can be isolated in optically active or racemic forms. Methods onhow to prepare optically active forms from optically inactive startingmaterials are known in the art, such as by resolution of racemicmixtures or by stereoselective synthesis. Many geometric isomers ofolefins, C═N double bonds, and the like can also be present in thecompounds described herein, and all such stable isomers are contemplatedin the present invention. Cis and trans geometric isomers of thecompounds of the present invention are described and may be isolated asa mixture of isomers or as separated isomeric forms.

When the compounds of the invention contain a chiral center, thecompounds can be any of the possible stereoisomers. In compounds with asingle chiral center, the stereochemistry of the chiral center can be(R) or (S). In compounds with two chiral centers, the stereochemistry ofthe chiral centers can each be independently (R) or (S) so theconfiguration of the chiral centers can be (R) and (R), (R) and (S); (S)and (R), or (S) and (S). In compounds with three chiral centers, thestereochemistry each of the three chiral centers can each beindependently (R) or (S) so the configuration of the chiral centers canbe (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and(S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S)and (S).

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art. An example method includes fractionalrecrystallization using a chiral resolving acid which is an opticallyactive, salt-forming organic acid. Suitable resolving agents forfractional recrystallization methods are, for example, optically activeacids, such as the D and L forms of tartaric acid, diacetyltartaricacid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid orthe various optically active camphorsulfonic acids such asβ-camphorsulfonic acid. Other resolving agents suitable for fractionalcrystallization methods include stereoisomerically pure forms ofa-methylbenzylamine (e.g., S and R forms, or diastereoisomerically pureforms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine,cyclohexylethylamine, 1, 2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on acolumn packed with an optically active resolving agent (e.g.,dinitrobenzoylphenylglycine). Suitable elution solvent composition canbe determined by one skilled in the art.

Compounds of the invention also include tautomeric forms. Tautomericforms result from the swapping of a single bond with an adjacent doublebond together with the concomitant migration of a proton. Tautomericforms include prototropic tautomers which are isomeric protonationstates having the same empirical formula and total charge. Exampleprototropic tautomers include ketone-enol pairs, amide-imidic acidpairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-iminepairs, and annular forms where a proton can occupy two or more positionsof a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H-and 4H-1, 2, 4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole.Tautomeric forms can be in equilibrium or sterically locked into oneform by appropriate substitution.

Compounds of the invention can also include all isotopes of atomsoccurring in the intermediates or final compounds. Isotopes includethose atoms having the same atomic number but different mass numbers.

The term “compound” as used herein is meant to include allstereoisomers, geometric isomers, tautomers, and isotopes of thestructures depicted. Compounds herein identified by name or structure asone particular tautomeric form are intended to include other tautomericforms unless otherwise specified (e.g., in the case of purine rings,unless otherwise indicated, when the compound name or structure has the9H tautomer, it is understood that the 7H tautomer is also encompassed).

All compounds, and pharmaceutically acceptable salts thereof, can befound together with other substances such as water and solvents (e.g.,hydrates and solvates) or can be isolated.

In some embodiments, the compounds of the invention, or salts thereof,are substantially isolated. By “substantially isolated” is meant thatthe compound is at least partially or substantially separated from theenvironment in which it was formed or detected. Partial separation caninclude, for example, a composition enriched in a compound of theinvention. Substantial separation can include compositions containing atleast about 50%, at least about 60%, at least about 70%, at least about80%, at least about 90%, at least about 95%, at least about 97%, or atleast about 99% by weight of the compounds of the invention, or saltthereof. Methods for isolating compounds and their salts are routine inthe art.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The expressions, “ambient temperature” and “room temperature,” as usedherein, are understood in the art, and refer generally to a temperature,e.g., a reaction temperature, that is about the temperature of the roomin which the reaction is carried out, for example, a temperature fromabout 20° C. to about 30° C.

The present invention also includes pharmaceutically acceptable salts ofthe compounds described herein. As used herein, “pharmaceuticallyacceptable salts” refers to derivatives of the disclosed compoundswherein the parent compound is modified by converting an existing acidor base moiety to its salt form. Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines; alkali or organic salts of acidicresidues such as carboxylic acids; and the like. The pharmaceuticallyacceptable salts of the present invention include the conventionalnon-toxic salts of the parent compound formed, for example, fromnon-toxic inorganic or organic acids. The pharmaceutically acceptablesalts of the present invention can be synthesized from the parentcompound which contains a basic or acidic moiety by conventionalchemical methods. Generally, such salts can be prepared by reacting thefree acid or base forms of these compounds with a stoichiometric amountof the appropriate base or acid in water or in an organic solvent, or ina mixture of the two; generally, non-aqueous media like ether, ethylacetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) oracetonitrile (MeCN) are preferred. Lists of suitable salts are found inRemington's Pharmaceutical Sciences, 17^(th) Ed., (Mack PublishingCompany, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977,66(1), 1-19, and in Stahl et al., Handbook of Pharmaceutical Salts:Properties, Selection, and Use, (Wiley, 2002). In some embodiments, thecompounds described herein include the N-oxide forms.

The following abbreviations may be used herein: ACN (acetonitrile); AcOH(acetic acid); Ac₂O (acetic anhydride); aq. (aqueous); atm.(atmosphere(s)); Boc (t-butoxycarbonyl); br (broad); Cbz(carboxybenzyl); calc. (calculated); d (doublet); dd (doublet ofdoublets); DCM (dichloromethane); DIAD (N, N′-diisopropylazidodicarboxylate); DIPEA (N, N-diisopropylethylamine); DMF (N,N-dimethylformamide); DMSO (dimethylsulfoxide); DMAP(4-(dimethylamino)pyridine); dppf(1,1′-bis(diphenylphosphino)ferrocene); Et (ethyl); EtOAc (ethylacetate); g (gram(s)); h (hour(s)); HATU (N, N, N,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate);HCl (hydrochloric acid); HPLC (high performance liquid chromatography);Hz (hertz); J (coupling constant); LCMS (liquid chromatography-massspectrometry); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoicacid); MgSO₄ (magnesium sulfate); MS (Mass spectrometry); Me (methyl);MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min.(minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal);NaHCO₃ (sodium bicarbonate); NaOH (sodium hydroxide); Na₂SO₄ (sodiumsulfate); NH₄Cl (ammonium chloride); NH₄OH (ammonium hydroxide); nM(nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf(trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM(picomolar); POCl₃ (phosphoryl chloride); RP-HPLC (reverse phase highperformance liquid chromatography); s (singlet); t (triplet ortertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (tripletof triplets); t-Bu (tert-butyl); TFA (trifluoroacetic acid); THF(tetrahydrofuran); tg (microgram(s)); tL (microliter(s)); tM(micromolar); wt % (weight percent), XPhos-Pd-G2(chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)).

Synthesis

Compounds of the invention, including salts thereof, can be preparedusing known organic synthesis techniques and can be synthesizedaccording to any of numerous possible synthetic routes.

The reactions for preparing compounds of the invention can be carriedout in suitable solvents which can be readily selected by one of skillin the art of organic synthesis. Suitable solvents can be substantiallynon-reactive with the starting materials (reactants), the intermediates,or products at the temperatures at which the reactions are carried out,e.g., temperatures which can range from the solvent's freezingtemperature to the solvent's boiling temperature. A given reaction canbe carried out in one solvent or a mixture of more than one solvent.Depending on the particular reaction step, suitable solvents for aparticular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection anddeprotection of various chemical groups. The need for protection anddeprotection, and the selection of appropriate protecting groups, can bereadily determined by one skilled in the art. The chemistry ofprotecting groups can be found, for example, in P. G. M. Wuts and T. W.Greene, Protective Groups in Organic Synthesis, 4^(th) Ed., Wiley &Sons, Inc., New York (2006), which is incorporated herein by referencein its entirety.

The compounds of the invention can be prepared according to Scheme 1.Briefly, the cyclic amine 1-1 is alkylated, for example, in the presenceof a base like K₂CO₃ to produce alkylated intermediate 1-2. Thealkylated intermediate is then treated with di-tert-butylhydrazine-1,2-dicarboxylate and base in the presence of Pd catalyst anddppf or XPhos-Pd-G2 as catalyst, with heating to form hydrazineintermediate 1-3. Ring closure is accomplished by reacting the hydrazineintermediate with acid R¹COOH (e.g., acetic acid) with heating to formthe tricyclic product 1-4.

1H-Imidazo[4,5-b]pyridine intermediates 2-3 can be provided by themethod of Scheme 2. Diaminopyridine 2-1 is subjected to reductiveamination with an aldehyde to form intermediate 2-2, followed bycyclization to form an imidazole 2-3 (such as heating withtriethylorthoacetate and p-toluenesulfonic acid in EtOH) that canfurther undergo triazole annulation as illustrated in Scheme 1. Use ofalternative aldehydes and reagents for imidazole formation can providealternative substitution on ring nitrogen and carbon atoms.

6H-Pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridines can be prepared by thegeneral synthetic steps shown in Scheme 3. The nitrogen in startingmaterial 3-1 is first protected with an appropriate protecting groupforming, for example, the phenylsulfonyl derivative 3-2. Then a basesuch as LDA is used to deprotonate the adjacent carbon yielding anintermediate that can be reacted with a variety of electrophiles, R⁴-Lv(where Lv is a leaving group such as halide, carbonate, sulfate, amine,and others) to provide intermediates 3-3. For example, methyl iodide,DMF, di-tertbutyldicarbonate, ethyl chloroformate,1,3,2-dioxathiolane-2,2-dioxide, 1,2-dibromo-1, 1,2,2-tetrachloroethane,and the like can be used to provide alkyl, carboxaldehyde, carboxylicester, hydroxyethyl and bromide substituents, and others are possible.Triazole formation can be carried out according to the last two steps ofScheme 1, to provide 3-4.

Hydrolytic removal of the phenylsulfonyl group, followed by alkylationwith Cy-L-Lv in the presence of a base such as NaH or K₂CO₃ and attemperatures from about 20 to about 50° C. affords 3-6. Substitutentsplaced on nitrogen or carbon via Scheme 3 can also undergo furtherfunctional group manipulations as designed by one skilled in the art. Insome cases (due to functionality present or protecting groups employed),the order of the last three steps of Scheme 3 can be changed. Forexample, the deprotection of phenylsulfonyl can be performed first,followed by alkylation and then by triazole formation.

Via intermediate 4-1, Palladium-catalyzed cross-coupling reactions suchas Suzuki, Stille, Negishi, and the like, can be utilized to substitutethe core with aromatic rings (Ar). The cross coupling step can beperformed after removal of the phenylsulfonyl protecting group of 4-1with base, followed by alkylation with Cy-L-Lv to provide cross-couplingsubstrates of type 4-2. Palladium-catalyzed cross-coupling can becarried out using, for example, Pd(PPh₃)₄ as catalyst and underconditions of heating. Triazole formation can subsequently be carriedout as described in Scheme 1 to provide compounds 4-4.

Alternatively, Palladium-catalyzed cross-coupling reactions such asSuzuki, Stille, or Negishi can be utilized to substitute the core withnon-aromatic rings (n-Ar). In certain cases, the cross-coupling reactionmay substitute the core with non-aromatic rings to form compounds of theinvention 4-6 in a single step from the brominated intermediate 4-2. Inother cases, the bromide intermediate 4-2 can be coupled withappropriate partners (for example, boronic acids, boronate esters,organotrifluoroborates or organostannane reagents) having anunsaturated, non-aromatic ring system R′ to yield compound 4-5. Afterthe triazole formation is carried out according to Scheme 1, the R′ of4-5 can optionally be reduced to form a saturated ring system to providecompounds of the invention 4-6.

Substitutents placed on nitrogen or carbon via Scheme 4 can also befurther

Buchwald coupling reactions can be utilized to substitute the core withamines as shown in Scheme 5. The bromide intermediate 5-1 can be coupledwith amines in the presence of base, a palladium catalyst and ligand,with heating, to form intermediates 5-2. Subsequent triazole formationcan be carried out according to Scheme 1 to afford compounds such as5-3.

Substitutents placed on carbon via Scheme 5 can also be furtherfunctionalized as desired and appropriate by conventional methods.

Intermediates 6-1 (where R is, e.g., alkyl) can be converted to amides6-3 by the general sequence shown in Scheme 6. Treatment with a basesuch as NaOH hydrolyzes the ester and removes the phenylsulfonylprotecting group. Alkylation with Cy-L-Lv in the presence of base (e.g.,NaH, K₂CO₃, Cs₂CO₃, etc) results in alkylation of both nitrogen andcarboxylate, and the resulting ester is again hydrolyzed by treatmentwith NaOH. The free carboxylic acid can be converted to carboxamides byreaction with amines in the presence of HATU or other coupling agentsand in the presence of Hunig's base or other bases.

Amides 7-5 can be prepared by an alternative route shown in Scheme 7.Treatment with a base such as NaOH hydrolyzes the ester and removes thephenylsulfonyl protecting group of starting material 7-1. Alkylationwith Cy-L-Lv (Lv is a leaving group) in the presence of base (NaH,K₂CO₃, Cs₂CO₃, etc) results in alkylation of both nitrogen andcarboxylate, to give intermediate 7-2. Triazole formation using themethod described in Scheme 1 affords 7-3. Hydrolysis to 7-4 followed byreaction with amines using HATU or other coupling agents in the presenceof Hunig's base or other bases results in the formation of desiredamides 7-5.

An alternative method of preparing intermediates is shown in Scheme 8.6-Chloro-2-methylpyridin-3-amine (8-1) can be mono-Boc protected bytreating with base and di-tert-butyldicarbonate, followed by base, toafford 8-2. The methyl group of 8-2 may be deprotonated using a strongbase such as sec-butyllithium and reacted with an appropriate ester,such as ethyl trifluoroacetate, to afford a ketone intermediate as shownin 8-3. Deprotection of the aniline followed by cyclization on treatmentwith acid furnishes substituted pyrrolo[3,2-b]pyridine 8-4.Intermediates such as 8-4 are useful for synthesizing tricycliccompounds of the invention such as 8-5.

As shown in Scheme 9, tricyclic intermediates such as 9-1 can be treatedwith halogenating reagents such as N-chlorosuccinimide orN-bromosuccinimide to afford halogenated intermediates 9-2 (X=halogen)that can be used for cross couplings. Removal of the protecting groupprovides 9-3, and the desired substituent can be introduced byalkylation to afford 9-4. Intermediates 9-4 are useful forBuchwald-Hartwig amination, Suzuki, Stille or Negishi cross couplings,to name a few. These transformations furnish products such as amines,amides, ureas, carbamates, arylated and heteroarylated products, forexample (9-5, 9-6, 9-7, R′=alkyl, cyclic, etc.). Heating in the presenceof an alkoxide can afford products such as 9-8. Additionally, suitableproducts may be further functionalized if desired.

As shown in Scheme 10, tricyclic intermediates such as 10-1 can betreated with nitrating reagents such as nitronium tetrafluoroborate toafford nitrated intermediates 10-2 that can be used for reduction andfunctionalization. Removal of the protecting group provides 10-3. Thedesired substituent can be introduced by alkylation to provideintermediates 10-4. Intermediates 10-4 can be reduced, for example usinghydrogenation over palladium on carbon to afford aniline 10-5. Productssuch as 10-5 may be treated with acylating and sulfonylating reagents(Lv=leaving group, R′=alkyl, cyclic, etc.), for example, to furnishproducts 10-6.

Methods of Use

Compounds of the invention are BET protein inhibitors and, thus, areuseful in treating diseases and disorders associated with activity ofBET proteins. For the uses described herein, any of the compounds of theinvention, including any of the embodiments thereof, may be used.

The compounds of the invention can inhibit one or more of BET proteinsBRD2, BRD3, BRD4, and BRD-t. In some embodiments, the BET protein isBRD2. In some embodiments, the BET protein is BRD3. In some embodiments,the BET protein is BRD4. In some embodiments, the BET protein is BRD-t.In some embodiments, the compounds of the invention selectively inhibitone or more BET proteins over another. “Selective” means that thecompound binds to or inhibits a BET protein with greater affinity orpotency, respectively, compared to a reference, such as another BETprotein. For example, the compounds can be selective for BRD2 over BRD3,BRD4 and BRD-t, selective for BRD3 over BRD2, BRD4 and BRD-t, selectivefor BRD4 over BRD2, BRD3 and BRD-t, or selective for BRD-t over BRD2,BRD3 and BRD4. In some embodiments, the compounds inhibit two or more ofthe BET proteins, or all of the BET proteins. In general, selectivitycan be at least about 5-fold, at least about 10-fold, at least about20-fold, at least about 50-fold, at least about 100-fold, at least about200-fold, at least about 500-fold or at least about 1000-fold.

In some embodiments, the present invention is directed to a method ofinhibiting BRD2 comprising contacting a compound of the invention withBRD2. In some embodiments, the present invention is directed to a methodof inhibiting BRD3 comprising contacting a compound of the inventionwith BRD3. In some embodiments, the present invention is directed to amethod of inhibiting BRD4 comprising contacting a compound of theinvention with BRD4. In some embodiments, the present invention isdirected to a method of inhibiting BRD-t comprising contacting acompound of the invention with BRD-t.

The compounds of the invention are therefore useful for treating BETprotein mediated disorders. The term “BET-mediated” refers to anydisease or condition in which one or more of the BET proteins, such asBRD2, BRD3, BRD4 and/or BRD-t, or a mutant thereof, plays a role, orwhere the disease or condition is associated with expression or activityof one or more of the BET proteins. The compounds of the invention cantherefore be used to treat or lessen the severity of diseases andconditions where BET proteins, such as BRD2, BRD3, BRD4, and/or BRD-t,or a mutant thereof, are known to play a role.

Diseases and conditions treatable using the compounds of the inventioninclude, but are not limited to, cancer and other proliferativedisorders, autoimmune disease, chronic inflammatory diseases, acuteinflammatory diseases, sepsis, and viral infection. The diseases can betreated by administering to an individual (e.g., a patient) in need ofthe treatment a therapeutically effective amount or dose of a compoundof the invention, or any of the embodiments thereof, or a pharmaceuticalcomposition thereof. The present disclosure also provides a compound ofthe invention, or any of the embodiments thereof, or a pharmaceuticalcomposition thereof, for use in treating a BET-mediated disease ordisorder. Also provided is the use of a compound of the invention, orany of the embodiments thereof, or a pharmaceutical composition thereof,in the manufacture of a medicament for treating a BET-mediated diseaseor disorder.

Diseases that can be treated with the compounds of the invention includecancers. The cancers can include, but are not limited to, adrenalcancer, acinic cell carcinoma, acoustic neuroma, acral lentiginousmelanoma, acrospiroma, acute eosinophilic leukemia, acute erythroidleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia,acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma,adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor,adenosquamous carcinoma, adipose tissue neoplasm, adrenocorticalcarcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia,AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft partsarcoma, ameloblastic fibroma, anaplastic large cell lymphoma,anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoidtumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocyticleukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer,bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor,Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma insitu, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma,chondroma, chordoma, choriocarcinoma, choroid plexus papilloma,clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-celllymphoma, cervical cancer, colorectal cancer, Degos disease,desmoplastic small round cell tumor, diffuse large B-cell lymphoma,dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonalcarcinoma, endocrine gland neoplasm, endodermal sinus tumor,enteropathy-associated T-cell lymphoma, esophageal cancer, fetus infetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroidcancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor,gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumorof the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosiscerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,gynandroblastoma, gallbladder cancer, gastric cancer, hairy cellleukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma,hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma,Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma,intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna,lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lungcancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma,acute lymphocytic leukemia, acute myelogenous leukemia, chroniclymphocytic leukemia, liver cancer, small cell lung cancer, non-smallcell lung cancer, MALT lymphoma, malignant fibrous histiocytoma,malignant peripheral nerve sheath tumor, malignant triton tumor, mantlecell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia,mediastinal germ cell tumor, medullary carcinoma of the breast,medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkelcell cancer, mesothelioma, metastatic urothelial carcinoma, mixedMullerian tumor, mucinous tumor, multiple myeloma, muscle tissueneoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma,nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma,neuroma, nodular melanoma, ocular cancer, oligoastrocytoma,oligodendroglioma, oncocytoma, optic nerve sheath meningioma, opticnerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor,papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma,polyembryoma, precursor T-lymphoblastic lymphoma, primary centralnervous system lymphoma, primary effusion lymphoma, primary peritonealcancer, prostate cancer, pancreatic cancer, pharyngeal cancer,pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma,retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation,rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor,sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer,small blue round cell tumors, small cell carcinoma, soft tissue sarcoma,somatostatinoma, soot wart, spinal tumor, splenic marginal zonelymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease,small intestine cancer, squamous carcinoma, stomach cancer, T-celllymphoma, testicular cancer, thecoma, thyroid cancer, transitional cellcarcinoma, throat cancer, urachal cancer, urogenital cancer, urothelialcarcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visualpathway glioma, vulvar cancer, vaginal cancer, Waldenstrom'smacroglobulinemia, Warthin's tumor, and Wilms' tumor. In someembodiments, the cancer can be adenocarcinoma, adult T-cellleukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer,brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectalcancer, esophageal cancer, gastrointestinal cancer, glioblastomamultiforme, glioma, gallbladder cancer, gastric cancer, head and neckcancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer,kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, livercancer, small cell lung cancer, non-small cell lung cancer,mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oralcancer, ovarian cancer, pituitary tumor, primary central nervous systemlymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renalcell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, smallintestine cancer, stomach cancer, T-cell lymphoma, testicular cancer,thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma,uterine cancer, vaginal cancer, or Wilms' tumor.

The diseases treatable using the compounds of the invention also includeMYC dependent cancers wherein the cancer is associated with at least oneof myc RNA expression or MYC protein expression. A patient can beidentified for such treatment by determining myc RNA expression or MYCprotein expression in the cancerous tissue or cells.

Diseases that can be treated with compounds of the invention alsoinclude non-cancerous proliferative disorders. Examples of proliferativedisorders that can be treated include, but are not limited to, benignsoft tissue tumors, bone tumors, brain and spinal tumors, eyelid andorbital tumors, granuloma, lipoma, meningioma, multiple endocrineneoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumorcerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cysticneoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, andcysts, Castleman disease, chronic pilonidal disease, dermatofibroma,pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.

The diseases and conditions that can be treated with the compounds ofthe invention also include chronic autoimmune and inflammatoryconditions. Examples of autoimmune and inflammatory conditions that canbe treated include acute, hyperacute or chronic rejection oftransplanted organs, acute gout, acute inflammatory responses (such asacute respiratory distress syndrome and ischemia/reperfusion injury),Addison's disease, agammaglobulinemia, allergic rhinitis, allergy,alopecia, Alzheimer's disease, appendicitis, atherosclerosis, asthma,osteoarthritis, juvenile arthritis, psoriatic arthritis, rheumatoidarthriti, satopic dermatitis, autoimmune alopecia, autoimmune hemolyticand thrombocytopenic states, autoimmune hypopituitarism, autoimmunepolyglandular disease, Behcet's disease, bullous skin diseases,cholecystitis, chronic idiopathic thrombocytopenic purpura, chronicobstructive pulmonary disease (COPD), cirrhosis, degenerative jointdisease, depression, dermatitis, dermatomyositis, eczema, enteritis,encephalitis, gastritis glomerulonephritis, giant cell arteritis,Goodpasture's syndrome, Guillain-Barre syndrome, gingivitis, Graves'disease, Hashimoto's thyroiditis, hepatitis, hypophysitis, inflammatorybowel disease (Crohn's disease and ulcerative colitis), inflammatorypelvic disease, irritable bowel syndrome, Kawasaki disease, LPS-inducedendotoxic shock, meningitis, multiple sclerosis, myocarditis, myastheniagravis, mycosis fungoides, myositis, nephritis, osteomyelitis,pancreatitis, Parkinson's disease, pericarditis, pernicious anemia,pneumonitis, primary biliary sclerosing cholangitis, polyarteritisnodosa, psoriasis, retinitis, scleritis, scleracierma, scleroderma,sinusitis, Sjogren's disease, sepsis, septic shock, sunburn, systemiclupus erythematosus, tissue graft rejection, thyroiditis, type Idiabetes, Takayasu's arteritis, urethritis, uveitis, vasculitis,vasculitis including giant cell arteritis, vasculitis with organinvolvement such as glomerulonephritis, vitiligo, Waldenstrommacroglobulinemia and Wegener's granulomatosis.

The diseases and conditions that can be treated with the compounds ofthe invention also include diseases and conditions which involveinflammatory responses to infections with bacteria, viruses, fungi,parasites or their toxins, such as sepsis, sepsis syndrome, septicshock, endotoxaemia, systemic inflammatory response syndrome (SIRS),multi-organ dysfunction syndrome, toxic shock syndrome, acute lunginjury, ARDS (adult respiratory distress syndrome), acute renal failure,fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes,sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis,malaria, SIRS associated with viral infections such as influenza, herpeszoster, herpes simplex and coronavirus.

Other diseases that can be treated with the compounds of the inventioninclude viral infections. Examples of viral infections that can betreated include Epstein-Barr virus, hepatitis B virus, hepatitis Cvirus, herpes virus, human immunodeficiency virus, human papillomavirus, adenovirus, poxvirus and other episome-based DNA viruses. Thecompounds can therefore be used to treat disease and conditions such asherpes simplex infections and reactivations, cold sores, herpes zosterinfections and reactivations, chickenpox, shingles, human papillomavirus, cervical neoplasia, adenovirus infections, including acuterespiratory disease, and poxvirus infections such as cowpox and smallpoxand African swine fever virus. In one particular embodiment, thecompounds of the invention are indicated for the treatment of humanpapilloma virus infections of skin or cervical epithelia.

The diseases and conditions that can be treated with the compounds ofthe invention also include conditions that are associated withischaemia-reperfusion injury. Examples of such conditions include, butare not limited to conditions such as myocardial infarction,cerebrovascular ischaemia (stroke), acute coronary syndromes, renalreperfusion injury, organ transplantation, coronary artery bypassgrafting, cardio-pulmonary bypass procedures and pulmonary, renal,hepatic, gastro-intestinal or peripheral limb embolism.

The compounds of the invention are also useful in the treatment ofdisorders of lipid metabolism via the regulation of APO-A1 such ashypercholesterolemia, atherosclerosis and Alzheimer's disease.

The compounds of the invention are also useful in the treatment offibrotic conditions such as idiopathic pulmonary fibrosis, renalfibrosis, post-operative stricture, keloid formation, scleroderma andcardiac fibrosis.

The compounds of the invention can also be used to treat ophthamologicalindications such as dry eye.

The compounds of the invention can also be used to treat heart diseasesuch as heart failure.

As used herein, the term “contacting” refers to the bringing together ofindicated moieties in an in vitro system or an in vivo system. Forexample, “contacting” a BET protein with a compound of the inventionincludes the administration of a compound of the present invention to anindividual or patient, such as a human, having a BET protein, as wellas, for example, introducing a compound of the invention into a samplecontaining a cellular or purified preparation containing the BETprotein.

As used herein, the term “individual” or “patient,” usedinterchangeably, refers to any animal, including mammals, preferablymice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep,horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers tothe amount of active compound or pharmaceutical agent that elicits thebiological or medicinal response that is being sought in a tissue,system, animal, individual or human by a researcher, veterinarian,medical doctor or other clinician.

As used herein, the term “treating” or “treatment” refers to inhibitingthe disease; for example, inhibiting a disease, condition or disorder inan individual who is experiencing or displaying the pathology orsymptomatology of the disease, condition or disorder (i.e., arrestingfurther development of the pathology and/or symptomatology) orameliorating the disease; for example, ameliorating a disease, conditionor disorder in an individual who is experiencing or displaying thepathology or symptomatology of the disease, condition or disorder (i.e.,reversing the pathology and/or symptomatology) such as decreasing theseverity of disease.

As used herein, the term “preventing” or “prevention” refers topreventing the disease; for example, preventing a disease, condition ordisorder in an individual who may be predisposed to the disease,condition or disorder but does not yet experience or display thepathology or symptomatology of the disease.

Combination Therapies

The compounds of the invention can be used in combination treatmentswhere the compound of the invention is administered in conjunction withother treatments such as the administration of one or more additionaltherapeutic agents. The additional therapeutic agents are typicallythose which are normally used to treat the particular condition to betreated. The additional therapeutic agents can include, e.g.,chemotherapeutics, anti-inflammatory agents, steroids,immunosuppressants, as well as Bcr-Abl, Flt-3, RAF, FAK, and JAK kinaseinhibitors for treatment of BET protein-associated diseases, disordersor conditions. The one or more additional pharmaceutical agents can beadministered to a patient simultaneously or sequentially.

In some embodiments, the compounds of the invention can be used incombination with a therapeutic agent that targets an epigeneticregulator. Examples of epigenetic regulators include the histone lysinemethyltransferases, histone arginine methyl transferases, histonedemethylases, histone deacetylases, histone acetylases, and DNAmethyltransferases. Histone deacetylase inhibitors include, e.g.,vorinostat.

For treating cancer and other proliferative diseases, the compounds ofthe invention can be used in combination with chemotherapeutic agents,or other anti-proliferative agents. The compounds of the invention canalso be used in combination with medical therapy such as surgery orradiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electronbeam radiotherapy, proton therapy, brachytherapy, and systemicradioactive isotopes. Examples of suitable chemotherapeutic agentsinclude any of: abarelix, aldesleukin, alemtuzumab, alitretinoin,allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase,azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib,busulfan intravenous, busulfan oral, calusterone, capecitabine,carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine,clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin,dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin,denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolonepropionate, eculizumab, epirubicin, erlotinib, estramustine, etoposidephosphate, etoposide, exemestane, fentanyl citrate, filgrastim,floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib,gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelinacetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinibmesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate,lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole,lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine,methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone,nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin,paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim,pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine,quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib,streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide,teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan,toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard,valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, andzoledronate.

For treating cancer and other proliferative diseases, the compounds ofthe invention can be used in combination with ruxolitinib or other JAKinhibitors, including JAK1 selective inhibitors. Additionally, thecompounds of the invention can be used in combination with inhibitors ofPI3Kd, PI3Kg, FGFR1, FGFR2, FGFR3, FGFR4, PIM1, PIM2, and PIM3.

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with a corticosteroid suchas triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone,or flumetholone.

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with an immune suppressantsuch as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol,Alcon), or cyclosporine (Restasis®).

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with one or more additionalagents selected from Dehydrex™ (Holles Labs), Civamide (Opko), sodiumhyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603,Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P)(Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen),15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine,doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301,Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali),oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101 (2S, 3S, 4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl,Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences),ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15(Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4(RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31(Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551(Othera), PAI-2 (University of Pennsylvania and Temple University),pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednoletabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611(Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab,mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267(TorreyPines Therapeutics), or thalidomide.

In some embodiments, the compound of the invention can be administeredin combination with one or more agents selected from an antibiotic,antiviral, antifungal, anesthetic, anti-inflammatory agents includingsteroidal and non-steroidal anti-inflammatories, and anti-allergicagents. Examples of suitable medicaments include aminoglycosides such asamikacin, gentamycin, tobramycin, streptomycin, netilmycin, andkanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin,ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin;naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin;paramomycin; colistimethate; bacitracin; vancomycin; tetracyclines;rifampin and its derivatives (“rifampins”); cycloserine; beta-lactams;cephalosporins; amphotericins; fluconazole; flucytosine; natamycin;miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen;ketorolac; suprofen; cromolyn; lodoxamide; levocabastin; naphazoline;antazoline; pheniramine; or azalide antibiotic.

Other examples of agents, one or more of which a provided compound mayalso be combined with include: a treatment for Alzheimer's Disease suchas donepezil and rivastigmine; a treatment for Parkinson's Disease suchas L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine,pergolide, trihexyphenidyl, and amantadine; an agent for treatingmultiple sclerosis (MS) such as beta interferon (e.g., Avonex® andRebif®), glatiramer acetate, and mitoxantrone; a treatment for asthmasuch as albuterol and montelukast; an agent for treating schizophreniasuch as zyprexa, risperdal, seroquel, and haloperidol; ananti-inflammatory agent such as a corticosteroid, such as dexamethasoneor prednisone, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide,and sulfasalazine; an immunomodulatory agent, includingimmunosuppressive agents, such as cyclosporin, tacrolimus, rapamycin,mycophenolate mofetil, an interferon, a corticosteroid,cyclophosphamide, azathioprine, and sulfasalazine; a neurotrophic factorsuch as an acetylcholinesterase inhibitor, an MAO inhibitor, aninterferon, an anti-convulsant, an ion channel blocker, riluzole, or ananti-Parkinson's agent; an agent for treating cardiovascular diseasesuch as a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, acalcium channel blocker, or a statin; an agent for treating liverdisease such as a corticosteroid, cholestyramine, an interferon, and ananti-viral agent; an agent for treating blood disorders such as acorticosteroid, an anti-leukemic agent, or a growth factor; or an agentfor treating immunodeficiency disorders such as gamma globulin.

Formulation, Dosage Forms and Administration

When employed as pharmaceuticals, the compounds of the invention can beadministered in the form of pharmaceutical compositions. Thesecompositions can be prepared in a manner well known in thepharmaceutical art, and can be administered by a variety of routes,depending upon whether local or systemic treatment is desired and uponthe area to be treated. Administration may be topical (includingtransdermal, epidermal, ophthalmic and to mucous membranes includingintranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalationor insufflation of powders or aerosols, including by nebulizer;intratracheal or intranasal), oral or parenteral. Parenteraladministration includes intravenous, intraarterial, subcutaneous,intraperitoneal intramuscular or injection or infusion; or intracranial,e.g., intrathecal or intraventricular, administration. Parenteraladministration can be in the form of a single bolus dose, or may be, forexample, by a continuous perfusion pump. Pharmaceutical compositions andformulations for topical administration may include transdermal patches,ointments, lotions, creams, gels, drops, suppositories, sprays, liquidsand powders. Conventional pharmaceutical carriers, aqueous, powder oroily bases, thickeners and the like may be necessary or desirable.

This invention also includes pharmaceutical compositions which contain,as the active ingredient, the compound of the invention or apharmaceutically acceptable salt thereof, in combination with one ormore pharmaceutically acceptable carriers (excipients). In someembodiments, the composition is suitable for topical administration. Inmaking the compositions of the invention, the active ingredient istypically mixed with an excipient, diluted by an excipient or enclosedwithin such a carrier in the form of, for example, a capsule, sachet,paper, or other container. When the excipient serves as a diluent, itcan be a solid, semi-solid, or liquid material, which acts as a vehicle,carrier or medium for the active ingredient. Thus, the compositions canbe in the form of tablets, pills, powders, lozenges, sachets, cachets,elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solidor in a liquid medium), ointments containing, for example, up to 10% byweight of the active compound, soft and hard gelatin capsules,suppositories, sterile injectable solutions, and sterile packagedpowders.

In preparing a formulation, the active compound can be milled to providethe appropriate particle size prior to combining with the otheringredients. If the active compound is substantially insoluble, it canbe milled to a particle size of less than 200 mesh. If the activecompound is substantially water soluble, the particle size can beadjusted by milling to provide a substantially uniform distribution inthe formulation, e.g., about 40 mesh.

The compounds of the invention may be milled using known millingprocedures such as wet milling to obtain a particle size appropriate fortablet formation and for other formulation types. Finely divided(nanoparticulate) preparations of the compounds of the invention can beprepared by processes known in the art, e.g., see International App. No.WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. Theformulations can additionally include: lubricating agents such as talc,magnesium stearate, and mineral oil; wetting agents; emulsifying andsuspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the invention can be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosagecontaining from about 5 to about 1,000 mg (1 g), more usually about 100mg to about 500 mg, of the active ingredient. The term “unit dosageforms” refers to physically discrete units suitable as unitary dosagesfor human subjects and other mammals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect, in association with a suitablepharmaceutical excipient.

The active compound may be effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It willbe understood, however, that the amount of the compound actuallyadministered will usually be determined by a physician, according to therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention. When referring to thesepreformulation compositions as homogeneous, the active ingredient istypically dispersed evenly throughout the composition so that thecomposition can be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, about 0.1 to about 1000 mg of the activeingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwisecompounded to provide a dosage form affording the advantage of prolongedaction. For example, the tablet or pill can comprise an inner dosage andan outer dosage component, the latter being in the form of an envelopeover the former. The two components can be separated by an enteric layerwhich serves to resist disintegration in the stomach and permit theinner component to pass intact into the duodenum or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials including a number of polymeric acids andmixtures of polymeric acids with such materials as shellac, cetylalcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the presentinvention can be incorporated for administration orally or by injectioninclude aqueous solutions, suitably flavored syrups, aqueous or oilsuspensions, and flavored emulsions with edible oils such as cottonseedoil, sesame oil, coconut oil, or peanut oil, as well as elixirs andsimilar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically acceptable excipients as describedsupra. In some embodiments, the compositions are administered by theoral or nasal respiratory route for local or systemic effect.Compositions can be nebulized by use of inert gases. Nebulized solutionsmay be breathed directly from the nebulizing device or the nebulizingdevice can be attached to a face masks tent, or intermittent positivepressure breathing machine. Solution, suspension, or powder compositionscan be administered orally or nasally from devices which deliver theformulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. Insome embodiments, ointments can contain water and one or morehydrophobic carriers selected from, for example, liquid paraffin,polyoxyethylene alkyl ether, propylene glycol, white vaseline, and thelike. Carrier compositions of creams can be based on water incombination with glycerol and one or more other components, e.g.,glycerinemonostearate, PEG-glycerinemonostearate and cetylstearylalcohol. Gels can be formulated using isopropyl alcohol and water,suitably in combination with other components such as, for example,glycerol, hydroxyethyl cellulose, and the like. In some embodiments,topical formulations contain at least about 0.1, at least about 0.25, atleast about 0.5, at least about 1, at least about 2, or at least about 5wt % of the compound of the invention. The topical formulations can besuitably packaged in tubes of, for example, 100 g which are optionallyassociated with instructions for the treatment of the select indication,e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient willvary depending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compositions can be administered to a patient alreadysuffering from a disease in an amount sufficient to cure or at leastpartially arrest the symptoms of the disease and its complications.Effective doses will depend on the disease condition being treated aswell as by the judgment of the attending clinician depending uponfactors such as the severity of the disease, the age, weight and generalcondition of the patient, and the like.

The compositions administered to a patient can be in the form ofpharmaceutical compositions described above. These compositions can besterilized by conventional sterilization techniques, or may be sterilefiltered. Aqueous solutions can be packaged for use as is, orlyophilized, the lyophilized preparation being combined with a sterileaqueous carrier prior to administration. The pH of the compoundpreparations typically will be between 3 and 11, more preferably from 5to 9 and most preferably from 7 to 8. It will be understood that use ofcertain of the foregoing excipients, carriers, or stabilizers willresult in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present invention can varyaccording to, for example, the particular use for which the treatment ismade, the manner of administration of the compound, the health andcondition of the patient, and the judgment of the prescribing physician.The proportion or concentration of a compound of the invention in apharmaceutical composition can vary depending upon a number of factorsincluding dosage, chemical characteristics (e.g., hydrophobicity), andthe route of administration. For example, the compounds of the inventioncan be provided in an aqueous physiological buffer solution containingabout 0.1 to about 10% w/v of the compound for parenteraladministration. Some typical dose ranges are from about 1 μg/kg to about1 g/kg of body weight per day. In some embodiments, the dose range isfrom about 0.01 mg/kg to about 100 mg/kg of body weight per day. Thedosage is likely to depend on such variables as the type and extent ofprogression of the disease or disorder, the overall health status of theparticular patient, the relative biological efficacy of the compoundselected, formulation of the excipient, and its route of administration.Effective doses can be extrapolated from dose-response curves derivedfrom in vitro or animal model test systems.

The compositions of the invention can further include one or moreadditional pharmaceutical agents such as a chemotherapeutic, steroid,anti-inflammatory compound, or immunosuppressant, examples of which arelisted hereinabove.

The compounds of the invention can be provided with or used incombination with a companion diagnostic. As used herein, the term“companion diagnostic” refers to a diagnostic device useful fordetermining the safe and effective use of a therapeutic agent. Forexample, a companion diagnostic may be used to customize dosage of atherapeutic agent for a given subject, identify appropriatesubpopulations for treatment, or identify populations who should notreceive a particular treatment because of an increased risk of a seriousside effect.

In some embodiments, the companion diagnostic is used to monitortreatment response in a patient. In some embodiments, the companiondiagnostic is used to identify a subject that is likely to benefit froma given compound or therapeutic agent. In some embodiments, thecompanion diagnostic is used to identify a subject having an increasedrisk of adverse side effects from administration of a therapeutic agent,compared to a reference standard. In some embodiments, the companiondiagnostic is an in vitro diagnostic or imaging tool selected from thelist of FDA cleared or approved companion diagnostic devices. In someembodiments, the companion diagnostic is selected from the list of teststhat have been cleared or approved by the Center for Devices andRadiological Health.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to labeled compounds ofthe invention (radio-labeled, fluorescent-labeled, etc.) that would beuseful not only in imaging techniques but also in assays, both in vitroand in vivo, for localizing and quantitating BET proteins in tissuesamples, including human, and for identifying BET protein ligands byinhibition binding of a labeled compound. Accordingly, the presentinvention includes BET protein assays that contain such labeledcompounds.

The present invention further includes isotopically-labeled compounds ofthe invention. An “isotopically” or “radio-labeled” compound is acompound of the invention where one or more atoms are replaced orsubstituted by an atom having an atomic mass or mass number differentfrom the atomic mass or mass number typically found in nature (i.e.,naturally occurring). Suitable radionuclides that may be incorporated incompounds of the present invention include but are not limited to ³H(also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O,¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. Theradionuclide that is incorporated in the instant radio-labeled compoundswill depend on the specific application of that radio-labeled compound.For example, for in vitro BET protein labeling and competition assays,compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I, or ³⁵S willgenerally be most useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I,¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful.

It is to be understood that a “radio-labeled” or “labeled compound” is acompound that has incorporated at least one radionuclide. In someembodiments the radionuclide is selected from the group consisting of³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br. In some embodiments, the compoundincorporates 1, 2, or 3 deuterium atoms.

The present invention can further include synthetic methods forincorporating radio-isotopes into compounds of the invention. Syntheticmethods for incorporating radio-isotopes into organic compounds are wellknown in the art, and an ordinary skill in the art will readilyrecognize the methods applicable for the compounds of invention.

A labeled compound of the invention can be used in a screening assay toidentify/evaluate compounds. For example, a newly synthesized oridentified compound (i.e., test compound) which is labeled can beevaluated for its ability to bind a BET protein by monitoring itsconcentration variation when contacting with the BET protein, throughtracking of the labeling. For example, a test compound (labeled) can beevaluated for its ability to reduce binding of another compound which isknown to bind to a BET protein (i.e., standard compound). Accordingly,the ability of a test compound to compete with the standard compound forbinding to the BET protein directly correlates to its binding affinity.Conversely, in some other screening assays, the standard compound islabeled and test compounds are unlabeled. Accordingly, the concentrationof the labeled standard compound is monitored in order to evaluate thecompetition between the standard compound and the test compound, and therelative binding affinity of the test compound is thus ascertained.

The invention will be described in greater detail by way of specificexamples. The following examples are offered for illustrative purposes,and are not intended to limit the invention in any manner. Those ofskill in the art will readily recognize a variety of non-criticalparameters which can be changed or modified to yield essentially thesame results. The compounds of the Examples were found to be inhibitorsof one or more BET proteins as described below.

EXAMPLES

Experimental procedures for compounds of the invention are providedbelow. Preparatory LC-MS purifications of some of the compounds preparedwere performed on Waters mass directed fractionation systems. The basicequipment setup, protocols, and control software for the operation ofthese systems have been described in detail in the literature. See e.g.“Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K.Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MSConfigurations and Methods for Parallel Synthesis Purification”, K.Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.Chem., 5, 670 (2003); and “Preparative LC-MS Purification: ImprovedCompound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A.Combs, J Combi. Chem., 6, 874-883 (2004). The compounds separated weretypically subjected to analytical liquid chromatography massspectrometry (LCMS) for purity analysis under the following conditions:Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ C₁₈ 5μm, 2.1×50 mm, Buffers: mobile phase A: 0.025% TFA in water and mobilephase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flowrate 2.0 mL/minute.

Some of the compounds prepared were also separated on a preparativescale by reverse-phase high performance liquid chromatography (RP-HPLC)with MS detector or flash chromatography (silica gel) as indicated inthe Examples. Typical preparative reverse-phase high performance liquidchromatography (RP-HPLC) column conditions are as follows:

pH=2 purifications: Waters Sunfire™ C₁₈ 5 μm, 19×100 mm column, elutingwith mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobilephase B: acetonitrile; the flow rate was 30 mL/minute, the separatinggradient was optimized for each compound using the Compound SpecificMethod Optimization protocol as described in the literature [see“Preparative LCMS Purification: Improved Compound Specific MethodOptimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem.,6, 874-883 (2004)]. Typically, the flow rate used with the 30×100 mmcolumn was 60 mL/minute.

pH=10 purifications: Waters XBridge C₁₈ 5 μm, 19×100 mm column, elutingwith mobile phase A: 0.15% NH₄OH in water and mobile phase B:acetonitrile; the flow rate was 30 mL/minute, the separating gradientwas optimized for each compound using the Compound Specific MethodOptimization protocol as described in the literature [See “PreparativeLCMS Purification: Improved Compound Specific Method Optimization”, K.Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)].Typically, the flow rate used with 30×100 mm column was 60 mL/minute.

Example 1:6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine

To a mixture of 5-chloro-1H-pyrrolo[3,2-b]pyridine (0.50 g, 3.3 mmol,Adesis) and K₂CO₃ (1.4 g, 9.8 mmol) in DMF (12 mL) at 0° C. was addedbenzyl bromide (0.43 mL, 3.6 mmol, Aldrich) dropwise. The mixture wasallowed to warm to ambient temperature and stir overnight. The reactionmixture was partitioned between EtOAc and water. The organic layer waswashed with water (3×), brine, dried over sodium sulfate, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-20%EtOAc in hexanes afforded product as a clear oil (0.77 g, 97%).

¹H NMR (300 MHz, CDCl₃) δ 7.48 (d, J=8.6 Hz, 1H), 7.38 (d, J=3.2 Hz,1H), 7.37-7.27 (m, 3H), 7.13-7.05 (m, 2H), 7.07 (d, J=8.6 Hz, 1H), 6.68(d, J=3.2 Hz, 1H), 5.32 (s, 2H); LCMS (M+H)⁺: 243.0, 244.9.

Step 2. di-tert-butyl1-(1-benzyl-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

A sealable vial was charged with1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.25 g, 1.0 mmol, from Step1), di-tert-butyl hydrazine-1,2-dicarboxylate (0.239 g, 1.03 mmol,Aldrich), tris(dibenzylideneacetone)dipalladium(0) (0.075 g, 0.082 mmol,Aldrich), 1,1′-bis(diphenylphosphino)ferrocene (0.0685 g, 0.124 mmol,Aldrich), cesium carbonate (0.336 g, 1.03 mmol), and toluene (2 mL). Themixture was degassed by a stream of nitrogen through the solution andthe vial was then sealed and heated to 100° C. for 2 days. The crudereaction mixture was diluted with DCM, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanesafforded product (0.13 g, 29%).

¹H NMR (300 MHz, CDCl₃) δ 7.55 (d, J=8.7 Hz, 1H), 7.47-7.02 (m, 7H),6.67 (d, J=3.1 Hz, 1H), 5.31 (s, 2H), 1.49 (s, 9H), 1.46 (s, 9H); LCMS(M+H)⁺: 439.1.

Step 3.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

di-tert-Butyl1-(1-benzyl-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate(31 mg, 0.071 mmol, from Step 2) in acetic acid (4.0 mL) was heated inthe microwave to 180° C. for 5 minutes. The solvent was removed in vacuoand the mixture was reconstituted in MeOH and purified using preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) and the eluent was frozen and lyophilized toafford a white powder (12 mg, 65%).

¹H NMR (300 MHz, CDCl₃) δ 7.41-7.22 (m, 5H), 7.17-7.04 (m, 3H), 6.79 (d,J=3.1 Hz, 1H), 5.37 (s, 2H), 2.99 (s, 3H); LCMS (M+H)⁺: 263.1.

Example 2:6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

To a suspension of 5-chloro-1H-pyrrolo[3,2-b]pyridine (5.0 g, 33 mmol,Adesis) in DCM (42 mL) was added benzenesulfonyl chloride (5.4 mL, 43mmol, Aldrich), triethylamine (7.3 mL, 52 mmol) and4-dimethylaminopyridine (0.40 g, 3.3 mmol). After stirring at roomtemperature for 1 hour, the mixture was diluted with EtOAc, washed withwater (2×), brine, dried over sodium sulfate, filtered and concentrated.The product was purified by flash chromatography, eluting with agradient from 0-20% EtOAc in hexanes to afford product as a white solid(8.7 g, 90%).

¹H NMR (300 MHz, CDCl₃) δ 8.23 (d, J=8.7 Hz, 1H), 7.86 (d, J=7.5 Hz,2H), 7.81 (d, J=3.7 Hz, 1H), 7.61 (t, J=7.4 Hz, 1H), 7.49 (dd, J=7.7,7.7 Hz, 2H), 7.26 (d, J=8.6 Hz, 1H), 6.81 (d, J=3.7 Hz, 1H); LCMS(M+H)⁺: 292.9, 294.9.

Step 2. 5-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

1.6 M n-butyllithium in hexanes (24 mL, 39 mmol) was added to a solutionof N,N-diisopropylamine (5.8 mL, 42 mmol) in THF (80 mL) at −78° C.Following complete addition, the mixture was allowed to stir at 0° C.for 30 minutes and was then re-cooled to −78° C. A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (7.6 g, 26 mmol,from Step 1) in THF (38 mL) was added dropwise. After stirring at −78°C. for 1 hour, methyl iodide (3.2 mL, 52 mmol) was added. The mixturewas allowed to slowly reach room temperature, at which time it wasquenched by the addition of saturated NH₄Cl. The product was extractedwith EtOAc, and the extracts were washed with water (2×), brine, driedover sodium sulfate, filtered and concentrated to afford product as ayellow oil which was used without further purification (8.0 g, 100%).

¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, J=8.7 Hz, 1H), 7.75 (d, J=7.5 Hz,2H), 7.61 (t, J=7.5 Hz, 1H), 7.48 (dd, J=7.8, 7.8 Hz, 2H), 7.21 (d,J=8.7 Hz, 1H), 6.49 (s, 1H), 2.63 (s, 3H); LCMS (M+H)⁺: 306.9, 308.9.

Step 3. di-tert-butyl1-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A flask was charged with5-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (9.0 g,29 mmol, prepared as described in Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (6.8 g, 29 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (2.3 g, 2.9 mmol, Aldrich), cesium carbonate (9.56 g, 29.3 mmol),and toluene (94 mL). The mixture was degassed by a stream of nitrogenthrough the solution. The mixture was then heated to 100° C. overnight.After cooling to room temperature, the reaction mixture was diluted withDCM, filtered and concentrated. Flash chromatography, eluting with agradient from 0-30% EtOAc in hexanes afforded product as a white solid(9.5 g, 64%).

¹H NMR (400 MHz, cdcl₃) δ 8.39 (dd, J=8.9, 0.6 Hz, 1H), 7.76 (dd, J=8.5,1.2 Hz, 2H), 7.62-7.55 (m, 2H), 7.50-7.42 (m, 2H), 7.03 (br s, 1H),6.47-6.46 (m, 1H), 2.62 (d, J=1.1 Hz, 3H), 1.51 (s, 9H), 1.46 (s, 9H);LCMS (M+H)⁺: 503.2.

Step 4.1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(Example 2a)

di-tert-Butyl1-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(9.4 g, 19 mmol, from Step 3) in AcOH (150 mL) was heated in the rangeof 115-120 OC for 20 hours. Upon cooling to room temperature, thesolvent was removed in vacuo. After this cyclization, purification viaHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) afforded1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine.

¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, J=10.0 Hz, 1H), 7.81 (dd, J=8.4, 1.1Hz, 2H), 7.63 (tt, J=6.9, 1.1 Hz, 1H), 7.52 (d, J=10.0 Hz, 1H),7.54-7.48 (m, 2H), 6.71 (s, 1H), 2.93 (s, 3H), 2.68 (s, 3H); LCMS(M+H)⁺: 327.1.

Step 5. 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The crude residue obtained on evaporation of AcOH in Step 4 wasre-dissolved in 1:1 THF:MeOH (304 mL) and 2.8 M sodium hydroxide inwater (170 mL, 490 mmol) was added.

The reaction was stirred for 20 minutes. The mixture was diluted withbrine, extracted with three portions of DCM, and also one portion ofCHCl₃ containing 10% iPrOH (250 mL). The combined organic extracts weredried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-10% MeOH in DCM affordedproduct as a yellow solid (2.8 g, 79%).

¹H NMR (300 MHz, d₆-DMSO) δ 11.72 (br s, 1H), 7.43 (d, J=9.5 Hz, 1H),7.17 (d, J=9.5 Hz, 1H), 6.64 (m, 1H), 2.84 (s, 3H), 2.42 (s, 3H); LCMS(M+H)⁺: 187.1.

Step 6.6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (10. mg,0.054 mmol, from Step 5) in DMF (1.5 mL) was treated with K₂CO₃ (22 mg,0.16 mmol) and a solution of benzyl bromide (6.4 μL, 0.054 mmol,Aldrich) in DMF (0.10 mL). After stirring for 2 hours, the mixture wasdiluted with MeCN, filtered and purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)to afford product (12 mg, 81%).

¹H NMR (300 MHz, CDCl₃) δ 7.30-7.08 (m, 5H), 6.92-6.83 (m, 2H), 6.55 (s,1H), 5.28 (s, 2H), 2.92 (s, 3H), 2.35 (s, 3H); LCMS (M+H)⁺: 277.2.

Example 3:1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

This compound was isolated from the mixture obtained in Example 2, Steps1-4, during a preparation wherein the methylation in Step 2 wasincomplete. The product was isolated by preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of 18.2% to 40.4% MeCN/H₂Ocontaining 0.15% NH₄OH, over 12 minutes at a flow rate of 60 mL/min).

¹H NMR (300 MHz, CDCl₃) δ 7.97 (d, J=10.0 Hz, 1H), 7.95-7.88 (m, 2H),7.68 (d, J=3.7 Hz, 1H), 7.67-7.60 (m, 1H), 7.57 (d, J=10.0 Hz, 1H), 7.52(dd, J=7.7, 7.7 Hz, 2H), 6.99 (d, J=3.7 Hz, 1H), 2.95 (s, 3H); LCMS(M+H)⁺: 313.0.

Example 4:1-methyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(Racemic Mixture)

To a mixture of 1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(10 mg, 0.058 mmol, isolated from Example 2, Step 5 during a preparationwherein the methylation of Step 2 of that Example was incomplete) andK₂CO₃ (0.024 g, 0.17 mmol) in DMF (0.22 mL) was added1-(bromoethyl)benzene (12 μL, 0.087 mmol, Acros). The mixture was heatedto 45° C. for 3 hours. The mixture was diluted with MeCN and filtered,then the product was isolated by preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (3.3mg, 20%).

¹H NMR (300 MHz, CDCl₃) δ 7.45-7.16 (m, 6H), 7.16-7.00 (m, 2H), 6.82 (d,J=3.2 Hz, 1H), 5.68 (q, J=7.0 Hz, 1H), 2.99 (s, 3H), 1.97 (d, J=7.0 Hz,3H); LCMS (M+H)⁺: 277.1.

Examples 5a and 5b:(S)-1,7-dimethyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5a) and(R)-1,7-dimethyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5b) (Single Enantiomers Isolated)

K₂CO₃ (56 mg, 0.40 mmol) and (1-bromoethyl)-benzene (27 μL, 0.20 mmol)were added to a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (25 mg,0.13 mmol, from Example 2, Step 5) in DMF (3.8 mL). The reaction wasstirred overnight. Additional (1-bromoethyl)-benzene (18 μL, 0.13 mmol,Acros) was added and the reaction mixture was heated at 50° C. for onehour. Upon cooling to room temperature, the reaction mixture was dilutedwith ACN and filtered, then was purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)to afford the racemic product (12.6 mg, 32%). The enantiomers wereseparated by chiral chromatography (Phenomenex Lux Cellulose C-1, 5 μm,21.2×250 mm, 45% EtOH/hexane at 18 mL/min, loading 6 mg/900 μL).

Enantiomer 1 retention time: 7.7 min, obtained 4.3 mg, 11% yield.Enantiomer 2 retention time: 16.5 min, obtained 5.1 mg, 13% yield.

Enantiomer 1: ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.27 (m, 3H), 7.21-7.06 (m,3H), 6.99 (d, J=9.8 Hz, 1H), 6.59 (s, 1H), 5.77 (q, J=7.1 Hz, 1H), 2.97(s, 3H), 2.47 (s, 3H), 1.98 (d, J=7.2 Hz, 3H); LCMS (M+H)⁺: 291.0.

Enantiomer 2: ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.27 (m, 3H), 7.21-7.06 (m,3H), 6.99 (d, J=9.8 Hz, 1H), 6.59 (s, 1H), 5.77 (q, J=7.0 Hz, 1H), 2.97(s, 3H), 2.47 (s, 3H), 1.98 (d, J=7.2 Hz, 3H); LCMS (M+H)⁺: 291.0.

Example 6:1,7-dimethyl-6-(2-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (6.4 mg, 0.16 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(15 mg, 0.080 mmol, Example 2, Step 5) in DMF (2.2 mL). After stirringfor 10 minutes, 1-bromo-2-phenylethane (22 μL, 0.16 mmol, Aldrich) wasadded dropwise. After stirring for 1 hour, additional sodium hydride(3.2 mg, 0.080 mmol, 60% in mineral oil) and 1-bromo-2-phenylethane (11μL, 0.080 mmol) were added. The crude reaction mixture was diluted withwater and MeOH, filtered and purified by preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)to afford product as a light yellow powder (4.8 mg, 20%).

¹H NMR (400 MHz, CDCl₃) δ 7.32-7.16 (m, 5H), 7.00-6.89 (m, 2H), 6.46 (s,1H), 4.32 (t, J=6.8 Hz, 2H), 3.04 (t, J=6.8 Hz, 2H), 2.96 (s, 3H), 2.14(s, 3H); LCMS (M+H)⁺: 291.2.

Example 7:1,7-dimethyl-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

K₂CO₃ (44 mg, 0.32 mmol) and 2-(bromomethyl)pyridine hydrobromide (0.027g, 0.11 mmol, Aldrich) were added to a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (20. mg,0.11 mmol) in DMF (3.0 mL, 39 mmol). After stirring at room temperaturefor 2 hours, the reaction was heated to 50° C. for 35 minutes. Thereaction mixture was diluted with MeCN, filtered and purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) to afford product (8.9 mg, 30%).

¹H NMR (300 MHz, CDCl₃) δ 8.54 (d, J=4.8 Hz, 1H), 7.52 (td, J=7.7, 1.7Hz, 1H), 7.26 (d, J=9.7 Hz, 1H), 7.20 (d, J=9.7 Hz, 1H), 7.15 (dd,J=7.2, 4.6 Hz, 1H), 6.58 (s, 1H), 6.52 (d, J=7.9 Hz, 1H), 5.39 (s, 2H),2.92 (s, 3H), 2.39 (s, 3H); LCMS (M+H)⁺: 278.0.

Example 8:6-(2-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

K₂CO₃ (44 mg, 0.32 mmol) and 1-(bromomethyl)-2-chloro-benzene (0.022 g,0.11 mmol, Aldrich) were added to a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (20. mg,0.11 mmol, from Example 2, Step 5) in DMF (3.0 mL). The reaction washeated to 50° C. for 35 minutes. The reaction mixture was diluted withMeCN, filtered and purified by preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (2.6 mg,8%).

¹H NMR (300 MHz, CD₃OD) δ 7.56 (d, J=9.7 Hz, 1H), 7.49 (dd, J=7.9, 1.0Hz, 1H), 7.27 (td, J=7.9, 1.4 Hz, 1H), 7.22 (d, J=9.7 Hz, 1H), 7.14 (td,J=7.7, 0.7 Hz, 1H), 6.90 (s, 1H), 6.27 (dd, J=7.7, 0.7 Hz, 1H), 5.58 (s,2H), 2.99 (s, 3H), 2.41 (s, 3H); LCMS (M+H)⁺: 311.0, 313.0.

Example 9:6-(3-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example8, using 1-(bromomethyl)-3-chloro-benzene (0.022 g, 0.11 mmol, Aldrich)(1.8 mg, 5%).

¹H NMR (300 MHz, CD₃OD) δ 7.62 (d, J=9.7 Hz, 1H), 7.33-7.25 (m, 2H),7.22 (d, J=9.7 Hz, 1H), 7.03-6.96 (m, 1H), 6.92-6.86 (m, 1H), 6.86-6.83(m, 1H), 5.51 (s, 2H), 2.97 (s, 3H), 2.44 (s, 3H); LCMS (M+H)⁺: 311.0,313.0.

Example 10:6-(4-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example8, using 1-(bromomethyl)-4-chlorobenzene (0.022 g, 0.11 mmol, Aldrich)(1.9 mg, 6%).

¹H NMR (300 MHz, CD₃OD) δ 7.63 (dd, 1H), 7.30 (d, J=8.6 Hz, 2H), 7.22(d, J=9.7 Hz, 1H), 6.97 (d, J=8.7 Hz, 2H), 6.84 (t, J=0.8 Hz, 1H), 5.49(s, 2H), 2.97 (s, 3H), 2.44 (d, J=0.7 Hz, 3H), LCMS (M+H)⁺: 311.0,312.9.

Example 11:1,7-dimethyl-6-(pyridin-3-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (13 mg, 0.32 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(20 mg, 0.1 mmol, from Example 2, Step 5) in DMF (3.0 mL). Afterstirring for 10 minutes, a solution of 3-(bromomethyl)pyridinehydrobromide (0.027 g, 0.11 mmol, Aldrich) in DMF (0.3 mL) was added.The mixture was stirred for 45 minutes and then quenched by the additionof water, diluted to 5 mL with MeCN, filtered and purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) (8 mg, 30%).

¹H NMR (300 MHz, CD₃OD) δ 8.44 (dd, J=4.2, 2.2 Hz, 1H), 8.29 (s, 1H),7.64 (d, J=9.7 Hz, 1H), 7.43-7.32 (m, 2H), 7.22 (d, J=9.7 Hz, 1H), 6.84(s, 1H), 5.58 (s, 2H), 2.95 (s, 3H), 2.45 (s, 3H); LCMS (M+H)⁺: 278.1.

Example 12:1,7-dimethyl-6-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (13 mg, 0.32 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(20 mg, 0.1 mmol, from Example 2, Step 5) in DMF (3.0 mL). Afterstirring for 10 minutes, a solution of 4-(bromomethyl)pyridinehydrobromide (0.027 g, 0.11 mmol, Aldrich) in DMF (0.8 mL) was added.The mixture was stirred for 45 minutes and then quenched by the additionof water, diluted to 5 mL with MeCN, filtered and purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) (1.0 mg, 3%).

¹H NMR (300 MHz, CD₃OD) δ 8.46 (d, J=6.1 Hz, 2H), 7.62 (d, J=9.8 Hz,1H), 7.24 (d, J=9.7 Hz, 1H), 7.01 (d, J=5.9 Hz, 2H), 6.91 (s, 1H), 5.62(s, 2H), 3.00 (s, 3H), 2.44 (s, 3H); LCMS (M+H)⁺: 278.2.

Example 13:6-(cyclopentylmethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (13 mg, 0.32 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(20 mg, 0.1 mmol, from Example 2, Step 5) in DMF (3.0 mL). Afterstirring for 15 minutes, (iodomethyl)cyclopentane (0.022 g, 0.11 mmol,Acros) was added. After stirring for 45 minutes at room temperature,excess NaH (13 mg, 0.32 mmol, 60% in mineral oil) and(iodomethyl)cyclopentane (0.022 g, 0.11 mmol) were added and thereaction was continued for 20 minutes and then was quenched by theaddition of water and diluted to 5 mL volume with MeCN. The resultingsolution was filtered and purified by preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)(4 mg, 10%).

¹H NMR (300 MHz, CD₃OD) δ 7.74 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.7 Hz,1H), 6.74 (s, 1H), 4.18 (d, J=7.7 Hz, 2H), 2.95 (s, 3H), 2.52 (s, 3H),2.45-2.32 (m, 1H), 1.82-1.50 (m, 6H), 1.41-1.26 (m, 2H); LCMS (M+H)⁺:269.1.

Example 14:6-(2-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (10.0 mg,0.0537 mmol, from Example 2, Step 5) in DMF (1.5 mL) was added sodiumhydride (0.0065 g, 0.16 mmol, 60% in mineral oil). After stirring for 10minutes, 1-(bromomethyl)-2-fluorobenzene (0.010 g, 0.054 mmol, Aldrich)was added. After stirring for 45 minutes, the reaction was quenched withwater, diluted with MeCN and filtered, then was purified by preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) (7 mg, 40%).

¹H NMR (300 MHz, CD₃OD) δ 7.66 (d, J=10.1 Hz, 1H), 7.36-7.27 (m, 1H),7.23 (d, J=9.7 Hz, 1H), 7.16 (ddd, J=10.4, 8.3, 1.1 Hz, 1H), 7.05 (td,J=7.6, 1.1 Hz, 1H), 6.90-6.77 (m, 1H), 6.66-6.59 (m, 1H), 5.57 (s, 2H),2.98 (s, 3H), 2.46 (s, 3H); LCMS (M+H)⁺: 295.0.

Example 15:6-(3-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared as described in Example 14, usinga-bromo-3-fluorotoluene (0.010 g, 0.054 mmol, Aldrich) (7 mg, 40%).

¹H NMR (300 MHz, CD₃OD) δ 7.63 (dd, J=9.7, 0.7 Hz, 1H), 7.32 (td, J=8.0,5.9 Hz, 1H), 7.23 (d, J=9.7 Hz, 1H), 7.04-6.94 (m, 1H), 6.89-6.83 (m,1H), 6.79 (ddd, J=7.7, 1.6, 0.8 Hz, 1H), 6.75-6.67 (m, 1H), 5.53 (s,2H), 2.98 (s, 3H), 2.45 (d, J=0.6 Hz, 3H); LCMS (M+H)⁺: 295.0.

Example 16:6-(4-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared as described in Example 14, usinga-bromo-4-fluorotoluene (0.010 g, 0.054 mmol, Aldrich) (7 mg, 40%).

¹H NMR (300 MHz, CD₃OD) δ 7.63 (d, J=9.7 Hz, 1H), 7.21 (d, J=9.7 Hz,1H), 7.03 (m, 4H), 6.83 (s, 1H), 5.48 (s, 2H), 2.96 (s, 3H), 2.44 (s,3H); LCMS (M+H)⁺: 295.0.

Example 17:1,7-dimethyl-6-(2-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (15.0 mg,0.0806 mmol, from Example 2, Step 5) in DMF (2.2 mL) was added sodiumhydride (0.0098 g, 0.24 mmol, 60% in mineral oil). After stirring for 10minutes, 1-(bromomethyl)-2-methylbenzene (0.015 g, 0.080 mmol, Aldrich)was added. After stirring for 45 minutes, the reaction was quenched bythe addition of water and diluted to 5 mL volume with MeCN. The solutionwas filtered and purified by preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (9 mg, 40%).

¹H NMR (300 MHz, CD₃OD) δ 7.51 (d, J=9.7 Hz, 1H), 7.29-7.08 (m, 3H),6.97 (dd, J=7.5, 7.5 Hz, 1H), 6.86 (s, 1H), 6.09 (d, J=7.6 Hz, 1H), 5.46(s, 2H), 2.99 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H); LCMS (M+H)⁺: 291.0.

Example 18:1,7-dimethyl-6-(3-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared as described in Example 17, using1-(bromomethyl)-3-methylbenzene (0.015 g, 0.080 mmol, Aldrich) (8 mg,30%).

¹H NMR (300 MHz, CD₃OD) δ 7.60 (d, J=9.7 Hz, 1H), 7.19 (d, J=9.7 Hz,1H), 7.16 (t, J=7.6 Hz, 1H), 7.06 (d, J=7.6 Hz, 1H), 6.82 (s, 1H), 6.80(s, 1H), 6.76 (d, J=7.6 Hz, 1H), 5.44 (s, 2H), 2.96 (s, 3H), 2.43 (s,3H), 2.24 (s, 3H); LCMS (M+H)⁺:291.0.

Example 19:1,7-dimethyl-6-(4-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared as described in Example 17, using1-(bromomethyl)-4-methylbenzene (0.015 g, 0.080 mmol, Aldrich) (8 mg,30%).

¹H NMR (300 MHz, CD₃OD) δ 7.60 (dd, J=9.7, 0.6 Hz, 1H), 7.18 (d, J=9.7Hz, 1H), 7.10 (d, J=7.9 Hz, 2H), 6.88 (d, J=8.1 Hz, 2H), 6.79 (s, 1H),5.42 (s, 2H), 2.95 (s, 3H), 2.43 (s, 3H), 2.27 (s, 3H); LCMS (M+H)⁺:291.0.

Example 20:3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-6-yl)methyl]benzonitrile

The title compound was prepared as described in Example 17, usingm-cyanobenzyl bromide (0.016 g, 0.080 mmol, Aldrich) (4 mg, 20%).

¹H NMR (300 MHz, CD₃OD) δ 7.67-7.62 (m, 1H), 7.63 (dd, J=9.8, 0.6 Hz,1H), 7.50 (t, J=7.8 Hz, 1H), 7.38 (s, 1H), 7.24 (d, J=9.6 Hz, 1H),7.27-7.21 (m, 1H), 6.93-6.86 (m, 1H), 5.60 (s, 2H), 2.99 (s, 3H), 2.46(d, J=0.5 Hz, 3H); LCMS (M+H)⁺: 302.0.

Example 21:1,7-dimethyl-6-(quinolin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared as described in Example 17, using2-(chloromethyl)quinoline hydrochloride (0.017 g, 0.080 mmol, TCI) (4mg, 20%).

¹H NMR (300 MHz, CD₃OD) δ 8.25 (d, J=8.5 Hz, 1H), 8.03-7.97 (m, 1H),7.89 (dd, J=8.1, 1.1 Hz, 1H), 7.77 (ddd, J=8.4, 6.9, 1.4 Hz, 1H), 7.73(d, J=9.8 Hz, 1H), 7.59 (ddd, J=8.2, 7.0, 1.2 Hz, 1H), 7.23 (d, J=9.7Hz, 1H), 6.97 (d, J=8.5 Hz, 1H), 6.90 (s, 1H), 5.78 (s, 2H), 3.00 (s,3H), 2.52 (s, 3H); LCMS (M+H)⁺: 328.0.

Example 22:6-(3-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (50.0 mg,0.268 mmol, from Example 2, Step 5) in DMF (4 mL) was added sodiumhydride (0.032 g, 0.81 mmol, 60% in mineral oil). After stirring for 10minutes, 1-(bromomethyl)-3-methoxybenzene (0.038 mL, 0.27 mmol, Aldrich)was added and the reaction was stirred for 45 minutes and was quenchedby the addition of water and diluted with MeCN, filtered and purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) (0.04 g, 50%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.63 (d, J=9.7 Hz, 1H), 7.23 (d, J=9.7 Hz,1H), 7.21 (t, J=7.9 Hz, 1H), 6.85-6.78 (m, 1H), 6.81 (s, 1H), 6.58 (s,1H), 6.48 (d, J=7.6 Hz, 1H), 5.48 (s, 2H), 3.68 (s, 3H), 2.87 (s, 3H),2.38 (s, 3H); LCMS (M+H)⁺: 307.1.

Example 23:3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenol

To6-(3-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.030 g, 0.098 mmol, from Example 22) in DCM (4 mL) at −78° C. wasadded 1.0 M BBr₃ in DCM (0.57 mL, 0.57 mmol, Aldrich) and the mixturewas allowed to warm to ambient temperature. The reaction was quenched bythe addition of water, and saturated NaHCO₃ solution was added. DCM wasremoved by rotary evaporation and the aqueous mixture was diluted withMeOH, filtered and purified by preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (0.02 g,70%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.37 (br s, 1H), 7.63 (d, J=9.7 Hz, 1H),7.23 (d, J=9.7 Hz, 1H), 7.09 (t, J=7.9 Hz, 1H), 6.81 (s, 1H), 6.61 (dd,J=8.0, 2.2 Hz, 1H), 6.45 (d, J=7.5 Hz, 1H), 6.39-6.24 (m, 1H), 5.43 (s,2H), 2.87 (s, 3H), 2.37 (s, 3H); LCMS (M+H)⁺: 293.1.

Example 24:1,7-dimethyl-6-(1-phenylpentyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(racemic mixture)

Step 1. (1-bromopentyl)benzene (Racemic Mixture Prepared)

PBr₃ (0.171 mL, 1.82 mmol, Aldrich) was added to a solution of1-phenylpentan-1-ol (0.500 g, 3.04 mmol, Alfa Aesar) in Et₂O (3.2 mL) at0° C. The reaction was allowed to reach ambient temperature and then wasquenched with ice water and diluted with hexanes. The layers wereseparated and the organic layer was washed with water and then withbrine, dried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with hexanes afforded product (0.15 g, 22%).

¹H NMR (300 MHz, CDCl₃) δ 7.44-7.26 (m, 5H), 4.95 (t, J=7.5 Hz, 1H),2.48-1.87 (m, 2H), 1.52-1.12 (m, 4H), 0.89 (t, J=7.0 Hz, 3H).

Step 2.1,7-dimethyl-6-(1-phenylpentyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(Racemic Mixture Prepared)

Sodium hydride (0.011 g, 0.27 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50.0 mg, 0.268 mmol, from Example 2, Step 5) in DMF (6 mL). Afterstirring for 10 minutes, (1-bromopentyl)benzene (0.061 g, 0.27 mmol,from Step 1) was added. After stirring for 45 minutes, the reaction wasquenched by the addition of water and the mixture was diluted with MeCN,filtered and purified via preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (0.01 g,10%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.39 (d, J=9.0 Hz, 1H), 7.34 (dd, J=7.4, 7.4Hz, 2H), 7.26 (t, J=7.1 Hz, 1H), 7.19 (d, J=7.6 Hz, 2H), 7.11 (d, J=9.8Hz, 1H), 6.80 (s, 2H), 5.78 (dd, J=10.7, 4.5 Hz, 1H), 2.86 (s, 3H),2.54-2.27 (m, 2H), 2.42 (s, 3H), 1.41-1.20 (m, 4H), 0.92-0.80 (m, 2H),0.79 (t, J=7.0 Hz, 3H); LCMS (M+H)⁺: 333.2.

Example 25N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}acetamidetrifluoroacetate salt

Step 1.1,7-dimethyl-6-(3-nitrobenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (0.011 g, 0.27 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50.0 mg, 0.268 mmol, from Example 2, Step 5) in DMF (6 mL). Afterstirring for 10 minutes, 1-(chloromethyl)-3-nitro-benzene, (0.058 g,0.34 mmol, Aldrich) was added. After stirring for 45 minutes, thereaction was quenched by the addition of water and the mixture wasdiluted with MeCN, filtered and purified via preparative HPLC-MS toafford product as a yellow solid (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH) (0.065 g, 75%).

¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, J=8.1 Hz, 1H), 7.90 (s, 1H), 7.50 (t,J=7.9 Hz, 1H), 7.34 (d, J=9.7 Hz, 1H), 7.22-7.11 (m, 2H), 6.68 (s, 1H),5.45 (s, 2H), 3.00 (s, 3H), 2.43 (s, 3H); LCMS (M+H)⁺: 322.1.

Step 2.N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}acetamidetrifluoroacetate salt

A mixture of1,7-dimethyl-6-(3-nitrobenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.030 g, 0.093 mmol, from Step 1), iron (0.026 g, 0.47 mmol) and NH₄Cl(0.010 g, 0.19 mmol) in EtOH (2 mL) and H₂O (0.4 mL) was heated to 90°C. for 30 minutes. Upon cooling to room temperature, the reactionmixture was diluted with EtOAc and filtered through celite. The filtratewas dried over sodium sulfate, decanted and concentrated. The crudeproduct was dissolved in DCM (2 mL) and Ac₂O (0.0088 mL, 0.093 mmol,Sigma-Aldrich) and DMAP (0.004 g, 0.03 mmol) were added. The reactionwas stirred overnight. 1.0 M NaOH (2 mL) and MeOH (2 mL) were added.After stirring for 15 minutes, the reaction mixture was diluted withwater, and extracted with three portions of DCM and three portions ofEtOAc. All extracts were combined, dried over sodium sulfate, filteredand concentrated. The product was purified by preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH followed by a further purification: Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA) (0.01 g, 24%).

¹H NMR (300 MHz, CD₃OD) δ 8.29 (d, J=9.5 Hz, 1H), 7.45 (d, J=9.5 Hz,1H), 7.38 (s, 1H), 7.31-7.23 (m, 2H), 7.13 (s, 1H), 6.89-6.80 (m, 1H),5.64 (s, 2H), 3.10 (s, 3H), 2.58 (s, 3H), 2.03 (s, 3H); ¹⁹F NMR (282MHz, CD₃OD) δ −77.69 (s); LCMS (M+H)⁺: 334.1.

Example 26:{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanoltrifluoroacetate salt

Step 1. methyl3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoate

Sodium hydride (0.043 g, 1.1 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(200.0 mg, 1.074 mmol, from Example 2, Step 5) in DMF (20 mL). After 10minutes, methyl 3-(bromomethyl)benzoate (0.25 g, 1.1 mmol, Alfa Aesar)was added. After 45 minutes, the reaction mixture was poured into pH 7buffer and the product was extracted with three portions of EtOAc. Thecombined organic extracts were washed with water, then brine, dried oversodium sulfate, filtered and concentrated and used without furtherpurification.

LCMS (M+H)⁺: 335.1.

Step 2.{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanoltrifluoroacetate salt

To a solution of methyl3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoate(0.090 g, 0.27 mmol, from Step 1) in THF (3 mL) and EtOH (2 mL) at 0° C.was added LiBH₄ (0.038 g, 1.6 mmol, 90% purity reagent, Aldrich) and themixture was allowed to warm to room temperature. After 2 hours,additional LiBH₄ (0.078 g, 3.2 mmol) was added and THF (2 mL) was usedto rinse material down from the walls of the flask. The reaction wasstirred overnight. MeOH (2 mL) and additional LiBH₄ (0.069 g, 2.9 mmol)were then added. After an additional few hours, the reaction wasquenched by the addition of brine, and the product was extracted usingEtOAc. The extracts were dried over sodium sulfate, filtered andconcentrated and the crude product was used in the next step. A portionwas purified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA).

¹H NMR (300 MHz, CD₃OD) δ 8.28 (d, J=9.3 Hz, 1H), 7.45 (d, J=9.5 Hz,1H), 7.37-7.22 (m, 2H), 7.13 (s, 1H), 7.03 (s, 1H), 6.95 (d, J=7.1 Hz,1H), 5.66 (s, 2H), 4.52 (s, 2H), 3.10 (s, 3H), 2.58 (s, 3H); ¹⁹F NMR(282 MHz, CD₃OD) δ −77.47 (s); LCMS (M+H)⁺: 307.1.

Example 27:1-(3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzyl)azetidin-3-olbis-trifluoroacetate salt

Diisopropylethylamine (0.14 mL, 0.81 mmol) and methanesulfonic anhydride(0.094 g, 0.54 mmol, Aldrich) were added to a solution of the crudeproduct of Example 26, Step 2 in DCM (5 mL) at 0° C. After 30 minutes,solvent was removed in vacuo and the residue was dissolved in THF (2 mL)and MeOH (2 mL). Half of this solution was treated with excess3-hydroxyazetidine HCl (130 mg, 1.19 mmol, Oakwood) anddiisopropylethylamine (0.3 mL, 1.72 mmol) and was stirred overnight. Theproduct was purified by preparative HPLC-MS (Waters SunFire C18, elutingwith a gradient of MeCN/H₂O containing 0.1% TFA) (7.5 mg, 10%).

¹H NMR (300 MHz, CD₃OD) δ 8.17 (d, J=9.6 Hz, 1H), 7.49-7.33 (m, 3H),7.16 (s, 1H), 7.14-7.07 (m, 2H), 5.69 (s, 2H), 4.70-4.42 (m, 1H), 4.33(s, 2H), 4.30-4.16 (m, 2H), 3.97-3.75 (m, 2H), 3.09 (s, 3H), 2.55 (s,3H); ¹⁹F NMR (282 MHz, CD₃OD) δ −77.38 (s); LCMS (M+H)⁺: 362.1.

Example 28:6-[3-(azetidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Half of the solution of intermediate mesylate from Example 27 wastreated with excess azetidine (0.1 mL, 1.5 mmol, Aldrich) anddiisopropylethylamine (0.15 mL, 0.86 mmol) and the reaction was stirredovernight. The product was purified by preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFAthen followed by further purification: Waters XBridge C18, eluting witha gradient of MeCN/H₂O containing 0.15% NH₄OH) (3 mg, 10%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (dd, J=9.7, 0.5 Hz, 1H), 7.29-7.16 (m,2H), 7.10 (d, J=7.8 Hz, 1H), 6.94 (s, 1H), 6.84-6.75 (m, 2H), 5.49 (s,2H), 3.41 (s, 2H), 3.01 (t, J=6.9 Hz, 4H), 2.86 (s, 3H), 2.37 (s, 3H),1.89 (p, J=7.0 Hz, 2H); LCMS (M+H)⁺: 346.0.

Example 29:2-(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-phenylethanol(Racemic Mixture Prepared)

Step 1. ethyl(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)(phenyl)acetate (Racemic Mixture Prepared)

Sodium hydride (110 mg, 2.7 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.500 g, 2.68 mmol, from Example 2, Step 5) in DMF (50 mL). After 15minutes, a solution of ethyl-alpha-bromophenyl acetate (0.70 mL, 4.0mmol, Aldrich) in DMF (10 mL) was added dropwise. The mixture wasstirred for 15 minutes at room temperature and then was poured into pH 7buffer and diluted with EtOAc and water. The layers were separated andthe aqueous was extracted again with EtOAc. The combined organicextracts were washed with water, then brine, dried over sodium sulfate,filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 5-10% MeOH in DCM (187 mg,20%).

LCMS (M+H)⁺: 349.2.

Step 2.2-(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-phenylethanol(Racemic Mixture Prepared)

Ethyl(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)(phenyl)acetate(0.008 g, 0.02 mmol, from Step 1) was dissolved in MeOH (0.5 mL) and THF(0.5 mL) and LiBH₄ (0.0025 g, 0.10 mmol, 90% purity, Aldrich) was added.The reaction was stirred for 4 hours and additional LiBH₄ (0.006 g, 0.25mmol) was added and the reaction continued for a further 3 hours. Thereaction was quenched by the addition of water and diluted with MeCN,filtered and purified by preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (5 mg, 70%).

¹H NMR (400 MHz, CD₃OD) δ 7.41-7.27 (m, 4H), 7.26-7.19 (m, 2H), 7.04 (d,J=9.8 Hz, 1H), 6.84 (s, 1H), 5.85 (dd, J=8.6, 5.3 Hz, 1H), 4.58 (dd,J=11.6, 5.2 Hz, 1H), 4.43 (dd, J=11.6, 8.7 Hz, 1H), 2.97 (s, 3H), 2.55(s, 3H); LCMS (M+H)⁺: 307.1.

Example 30:3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzamidetrifluoroacetate salt

Step 1.3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]BenzoicAcid Ammonium Salt

To a solution of methyl3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoate(0.090 g, 0.27 mmol, prepared as in Example 26, Step 1) in 1,4-dioxane(2 mL), H₂O (1 mL) and MeOH (1 mL) was added LiOH, monohydrate (0.056 g,1.3 mmol) and the reaction was stirred overnight. Further LiOH—H₂O(0.050 g, 1.1 mmol) was added and the reaction was continued for 8hours. The reaction mixture was diluted with additional water, filteredand purified via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH) (74 mg, 86%).

LCMS (M+H)⁺: 321.1.

Step 2.3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzamide,Trifluoroacetate Salt

To a solution of3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoicacid (0.074 g, 0.23 mmol, as ammonium salt, from Step 1) in DCM (5 mL)containing DMF (0.004 mL, 0.05 mmol) was added oxalyl chloride (0.020mL, 0.23 mmol, Aldrich). Additional portions of oxalyl chloride (0.020mL, 0.24 mmol) were added (twice) and the reaction was stirred for 30minutes. The mixture was heated to reflux and a single additionalportion of oxalyl chloride (0.020 mL, 0.23 mmol) was added while thesolution was hot. One-third of this solution was added to ammoniumhydroxide solution (2 mL, 14.8 N). MeCN (1 mL) was added and thebiphasic mixture was stirred vigorously overnight. DCM was removed invacuo and the remaining aqueous mixture was diluted with additionalMeCN, filtered and purified by preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA) (8 mg, 24%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.21 (d, J=9.4 Hz, 1H), 7.94 (br s, 1H),7.76 (d, J=8.0 Hz, 1H), 7.58 (s, 1H), 7.48 (d, J=9.4 Hz, 1H), 7.39 (t,J=7.7 Hz, 1H), 7.35 (br s, 1H), 7.14 (d, J=7.9 Hz, 1H), 7.10 (s, 1H),5.69 (s, 2H), 2.98 (s, 3H), 2.49 (s, 3H); ¹⁹F NMR (282 MHz, d₆-DMSO) δ−74.35 (s); LCMS (M+H)⁺: 320.0.

Example 31:3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-N-hydroxybenzamidetrifluoroacetate salt

One-third portion of the crude acid chloride (0.077 mmol) from Example30, Step 2 was added to a solution of hydroxylamine HCl (0.048 g, 0.69mmol, Aldrich) and diisopropylethylamine (0.12 mL, 0.69 mmol) in DCM (1mL). MeCN (1 mL) was added and the reaction was stirred overnight. DCMwas removed in vacuo and the reaction mixture was diluted with MeOH,filtered and purified by preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA) (10 mg, 29%).

¹H NMR (300 MHz, d₆-DMSO) δ 11.21 (s, 1H), 9.04 (br s, 1H), 8.22 (d,J=9.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.49 (d, J=9.6 Hz, 1H), 7.45 (s,1H), 7.39 (t, J=7.7 Hz, 1H), 7.14 (d, J=8.2 Hz, 1H), 7.10 (s, 1H), 5.70(s, 2H), 2.98 (s, 3H), 2.49 (s, 3H); ¹⁹F NMR (282 MHz, d₆-DMSO) δ −74.27(s); LCMS (M+H)⁺: 336.0.

Example 32:3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-N-methylbenzamidetrifluoroacetate salt

To a solution of3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoicacid (0.025 g, 0.078 mmol, prepared as in Example 30, Step 1 andisolated by preparative HPLC-MS [Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA]) in DMF (1.0 mL) was addeddiisopropylethylamine (0.054 mL, 0.31 mmol) andN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.055 g, 0.14 mmol, Aldrich). After stirring for 10minutes, 2.0 M methylamine in THF (0.50 mL, 1.0 mmol, Aldrich) was addedand the reaction was stirred for 2 hours. The reaction mixture wasdiluted with MeOH and purified by preparative HPLC-MS (Waters SunFireC18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA) (10 mg,40%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.44 (q, J=4.3 Hz, 1H), 8.31 (d, J=9.6 Hz,1H), 7.71 (d, J=7.9 Hz, 1H), 7.60-7.46 (m, 2H), 7.40 (t, J=7.7 Hz, 1H),7.20-7.09 (m, 2H), 5.72 (s, 2H), 3.00 (s, 3H), 2.72 (d, J=4.5 Hz, 3H),2.50 (s, 3H); ¹⁹F NMR (282 MHz, d₆-DMSO) δ −74.49 (s); LCMS (M+H)⁺:334.0.

Example 33:3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-N-ethylbenzamidetrifluoroacetate salt

The title compound was prepared as described for Example 32, usingethylamine (0.050 mL, 0.89 mmol, Aldrich) (10 mg, 40%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.49 (t, J=5.4 Hz, 1H), 8.31 (d, J=9.6 Hz,1H), 7.72 (d, J=7.9 Hz, 1H), 7.57 (s, 1H), 7.53 (d, J=9.5 Hz, 1H), 7.40(t, J=7.7 Hz, 1H), 7.15 (s, 1H), 7.10 (d, J=7.6 Hz, 1H), 5.72 (s, 2H),3.36-3.07 (m, 2H), 3.00 (s, 3H), 2.50 (s, 3H), 1.07 (t, J=7.2 Hz, 3H);¹⁹F NMR (282 MHz, d₆-DMSO) δ −74.49 (s); LCMS (M+H)⁺: 348.0.

Example 34:6-(4-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (0.032 g, 0.81 mmol, 60% in mineral oil) was added to asolution of 1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50.0 mg, 0.268 mmol, Example 2, Step 5) in DMF (4 mL). After 10minutes, p-methoxybenzyl chloride (0.036 mL, 0.27 mmol, Aldrich) wasadded. The reaction was stirred for 45 minutes, then was quenched withwater, diluted with MeCN, filtered and purified by preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH) to afford product as a white solid (49 mg, 60%).

¹H NMR (300 MHz, CDCl₃) δ 7.31 (d, J=9.6 Hz, 1H), 7.24 (d, J=9.6 Hz,1H), 6.89 (d, J=8.7 Hz, 2H), 6.83 (d, J=8.8 Hz, 2H), 6.61-6.59 (m, 1H),5.28 (s, 2H), 3.77 (s, 3H), 2.98 (s, 3H), 2.42 (s, 3H); LCMS (M+H)⁺:307.2.

Example 35:4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenol

1.0 M Boron tribromide in DCM (0.54 mL, 0.54 mmol, Aldrich) was added toa solution of6-(4-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(42 mg, 0.137 mmol, from Example 34) in DCM (4 mL) at −78° C., and thereaction was allowed to slowly reach room temperature. The reaction wasquenched by the addition of water, followed by saturated NaHCO₃solution. DCM was removed in vacuo and the mixture was diluted withMeOH, filtered and purified by preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (27 mg,67%). ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, J=9.7 Hz, 1H), 7.14 (d, J=9.7Hz, 1H), 6.81 (d, J=8.6 Hz, 2H), 6.72 (d, J=8.6 Hz, 2H), 6.56 (s, 1H),5.23 (s, 2H), 2.95 (s, 3H), 2.45 (s, 3H); LCMS (M+H)⁺: 293.1.

Example 36:2-({3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}amino)ethanol

Step 1.{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol

To a suspension of methyl3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoate(0.96 g, 2.7 mmol, prepared as in Example 26, Step 1) in THF (90 mL) at0° C. was added dropwise a solution of 1.0 M LiAlH₄ in THF (4.0 mL, 4.0mmol, Aldrich). After 20 minutes, additional 1.0 M LiAlH₄ in THF (1.3mL, 1.3 mmol) was added. After 20 additional minutes, the reaction wasquenched by the dropwise addition of water. The reaction was cooled to0° C. and excess Rochelle's salt was added and stirred until thesolution was clear. Sodium sulfate was then added, the mixture wasfiltered through celite and the solvent was removed in vacuo. Flashchromatography, eluting with a gradient from 0-10% MeOH in DCM affordedproduct as a light yellow solid (0.61 g, 74%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.24 (m, 3H), 7.21 (d, J=9.7 Hz, 1H),7.01 (s, 1H), 6.85-6.80 (m, 1H), 6.62 (s, 1H), 5.35 (s, 2H), 4.66 (s,2H), 2.98 (s, 3H), 2.43 (s, 3H), 1.98 (br s, 1H).

LCMS (M+H)⁺: 307.0.

Step 2.2-({3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}amino)ethanol

Diisopropylethylamine (26 μL, 0.15 mmol) and methanesulphonic anhydride(13 mg, 0.073 mmol, Aldrich) were added to a solution of{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol(15 mg, 0.049 mmol, from Step 1) in DCM (1.0 mL). The mixture wasstirred until mesylate formation was determined complete as judged byLCMS, and the mixture was then concentrated. The residue wasre-dissolved in a mixture of THF (0.50 mL) and MeOH (0.50 mL) andethanolamine (12 μL, 0.20 mmol, Aldrich) was added and the reaction wasstirred for 1.5 hours. The crude reaction mixture was purified usingpreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) (8.5 mg, 50%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (dd, J=9.7, 0.6 Hz, 1H), 7.27-7.15 (m,3H), 7.05 (s, 1H), 6.81 (s, 1H), 6.76 (dt, J=6.7, 1.9 Hz, 1H), 5.49 (s,2H), 4.44 (t, J=5.2 Hz, 1H), 3.62 (s, 2H), 3.39 (q, J=5.6 Hz, 2H), 2.87(s, 3H), 2.49-2.44 (m, 2H), 2.38 (s, 3H); LCMS (M+H)⁺: 350.2.

Example 37:2-[{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}(methyl)amino]ethanol

The title compound was prepared according to the methods of Example 36using 2-(methylamino)ethanol (16 μL, 0.20 mmol, Aldrich) (10 mg, 56%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.65 (d, J=9.7 Hz, 1H), 7.28-7.13 (m, 3H),7.06 (s, 1H), 6.80 (s, 1H), 6.77 (d, J=7.3 Hz, 1H), 5.50 (s, 2H), 4.35(t, J=5.4 Hz, 1H), 3.48-3.40 (m, 2H), 3.42 (s, 2H), 2.87 (s, 3H),2.40-2.32 (m, 2H), 2.38 (s, 3H), 2.09 (s, 3H).

LCMS (M+H)⁺: 364.2.

Example 38:1,7-dimethyl-6-[3-(morpholin-4-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the methods of Example 36using morpholine (17 μL, 0.20 mmol, Aldrich) (8.8 mg, 48%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.63 (d, J=9.7 Hz, 1H), 7.28-7.19 (m, 2H),7.15 (d, J=7.5 Hz, 1H), 6.99 (s, 1H), 6.86-6.77 (m, 2H), 5.51 (s, 2H),3.53-3.42 (m, 4H), 3.38 (s, 2H), 2.87 (s, 3H), 2.38 (s, 3H), 2.33-2.20(m, 4H); LCMS (M+H)⁺: 376.2.

Example 39:(1r,3r)-3-((3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzyl)amino)cyclobutanol

Prepared by the method of Example 36 using trans-3-aminocyclobutanolhydrochloride (24 mg, 0.20 mmol, Advanced ChemBlocks, Inc.) anddiisopropylethylamine (43 μL, 0.24 mmol) and stirring the displacementreaction overnight (5.9 mg, 32%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.26-7.14 (m, 3H),7.06 (s, 1H), 6.81 (s, 1H), 6.76-6.70 (m, 1H), 5.49 (s, 2H), 4.80 (d,J=4.4 Hz, 1H), 4.27-4.13 (m, 1H), 3.50 (s, 2H), 2.87 (s, 3H), 2.39 (s,3H), 1.98-1.76 (m, 4H).

LCMS (M+H)⁺: 376.2.

Example 40:1-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N,N-dimethylmethanamine

The title compound was prepared according to the methods of Example 36using 2.0 M dimethylamine in THF (98 μL, 0.20 mmol, Aldrich) (7.9 mg,48%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.65 (d, J=9.7 Hz, 1H), 7.28-7.18 (m, 2H),7.14 (d, J=7.6 Hz, 1H), 7.03 (s, 1H), 6.84-6.75 (m, 2H), 5.51 (s, 2H),3.30 (s, 2H), 2.87 (s, 3H), 2.37 (s, 3H), 2.06 (s, 6H); LCMS (M+H)⁺:334.0.

Example 41:1-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N-methylmethanamine

The title compound was prepared according to the methods of Example 36using 2.0 M methylamine in THF (98 μL, 0.20 mmol, Aldrich) and stirringthe displacement reaction overnight (4.5 mg, 29%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.27-7.13 (m, 3H),7.04 (s, 1H), 6.81 (s, 1H), 6.80-6.71 (m, 1H), 5.49 (s, 2H), 3.54 (s,2H), 2.87 (s, 3H), 2.38 (s, 3H), 2.18 (s, 3H); LCMS (M+H)⁺: 320.0.

Example 42:N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}ethanamine

The title compound was prepared according to the methods of Example 36using ethylamine (27.6 μL, 0.490 mmol, Aldrich) (9.0 mg, 55%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.63 (d, J=9.7 Hz, 1H), 7.26-7.14 (m, 3H),7.03 (s, 1H), 6.81 (s, 1H), 6.79-6.73 (m, 1H), 5.49 (s, 2H), 3.59 (s,2H), 2.87 (s, 3H), 2.43 (q, J=7.1 Hz, 2H), 2.38 (s, 3H), 0.93 (t, J=7.1Hz, 3H); LCMS (M+H)⁺: 334.2.

Example 43:N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N′-ethylureatrifluoroacetate salt

Step 1.3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]aniline

1,7-Dimethyl-6-(3-nitrobenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.16 g, 0.50 mmol, from Example 25, Step 1) in methanol (100 mL) washydrogenated for 6.5 hours under 1 atmosphere of hydrogen provided by aballoon, over 10% palladium on activated carbon (100 mg, 0.10 mmol,Degussa type, Aldrich). The reaction mixture was filtered through celiteand concentrated to afford product as light yellow solid, which was usedwithout further purification (0.14 g, 96%).

LCMS (M+H)⁺: 292.0.

Step 2.N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N′-ethylureatrifluoroacetate salt

3-[(1,7-Dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]aniline(10 mg, 0.034 mmol, from Step 1) was dissolved in a mixture of THF (1.0mL) and DCM (0.40 mL) and triethylamine (14 μL, 0.10 mmol) and ethane,isocyanato-(12 μL, 0.17 mmol, Aldrich) were added. The product waspurified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA) (8.3 mg, 51%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.47 (s, 1H), 8.24 (d, J=9.6 Hz, 1H), 7.50(d, J=9.5 Hz, 1H), 7.26-7.10 (m, 3H), 7.09 (s, 1H), 6.52 (d, J=7.6 Hz,1H), 6.11 (t, J=5.4 Hz, 1H), 5.58 (s, 2H), 3.05 (dq, J=7.1, 5.3 Hz, 2H),2.98 (s, 3H), 2.50 (s, 3H), 0.99 (t, J=7.2 Hz, 3H); LCMS: (M+H)⁺: 363.2.

Example 44:N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}urea

To a solution of3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]aniline(16 mg, 0.055 mmol, from Example 43, Step 1) in THF (1.6 mL) and DCM(0.64 mL) were added triethylamine (23 μL, 0.16 mmol) and triphosgene(16 mg, 0.055 mmol, Aldrich). The mixture was stirred for 15 minutes,then NH₄OH solution (43 μL, 14.8 N) was added. After stirring for 30minutes, the product was precipitated as a yellow solid, re-dissolved inMeOH and filtered, then purified via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) (5.5mg, 30%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.46 (s, 1H), 7.64 (d, J=9.7 Hz, 1H), 7.33(d, J=8.2 Hz, 1H), 7.23 (d, J=9.7 Hz, 1H), 7.13 (t, J=7.9 Hz, 1H), 6.95(t, J=1.7 Hz, 1H), 6.81 (s, 1H), 6.53 (d, J=7.6 Hz, OH), 5.76 (s, 2H),5.45 (s, 2H), 2.87 (s, 3H), 2.38 (s, 3H); LCMS (M+H)⁺: 335.2.

Example 45:1,7-dimethyl-6-[3-(pyrrolidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol(15 mg, 0.049 mmol, from Example 36, Step 1) in DCM (1.0 mL) was addeddiisopropylethylamine (26 μL, 0.15 mmol) followed by methanesulphonicanhydride (17 mg, 0.098 mmol). After mesylate formation was determinedto be complete as judged by LCMS, solvent was removed in vacuo and theresidue was re-dissolved in a mixture of THF (0.50 mL) and methanol(0.50 mL). Pyrrolidine (0.016 mL, 0.20 mmol, Aldrich) was added and thereaction was stirred for 2.5 hours. The product was purified usingpreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) (11.4 mg, 65%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.7 Hz,1H), 7.22 (t, J=7.5 Hz, 1H), 7.15 (d, J=7.6 Hz, 1H), 7.01 (s, 1H), 6.80(s, 1H), 6.78 (d, J=7.6 Hz, 1H), 5.51 (s, 2H), 3.47 (s, 2H), 2.87 (s,3H), 2.37 (s, 3H), 2.35-2.23 (m, 4H), 1.60 (p, J=3.0 Hz, 4H); LCMS(M+H)⁺: 360.2.

Example 46:1,7-dimethyl-6-[3-(piperidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example45, using piperidine (0.019 mL, 0.20 mmol, Aldrich) (11.1 mg, 61%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.63 (d, J=9.7 Hz, 1H), 7.22 (t, J=7.5 Hz,1H), 7.22 (d, J=9.7 Hz, 1H), 7.13 (d, J=7.7 Hz, 1H), 6.97 (s, 1H),6.84-6.78 (m, 1H), 6.81 (s, 1H), 5.51 (s, 2H), 3.33 (s, 2H), 2.87 (s,3H), 2.38 (s, 3H), 2.24-2.15 (m, 4H), 1.43-1.26 (m, 6H); LCMS (M+H)⁺:374.2.

Example 47:1,7-dimethyl-6-{3-[(4-methylpiperazin-1-yl)methyl]benzyl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example45, using 1-methyl-piperazine (0.022 mL, 0.20 mmol, Aldrich) (10.7 mg,56%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.62 (d, J=9.7 Hz, 1H), 7.23 (t, J=7.6 Hz,1H), 7.21 (d, J=9.8 Hz, 1H), 7.12 (d, J=7.6 Hz, 1H), 6.92 (s, 1H), 6.84(d, J=7.7 Hz, 1H), 6.81 (s, 1H), 5.51 (s, 2H), 3.35 (s, 2H), 2.87 (s,3H), 2.37 (s, 3H), 2.31-2.07 (m, 8H), 2.05 (s, 3H); LCMS (M+H)⁺: 389.2.

Example 48:1,7-dimethyl-6-[3-(piperazin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example45, using tert-butyl piperazine-1-carboxylate (36 mg, 0.20 mmol, BetaPharma). Following the displacement step, solvent was removed in vacuoand replaced with DCM (0.50 mL) and 4.0 M hydrogen chloride in dioxane(0.25 mL, 1.0 mmol). After stirring for 20 minutes, solvent was againremoved in vacuo and the residue was re-dissolved in MeOH/H₂O andpurified using preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH) (12.8 mg, 70%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.63 (d, J=9.7 Hz, 1H), 7.28-7.18 (m, 2H),7.14 (d, J=7.6 Hz, 1H), 6.99 (s, 1H), 6.85-6.76 (m, 2H), 5.51 (s, 2H),3.34 (s, 2H), 2.87 (s, 3H), 2.57 (dd, J=4.6, 4.6 Hz, 4H), 2.38 (s, 3H),2.28-2.10 (m, 4H); LCMS (M+H)⁺: 375.2

Example 49:{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol

Step 1. methyl4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzoate

To a solution of1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine (0.15 g,0.80 mmol, prepared as in Example 2, Step 5) in DMF (20 mL) was addedsodium hydride (42 mg, 1.0 mmol, 60% in mineral oil). This was stirredfor 10 minutes, followed by the addition of methyl 4-bromomethylbenzoate(0.18 g, 0.80 mmol, Aldrich). After 45 minutes, the reaction mixture waspoured into saturated NH₄Cl solution and extracted with six portions ofEtOAc. The combined extracts were washed twice with water, once withbrine, dried over sodium sulfate, filtered and concentrated affordproduct as a light yellow solid, which was used without furtherpurification in the next Step.

Step 2.{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol

1.0 M LiAlH₄ in THF (1.6 mL, 1.6 mmol, Aldrich) was added dropwise to asolution of the crude product of Step 1 in THF (27 mL) at 0° C. After 30minutes, the reaction was quenched at 0° C. by the dropwise addition ofa small amount of water, followed by excess amount of Rochelle's salt.After 10 minutes, sodium sulfate was added and enough DCM to afford atransparent yellow solution. The mixture was then filtered throughcelite and the solvent was removed in vacuo. Flash chromatography,eluting with a gradient from 0-10% MeOH in DCM afforded product as alight yellow solid (0. 11 g, 44% for two steps).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.24 (d, J=8.0 Hz,2H), 7.22 (d, J=9.7 Hz, 1H), 6.95 (d, J=8.2 Hz, 2H), 6.81 (s, 1H), 5.49(s, 2H), 5.13 (t, J=5.7 Hz, 1H), 4.42 (d, J=5.6 Hz, 2H), 2.87 (s, 3H),2.39 (s, 3H); LCMS (M+H)⁺: 307.2.

Example 50:6-[4-(azetidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example45, using the alcohol of Example 49 as starting material and usingazetidine (0.013 mL, 0.20 mmol, Aldrich) in the displacement, which wasperformed overnight (8.0 mg, 47%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.7 Hz,1H), 7.17 (d, J=8.1 Hz, 2H), 6.92 (d, J=8.1 Hz, 2H), 6.80 (s, 1H), 5.48(s, 2H), 3.42 (s, 2H), 3.03 (t, J=6.9 Hz, 4H), 2.86 (s, 3H), 2.37 (s,3H), 1.91 (p, J=6.9 Hz, 2H); LCMS (M+H)⁺: 346.2.

Example 51:1,7-dimethyl-6-[4-(pyrrolidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The title compound was prepared according to the procedures of Example45, using the alcohol of Example 49 as starting material and usingpyrrolidine (0.016 mL, 0.20 mmol, Aldrich) in the displacement, whichwas performed overnight (11.2 mg, 64%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.65 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.8 Hz,1H), 7.22 (d, J=7.7 Hz, 2H), 6.93 (d, J=8.1 Hz, 2H), 6.80 (s, 1H), 5.49(s, 2H), 3.48 (s, 2H), 2.87 (s, 3H), 2.38 (s, 3H), 2.37-2.31 (m, 4H),1.63 (p, J=3.1 Hz, 4H); LCMS (M+H)⁺: 360.2.

Example 52:1-{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}azetidin-3-ol

The title compound was prepared according to the procedures of Example45, using the alcohol of Example 49 as starting material and usingazetidin-3-ol hydrochloride (21 mg, 0.20 mmol, Oakwood) anddiisopropylethylamine (34 μL, 0.20 mmol) in the displacement, which wasperformed overnight (10.3 mg, 58%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.7 Hz,1H), 7.17 (d, J=8.0 Hz, 2H), 6.92 (d, J=8.0 Hz, 2H), 6.80 (s, 1H), 5.48(s, 2H), 5.25 (d, J=6.5 Hz, 1H), 4.11 (p, J=6.3 Hz, 1H), 3.46 (s, 2H),3.40 (td, J=6.0, 1.9 Hz, 2H), 2.87 (s, 3H), 2.68 (td, J=6.2, 1.9 Hz,2H), 2.38 (s, 3H); LCMS (M+H)⁺: 362.0

Example 53:1-{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N,N-dimethylmethanamine

The title compound was prepared according to the procedures of Example45, using the alcohol of Example 49 as starting material and using 2.0 Mdimethylamine in THF (0.15 mL, 0.30 mmol, Aldrich) in the displacement(8.0 mg, 49%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.65 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.5 Hz,1H), 7.20 (d, J=8.0 Hz, 2H), 6.94 (d, J=8.0 Hz, 2H), 6.80 (s, 1H), 5.49(s, 2H), 3.29 (s, 2H), 2.87 (s, 3H), 2.38 (s, 3H), 2.07 (s, 6H); LCMS(M+H)⁺: 334.2.

Example 54:6-{3-[(3-methoxyazetidin-1-yl)methyl]benzyl}-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol(25 mg, 0.082 mmol, from Example 36, Step 1) in DCM (1.7 mL) was addedN,N-diisopropylethylamine (43 μL, 0.24 mmol) followed bymethanesulphonic anhydride (28 mg, 0.16 mmol). When mesylate formationwas deemed complete as judged by LCMS, solvent was removed in vacuo. Theresidue was re-dissolved in a mixture of THF (0.83 mL) and methanol(0.83 mL) and 3-methoxyazetidine hydrochloride (60. mg, 0.49 mmol) andN,N-diisopropylethylamine (85 μL, 0.49 mmol) were added. When thedisplacement step was complete, the product was purified by preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) (11.1 mg, 36%).

¹H NMR (400 MHz, DMSO) δ 7.64 (d, J=9.7 Hz, 1H), 7.22 (d, J=9.7 Hz, 1H),7.23-7.18 (m, 1H), 7.11 (d, J=7.6 Hz, 1H), 6.94 (s, 1H), 6.86-6.71 (m,2H), 5.50 (s, 2H), 3.88 (p, J=5.7 Hz, 1H), 3.47 (s, 2H), 3.08 (s, 3H),2.87 (s, 3H), 3.35 (td, J=6.1, 1.8 Hz, 2H), 2.73 (td, J=5.8, 1.7 Hz,2H), 2.37 (s, 3H); LCMS (M+H)⁺: 376.2.

Example 55:3-benzyl-2,8-dimethyl-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. N3-benzyl-6-chloropyridine-2,3-diamine

A mixture of 6-chloro-2,3-diaminopyridine (2.00 g, 13.9 mmol,Combi-Blocks) and benzaldehyde (1.48 g, 13.9 mmol, Aldrich) in1,2-dichloroethane (50 mL) was treated with acetic acid (0.2 mL, 3 mmol)and the mixture was allowed to stir for 30 minutes. Na(OAc)₃BH (8.8 g,42 mmol) was added and the reaction was stirred overnight. The reactionwas quenched with water, then poured into saturated NaHCO₃ solution. Theproduct was extracted with three portions of DCM, and the combinedextracts were washed with saturated NaHCO₃ solution and brine, driedover sodium sulfate, filtered and concentrated. Flash chromatography,eluting with a gradient from 0-75% EtOAc in hexanes was used to affordpurified product.

LCMS (M+H)⁺: 234.1, 236.1.

Step 2. 1-benzyl-5-chloro-2-methyl-1H-imidazo[4,5-b]pyridine

A mixture of N3-benzyl-6-chloropyridine-2,3-diamine (2.56 g, 11.0 mmol,from Step 1), triethyl orthoacetate (15.7 mL, 85.6 mmol, Aldrich) andp-toluenesulfonic acid (0.59 g, 3.4 mmol, Aldrich) in EtOH (55 mL) washeated to reflux for 1.5 hours. The reaction was cooled to roomtemperature and solvent was evaporated. The residue was partitionedbetween EtOAc and water. The organic layer was washed with saturatedNaHCO₃ solution, and brine, dried over sodium sulfate, filtered andconcentrated. The product began to crystallize and was triturated withhexanes over the weekend. The white solid was isolated by filtration(2.0 g, 71%).

¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, J=8.3 Hz, 1H), 7.37-7.29 (m, 3H),7.13 (d, J=8.3 Hz, 1H), 7.05-7.00 (m, 2H), 5.32 (s, 2H), 2.64 (s, 3H);LCMS (M+H)⁺: 258.0, 260.1.

Step 3. di-tert-butyl 1-(1-benzyl-2-methyl-1H-imidazo[4,5-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

A reaction vessel was charged with1-benzyl-5-chloro-2-methyl-1H-imidazo[4,5-b]pyridine (1.00 g, 3.88 mmol,from Step 2), di-tert-butyl hydrazine-1,2-dicarboxylate (1.0 g, 4.3mmol, Aldrich), cesium carbonate (1.26 g, 3.88 mmol),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.305 g, 0.39 mmol, Aldrich) and toluene (20 mL). The mixture wasdegassed by bubbling a stream of nitrogen through the solution for 10-15minutes. The vessel was then sealed and heated to 110° C. for 9 hours.Upon cooling to room temperature, the mixture was applied to silica gelfor flash chromatography, and a first pass purification was performed byeluting with a gradient from 0-100% EtOAc in hexanes, followed byelution with a gradient from 0-10% MeOH/DCM. A second purification ofthe material thus isolated was performed eluting with 100% EtOAc. (0.97g, 55%).

¹H NMR (300 MHz, CD₃OD) δ 7.80 (d, J=8.6 Hz, 1H), 7.49 (d, J=8.6 Hz,1H), 7.43-7.24 (m, 3H), 7.18-7.08 (m, 2H), 5.49 (s, 2H), 2.61 (s, 3H),1.50 (s, 9H), 1.49 (s, 9H); LCMS (M+H)⁺: 454.2.

Step 4.3-benzyl-2,8-dimethyl-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridine

di-tert-Butyl 1-(1-benzyl-2-methyl-1H-imidazo[4,5-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate (0.075 g, 0.16 mmol, fromStep 3) was dissolved in acetic acid (3 mL) and was heated in themicrowave to 180° C. for 5 minutes. Solvent was removed in vacuo, thecrude product was reconstituted in MeCN and purified via preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) to afford product (27 mg, 59%).

¹H NMR (300 MHz, CD₃OD) δ 7.67 (d, J=9.7 Hz, 1H), 7.43-7.26 (m, 4H),7.21-7.12 (m, 2H), 5.57 (s, 2H), 3.11 (s, 3H), 2.62 (s, 3H); LCMS(M+H)⁺: 278.0.

Example 56:(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol

Step 1.5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde

1.6 M n-Butyllithium in hexanes (1.6 mL, 2.6 mmol) was added dropwise toa solution of N,N-diisopropylamine (0.38 mL, 2.7 mmol) in THF (5.5 mL)at −78° C. Upon complete addition, the reaction temperature was raisedto 0° C. for 30 minutes. After re-cooling to −78° C.,5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (0.50 g, 1.7 mmol,prepared as in Example 2, Step 1) in THF (2.5 mL) was added dropwise.After stirring for 1 hour at −78° C., N,N-dimethylformamide (0.26 mL,3.4 mmol) was added. After 25 minutes, the reaction was quenched by theaddition of saturated NH₄Cl solution into the −78° C. mixture. Afterwarming to room temperature, the mixture was diluted with water andextracted with EtOAc. The combined extracts were washed twice withwater, once with brine, dried over sodium sulfate, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-20%EtOAc in hexanes afforded product as a white solid (0.43 g, 78%).

¹H NMR (300 MHz, CDCl₃) δ 10.53 (s, 1H), 8.52 (d, J=8.9 Hz, 1H), 7.80(d, J=7.5 Hz, 2H), 7.63 (t, J=7.5 Hz, 1H), 7.55-7.45 (m, 2H), 7.45 (d,J=9.0 Hz, 1H). LCMS (M+H)⁺: 321.0.

Step 2. 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde

A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde(0.42 g, 1.3 mmol, prepared in Step 1) in THF (10 mL) was added to amixture of 2.8 M NaOH (12 mL, 34 mmol) and MeOH (10 mL) at 0° C. After40 minutes, the reaction was allowed to come to room temperature andstir for 30 minutes. Saturated NH₄Cl was added and was extracted twicewith DCM. The extracts were washed with water and then with brine, driedover sodium sulfate, filtered and concentrated. Flash chromatography,eluting with a gradient from 0-30% EtOAc in hexanes afforded product asa white solid (0.19 g, 80%).

¹H NMR (300 MHz, CDCl₃) δ 9.96 (s, 1H), 9.14 (s, 1H), 7.77 (dd, J=8.7,0.9 Hz, 1H), 7.38 (dd, J=2.1, 0.9 Hz, 1H), 7.33 (d, J=8.7 Hz, 1H). LCMS(M+H)⁺: 180.9.

Step 3. (1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl)methanol

K₂CO₃ (0.39 g, 2.8 mmol) and benzyl bromide (0.12 mL, 1.0 mmol) wereadded to a solution of 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde(0.17 g, 0.94 mmol, from Step 1) in DMF (3.6 mL). After 15 minutes, thereaction mixture was partitioned between EtOAc and water, and theorganic layer was washed with two portions of water, one portion ofbrine, then dried over sodium sulfate, filtered and concentrated toafford 0.26 g of crude1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde as a yellowsolid. Sodium tetrahydroborate (53 mg, 1.4 mmol) was added to a solutionof the crude aldehyde in THF (5.0 mL) and EtOH (5.0 mL). After 15minutes, the reaction mixture was quenched with saturated NH₄Cl, and wasextracted with EtOAc. The extracts were washed with water followed bybrine, dried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-40% EtOAc in hexanesafforded purified product as a white solid (0.21 g, 82%). ¹H NMR (300MHz, CDCl₃) δ 7.45 (d, J=8.6 Hz, 1H), 7.33-7.25 (m, 3H), 7.06 (d, J=8.6Hz, 1H), 7.03-6.88 (m, 2H), 6.66 (s, 1H), 5.47 (s, 2H), 4.78 (s, 2H).

LCMS (M+H)⁺: 273.1.

Step 4.1-benzyl-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-1H-pyrrolo[3,2-b]pyridine

tert-Butyldimethylsilyl chloride (0.12 g, 0.81 mmol) and 1H-imidazole(60. mg, 0.88 mmol) were added to a solution of(1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl)methanol (0.20 g, 0.73mmol, from Step 2) in DCM (10 mL) After stirring for 4 hours, additionaltert-butyldimethylsilyl chloride (33 mg, 0.22 mmol) and 1H-imidazole (15mg, 0.22 mmol) were added and the reaction was continued for one hour.The mixture was filtered and the filtrate was concentrated. The productwas purified by flash chromatography, eluting with a gradient from 0-10%EtOAc in hexanes to afford a white solid (0.26 g, 92%).

¹H NMR (300 MHz, CDCl₃) δ 7.40 (d, J=8.6 Hz, 1H), 7.33-7.20 (m, 3H),7.03 (d, J=8.6 Hz, 1H), 6.99-6.92 (m, 2H), 6.59 (s, 1H), 5.44 (s, 2H),4.78 (s, 2H), 0.85 (s, 9H), 0.03 (s, 6H).

LCMS (M+H)⁺: 387.0.

Step 5. di-tert-butyl1-[1-benzyl-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A flask was charged with1-benzyl-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-chloro-1H-pyrrolo[3,2-b]pyridine(0.25 g, 0.65 mmol, from Step 3), di-tert-butylhydrazine-1,2-dicarboxylate (0.15 g, 0.65 mmol),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (51 mg, 0.065 mmol), Cs₂CO₃ (0.210 g, 0.646 mmol) and toluene (2.1mL). The mixture was degassed by a stream of nitrogen through thesolution. The mixture was then sealed and heated to 105° C. for 70minutes. The reaction was diluted with DCM, filtered and concentrated.Purification via flash chromatography, eluting with a gradient from0-10% EtOAc in hexanes afforded product as a white solid (0.20 g, 53%).

¹H NMR (300 MHz, CDCl₃) δ 7.47 (d, J=8.6 Hz, 1H), 7.35-7.18 (m, 4H),6.99 (d, J=7.9 Hz, 2H), 6.57 (s, 1H), 5.44 (s, 2H), 4.77 (s, 2H), 1.49(s, 9H), 1.46 (s, 9H), 0.85 (s, 9H), 0.02 (s, 6H).

LCMS (M+H)⁺: 583.3.

Step 6.(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol

di-tert-Butyl1-[1-benzyl-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.20 g, 0.34 mmol, from Step 4) in AcOH (2.7 mL) was heated in themicrowave to a temperature of 180 OC for 5 minutes. Acetic acid wasremoved in vacuo and the residue was then stirred with NaOH (69 mg, 1.7mmol) in THF (2.0 mL) and water (2 mL) for 20 minutes. The product waspurified by preparative HPLC-MS (C18 eluting with a gradient of MeCN andH₂O containing 0.15% NH₄OH). Yield: (38 mg, 38%).

¹H NMR (300 MHz, CDCl₃) δ 7.40-7.18 (m, 5H), 7.03-6.94 (m, 2H), 6.72 (s,1H), 5.54 (s, 2H), 4.76 (d, J=5.2 Hz, 2H), 2.95 (s, 3H). LCMS (M+H)⁺:293.1.

Example 57:6-benzyl-7-(1H-imidazol-1-ylmethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

(6-Benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol(13 mg, 0.044 mmol, from Example 56) and N,N-carbonyldiimidazole (14 mg,0.089 mmol, Aldrich) in MeCN (2.0 mL) were stirred for 75 minutes,followed by the addition of N,N-carbonyldiimidazole (7.2 mg, 0.044 mmol)and 1H-imidazole (26 mg, 0.38 mmol). The reaction was then stirredovernight and purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH) to afford product (2.5mg, 16%).

¹H NMR (300 MHz, CD₃OD) δ 7.64 (s, 1H), 7.60 (d, J=9.8 Hz, 1H), 7.32 (d,J=9.8 Hz, 1H), 7.27-7.19 (m, 3H), 7.15 (s, 1H), 7.09 (s, 1H), 6.89 (s,1H), 6.87-6.80 (m, 2H), 5.56 (s, 2H), 5.47 (s, 2H), 3.00 (s, 3H). LCMS(M+H)⁺: 343.1.

Example 58:6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. tert-butyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

1.6 M n-Butyllithium in hexanes (1.9 mL, 3.1 mmol) was added dropwise toa solution of N,N-diisopropylamine (0.46 mL, 3.3 mmol) intetrahydrofuran (6.6 mL, 82 mmol) at −78° C. After complete addition,the reaction temperature was raised to 0° C. for 30 minutes, followed byre-cooling to −78° C. A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (0.600 g, 2.05mmol, prepared as in Example 2, Step 1) in THF (3.0 mL) was then addeddropwise, and the reaction was stirred at −78° C. for 1 hour.Di-tert-butyldicarbonate (0.89 g, 4.1 mmol, Aldrich) dissolved in THF(3.0 mL) was then added and the mixture was poured cold (from −78° C.bath) into a separatory funnel containing water. Ethyl acetate wasadded, and the mixture was extracted and layers separated. The aqueousphase was extracted with an additional three portions of EtOAc. Thecombined organics were washed with water, followed by brine, were driedover sodium sulfate, decanted, and the solvent removed in vacuo. Flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanesafforded purified product (0.58 g, 72%).

¹H NMR (300 MHz, CDCl₃) δ 8.32 (d, 1H), 8.08-7.97 (m, 2H), 7.68-7.58 (m,1H), 7.57-7.47 (m, 2H), 7.32 (d, J=8.8 Hz, 1H), 7.05 (s, 1H), 1.61 (s,9H). LCMS (M+H)⁺: 393.1/395.1

Step 2. di-tert-butyl1-[2-(tert-butoxycarbonyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

tert-Butyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(0.500 g, 1.27 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.32 g, 1.4 mmol) and Cs₂CO₃ (0.41 g, 1.3mmol) were combined in toluene (6 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.10 g, 0.13 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes and was heated to110° C. for 4 hours. The reaction mixture was cooled to roomtemperature, partitioned between EtOAc and water, the aqueous phase wasextracted a total of three times. The combined extracts were dried oversodium sulfate, filtered and concentrated. Flash chromatography, elutingwith a gradient from 0-30% EtOAc in hexanes afforded purified product(0.43 g, 57%).

¹H NMR (300 MHz, CDCl₃) δ 8.33 (d, J=9.1 Hz, 1H), 8.29 (s, 1H), 8.00 (d,J=8.0 Hz, 2H), 7.77 (d, J=8.9 Hz, 1H), 7.57 (t, J=7.4 Hz, 1H), 7.47 (t,J=7.7 Hz, 2H), 7.14 (s, 1H), 1.57 (s, 9H), 1.43 (s, 9H), 1.39 (s, 9H).LCMS (M+H)⁺: 589.0.

Step 3.1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

A solution of di-tert-butyl1-[2-(tert-butoxycarbonyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.430 g, 0.730 mmol, from Step 2) in AcOH (7 mL) was heated in themicrowave to a temperature of 180 OC for 3 minutes. The solid productwas isolated by filtration and air dried, and used without furtherpurification. Yield: (0.106 g, 41%). LCMS (M+H)⁺: 357.1.

Step 4.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

To a suspension of1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.106 g, 0.297 mmol, from Step 3) in THF (2 mL) and methanol (2mL) was added 1.0 M NaOH (2 mL, 2 mmol) and the reaction was stirred for1 hour. The reaction was diluted with methanol and was purified bypreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). The eluent was evaporated and the resultingsolid was dissolved in DMF (3 mL). K₂CO₃ (0.16 g, 1.2 mmol) followed bybenzyl bromide (0.053 mL, 0.45 mmol) were added and the reaction wasstirred overnight. The reaction was diluted with water and extractedwith three portions of ethyl acetate. The combined extracts were washedwith water, then brine, dried over sodium sulfate, filtered andconcentrated. The residue was stirred with 1.0 N NaOH (2 mL) in THF (2mL) and MeOH (2 mL) for 1 hour. Purified via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH) affordedproduct (34 mg, 37%). ¹H NMR (300 MHz, CD₃OD) δ 7.62 (dd, J=9.8, 0.7 Hz,1H), 7.44 (d, J=0.6 Hz, 1H), 7.29 (d, J=9.8 Hz, 1H), 7.26-7.08 (m, 5H),6.15 (s, 2H), 2.99 (s, 3H). LCMS (M+H)⁺: 307.1.

Step 5.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.0096 g, 0.031 mmol, from Step 4) in DMF (0.5 mL) was addedN,N-diisopropylethylamine (0.022 mL, 0.12 mmol) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.021 g, 0.056 mmol). The reaction was stirred for2 minutes before 28% NH₄OH was added (0.1 mL). The mixture was dilutedwith MeOH and purified purified via preparative HPLC-MS (C18 elutingwith a gradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (5 mg,50%).

¹H NMR (300 MHz, CD₃OD) δ 7.72 (d, J=10.9 Hz, 1H), 7.70 (s, 1H), 7.42(dd, J=9.8, 1.3 Hz, 1H), 7.34-7.16 (m, 3H), 7.11 (d, J=7.6 Hz, 2H), 6.04(s, 2H), 3.00 (s, 3H). LCMS (M+H)⁺: 306.0.

Example 59:6-benzyl-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.0067 g, 0.022 mmol, Example 58, Step 4) in DMF (0.3 mL) wasadded N,N-diisopropylethylamine (0.015 mL, 0.087 mmol, Aldrich) followedby N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.015 g, 0.039 mmol, Aldrich). After 2 minutes,ethylamine (0.0123 mL, 0.219 mmol, Aldrich) was introduced. When thereaction was determined complete by LCMS, the mixture was diluted withMeOH and purified via preparative HPLC-MS (C18 eluting with a gradientof MeCN and H₂O containing 0.15% NH₄OH). Yield: (5 mg, 70%).

¹H NMR (300 MHz, CD₃OD) δ 7.73 (d, J=9.9 Hz, 1H), 7.58 (s, 1H), 7.41(dd, J=9.9, 0.9 Hz, 1H), 7.32-7.17 (m, 3H), 7.10 (d, J=8.1 Hz, 2H), 6.00(s, 2H), 3.39 (q, J=7.3 Hz, 2H), 3.01 (s, 3H), 1.21 (t, J=7.2 Hz, 3H).LCMS (M+H)⁺: 334.0.

Example 60:1-[(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)carbonyl]azetidine-3-carbonitrile

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.010 g, 0.034 mmol, Example 58, Step 4) in DMF (0.5 mL) was addedN,N-diisopropylethylamine (0.035 mL, 0.20 mmol) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.023 g, 0.060 mmol). After stirring for 2 minutes,azetidine-3-carbonitrile hydrochloride (0.012 g, 0.10 mmol, PharmaBlock)was added. When the reaction was determined complete by LCMS, themixture was diluted with MeOH and purified via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH). Yield:(6 mg, 50%).

¹H NMR (300 MHz, CD₃OD) δ 7.76 (d, J=9.8 Hz, 1H), 7.46 (dd, J=9.9, 1.1Hz, 1H), 7.33 (s, 1H), 7.31-7.18 (m, 3H), 7.11 (d, J=7.8 Hz, 2H), 5.86(s, 2H), 4.56 (br m, 4H), 3.74 (ddd, J=15.6, 8.7, 6.6 Hz, 1H), 3.00 (s,3H). LCMS (M+H)⁺: 371.0.

Example 61:2-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)ethanol

Step 1.2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

1.6 M n-Butyllithium in hexanes (12 mL, 19 mmol) was added dropwise to asolution of N,N-diisopropylamine (2.9 mL, 20. mmol) in THF (41 mL) at−78° C. After complete addition, the reaction temperature was raised to0° C. for 30 minutes, followed by re-cooling to −78° C. A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (3.74 g, 12.8mmol, prepared as in Example 2, Step 1) in THF (19 mL) was addeddropwise. After stirring for 1 h at −78° C., 1,3,2-dioxathiolane2,2-dioxide (3.2 g, 26 mmol, Aldrich) in THF (9.4 mL) was added. Thecold bath was then removed and the mixture was allowed to warm to roomtemperature over 1 hour. The reaction was cooled to 0° C. and 12.0 Mhydrogen chloride in water (6.4 mL, 77 mmol), then was allowed to warmto room temperature and stir overnight. The mixture was then neutralizedwith NaHCO₃ and was extracted with two portions of EtOAc. The combinedextracts were dried over sodium sulfate, filtered and concentrated toafford the crude alcohol, which was dissolved in DCM (100. mL), andtert-butyldimethylsilyl chloride (2.9 g, 19 mmol, Aldrich) and1H-imidazole (1.4 g, 20. mmol, Aldrich) were added. After 15 minutes,the mixture was washed with water, brine, dried over sodium sulfate,filtered and concentrated. Flash chromatography, eluting with a gradientfrom 0-10% EtOAc in hexanes afforded product as a light yellow oil (5.02g, 87%).

¹H NMR (300 MHz, CDCl₃) δ 8.37 (dd, J=8.7, 0.7 Hz, 1H), 7.75-7.65 (m,2H), 7.63-7.53 (m, 1H), 7.49-7.41 (m, 2H), 7.20 (d, J=8.7 Hz, 1H),6.68-6.56 (m, 1H), 3.97 (t, J=6.2 Hz, 2H), 3.21 (t, J=6.2 Hz, 2H), 0.84(s, 9H), −0.00 (s, 6H). LCMS (M+H)⁺: 450.9.

Step 2. di-tert-butyl1-[2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A flask was charged with2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine(5.0 g, 11 mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate(2.8 g, 12 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.77 g, 0.98 mmol, Aldrich), Cs₂CO₃ (3.61 g, 11.1 mmol, Aldrich)and toluene (35 mL). The mixture was degassed by a stream of nitrogenthrough the solution. The mixture was then heated to 108° C. for 3 hthen overnight at 100° C. The mixture was cooled to room temperature anddiluted with DCM, then was filtered and the filtrate was concentrated.Flash chromatography, eluting with a gradient from 0-20% EtOAc inhexanes afforded product as a light yellow solid (4.9 g, 68%).

¹H NMR (300 MHz, CDCl₃) δ 8.39 (d, J=9.0 Hz, 1H), 7.77-7.65 (m, 2H),7.65-7.50 (m, 2H), 7.50-7.38 (m, 2H), 7.01 (s, 1H), 6.59 (s, 1H), 3.97(t, J=6.4 Hz, 2H), 3.22 (t, J=6.4 Hz, 2H), 1.51 (s, 9H), 1.47 (s, 9H),0.86 (s, 9H), 0.02 (s, 6H). LCMS (M+H)⁺: 647.2.

Step 3.7-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

di-tert-Butyl1-[2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(4.9 g, 7.6 mmol, from Step 2) in AcOH (60 mL) was divided into portionsand each was heated in the microwave to a temperature of 180 OC for 4minutes. The portions were combined and AcOH was removed in vacuo andthe residue was dissolved in tetrahydrofuran (61 mL) and methanol (61mL) and cooled to 0° C. 2.8 M NaOH (70 mL, 200 mmol) was added. Afterstirring for 15 minutes, sat'd NH₄Cl was added and the product wasextracted with DCM. The combined extracts were dried over sodiumsulfate, filtered and concentrated. Flash chromatography, eluting with agradient from 0-10% MeOH in DCM afforded product as an off-white solid(1.2 g, 48%).

¹H NMR (300 MHz, CDCl₃) δ 9.42 (br s, 1H), 7.35 (d, J=9.7 Hz, 1H), 7.30(d, J=9.6 Hz, 1H), 6.56 (s, 1H), 3.97 (t, J=5.5 Hz, 2H), 3.01 (t, J=5.5Hz, 2H), 2.97 (s, 3H), 0.96 (s, 9H), 0.11 (s, 6H). LCMS (M+H)⁺: 331.0.

Step 4.2-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)ethanol

Sodium hydride (0.10 g, 2.5 mmol, 60% in mineral oil) was added to asolution of7-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.64 g, 1.9 mmol, from Step 3) in DMF (40 mL) at 0° C. After 10minutes, benzyl bromide (0.28 mL, 2.3 mmol) was added and the reactionwas stirred for 15 minutes. The reaction was quenched by the addition ofsat'd NH₄Cl and the product was extracted with EtOAc. The combinedextracts were washed with two portions of water, one portion of brine,dried over sodium sulfate, filtered and concentrated to afford the crudebenzylated product as a yellow solid. The silyl protecting group wasremoved by stirring with 12.0 M HCl (1.0 mL, 12 mmol) in EtOH (40 mL)for 80 minutes. The reaction was neutralized with sat'd NaHCO₃ solutionand the aqueous layer was saturated by the addition of solid NaCl, thenthe product was extracted with DCM. The extract was dried over sodiumsulfate, filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-10% MeOH in DCM to affordproduct as a white solid (0.46 g, 78%).

¹H NMR (300 MHz, CDCl₃) δ 7.32-7.22 (m, 3H), 7.01 (s, 2H), 6.93-6.86 (m,2H), 6.51 (s, 1H), 5.45 (s, 2H), 4.45 (br s, 1H), 4.03 (t, J=5.5 Hz,2H), 2.95 (t, J=5.7 Hz, 2H), 2.88 (s, 3H).

LCMS (M+H)⁺: 307.0.

Example 62:6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 2-bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridinetrifluoroacetate salt

1.6 M n-Butyllithium in hexanes (1.6 mL, 2.6 mmol) was added toN,N-diisopropylamine (0.38 mL, 2.7 mmol) in THF (5.5 mL) at −78° C. Uponcomplete addition, the reaction temperature was raised to 0° C. for 30minutes, then was re-cooled to −78° C. A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (0.500 g, 1.71mmol, prepared as in Example 2, Step 1) in THF (1 mL) was added dropwiseand the reaction was allowed to stir for 1 hour at −78° C. at which time1,2-dibromo-1,1,2,2-tetrachloroethane (0.89 g, 2.7 mmol, Aldrich) as asolution in THF (1 mL) was added. The reaction was allowed to stir withwarming to room temperature overnight. The reaction was quenched withwater and the product was extracted with ethyl acetate four times. Thecombined organics were washed with water, followed by brine, dried oversodium sulfate, decanted, and the solvent removed in vacuo. Flashchromatography, eluting with a gradient from 0-30% EtOAc in hexanesafford the crude product. The product so obtained was purified inseveral injections of 45 mg/5 mL of THF via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.1% TFA). Eluent wasevaporated to afford product as the TFA salt (268 mg, 32%).

¹H NMR (300 MHz, CDCl₃) δ 8.48 (d, J=8.8 Hz, 1H), 7.95-7.79 (m, 2H),7.70-7.58 (m, 1H), 7.57-7.43 (m, 2H), 7.27 (d, J=8.8 Hz, 1H), 6.87 (s,1H). LCMS (M+H)⁺: 370.9/372.9.

Step 2. 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine

1.0 M NaOH in water (5 mL, 5 mmol) was added to a solution of2-bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridinetrifluoroacetate (0.268 g, 0.552 mmol, from Step 1) in THF (5 mL) andmethanol (5 mL) and the reaction was stirred for 1 hour. Water was addedand THF and MeOH were removed in vacuo. The product was extracted withEtOAc. The extracts were dried over sodium sulfate, filtered andconcentrated. A solution of this residue in DMF (3 mL) was treated withK₂CO₃ (0.23 g, 1.6 mmol) and benzyl bromide (0.0656 mL, 0.552 mmol,Aldrich). After stirring overnight, the reaction was partitioned betweenwater and ethyl acetate and extracted a total of three times. Thecombined extracts were dried over sodium sulfate, filtered andconcentrated. The product was purified by flash chromatography, elutingwith a gradient from 0-30% EtOAc in hexanes to afford product as a whitecrystalline solid.

Yield: (177 mg, 99%).

¹H NMR (300 MHz, CDCl₃) δ 7.41 (d, J=8.6 Hz, 1H), 7.34-7.21 (m, 3H),7.08-6.97 (m, 3H), 6.80 (s, 1H). LCMS (M+H)⁺: 322.8 (most abundant).

Step 3.1-benzyl-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.088g, 0.27 mmol, from Step 2),1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.084 g, 0.30 mmol, Aldrich) and Na₂CO₃ (0.14 g, 1.4 mmol) in1,2-dimethoxyethane (3 mL) and water (0.5 mL) was degassed by a streamof nitrogen through the solution for 10 minutes.Tetrakis(triphenylphosphine)palladium(0) (0.032 g, 0.027 mmol, Strem)was added, the vial was capped and heated to reflux for 15 minutes.After cooling to room temperature, the mixture was partitioned between10% sodium thiosulfate solution and EtOAc. The aqueous layer wasextracted three times with ethyl acetate. The combined extracts weredried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with 25% EtOAc in hexanes afforded product.Yield: (75 mg, 68%).

¹H NMR (300 MHz, CDCl₃) δ 7.63 (d, J=1.7 Hz, 1H), 7.51 (d, J=8.6 Hz,1H), 7.29-7.20 (m, 3H), 7.14 (d, J=8.6 Hz, 1H), 6.95 (s, 1H), 6.91-6.80(m, 2H), 6.31 (d, J=1.8 Hz, 1H), 5.35 (d, J=16.8 Hz, 1H), 5.28 (d,J=16.8 Hz, 1H), 5.18 (dd, J=10.5, 2.2 Hz, 1H), 4.09-3.98 (m, 1H), 3.52(td, J=11.7, 2.2 Hz, 1H), 2.57-2.39 (m, 1H), 2.20-1.89 (m, 1H),1.81-1.57 (m, 2H), 1.56-1.41 (m, 2H). LCMS (M+H)⁺: 393.1/395.1.

Step 4. di-tert-butyl1-{1-benzyl-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate

1-Benzyl-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridine(0.075 g, 0.19 mmol, from Step 3), di-tert-butylhydrazine-1,2-dicarboxylate (0.049 g, 0.21 mmol, Aldrich) and Cs₂CO₃(0.062 g, 0.19 mmol, Aldrich) were combined in toluene (1.7 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.015 g, 0.019 mmol, Aldrich) was added. The mixture was degassedby a stream of nitrogen through the solution for 10 minutes. The vialwas sealed and heated to 110° C. for 3 hours. Additional reagents andcatalyst (same of each as the initial quantities) were added, themixture was degassed again and the reaction mixture was then heated inthe microwave to 140° C. for 10 minutes. After cooling to roomtemperature, the reaction mixture was partitioned between EtOAc andwater, the aqueous layer was extracted three times, and the combinedextracts were dried over sodium sulfate, filtered and concentrated. Theproduct was purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (45 mg, 40%).

¹H NMR (300 MHz, CDCl₃) δ 7.62 (d, J=1.5 Hz, 1H), 7.58 (d, J=8.7 Hz,1H), 7.55-7.46 (br, 1H), 7.27-7.12 (m, 4H), 6.91 (s, 1H), 6.90-6.84 (m,2H), 6.29 (d, J=1.8 Hz, 1H), 5.33 (d, J=16.8 Hz, 1H), 5.26 (d, J=16.9Hz, 1H), 5.22-5.14 (m, 1H), 4.09-3.97 (m, 1H), 3.59-3.47 (m, 1H), 2.46(qd, J=13.2, 12.7, 3.9 Hz, 1H), 2.07-1.23 (m, 5H), 1.51 (s, 9H), 1.48(s, 9H).

LCMS (M+H)⁺: 589.3.

Step 5.6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A mixture of di-tert-butyl1-{1-benzyl-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(0.045 g, 0.076 mmol, from Step 4) in AcOH (3 mL) was heated in themicrowave to 180° C. for 5 minutes. The AcOH was removed in vacuo andthe residue was re-dissolved in MeOH and purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN and H₂O containing 0.15%NH₄OH). Yield: (6 mg, 20%).

¹H NMR (300 MHz, CDCl₃) δ 7.65 (d, J=2.2 Hz, 1H), 7.36 (d, J=9.7 Hz,1H), 7.30-7.20 (m, 4H), 7.08 (s, 1H), 7.05 (d, J=6.4 Hz, 2H), 6.58 (d,J=2.3 Hz, 1H), 5.87 (s, 2H), 3.04 (s, 3H).

LCMS (M+H)⁺: 329.1.

Example 63:6-benzyl-1-methyl-7-(1H-pyrazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1.1-benzyl-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4yl]-H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.120g, 0.373 mmol, from Example 62, Step 2),1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.11 g, 0.41 mmol, Aldrich) and Na₂CO₃ (0.20 g, 1.9 mmol) in1,2-dimethoxyethane (4 mL) and water (0.7 mL) was degassed by a streamof nitrogen through the solution for 10 minutes.Tetrakis(triphenylphosphine)palladium(0) (0.043 g, 0.037 mmol) wasadded, and the reaction was heated to reflux for 1.5 hours. Upon coolingto room temperature, the mixture was partitioned between water andEtOAc, and the aqueous layer was extracted a total of three times. Thecombined extracts were dried over sodium sulfate, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-50%EtOAc in hexanes afforded product. Yield: (0.106 g, 72%).

¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J=0.7 Hz, 1H), 7.58 (d, J=0.7 Hz,1H), 7.40 (dd, J=8.5, 0.8 Hz, 1H), 7.34-7.26 (m, 3H), 7.03 (d, J=8.5 Hz,1H), 6.99-6.94 (m, 2H), 6.73 (d, J=0.8 Hz, 1H), 5.40 (s, 2H), 5.38 (dd,J=6.6, 5.5 Hz, 1H), 4.09-4.02 (m, 1H), 3.74-3.65 (m, 1H), 2.13-1.95 (m,3H), 1.77-1.58 (m, 3H). LCMS (M+H)⁺: 393.1.

Step 2. di-tert-butyl1-{1-benzyl-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate

1-Benzyl-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[3,2-b]pyridine(0.106 g, 0.270 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.069 g, 0.30 mmol) and Cs₂CO₃ (0.088 g,0.27 mmol) were combined in toluene (2.4 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.021 g, 0.027 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction washeated to 110° C. for 1.5 hours, at which time additional reagents andcatalyst were added (same of each as the initial quantities) and themixture was degassed again and was heated in the microwave to 140° C.for 10 minutes. The reaction mixture was partitioned between EtOAc andwater, extracted three times and the combined extracts were dried oversodium sulfate, filtered, and concentrated. The resulting product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH). Yield (71 mg, 44%).

¹H NMR (400 MHz, CDCl₃) δ 7.65 (s, 1H), 7.58 (d, J=0.6 Hz, 1H), 7.46 (d,J=8.6 Hz, 1H), 7.34-7.23 (m, 4H), 7.03-6.96 (m, 2H), 6.72 (s, 1H), 5.39(s, 2H), 5.39-5.34 (m, 1H), 4.11-4.00 (m, 1H), 3.77-3.61 (m, 1H),2.16-1.98 (m, 3H), 1.77-1.57 (m, 3H), 1.49 (s, 9H), 1.46 (s, 9H). LCMS(M+H)⁺: 589.1.

Step 3.6-benzyl-1-methyl-7-(1H-pyrazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

di-tert-Butyl1-{1-benzyl-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(68 mg, 0.12 mmol, from Step 2) in AcOH (4 mL) was heated in themicrowave to 180° C. for 9 minutes. The acetic acid was removed invacuo, and the residue was reconstituted in MeOH and purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (17 mg, 45%).

¹H NMR (400 MHz, CD₃OD) δ 7.85 (br s, 1H), 7.73 (br s, 1H), 7.63 (d,J=9.7 Hz, 1H), 7.36-7.21 (m, 4H), 7.17 (s, 1H), 6.99 (d, J=6.9 Hz, 2H),5.63 (s, 2H), 3.03 (s, 3H). LCMS (M+H)⁺: 329.0.

Example 64:[4-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]acetonitrile

A solution of6-benzyl-1-methyl-7-(1H-pyrazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(14 mg, 0.043 mmol, from Example 63) in DMF (0.56 mL, 7.2 mmol) wastreated with NaH (5.1 mg, 0.21 mmol). After 10 minutes, the mixture wastreated with chloroacetonitrile (8.1 μL, 0.13 mmol, Fluka). After 10minutes, the reaction was quenched by the addition of water. The productwas purified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN and H₂O containing 0.15% NH₄OH). Yield: (7.0 mg, 45%).

¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J=0.6 Hz, 1H), 7.55 (s, 1H), 7.38 (d,J=9.7 Hz, 1H), 7.36-7.30 (m, 3H), 7.23 (dd, J=9.8, 0.6 Hz, 1H),7.00-6.93 (m, 2H), 6.88 (d, J=0.6 Hz, 1H), 5.44 (s, 2H), 5.10 (s, 2H),3.03 (s, 3H). LCMS (M+H)⁺: 368.0.

Example 65:[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]acetonitrile

By the method of Example 62, Step 5, followed by the method of Example64,[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]acetonitrilewas prepared from di-tert-butyl1-{1-benzyl-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(20 mg, 0.034 mmol, from Example 62, Step 4). The major isomer wasisolated. Yield: (2.5 mg, 20% over the two steps).

¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, J=2.4 Hz, 1H), 7.39 (d, J=9.7 Hz,1H), 7.31-7.22 (m, 4H), 7.06 (s, 1H), 7.04 (d, J=7.3 Hz, 2H), 6.61 (d,J=2.4 Hz, 1H), 5.88 (s, 2H), 5.10 (s, 2H), 3.03 (s, 3H). LCMS (M+H)⁺:368.0.

Example 66:6-benzyl-1-methyl-7-(1,3-thiazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-(1,3-thiazol-4-yl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and4-(tributylstannyl)-1,3-thiazole (0.12 g, 0.31 mmol, Synthonix) intoluene (6.0 mL) was degassed by a stream of nitrogen through thesolution. Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol)was added and the mixture was heated to 110° C. for 2 hours, then at100° C. overnight. Solvent was removed in vacuo and the residue wasdissolved in MeCN and filtered, then purified via preparative HPLC-MS(C18 eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH).Yield: (35 mg, 34%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.30 (d, J=1.9 Hz, 1H), 8.29 (d, J=1.9 Hz,1H), 7.99 (dd, J=8.6, 0.8 Hz, 1H), 7.27-7.13 (m, 4H), 7.10 (d, J=0.7 Hz,1H), 6.98-6.91 (m, 2H), 5.97 (s, 2H). LCMS (M+H)⁺: 326.1/328.1.

Step 2.6-benzyl-1-methyl-7-(1,3-thiazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1,3-thiazol-4-yl)-1H-pyrrolo[3,2-b]pyridine (32 mg,0.098 mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (27mg, 0.12 mmol) and Cs₂CO₃ (32 mg, 0.098 mmol) were combined in toluene(3.0 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (7.7 mg, 0.0098 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction washeated to 108° C. overnight. Additional di-tert-butylhydrazine-1,2-dicarboxylate (23 mg, 0.098 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (7.7 mg, 0.0098 mmol) were added. The reaction was heated to 110°C. over a second night. The mixture was partitioned between EtOAc andwater, extracted three times, and the combined extracts were dried oversodium sulfate, filtered and concentrated. The intermediatedi-tert-butyl1-[1-benzyl-2-(1,3-thiazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylatewas purified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN and H₂O containing 0.15% NH₄OH) and the eluent was evaporated. Theproduct was dissolved in AcOH (0.60 mL) and was heated in the microwaveto a temperature of 156° C. for 5 minutes. The AcOH was removed in vacuoand the sample was reconstituted and purified via preparative HPLC-MS(C18 eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH).Yield: (1.0 mg, 2.9%).

¹H NMR (400 MHz, CD₃OD) δ 9.11 (d, J=2.0 Hz, 1H), 7.93 (d, J=2.0 Hz,1H), 7.70 (d, J=9.6 Hz, 1H), 7.42 (d, J=0.5 Hz, 1H), 7.32 (d, J=9.8 Hz,1H), 7.26-7.15 (m, 3H), 7.03-6.97 (m, 2H), 6.00 (s, 2H), 3.04 (s, 3H).LCMS (M+H)⁺: 346.1.

Example 67:6-benzyl-1-methyl-7-(1,3-thiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-(1,3-thiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and2-(tributylstannyl)-1,3-thiazole (0.12 g, 0.31 mmol, Aldrich) in toluene(6.0 mL) was degassed by a stream of nitrogen through the solution.Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol) was addedand the mixture was heated to 110° C. for 4 hours. Toluene was removedin vacuo and the residue was dissolved in MeCN, filtered, and purifiedvia preparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (33 mg, 32%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.05 (dd, J=8.7, 0.8 Hz, 1H), 8.02 (d, J=3.3Hz, 1H), 7.93 (d, J=3.3 Hz, 1H), 7.30 (d, J=0.7 Hz, 1H), 7.28 (d, J=8.7Hz, 1H), 7.26-7.15 (m, 3H), 7.03-6.96 (m, 2H), 6.10 (s, 2H). LCMS(M+H)⁺: 326.1/328.1.

Step 2.6-benzyl-1-methyl-7-(1,3-thiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1,3-thiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine (30 mg,0.092 mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (26mg, 0.11 mmol) and Cs₂CO₃ (30 mg, 0.092 mmol) were combined in toluene(2.8 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (7.2 mg, 0.0092 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction washeated to 110° C. overnight. The intermediate di-tert-butyl1-[1-benzyl-2-(1,3-thiazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylatewas purified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN and H₂O containing 0.15% NH₄OH) and was isolated in the amount of20 mg after evaporation of eluent. The resulting residue was dissolvedin acetic acid (1.9 mL) and heated in the microwave to a temperature of165° C. for 5 minutes. AcOH was removed in vacuo and the residue wasreconstituted and purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (4.6 mg, 14%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.95 (d, J=3.3 Hz, 1H), 7.85 (d, J=3.3 Hz,1H), 7.70 (dd, J=9.8, 0.6 Hz, 1H), 7.56 (d, J=0.5 Hz, 1H), 7.46 (d,J=9.8 Hz, 1H), 7.30-7.16 (m, 3H), 7.08-6.98 (m, 2H), 6.18 (s, 2H), 2.97(s, 3H). LCMS (M+H)⁺: 346.1.

Example 68:6-benzyl-1-methyl-7-pyridin-2-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-pyridin-2-yl-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and 2-(tributylstannyl)pyridine(0.11 g, 0.31 mmol, Aldrich) in toluene (6.0 mL) was degassed by astream of nitrogen through the solution for 10 minutes.Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol) was addedand the mixture was stirred at 110° C. for 6 hours. Solvent was removedin vacuo and the residue was dissolved in MeCN, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-20%EtOAc in hexanes afforded desired product (40 mg, 40%).

¹H NMR (400 MHz, CDCl₃) δ 8.66-8.63 (m, 1H), 7.79-7.73 (m, 2H), 7.52(dd, J=8.6, 0.8 Hz, 1H), 7.28-7.15 (m, 4H), 7.08 (d, J=8.6 Hz, 1H), 7.02(d, J=0.8 Hz, 1H), 6.99-6.93 (m, 2H), 5.97 (s, 2H). LCMS (M+H)⁺: 319.9.

Step 2.6-benzyl-1-methyl-7-pyridin-2-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-pyridin-2-yl-1H-pyrrolo[3,2-b]pyridine (38 mg, 0.12mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (41 mg,0.18 mmol) and Cs₂CO₃ (58 mg, 0.18 mmol) were combined in toluene (4.1mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (9.3 mg, 0.012 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction washeated to 110° C. overnight. The mixture was diluted with DCM, filteredand concentrated. Flash chromatography, eluting with a gradient from0-40% EtOAc in hexanes afforded 20 mg of intermediate di-tert-butyl1-(1-benzyl-2-pyridin-2-yl-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate,which was then dissolved in AcOH (2.4 mL) and heated in the microwave toa temperature of 180 OC for 6 minutes. The resulting product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH). Yield: (4.0 mg, 10%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.62 (ddd, J=4.8, 1.8, 0.9 Hz, 1H), 8.03(dt, J=8.1, 1.0 Hz, 1H), 7.90 (td, J=7.8, 1.8 Hz, 1H), 7.70 (dd, J=9.8,0.6 Hz, 1H), 7.60 (d, J=0.6 Hz, 1H), 7.39 (d, J=9.8 Hz, 1H), 7.34 (ddd,J=7.5, 4.8, 1.1 Hz, 1H), 7.24-7.10 (m, 3H), 7.00-6.94 (m, 2H), 6.23 (s,2H), 2.96 (s, 3H). LCMS (M+H)⁺: 340.0.

Example 69:6-benzyl-1-methyl-7-(1,3-thiazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-(1,3-thiazol-5-yl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.15g, 0.47 mmol, from Example 62, Step 2) and5-(tributylstannyl)-1,3-thiazole (0.17 g, 0.47 mmol, Synthonix) intoluene (9.0 mL) was degassed using a stream of nitrogen through thesolution. Tetrakis(triphenylphosphine)palladium(0) (54 mg, 0.047 mmol)was added and the mixture was heated to 110° C. for 5 hours. Solvent wasremoved in vacuo and the residue was dissolved in MeCN, filtered, andpurified by flash chromatography, eluting with a gradient from 0-40%EtOAc in hexanes. Yield: (67 mg, 44%). LCMS (M+H)⁺: 325.9.

Step 2.6-benzyl-1-methyl-7-(1,3-thiazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1,3-thiazol-5-yl)-1H-pyrrolo[3,2-b]pyridine (67 mg,0.20 mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (72mg, 0.31 mmol) and Cs₂CO₃ (100 mg, 0.31 mmol) were combined in toluene(7.2 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (16 mg, 0.020 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction wasstirred at 110° C. overnight, then was cooled, diluted with DCM,filtered and concentrated. Flash chromatography, eluting with a gradientfrom 0-50% EtOAc in hexanes afforded intermediate di-tert-butyl1-[1-benzyl-2-(1,3-thiazol-5-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate.This intermediate was heated in the microwave as a solution in AcOH (3.0mL) to 180° C. for 6 minutes. AcOH was removed in vacuo, the residue wasreconstituted, and the product was concentrated and purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (12.5 mg, 18%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.17 (d, J=0.6 Hz, 1H), 8.10 (d, J=0.6 Hz,1H), 7.73 (dd, J=9.8, 0.5 Hz, 1H), 7.41 (d, J=9.8 Hz, 1H), 7.37 (s, 1H),7.31-7.17 (m, 3H), 6.90 (d, J=7.0 Hz, 2H), 5.71 (s, 2H), 2.93 (s, 3H).LCMS (M+H)⁺: 346.1.

Example 70:6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1.1-benzyl-5-chloro-2-(1-methyl-1H-imidazol-4-yl)-H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and1-methyl-4-(tributylstannyl)-1H-imidazole (0.12 g, 0.31 mmol, Aldrich)in toluene (6.0 mL) was degassed.Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol) was addedand the mixture was heated to 110° C. for 7 hours. Toluene was removedin vacuo and the mixture was dissolved in MeCN and filtered. Flashchromatography, eluting with a gradient from 0-70% EtOAc in hexanesafforded purified product (24 mg, 24%).

¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J=1.0 Hz, 1H), 7.39 (dd, J=8.5, 0.8Hz, 1H), 7.26-7.16 (m, 4H), 7.03-6.97 (m, 2H), 6.98 (d, J=8.5 Hz, 1H),6.79 (d, J=0.7 Hz, 1H), 5.88 (s, 2H), 3.73 (s, 3H). LCMS (M+H)⁺: 323.1.

Step 2.6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1-methyl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridine(22 mg, 0.068 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (24 mg, 0.10 mmol) and Cs₂CO₃ (33 mg, 0.10mmol) were combined in toluene (2.4 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (5.4 mg, 0.0068 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction wasstirred at 120° C. overnight. The mixture was diluted with DCM, filteredand concentrated. Purification via preparative HPLC-MS (C18 eluting witha gradient of MeCN and H₂O containing 0.15% NH₄OH) afforded 5.6 mg ofintermediate di-tert-butyl1-[1-benzyl-2-(1-methyl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylatewhich was dissolved in acetic acid (1.1 mL) and heated in the microwaveto 180° C. for 6 minutes. AcOH was removed in vacuo and the sample wasreconstituted and purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (3.0 mg 13%).

¹H NMR (400 MHz, CD₃OD) δ 7.75 (s, 1H), 7.62 (d, J=9.7 Hz, 1H), 7.33 (s,1H), 7.28-7.16 (m, 5H), 7.01-6.95 (m, 2H), 5.82 (s, 2H), 3.75 (s, 3H),3.02 (s, 3H). LCMS (M+H)⁺: 343.0.

Example 71:6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1.1-benzyl-5-chloro-2-(1-methyl-1H-imidazol-5-yl)-H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and1-methyl-5-(tributylstannyl)-1H-imidazole (0.12 g, 0.31 mmol, Aldrich)in toluene (6.0 mL) was degassed by a stream of nitrogen through thesolution. Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol)was added and the mixture was stirred at 110° C. for 7 hours. Toluenewas removed in vacuo, and the residue was dissolved in MeCN andfiltered. Flash chromatography, eluting with a gradient from 0-70% EtOAcin hexanes afforded product as a white solid (35 mg, 35%).

¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.53 (dd, J=8.6, 0.8 Hz, 1H),7.28-7.21 (m, 3H), 7.14 (d, J=8.6 Hz, 1H), 7.10 (d, J=1.0 Hz, 1H),6.90-6.81 (m, 2H), 6.78 (d, J=0.8 Hz, 1H), 5.33 (s, 2H), 3.48-3.35 (m,3H). LCMS (M+H)⁺: 322.9.

Step 2.6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1-methyl-1H-imidazol-5-yl)-1H-pyrrolo[3,2-b]pyridine(33 mg, 0.10 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (36 mg, 0.15 mmol) and Cs₂CO₃ (50 mg, 0.15mmol) were combined in toluene (3.6 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (8.0 mg, 0.010 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction wasstirred at 120° C. overnight. The mixture was diluted with DCM, filteredand concentrated. Purification via preparative HPLC-MS (C18 eluting witha gradient of MeCN and H₂O containing 0.15% NH₄OH) afforded intermediatedi-tert-butyl1-[1-benzyl-2-(1-methyl-1H-imidazol-5-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylateas 10 mg of light yellow oil. The oil was dissolved in AcOH (1.6 mL) andheated in the microwave to a temperature of 180 OC for 7 minutes. TheAcOH was removed in vacuo and the product was purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN and H₂O containing 0.15%NH₄OH). Yield: (4.5 mg, 13%).

¹H NMR (400 MHz, CD₃OD) δ 7.80-7.76 (m, 2H), 7.40 (d, J=9.8 Hz, 1H),7.25 (ddd, J=8.3, 5.2, 1.1 Hz, 4H), 7.08 (s, 1H), 6.88 (dd, J=7.6, 1.9Hz, 1H), 5.47 (s, 2H), 3.42 (s, 3H), 3.01 (s, 3H). LCMS (M+H)⁺: 343.0.

Example 72:6-benzyl-1-methyl-7-(3-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-(3-thienyl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and 3-thienylboronic acid (0.044g, 0.34 mmol, Aldrich) and Na₂CO₃ (0.16 g, 1.6 mmol) in1,2-dimethoxyethane (3 mL) and water (0.6 mL) was degassed by a streamof nitrogen through the solution for 10 minutes.Tetrakis(triphenylphosphine)palladium(0) (0.036 g, 0.031 mmol) was addedand the reaction was stirred at reflux for 15 minutes. Upon cooling toroom temperature, the reaction was diluted with water. The product wasextracted with EtOAc, and the combined extracts were washed with brine,dried over sodium sulfate, filtered, and concentrated. Flashchromatography, eluting with a gradient from 0-20% EtOAc in hexanesafforded product as a light yellow solid (47 mg, 47%). ¹H NMR (400 MHz,CDCl₃) δ 7.43-7.37 (m, 2H), 7.36-7.27 (m, 4H), 7.20 (dd, J=5.0, 1.3 Hz,1H), 7.05 (d, J=8.5 Hz, 1H), 7.02-6.96 (m, 2H), 6.80 (d, J=0.8 Hz, 1H),5.43 (s, 2H). LCMS (M+H)⁺: 324.9.

Step 2.6-benzyl-1-methyl-7-(3-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(3-thienyl)-1H-pyrrolo[3,2-b]pyridine (44 mg, 0.14mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (47 mg,0.20 mmol) and Cs₂CO₃ (66 mg, 0.20 mmol) were combined in toluene (4.7mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (11 mg, 0.014 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction wasstirred at 120° C. overnight. The mixture was then diluted with DCM,filtered, and concentrated. Purification via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH) affordedintermediate di-tert-butyl1-[1-benzyl-2-(3-thienyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(30.4 mg). This intermediate was dissolved in AcOH (2.2 mL) and heatedin the microwave at a temperature of 180 OC for 7 minutes. AcOH wasremoved in vacuo and the product was purified via preparative HPLC-MS(C18 eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH).Yield: (12.4 mg, 26%).

¹H NMR (300 MHz, CDCl₃) δ 7.48-7.14 (m, 8H), 7.01 (d, J=7.0 Hz, 2H),6.93 (s, 1H), 5.50 (s, 2H), 3.04 (s, 3H). LCMS (M+H)⁺: 345.2.

Example 73:6-benzyl-1-methyl-7-(2-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-2-(2-thienyl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.10g, 0.31 mmol, from Example 62, Step 2) and tributyl(2-thienyl)stannane(0.12 g, 0.31 mmol, Aldrich) in toluene (6.0 mL) was degassed.Tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol) was addedand the mixture was heated to 110° C. for 3 hours. Solvent was removedin vacuo. Flash chromatography, eluting with a gradient from 0-20% EtOAcin hexanes afforded product as a light yellow solid (88 mg, 87%).

¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38 (m, 2H), 7.34-7.26 (m, 3H),7.12-7.03 (m, 3H), 7.02-6.96 (m, 2H), 6.86 (d, J=0.8 Hz, 1H), 5.49 (s,2H). LCMS (M+H)⁺: 324.9.

Step 2.6-benzyl-1-methyl-7-(2-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(2-thienyl)-1H-pyrrolo[3,2-b]pyridine (84 mg, 0.26mmol, from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (90 mg,0.39 mmol) and Cs₂CO₃ (130 mg, 0.39 mmol) were combined in toluene (5.0mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (20 mg, 0.026 mmol) was added. The mixture was degassed by astream of nitrogen through the solution for 10 minutes. The reaction wasstirred at 120° C. overnight. The mixture was diluted with DCM, filteredand concentrated, then reconstituted and purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN and H₂O containing 0.15%NH₄OH) to afford 30.8 mg of di-tert-butyl1-[1-benzyl-2-(2-thienyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate.This intermediate was dissolved in AcOH (2.2 mL) and was heated in themicrowave to a temperature of 180 OC for 7 minutes. AcOH was removed invacuo and the product was purified via preparative HPLC-MS (C18 elutingwith a gradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (11.3mg, 13%).

¹H NMR (300 MHz, CDCl₃) δ 7.45-7.27 (m, 5H), 7.21 (d, J=9.8 Hz, 1H),7.12-7.04 (m, 2H), 7.03-6.99 (m, 2H), 6.98 (s, 1H), 5.55 (s, 2H), 3.04(s, 3H). LCMS (M+H)⁺: 345.2.

Example 74:6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1.1-benzyl-5-chloro-2-(1-trityl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridine

A mixture of 1-benzyl-2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (0.15g, 0.47 mmol, from Example 62, Step 2) and4-(tributylstannyl)-1-trityl-1H-imidazole (0.28 g, 0.47 mmol, Synthonix)in toluene (9.0 mL) was degassed.Tetrakis(triphenylphosphine)palladium(0) (54 mg, 0.047 mmol) was addedand the reaction was stirred at 110° C. for 17 h. Solvent was removed invacuo and the product was purified by flash chromatography, eluting witha gradient from 0-35% EtOAc in hexanes to afford product as a whitesolid (0.17 g, 66%).

¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J=1.4 Hz, 1H), 7.43 (dd, J=8.5, 0.8Hz, 1H), 7.38-7.28 (m, 9H), 7.22-7.17 (m, 3H), 7.14-7.06 (m, 6H), 7.04(d, J=1.4 Hz, 1H), 6.99 (d, J=8.5 Hz, 1H), 6.95-6.86 (m, 2H), 6.77 (d,J=0.7 Hz, 1H), 5.74 (s, 2H). LCMS (M+H)⁺: 551.2.

Step 2.6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1-Benzyl-5-chloro-2-(1-trityl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridine(160 mg, 0.29 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.10 g, 0.44 mmol) and Cs₂CO₃ (0.14 g, 0.44mmol) were combined in toluene (10 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (23 mg, 0.029 mmol) was added. The mixture was degassed with astream of nitrogen through the solution and was then heated in themicrowave to 140° C. for 30 minutes. Excess reagents were added, themixture was again degassed, then heated in the microwave to 140° C. for66 additional minutes. The reaction was cooled and diluted with DCM,filtered, and concentrated. Flash chromatography, eluting with agradient from 0-50% EtOAc in hexanes afforded di-tert-butyl1-[1-benzyl-2-(1-trityl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylateas a light yellow oil (67 mg). This intermediate was dissolved in AcOH(3.0 mL) and heated in the microwave to 180° C. for 15 minutes. Aceticacid was removed in vacuo. The product was purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN and H₂O containing 0.15%NH₄OH). Yield: (16 mg, 17%).

¹H NMR (300 MHz, CD₃OD) δ 7.84 (s, 1H), 7.66 (d, J=9.7 Hz, 1H),7.42-7.10 (m, 6H), 6.99 (d, J=7.5 Hz, 2H), 5.81 (s, 2H), 3.03 (s, 3H).LCMS (M+H)⁺: 329.0.

Example 75:6-benzyl-1-methyl-7-[1-(2-morpholin-4-ylethyl)-1H-imidazol-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A mixture of6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(4.2 mg, 0.013 mmol, from Example 74), 4-(2-chloroethyl)morpholinehydrochloride (7.1 mg, 0.038 mmol, Aldrich) and Cs₂CO₃ (21 mg, 0.064mmol) in DMF (0.21 mL) was stirred at 70° C. for one hour, followed byheating in the microwave to 140° C. for 30 minutes. The product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH). Yield: (1.6 mg, 28%).

¹H NMR (300 MHz, CD₃OD) δ 7.84 (s, 1H), 7.64 (d, J=9.8 Hz, 1H), 7.44 (s,1H), 7.32-7.17 (m, 5H), 7.05-6.93 (m, 2H), 5.82 (s, 2H), 4.16 (t, J=6.0Hz, 2H), 3.66-3.48 (m, 4H), 3.03 (s, 3H), 2.68 (t, J=6.0 Hz, 2H),2.50-2.35 (m, 4H). LCMS (M+H)⁺: 442.0.

Example 76:6-benzyl-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (4.0 mg, 0.099 mmol, 60% in mineral oil) was added to asolution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(6.5 mg, 0.020 mmol, from Example 62) in DMF (0.20 mL). After 10minutes, methyl iodide (3.7 μL, 0.059 mmol, Aldrich) was added. After 15minutes reaction time, the reaction was quenched with water. The productwas purified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN and H₂O containing 0.15% NH₄OH) and the major isomer was isolated.Yield: (2.7 mg, 40%).

¹H NMR (500 MHz, d₆-DMSO) δ 7.79 (d, J=2.3 Hz, 1H), 7.60 (d, J=9.8 Hz,1H), 7.58-7.48 (m, 1H), 7.30 (s, 1H), 7.28 (d, J=9.7 Hz, 1H), 7.26-7.22(m, 2H), 7.20-7.15 (m, 1H), 7.04 (d, J=7.3 Hz, 2H), 6.76 (d, J=2.3 Hz,1H), 6.04 (s, 2H), 3.88 (s, 3H), 2.93 (s, 3H). LCMS (M+H)⁺: 343.0.

Example 77:6-benzyl-1-methyl-7-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A mixture of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(4.2 mg, 0.013 mmol, from Example 62), 4-(2-chloroethyl)morpholinehydrochloride (7.1 mg, 0.038 mmol, Aldrich) and Cs₂CO₃ (21 mg, 0.064mmol) in DMF (0.21 mL) was heated at 70° C. overnight. The product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH) and the major isomer was isolated.Yield: (2.4 mg, 42%).

¹H NMR (300 MHz, CD₃OD) δ 7.72 (d, J=2.4 Hz, 1H), 7.63 (dd, J=9.7, 0.6Hz, 1H), 7.33-7.13 (m, 5H), 7.07-6.97 (m, 2H), 6.68 (d, J=2.3 Hz, 1H),6.03 (s, 2H), 4.30 (t, J=6.3 Hz, 2H), 3.70-3.45 (m, 4H), 3.02 (s, 3H),2.78 (t, J=6.3 Hz, 2H), 2.51-2.27 (m, 4H). LCMS (M+H)⁺: 442.0.

Example 78:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanenitrile

2-Propenenitrile (3.0 μL, 0.046 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (2.3 μL, 0.015 mmol) were added to asolution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5.0 mg, 0.015 mmol, from Example 62) in acetonitrile (0.20 mL). After 3minutes at room temperature, the reaction was found to be complete andwas purified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN and H₂O containing 0.15% NH₄OH). Yield: (3.9 mg, 67%).

¹H NMR (300 MHz, CD₃OD) δ 7.78 (d, J=2.4 Hz, 1H), 7.65 (d, J=9.8 Hz,1H), 7.33-7.15 (m, 5H), 7.10-7.01 (m, 2H), 6.74 (d, J=2.4 Hz, 1H), 6.03(s, 2H), 4.45 (t, J=6.3 Hz, 2H), 3.02 (s, 3H), 2.98 (t, J=6.3 Hz, 2H).LCMS (M+H)⁺: 382.0.

Example 79:6-benzyl-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (3.3 mg, 0.082 mmol, 60% in mineral oil) was added to asolution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5.4 mg, 0.016 mmol, from Example 62) in DMF (0.20 mL). After 10minutes, iodoethane (3.9 μL, 0.049 mmol, Aldrich) was introduced. After15 minutes reaction time, the reaction was quenched with water. Theproduct was purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (3.1 mg, 53%).

¹H NMR (400 MHz, CD₃OD) δ 7.68 (d, J=2.3 Hz, 1H), 7.63 (dd, J=9.7, 0.6Hz, 1H), 7.32-7.09 (m, 5H), 7.09-6.96 (m, 2H), 6.63 (d, J=2.3 Hz, 1H),5.98 (s, 2H), 4.21 (q, J=7.3 Hz, 2H), 3.01 (s, 3H), 1.45 (t, J=7.3 Hz,3H). LCMS (M+H)⁺: 357.2.

Example 80:6-benzyl-7-(1-ethyl-1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Sodium hydride (3.1 mg, 0.078 mmol, 60% in mineral oil) was added to asolution of6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5.1 mg, 0.016 mmol, from Example 74) in DMF (0.20 mL). After 10minutes, iodoethane (3.7 μL, 0.046 mmol, Aldrich) was introduced and thereaction was allowed to proceed for 15 minutes, at which time it wasquenched with water. Purification via preparative HPLC-MS (C18 elutingwith a gradient of MeCN and H₂O containing 0.15% NH₄OH) afforded product(3.4 mg, 61%).

¹H NMR (300 MHz, CD₃OD) δ 7.81 (s, 1H), 7.64 (d, J=9.7 Hz, 1H), 7.40 (s,1H), 7.30-7.13 (m, 5H), 7.02-6.93 (m, 2H), 5.82 (s, 2H), 4.08 (q, J=7.3Hz, 2H), 3.01 (s, 3H), 1.44 (t, J=7.3 Hz, 3H). LCMS (M+H)⁺: 357.2.

Example 81:3-[4-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-imidazol-1-yl]propanenitrile

A mixture of6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(4.3 mg, 0.013 mmol, from Example 74) and 2-propenenitrile (2.6 μL,0.039 mmol, Aldrich) in MeCN (0.17 mL) was treated with1,8-diazabicyclo[5.4.0]undec-7-ene (2.0 μL, 0.013 mmol, Aldrich). Thereaction was allowed to proceed for 15 minutes, then was purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (3.3 mg, 66%).

¹H NMR (400 MHz, CD₃OD) δ 7.91 (d, J=1.0 Hz, 1H), 7.65 (dd, J=9.7, 0.6Hz, 1H), 7.50 (d, J=1.1 Hz, 1H), 7.30-7.15 (m, 5H), 7.04-6.97 (m, 2H),4.37 (t, J=6.4 Hz, 2H), 3.01 (s, 3H), 3.01 (t, J=6.4 Hz, 2H). LCMS(M+H)⁺: 382.0.

Example 82:6-benzyl-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. ethyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

1.6 M n-Butyllithium in hexanes (9.6 mL, 15 mmol) was added dropwise toa solution of N,N-diisopropylamine (2.3 mL, 16 mmol) in THF (43 mL) at−78° C. Following complete addition, the temperature of the reaction wasraised to 0° C. for 30 minutes and then was re-cooled to −78° C.5-Chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (3.00 g, 10.2mmol, from Example 2, Step 1) in THF (8 mL) was added dropwise and thereaction was stirred for 1 hour, at which time ethyl chloroformate (1.4mL, 14 mmol, Alfa Aesar) was added. The reaction was allowed to stir at−78° C. for 2 hours and was then allowed to warm to room temperature.The mixture was poured into dilute HCl and extracted with three portionsof ethyl acetate. The combined extracts were dried over sodium sulfate,decanted, and the solvent was removed in vacuo. Flash chromatographyeluting with a gradient from 0-50% EtOAc in hexanes afforded product asan off white solid (1.8 g, 48%).

¹H NMR (400 MHz, CDCl₃) δ 8.41 (dd, J=8.9, 0.8 Hz, 1H), 8.07-8.01 (m,2H), 7.67-7.62 (m, 1H), 7.58-7.51 (m, 2H), 7.37 (d, J=8.9 Hz, 1H), 7.21(d, J=0.7 Hz, 1H), 4.42 (q, J=7.1 Hz, 2H), 1.40 (t, J=7.1 Hz, 3H). LCMS(M+H)⁺: 364.8.

Step 2. di-tert-butyl1-[2-(ethoxycarbonyl)-1-(phenylsulfonyl)-H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

Ethyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(1.80 g, 4.93 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (1.3 g, 5.4 mmol, Aldrich) and Cs₂CO₃ (1.6g, 4.9 mmol, Aldrich) were combined in toluene (20 mL, 200 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.39 g, 0.49 mmol, Aldrich) was added. The mixture was degassedby a stream of nitrogen through the solution for 10 minutes. Thereaction was stirred at 110° C. for 3.5 hours. The reaction was cooledto room temperature, water was added and the product was extracted withfive portions of EtOAc. The combined extracts were dried over sodiumsulfate, filtered and concentrated. Flash chromatography, eluting with agradient from 0-50% EtOAc in hexanes afforded product as a yellow foam(2.11 g, 76%).

¹H NMR (400 MHz, CDCl₃) δ 8.42 (dd, J=9.2, 0.8 Hz, 1H), 8.06-7.97 (m,2H), 7.80 (br d, J=8.9 Hz, 1H), 7.66-7.56 (m, 1H), 7.54-7.48 (m, 2H),7.33 (br s, 1H), 7.23 (d, J=0.6 Hz, 1H), 4.40 (q, J=7.1 Hz, 2H), 1.50(s, 9H), 1.46 (d, J=3.3 Hz, 9H), 1.38 (t, J=7.1 Hz, 3H). LCMS (M+H)⁺:560.9.

Step 3.1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

A solution of di-tert-butyl1-[2-(ethoxycarbonyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(2.11 g, 3.76 mmol, from Step 2) in AcOH (32 mL) was split into fourportions and each was heated in the microwave to a temperature of 180 OCfor 3 minutes. The reaction contents were pooled and the AcOH wasremoved in vacuo. The residue was azeotroped with toluene twice. Theresidue was reconstituted in EtOH (10 mL) and was treated with 1.0 MNaOH (10 mL, 10 mmol) overnight. Purification via preparative HPLC-MS(C18 eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH)afforded product (0.42 g, 50%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.44 (dd, J=9.6, 0.5 Hz, 1H), 7.22 (d, J=9.5Hz, 1H), 6.88 (d, J=0.5 Hz, 1H), 2.86 (s, 3H). LCMS (M+H)⁺: 216.9.

Step 4.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid trifluoroacetate salt

The mixture from Step 3 containing1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.298 g, 1.38 mmol) was mixed in DMF (6 mL) and acetonitrile (6mL) and was treated with Cs₂CO₃ (1.8 g, 5.5 mmol) and was stirred for 10minutes before the addition of benzyl bromide (0.30 mL, 2.5 mmol,Aldrich). The reaction was stirred overnight. Water was added and theproduct was extracted with three portions of EtOAc. The combinedextracts were dried over sodium sulfate, filtered and concentrated.Flash chromatography, eluting with a gradient from 0-10% MeOH in DCM,was used to purify the desired alkylated ester (265 mg). This wasstirred with 1.0 M NaOH (10 mL, 10 mmol) and methanol (10 mL) overnight.Some TFA was used to aid in dissolving insolubles and the product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.1% TFA). Yield: (44 mg, 7%). LCMS (M+H)⁺: 307.0.

Step 5.6-benzyl-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid trifluoroacetate (0.044 g, 0.10 mmol, from Step 4) in DMF (1 mL)was added N,N-diisopropylethylamine (0.17 mL, 0.98 mmol) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.14 g, 0.37 mmol). After stirring this combinationfor 2 minutes, 2.0 M methylamine in THF (0.42 mL, 0.84 mmol) was added.After a reaction time of 15 minutes, the reaction was diluted with MeOH,and the product was purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH) (0.03 g, 90%).

¹H NMR (400 MHz, CD₃OD) δ 7.71 (d, J=9.9 Hz, 1H), 7.56 (s, 1H), 7.40 (d,J=9.9 Hz, 1H), 7.31-7.16 (m, 3H), 7.09 (m, 2H), 6.01 (s, 2H), 2.99 (s,3H), 2.91 (s, 3H). LCMS (M+H)⁺: 319.9.

Example 83:6-benzyl-1-methyl-N-propyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. ethyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

1.6 M n-Butyllithium in hexanes (9.6 mL, 15 mmol) was added to asolution of N,N-diisopropylamine (2.3 mL, 16 mmol) in THF (43 mL) at−78° C. Upon complete addition, the reaction was warmed to 0° C. for 30minutes and then was re-cooled to −78° C. A solution of5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (3.00 g, 10.2mmol, from Example 2, Step 1) in THF (8 mL) was added dropwise. Afterstirring for one hour at −78° C., ethyl chloroformate (1.4 mL, 14 mmol,Alfa Aesar) was added and the reaction was stirred at −78° C. for 2hours, after which time it was allowed to warm to room temperature. Thereaction was poured into dilute HCl and the product was extracted withthree portions of ethyl acetate. The combined extracts were dried oversodium sulfate, decanted, and the solvent removed in vacuo. Flashchromatography, eluting with a gradient from 0-30% EtOAc in hexanesafforded product as a yellow solid (2.15 g, 57%).

¹H NMR (300 MHz, CDCl₃) δ 8.41 (dd, J=8.9, 0.8 Hz, 1H), 8.08-8.00 (m,2H), 7.70-7.61 (m, 1H), 7.59-7.49 (m, 2H), 7.37 (d, J=8.8 Hz, 1H), 7.21(d, J=0.8 Hz, 1H), 4.42 (q, J=7.1 Hz, 2H), 1.40 (t, J=7.1 Hz, 2H). LCMS(M+H)⁺: 365.0.

Step 2. di-tert-butyl1-[2-(ethoxycarbonyl)-1-(phenylsulfonyl)-H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

Ethyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(2.15 g, 5.89 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (1.5 g, 6.5 mmol, Aldrich) and Cs₂CO₃ (1.9g, 5.9 mmol, Aldrich) were combined in toluene (30 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.46 g, 0.59 mmol, Aldrich) was added. The mixture was degassedby a stream of nitrogen through the solution for 10 minutes. Thereaction was stirred at 110° C. for 3 hours. Upon cooling to roomtemperature, water was added and the product was extracted with threeportions of EtOAc. The combined extracts were dried over sodium sulfate,filtered, and concentrated. Flash chromatography, eluting with agradient from 0-40% EtOAc in hexanes afforded product as a yellow foam(2.54 g, 77%).

¹H NMR (300 MHz, CDCl₃) δ 8.43 (d, J=9.1 Hz, 1H), 8.03 (d, J=8.0 Hz,2H), 7.80 (d, J=9.2 Hz, 1H), 7.62 (t, J=7.2 Hz, 1H), 7.52 (t, J=7.7 Hz,2H), 7.22 (s, 1H), 7.11 (br s, 1H), 4.41 (q, J=7.0 Hz, 2H), 1.52 (s,9H), 1.47 (s, 9H), 1.39 (t, J=7.1 Hz, 3H). LCMS (M+H)⁺: 561.2.

Step 3. ethyl1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate

A solution of di-tert-butyl1-[2-(ethoxycarbonyl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(2.5 g, 4.4 mmol, from Step 2) in AcOH (40 mL) was split into 5 batchesand each was heated in the microwave to a temperature of 180° C. for 3minutes. The reaction contents were pooled and AcOH was removed invacuo. The residue was dissolved in EtOAc and washed with sat'd NaHCO₃solution, followed by brine. The organic layer was dried over sodiumsulfate, filtered and concentrated. Flash chromatography, eluting with agradient from 0-100% EtOAc in hexanes, followed by 10% MeOH in DCM asmobile phase afforded solid product (1.27 g, 74%).

¹H NMR (400 MHz, CDCl₃) δ 8.17 (dd, J=10.1, 0.7 Hz, 1H), 8.15-8.09 (m,2H), 7.71 (d, J=10.1 Hz, 1H), 7.71-7.66 (m, 1H), 7.61-7.55 (m, 2H), 7.41(d, J=0.7 Hz, 1H), 4.42 (q, J=7.1 Hz, 2H), 2.97 (s, 3H), 1.41 (t, J=7.1Hz, 3H). LCMS (M+H)⁺: 384.9.

Step 4. methyl6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate

To a suspension of ethyl1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(1.27 g, 3.30 mmol, Step 3) in THF (10 mL) was added 1.0 M NaOH (10 mL,10 mmol). The reaction was stirred for 3 hours. Additional 1.0 M NaOH(50 mL, 20 mmol), NaOH solid (5.0 g, 120 mmol) and THF (30 mL) wereadded and stirring was continued overnight. Some solids were removed byfiltration and were rinsed with water. The filtrate was acidified to pH˜4 by the addition of conc. HCl. The solid that was then suspended inthe aqueous layer was filtered off to obtain product containing1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid as a yellow solid. LCMS (M+H)⁺: 217.1.

Potassium carbonate (0.73 g, 5.3 mmol) and benzyl bromide (0.260 mL,2.19 mmol, Aldrich) were added to the carboxylic acid intermediate inDMF (10 mL). The reaction was stirred for 1 hour. Sodium hydride (0.053g, 1.3 mmol, 60% in mineral oil) was added and the reaction wascontinued for 30 minutes before pouring into water and filtering toprepare for HPLC purification. Samples prepared with the addition ofsome MeOH stood overnight and the methyl ester was then observed insignificant amount. Purification via preparative HPLC-MS (C18 elutingwith a gradient of MeCN and H₂O containing 0.15% NH₄OH) afforded methylester as product (80 mg, 7%).

¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J=9.9 Hz, 1H), 7.50 (d, J=0.7 Hz,1H), 7.35-7.23 (m, 4H), 7.06-7.01 (m, 2H), 5.93 (s, 2H), 3.91 (s, 3H),3.00 (s, 3H). LCMS (M+H)⁺: 320.9.

Step 5.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid trifluoroacetate salt

Methyl6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.080 g, 0.25 mmol, from Step 4) was stirred with 1.0 M NaOH (4.0 mL,4.0 mmol) in methanol (4.0 mL) overnight. Purification via preparativeHPLC-MS (C18 eluting with a gradient of MeCN and H₂O containing 0.1%TFA) afforded product as TFA salt (71 mg, 70%). LCMS (M+H)⁺: 307.1.

Step 6.6-benzyl-1-methyl-N-propyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid trifluoroacetate salt (0.013 g, 0.031 mmol, from Step 5) in DMF(0.5 mL) was added N,N-diisopropylethylamine (0.023 mL, 0.13 mmol)followed by N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.022 g, 0.059 mmol). After stirring for 2 minutes,1-propanamine (0.011 mL, 0.13 mmol, Aldrich) was added. The reaction wasstirred for 15 minutes, then was diluted with MeOH and purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (3.5 mg, 32%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.61 (t, J=5.5 Hz, 1H), 7.72 (d, J=9.8 Hz,1H), 7.69 (s, 1H), 7.45 (d, J=9.8 Hz, 1H), 7.30-7.23 (m, 2H), 7.23-7.16(m, 1H), 7.13-7.02 (m, 2H), 6.02 (s, 2H), 3.21 (q, J=6.7 Hz, 2H), 2.91(s, 3H), 1.52 (h, J=7.4 Hz, 2H), 0.87 (t, J=7.4 Hz, 3H).

LCMS (M+H)⁺: 348.2.

Example 84:6-benzyl-N-isopropyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Prepared as in Example 83, using 2-propanamine (0.011, 0.13 mmol,Aldrich) in Step 6. Yield: (3.5 mg, 32%).

¹H NMR (400 MHz, CD₃OD) δ 7.75 (dd, J=9.9, 0.7 Hz, 1H), 7.60 (d, J=0.7Hz, 1H), 7.41 (d, J=9.9 Hz, 1H), 7.32-7.16 (m, 3H), 7.14-7.06 (m, 2H),5.98 (s, 2H), 4.16 (p, J=6.6 Hz, 1H), 3.01 (s, 3H), 1.24 (d, J=6.6 Hz,6H). LCMS (M+H)⁺: 348.1.

Example 85:6-benzyl-N-cyclobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Prepared as in Example 83, using cyclobutanamine (0.011, 0.13 mmol,Aldrich) in Step 6. Yield: (3.5 mg, 31%).

¹H NMR (400 MHz, CD₃OD) δ 7.73 (dd, J=9.9, 0.5 Hz, 1H), 7.65 (d, J=0.5Hz, 1H), 7.41 (d, J=9.9 Hz, 1H), 7.30-7.18 (m, 3H), 7.12-7.04 (m, 2H),5.98 (s, 2H), 4.46 (p, J=8.4 Hz, 1H), 3.02 (s, 3H), 2.49-2.25 (m, 2H),2.23-1.99 (m, 2H), 1.90-1.70 (m, 2H). LCMS (M+H)⁺: 360.1.

Example 86:6-benzyl-1-methyl-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Prepared as in Example 83, using (2R)-1,1,1-trifluoropropan-2-aminehydrochloride (0.020 g, 0.13 mmol, SynQuest Labs) and additionalN,N-diisopropylethylamine (0.046 mL, 0.26 mmol) in Step 6. Yield: (3 mg,20%).

¹H NMR (400 MHz, CD₃OD) δ 7.77 (dd, J=9.9, 0.7 Hz, 1H), 7.73 (d, J=0.6Hz, 1H), 7.45 (d, J=9.9 Hz, 1H), 7.30-7.17 (m, 3H), 7.14-7.07 (m, 2H),6.01 (s, 2H), 4.88-4.78 (m, 1H), 3.02 (s, 3H), 1.42 (d, J=7.1 Hz, 3H).LCMS (M+H)⁺: 402.0.

Example 87:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]butanenitriletrifluoroacetate salt (racemate)

To a solution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt (0.013 g, 0.030 mmol, prepared as in Example 62but purified via preparative HPLC-MS (C18 eluting with a gradientcontaining MeCN and H₂O containing 0.1% TFA to provide the TFA salt) inacetonitrile (0.5 mL) was added 2-butenenitrile (0.016 mL, 0.2 mmol,Aldrich) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.024 mL, 0.160 mmol,Aldrich) and the reaction was stirred overnight. The product waspurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH) followed by subjecting to a secondpreparative HPLC-MS purification (C18 eluting with a gradient of MeCNand H₂O containing 0.1% TFA). Yield: (6 mg, 40%).

¹H NMR (300 MHz, CD₃OD) δ 8.30 (d, J=9.3 Hz, 1H), 7.87 (d, J=2.4 Hz,1H), 7.60 (s, 1H), 7.50 (d, J=9.5 Hz, 1H), 7.31-7.17 (m, 3H), 7.15-7.04(m, 2H), 6.91 (d, J=2.4 Hz, 1H), 6.20 (s, 2H), 4.85-4.70 (m, 1H), 3.15(s, 3H), 2.97 (d, J=6.4 Hz, 2H), 1.58 (d, J=6.7 Hz, 3H).

LCMS (M+H)⁺: 396.0.

Example 88:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-2-methylpropanenitriletrifluoroacetate salt (racemate)

Prepared as in Example 87, using 2-propenenitrile, 2-methyl- (0.04 mL,0.5 mmol, Aldrich) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.06 mL, 0.4mmol, Aldrich), which were added incrementally over the 24 hours thatthe reaction was conducted. Yield: (3 mg, 20%).

¹H NMR (300 MHz, CD₃OD) δ 8.21 (d, J=9.6 Hz, 1H), 7.84 (d, J=2.4 Hz,1H), 7.57 (s, 1H), 7.47 (d, J⁼9.6 Hz, 1H), 7.32-7.15 (m, 3H), 7.13-7.02(m, 2H), 6.91 (d, J=2.4 Hz, 1H), 6.20 (s, 2H), 4.41 (d, J=6.7 Hz, 2H),3.36-3.27 (m, 1H), 3.14 (s, 3H), 1.23 (d, J=7.1 Hz, 3H).

LCMS (M+H)⁺: 396.0.

Example 89:2-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N,N-dimethylethanamine

Sodium hydride (0.0041 g, 0.10 mmol, 60% in mineral oil) was added to asolution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt (0.013 g, 0.029 mmol, prepared as in Example 62but purified via preparative HPLC-MS (C18 eluting with a gradientcontaining MeCN and H₂O containing 0.1% TFA to provide the TFA salt) andβ-Dimethylaminoethyl chloride hydrochloride (0.0063 g, 0.044 mmol,Aldrich) in DMF (0.5 mL). The reaction was stirred at room temperaturefor 2 hours. Additional NaH (0.004 g, 0.1 mmol, 60% in mineral oil) wasadded and the reaction was continued for 2 additional hours. Thereaction was quenched by the addition of water, and was diluted withMeCN, filtered, and purified via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH). Yield: (6 mg, 50%).

¹H NMR (300 MHz, CD₃OD) δ 7.71 (d, J=2.4 Hz, 1H), 7.65 (d, J=9.8 Hz,1H), 7.34-7.15 (m, 5H), 7.09-6.98 (m, 2H), 6.68 (d, J=2.4 Hz, 1H), 6.03(s, 2H), 4.29 (t, J=6.6 Hz, 2H), 3.03 (s, 3H), 2.78 (t, J=6.6 Hz, 2H),2.20 (s, 6H). LCMS (M+H)⁺: 400.1.

Example 90:{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile

tert-Butyl 3-(cyanomethylene)azetidine-1-carboxylate (59 mg, 0.30 mmol,prepared as described in WO 2009114512) and1,8-diazabicyclo[5.4.0]undec-7-ene (23 μL, 0.15 mmol) were added to asolution of6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50 mg, 0.15 mmol, from Example 62) in acetonitrile (2.0 mL). Afterstirring for 20 minutes, 4.0 M HCl in dioxane (0.50 mL, 2.0 mmol) wasadded. After a further reaction time of 22 minutes, the solvent wasremoved in vacuo and the residue was dissolved in MeOH. Aqueous ammoniawas added to adjust pH=10. Purification via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH) affordedproduct as a white solid (28 mg, 44%).

¹H NMR (400 MHz, CD₃OD) δ 7.98 (d, J=2.5 Hz, 1H), 7.70 (d, J=9.8 Hz,1H), 7.38 (s, 1H), 7.30 (d, J=9.7 Hz, 1H), 7.28-7.15 (m, 3H), 7.09-7.01(m, 2H), 6.88 (d, J=2.5 Hz, 1H), 6.05 (s, 2H), 4.09 (d, J=10.1 Hz, 2H),3.78 (d, J=10.2 Hz, 2H), 3.34 (s, 2H), 3.05 (s, 3H). LCMS (M+H)⁺: 423.2.

Example 91:{1-acetyl-3-[3-(6-benzyl-1-methyl-66H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile

To{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile(8.0 mg, 0.019 mmol, from Example 90) was added acetyl chloride (1.6 μL,0.022 mmol, Aldrich) in DCM (0.50 mL), followed by triethylamine (5.3μL, 0.038 mmol). The reaction was complete in 5 minutes. Purificationvia preparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH) afforded desired product (8.2 mg, 93%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.20 (d, J=2.5 Hz, 1H), 7.74 (d, J=9.9 Hz,1H), 7.44 (s, 1H), 7.36 (d, J=9.7 Hz, 1H), 7.28-7.14 (m, 3H), 7.08-7.01(m, 2H), 6.99 (d, J=2.5 Hz, 1H), 6.05 (d, J=16.6 Hz, 1H), 6.01 (d,J=16.6 Hz, 1H), 4.54 (d, J=9.4 Hz, 1H), 4.40 (d, J=9.3 Hz, 1H), 4.24 (d,J=10.4 Hz, 1H), 4.12 (d, J=10.4 Hz, 1H), 3.55 (s, 2H), 2.95 (s, 3H),1.78 (s, 3H).

LCMS (M+H)⁺: 465.2.

Example 92:[3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-(methylsulfonyl)azetidin-3-yl]acetonitrile

To{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile(6.0 mg, 0.014 mmol, from Example 90) was added methanesulfonyl chloride(1.3 μL, 0.017 mmol, Aldrich) in DCM (0.50 mL), followed bytriethylamine (4.0 μL, 0.028 mmol). The reaction was complete in 4minutes. Purification via preparative HPLC-MS (C18 eluting with agradient of MeCN and H₂O containing 0.15% NH₄OH) afforded product (5.9mg, 83%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.24 (d, J=2.5 Hz, 1H), 7.73 (d, J=9.8 Hz,1H), 7.45 (s, 1H), 7.35 (d, J=9.7 Hz, 1H), 7.27-7.12 (m, 3H), 7.09-7.02(m, 2H), 7.00 (d, J=2.5 Hz, 1H), 6.04 (s, 2H), 4.39 (d, J=9.4 Hz, 2H),4.20 (d, J=9.4 Hz, 2H), 3.55 (s, 2H), 3.02 (s, 3H), 2.95 (s, 3H).

LCMS (M+H)⁺: 501.2.

Example 93:{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-methylazetidin-3-yl}acetonitrile

To a mixture of{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile(11 mg, 0.026 mmol, from Example 90) in DCM (0.50 mL) was addedformaldehyde (10 mg, 0.13 mmol, 37 wt % in water, Aldrich), followed bysodium triacetoxyborohydride (16 mg, 0.078 mmol). The reaction wascomplete in 18 minutes. Purification via preparative HPLC-MS (C18eluting with a gradient of MeCN and H₂O containing 0.15% NH₄OH) affordedproduct. Yield: (8.2 mg, 72%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.13 (d, J=2.5 Hz, 1H), 7.73 (d, J=9.7 Hz,1H), 7.41 (s, 1H), 7.34 (d, J=9.7 Hz, 1H), 7.27-7.14 (m, 3H), 7.08-7.01(m, 2H), 6.93 (d, J=2.5 Hz, 1H), 6.03 (s, 2H), 3.50 (d, J=7.8 Hz, 2H),3.47 (d, J=7.8 Hz, 2H), 3.41 (s, 2H), 2.94 (s, 3H), 2.27 (s, 3H).

LCMS (M+H)⁺: 437.2.

Example 94:6-benzyl-N,N,1-trimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid trifluoroacetate (0.015 g, 0.036 mmol, from Example 83, Step 5) inDMF (0.3 mL) was added N,N-diisopropylethylamine (0.058 mL, 0.33 mmol)followed by N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.048 g, 0.12 mmol). After stirring for 2 minutes,2.0 M dimethylamine in THF (0.14 mL, 0.28 mmol, Aldrich) was added.After 15 minutes reaction time, the reaction was diluted with MeOH andpurified via preparative HPLC-MS (C18 eluting with a gradient of MeCNand H₂O containing 0.15% NH₄OH). Yield: (1.2 mg, 10%).

¹H NMR (300 MHz, CD₃OD) δ 7.84 (d, J=9.9 Hz, 1H), 7.44 (d, J=9.8 Hz,1H), 7.36-7.24 (m, 3H), 7.22 (s, 1H), 7.17-7.07 (m, 2H), 5.62 (s, 2H),2.98 (s, 3H), 3.09-2.87 (broad, 6H).

LCMS (M+H)⁺: 334.1.

Example 95:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N,N-dimethylpropanamide

Step 1.3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanoicacid

Methyl acrylate (41 μL, 0.46 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (23 L, 0.15 mmol, Aldrich) were addedto6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50 mg, 0.15 mmol, from Example 62) in acetonitrile (2.0 mL, 38 mmol)and the reaction was stirred for 15 minutes. Purification viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH) afforded ester intermediate (36 mg, 57%). LCMS(M+H)⁺: 415.1. 1.0 M NaOH (1.0 mL, 1.0 mmol) was added to the ester inTHF (1.0 mL) and the reaction was continued for 20 minutes before beingacidified to pH ˜3-4 by the addition of 1.0 N HCl to cause theprecipitation of the product as a white solid. Most of the THF wasremoved in vacuo and the product was isolated by filtration and airdried. Yield: (31 mg, 51%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.84-7.79 (m, 1H), 7.68 (d, J=9.8 Hz, 1H),7.31 (d, J=9.7 Hz, 2H), 7.31 (s, 1H), 7.26-7.14 (m, 3H), 7.07-7.01 (m,2H), 6.75 (d, J=2.3 Hz, 1H), 6.03 (s, 2H), 4.34 (t, J=6.7 Hz, 2H), 2.93(s, 3H), 2.77 (t, J=6.7 Hz, 2H). LCMS (M+H)⁺: 401.0.

Step 2.3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N,N-dimethylpropanamide

To a solution of3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanoicacid (7.0 mg, 0.017 mmol, from Step 1) in DMF (0.3 mL) was addedN,N-diisopropylethylamine (12 μL, 0.070 mmol, Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (12 mg, 0.031 mmol, Aldrich). After stirring for 2minutes, 2.0 M dimethylamine in THF (0.070 mL, 0.14 mmol, Aldrich) wasadded. After 15 minutes, the reaction was diluted with MeOH and purifiedvia preparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (4.3 mg, 58%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.81 (d, J=2.3 Hz, 1H), 7.65 (d, J=9.8 Hz,1H), 7.32 (s, 1H), 7.30 (d, J=9.7 Hz, 1H), 7.27-7.14 (m, 3H), 7.07-7.00(m, 2H), 6.75 (d, J=2.3 Hz, 1H), 6.05 (s, 2H), 4.34 (t, J=6.8 Hz, 2H),2.93 (s, 3H), 2.82 (t, J=6.9 Hz, 2H), 2.80 (s, 3H), 2.75 (s, 3H).

LCMS (M+H)⁺: 428.0.

Example 96:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N-ethylpropanamide

To a solution of3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanoicacid (8.0 mg, 0.020 mmol, prepared as in Example 95, Step 1) in DMF(0.40 mL) was added N,N-diisopropylethylamine (14 μL, 0.080 mmol,Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (14 mg, 0.036 mmol, Aldrich). After stirring for 2minutes, ethylamine (11 L, 0.20 mmol, neat, Aldrich) was introduced, andthe reaction was stirred for 15 minutes. The reaction was diluted withMeOH, and purified via preparative HPLC-MS (C18 eluting with a gradientof MeCN and H₂O containing 0.15% NH₄OH). Yield: (3.3 mg, 39%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.88 (t, J=5.3 Hz, 1H), 7.77 (d, J=2.3 Hz,1H), 7.66 (d, J=9.8 Hz, 1H), 7.30 (d, J=9.7 Hz, 1H), 7.30 (s, 1H),7.26-7.15 (m, 3H), 7.07-7.01 (m, 2H), 6.73 (d, J=2.3 Hz, 1H), 6.04 (s,2H), 4.35 (t, J=6.9 Hz, 2H), 3.00 (qd, J=7.2, 5.6 Hz, 2H), 2.93 (s, 3H),2.62 (t, J=6.9 Hz, 2H), 0.94 (t, J=7.2 Hz, 3H). LCMS (M+H)⁺: 428.0.

Example 97:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N-methylpropanamide

Prepared by the method of Example 96, using 2.0 M methylamine in THF(80. L, 0.16 mmol, Aldrich). Yield: (3.7 mg, 45%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.84 (q, J=4.4 Hz, 1H), 7.77 (d, J=2.3 Hz,1H), 7.66 (d, J=9.8 Hz, 1H), 7.30 (d, J=9.7 Hz, 1H), 7.30 (s, 1H),7.26-7.14 (m, 3H), 7.07-7.01 (m, 2H), 6.73 (d, J=2.3 Hz, 1H), 6.04 (s,2H), 4.35 (t, J=6.9 Hz, 2H), 2.93 (s, 3H), 2.63 (t, J=6.9 Hz, 2H), 2.50(s, 3H). LCMS (M+H)⁺: 414.0.

Example 98:3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanamide

Prepared by the method of Example 96, using ammonia gas (Aldrich), whichwas bubbled through the mixture for 20 seconds. Yield: (3.4 mg, 43%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.77 (d, J=2.3 Hz, 1H), 7.67 (d, J=9.8 Hz,1H), 7.38 (s, 1H), 7.30 (d, J=9.7 Hz, 1H), 7.30 (s, 1H), 7.27-7.14 (m,3H), 7.07-7.01 (m, 2H), 6.92 (s, 1H), 6.73 (d, J=2.3 Hz, 1H), 6.03 (s,2H), 4.33 (t, J=6.9 Hz, 2H), 2.93 (s, 3H), 2.63 (t, J=6.9 Hz, 2H). LCMS(M+H)⁺: 400.2.

Example 99:6-(3-chlorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid

To a suspension of ethyl5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(2.50 g, 6.85 mmol, prepared as in Example 82, Step 1) in THF (20 mL)was added 1.0 M NaOH (20 mL, 20 mmol) and the reaction was stirredovernight. Concentrated HCl was added to acidify (to pH ˜2). The productwas extracted with ethyl acetate. The combined extracts were dried oversodium sulfate, filtered and concentrated to afford a white solid. Theyield was close to theoretical and the product was used without furtherpurification.

¹H NMR (400 MHz, CD₃OD) δ 7.89 (dd, J=8.7, 0.9 Hz, 1H), 7.30 (d, J=8.7Hz, 1H), 7.14 (d, J=0.9 Hz, 1H). LCMS (M+H)⁺: 196.8.

Step 2. 3-chlorobenzyl5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.200 g, 1.02mmol, from Step 1) in DMF (4 mL) was treated with Cs₂CO₃ (1.3 g, 4.1mmol). After 10 minutes, benzene, 1-(bromomethyl)-3-chloro- (0.27 mL,2.0 mmol, Aldrich) was added. The reaction was stirred over 4 nights.The reaction mixture was partitioned between water and ethyl acetate andafter separation of the layers, the aqueous layer was extracted withEtOAc three times. The combined extracts were dried over sodium sulfate,filtered, and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanes.Yield: (0.210 g, 46%).

¹H NMR (300 MHz, CDCl₃) δ 7.60 (dd, J=8.8, 0.8 Hz, 1H), 7.49 (d, J=0.8Hz, 1H), 7.44-7.13 (m, 7H), 7.01-6.94 (m, 1H), 6.88-6.80 (m, 1H), 5.79(s, 2H), 5.31 (s, 2H).

LCMS (M+H)⁺: 444.9/446.9.

Step 3. di-tert-butyl1-(1-(3-chlorobenzyl)-2-{[(3-chlorobenzyl)oxy]carbonyl}-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

3-Chlorobenzyl5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(0.210 g, 0.471 mmol, from Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (0.12 g, 0.52 mmol, Aldrich) and Cs₂CO₃(0.15 g, 0.47 mmol, Aldrich) were combined in toluene (4.2 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.037 g, 0.047 mmol, Aldrich) was added. The mixture was degassedby a stream of nitrogen through the solution for 10 minutes. Thereaction mixture was heated to 140° C. for 30 minutes. Upon cooling toroom temperature, the reaction mixture was partitioned between EtOAc andwater. The aqueous layer was extracted three times and the combinedorganic extracts were dried over sodium sulfate, filtered, andconcentrated. Flash chromatography (eluting with a slow gradient from0-20% EtOAc in hexanes, hold, then increase rapidly up to 80% EtOAc inhexanes) afforded purified product (146 mg, 48%). LCMS (M+H)⁺:641.0/643.0.

Step 4.6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

A solution of di-tert-butyl1-(1-(3-chlorobenzyl)-2-{[(3-chlorobenzyl)oxy]carbonyl}-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate(0.146 g, 0.228 mmol, from Step 3) in AcOH (4 mL) was heated in themicrowave to a temperature of 180 OC for 5 minutes. LCMS (M+H)⁺:465.0/467.0.

AcOH was removed in vacuo. The residue was dissolved in methanol (1 mL)and 1.0 M sodium hydroxide in water (5 mL, 5 mmol) was added.Tetrahydrofuran (2 mL) was then added to aid in solubility. The reactionwas stirred for 15 minutes, then was filtered and purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (34 mg, 44%). LCMS (M+H)⁺: 341.0.

Step 5.6-(3-chlorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.034 g, 0.10 mmol, from Step 4) in DMF (2 mL) was addedN,N-diisopropylethylamine (0.16 mL, 0.93 mmol, Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.12 g, 0.32 mmol, Aldrich) and then by 2.0 Mmethylamine in THF (0.40 mL, 0.80 mmol, Aldrich). After stirring for 15minutes, the reaction mixture was diluted with MeCN and purified viapreparative HPLC-MS (C18 eluting with a gradient of MeCN and H₂Ocontaining 0.15% NH₄OH). Yield: (25 mg, 71%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.63 (q, J=4.3 Hz, 1H), 7.72 (d, J=9.6 Hz,1H), 7.71 (s, 1H), 7.47 (d, J=9.9 Hz, 1H), 7.34-7.25 (m, 2H), 7.16 (s,1H), 7.04-6.93 (m, 1H), 6.02 (s, 2H), 2.91 (s, 3H), 2.79 (d, J=4.6 Hz,3H). LCMS (M+H)⁺: 354.1.

Example 100:6-benzyl-N-(trans-3-cyanocyclobutyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. benzyl 1-benzyl-5-chloro-H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.68 g, 3.4 mmol,from Example 99, Step 1) in DMF (20 mL) was treated with Cs₂CO₃ (4.5 g,14 mmol, Aldrich) and after 10 minutes, benzyl bromide (0.82 mL, 6.9mmol, Aldrich) was added. The reaction was stirred overnight. Water wasadded and the product was extracted with three portions of EtOAc. Thecombined organic extracts were washed with water and brine, dried oversodium sulfate, filtered, and concentrated. Flash chromatography,eluting with a gradient from 0-40% EtOAc in hexanes afforded product asa white crystalline solid (1.13 g, 87%).

¹H NMR (400 MHz, CDCl₃) δ 7.61 (dd, J=8.8, 0.8 Hz, 1H), 7.48 (d, J=0.8Hz, 1H), 7.43-7.23 (m, 8H), 7.20 (d, J=8.8 Hz, 1H), 7.02-6.94 (m, 2H),5.84 (s, 2H), 5.35 (s, 2H). LCMS (M+H)⁺: 377.0.

Step 2. di-tert-butyl1-{1-benzyl-2-[(benzyloxy)carbonyl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate

Benzyl 1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (1.13g, 3.00 mmol, from Step 1) and di-tert-butyl hydrazine-1,2-dicarboxylate(0.77 g, 3.3 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.24 g, 0.30 mmol, Aldrich) and Cs₂CO₃ (0.98 g, 3.0 mmol,Aldrich) were combined in toluene (27 mL) and the mixture was degassedby bubbling a stream of nitrogen through the solution for 10 minutes.The reaction was stirred at 110° C. for 5 hours. The reaction mixturewas partitioned between water and ethyl acetate, the aqueous wasextracted three times, the combined organic extracts were dried oversodium sulfate, filtered and concentrated. Flash chromatography, elutingwith a gradient from 0-40% EtOAc in hexanes was used to purify theproduct. Yield: (1.12 g, 65%).

¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=8.8 Hz, 1H), 7.68-7.59 (m, 1H),7.49 (s, 1H), 7.42-7.32 (m, 5H), 7.31-7.19 (m, 4H), 7.05-6.98 (m, 2H),5.82 (s, 2H), 5.33 (s, 2H). LCMS (M+H)⁺: 573.0.

Step 3.6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

A solution of di-tert-butyl1-{1-benzyl-2-[(benzyloxy)carbonyl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(1.125 g, 1.964 mmol, from Step 2) in AcOH (30 mL) was split intoportions and each was heated in the microwave to 180° C. for 10 minutes.The reactions were pooled and the AcOH was removed in vacuo. LCMS(M+H)⁺: 397.1.

The residue was dissolved in methanol (9 mL) and THF (20 mL) and 1.0 MNaOH (30 mL, 30 mmol) was added. When the hydrolysis reaction wascomplete the volatile solvents were evaporated and the solution wasfiltered and purified via preparative HPLC-MS (C18 eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH) in injections of 40 mg/5mL. Yield: (0.55 g, 91%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.50 (d, J=9.8 Hz, 1H), 7.20 (d, J=9.7 Hz,1H), 7.27-7.10 (m, 5H), 7.07 (s, 1H), 6.23 (s, 2H), 2.87 (s, 3H). LCMS(M+H)⁺: 306.9.

Step 4. trans-3-aminocyclobutanecarbonitrile trifluoroacetate salt

tert-Butyl (cis-3-hydroxycyclobutyl)carbamate (1.00 g, 5.34 mmol,Synthonix) was treated with triethylamine (1.5 mL, 11 mmol) andmethanesulfonyl chloride (0.50 mL, 6.4 mmol, Aldrich) in DCM (10 mL) at0° C. for 2 hours. Water was added and the product was extracted withEtOAc three times. The combined extracts were dried over sodium sulfate,filtered, and concentrated to affordcis-3-[(tert-butoxycarbonyl)amino]cyclobutyl methanesulfonate. Yield:(1.4 g, 99%).

cis-3-[(tert-Butoxycarbonyl)amino]cyclobutyl methanesulfonate (0.200 g,0.754 mmol) in DMF (3 mL) was treated with NaCN (55 mg, 1.13 mmol,Aldrich) and the reaction was heated in the microwave to 140° C. for 10minutes, followed by stirring overnight at 125° C. with an additional 55mg (1.13 mmol) of NaCN having been added. The reaction mixture waspartitioned between saturated NaHCO₃ solution and EtOAc. The aqueouslayer was extracted three additional times with EtOAc. The combinedextracts were dried over sodium sulfate, decanted, and the solvent wasremoved in vacuo. Flash chromatography, eluting with a gradient from0-50% EtOAc in hexanes, afforded tert-butyl(trans-3-cyanocyclobutyl)carbamate. Yield: (61 mg, 41%).

¹H NMR (400 MHz, CDCl₃) δ 4.77 (br s, 1H), 4.54-4.27 (m, 1H), 3.03 (ttd,J=9.4, 3.9, 1.3 Hz, 1H), 2.79-2.57 (m, 2H), 2.49-2.26 (m, 2H), 1.43 (s,9H).

tert-Butyl (trans-3-cyanocyclobutyl)carbamate (0.061 g, 0.31 mmol) wasstirred with TFA (2 mL) in DCM (4 mL) for 1 hour. The solvents wereremoved in vacuo and the residue was reconstituted in DCM and subjectedto rotary evaporation an additional 2 times to rid of excess TFA in theproduct, which was used without further purification in Step 5.

Step 5.6-benzyl-N-(trans-3-cyanocyclobutyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.045 g, 0.15 mmol, from Step 3) in DMF (1 mL) was addedN,N-diisopropylethylamine (0.15 mL, 0.86 mmol, Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.125 g, 0.329 mmol, Aldrich). After about 30seconds, trans-3-aminocyclobutanecarbonitrile trifluoroacetate (0.060 g,0.28 mmol, from Step 4) in DMF (2 mL) was added and the reaction wasstirred overnight. The reaction was diluted with MeCN and filtered, thenpurified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (35 mg, 62%).

¹H NMR (400 MHz, CD₃OD) δ 7.73 (dd, J=9.9, 0.5 Hz, 1H), 7.65 (d, J=0.5Hz, 1H), 7.43 (d, J=9.9 Hz, 1H), 7.30-7.18 (m, 3H), 7.13-7.04 (m, 2H),5.98 (s, 2H), 4.75 (pd, J=8.0, 1.2 Hz, 1H), 3.30-3.22 (m, 1H), 3.01 (s,3H), 2.78-2.64 (m, 2H), 2.63-2.47 (m, 2H). LCMS (M+H)⁺: 384.9.

Example 101:6-benzyl-N-(cis-3-cyanocyclobutyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Prepared by the method of Example 100, usingcis-3-aminocyclobutanecarbonitrile trifluoroacetate (0.040 g, 0.19 mmol,prepared as described in Example 100, Step 4, using tert-butyl(trans-3-hydroxycyclobutyl)carbamate obtained from Synthonix). Yield:(40 mg, 71%).

¹H NMR (400 MHz, CD₃OD) δ 7.72 (d, J=9.9 Hz, 1H), 7.67 (s, 1H), 7.42 (d,J=9.9 Hz, 1H), 7.29-7.16 (m, 3H), 7.11-7.01 (m, 2H), 5.98 (s, 2H),4.56-4.45 (m, 1H), 3.11-2.99 (m, 1H), 3.02 (s, 3H), 2.86-2.75 (m, 2H),2.50-2.38 (m, 2H). LCMS (M+H)⁺: 385.0.

Example 102:6-(3-fluorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

Step 1. 3-fluorobenzyl5-chloro-1-(3-fluorobenzyl)-H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.20 g, 1.0 mmol,from Example 99, Step 1) in DMF (4 mL) was treated with Cs₂CO₃ (1.3 g,4.1 mmol, Aldrich) and after 10 minutes, a-bromo-3-fluorotoluene (0.25mL, 2.0 mmol, Aldrich) was added. After stirring overnight, water wasadded and the product was extracted with three portions of EtOAc. Thecombined organic extracts were washed with water and brine, dried oversodium sulfate, filtered and concentrated. Flash chromatography, elutingwith a gradient from 0-40% EtOAc in hexanes afforded product as a whitecrystalline solid (0.40 g, 95%).

¹H NMR (400 MHz, CDCl₃) δ 7.61 (dd, J=8.8, 0.7 Hz, 1H), 7.50 (d, J=0.7Hz, 1H), 7.34 (td, J=7.9, 5.9 Hz, 1H), 7.24 (d, J=8.8 Hz, 1H), 7.27-7.20(m, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.09 (dt, J=9.6, 1.8 Hz, 1H), 7.04 (td,J=8.3, 2.6 Hz, 1H), 6.94 (td, J=8.5, 2.3 Hz, 1H), 6.76 (d, J=7.6 Hz,1H), 6.69-6.63 (m, 1H), 5.82 (s, 2H), 5.33 (s, 2H). LCMS (M+H)⁺: 412.9.

Step 2. di-tert-butyl1-(1-(3-fluorobenzyl)-2-{[(3-fluorobenzyl)oxy]carbonyl}-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

3-Fluorobenzyl5-chloro-1-(3-fluorobenzyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(0.40 g, 0.97 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.25 g, 1.1 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.076 g, 0.097 mmol, Aldrich), and Cs₂CO₃ (0.32 g, 0.97 mmol,Aldrich) were combined in toluene (8.6 mL) and the mixture was degassedby a stream of nitrogen through the solution for 10 minutes. Thereaction was stirred at 110° C. for 6 hours. The reaction mixture waspartitioned between water and ethyl acetate, the aqueous was extractedthree times, and the combined extracts were dried over sodium sulfate,filtered and concentrated. Flash chromatography, eluting with a gradientfrom 0-40% EtOAc in hexanes, was used to purify the product. Yield:(0.33 g, 56%).

¹H NMR (400 MHz, CDCl₃) δ 8.64 (br s, 1H), 7.76-7.53 (m, 3H), 7.32 (td,J=7.9, 5.8 Hz, 1H), 7.21 (td, J=8.0, 5.9 Hz, 1H), 7.14 (d, J=7.7 Hz,1H), 7.07 (dt, J=9.5, 1.9 Hz, 1H), 7.02 (td, J=8.7, 2.2 Hz, 1H), 6.91(td, J=8.4, 2.1 Hz, 1H), 6.79 (d, J=7.7 Hz, 1H), 6.68 (dt, J=9.6, 1.9Hz, 1H), 5.80 (s, 2H), 5.30 (s, 2H), 1.41 (s, 9H), 1.37 (s, 9H). LCMS(M+H)⁺: 609.0.

Step 3.6-(3-fluorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

A solution of di-tert-butyl1-(1-(3-fluorobenzyl)-2-{[(3-fluorobenzyl)oxy]carbonyl}-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate(0.33 g, 0.54 mmol, from Step 2) in AcOH (10 mL) was heated in portions,in the microwave, to 180° C. for 10 minutes each. The reactions werepooled and AcOH was removed in vacuo. The residue was dissolved inmethanol (2 mL) and 1.0 M NaOH in water (10 mL, 10 mmol) was added. Whenthe hydrolysis reaction was complete, it was filtered, diluted with MeCNand H₂O and then purified via preparative HPLC-MS (C18 eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (0.17 g, 97%). LCMS(M+H)⁺: 325.3.

Step 4.6-(3-fluorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide

To a solution of6-(3-fluorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.050 g, 0.15 mmol, from Step 3) in DMF (3 mL) was addedN,N-diisopropylethylamine (0.25 mL, 1.4 mmol, Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (0.18 g, 0.49 mmol, Aldrich). After the reaction wasstirred for 30 seconds, 2.0 M Methylamine in THF (0.62 mL, 1.2 mmol,Aldrich) was added. After 1 hour, the reaction was diluted with MeCN andpurified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH).

Yield: (35 mg, 67%).

¹H NMR (300 MHz, CD₃OD) δ 7.74 (d, J=9.9 Hz, 1H), 7.62 (s, 1H), 7.45 (d,J=9.8 Hz, 1H), 7.40-7.24 (m, 1H), 7.06-6.91 (m, 2H), 6.91-6.82 (m, 1H),6.04 (s, 2H), 3.02 (s, 3H), 2.92 (s, 3H). LCMS (M+H)⁺: 337.9.

Example 103:3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N,N-dimethylpropanamide

Step 1. 2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine

2-Bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (20.7 g,44.6 mmol, prepared as in Example 62, Step 1, but isolated as the freebase) in THF (300 mL) was stirred with 1N NaOH (300 mL, 300 mmol)overnight. The reaction mixture was extracted with EtOAc three times.The combined extracts were dried over sodium sulfate, filtered, andconcentrated to afford 2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine intheoretical yield. LCMS (M+H)⁺: 233.0 (most abundant).

Step 2. 2-bromo-5-chloro-1-(3-chlorobenzyl)-H-pyrrolo[3, 2-b]pyridine

K₂CO₃ (0.97 g, 7.0 mmol) and 1-(bromomethyl)-3-chlorobenzene (0.74 mL,5.6 mmol, Aldrich) were added to a solution of2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (1.5 g, 4.7 mmol, fromStep 1) in DMF (20 mL). After a reaction time of 75 minutes, thereaction was diluted with ethyl acetate and washed with water threetimes, followed by one wash with brine. The organic layer was dried oversodium sulfate, filtered, and concentrated. Flash chromatography,loading in DCM, eluting with a gradient from 0-10% EtOAc in hexanes,afforded product as a white solid. Yield (1.3 g, 70%).

¹H NMR (300 MHz, CDCl₃) δ 7.41 (d, J=8.6 Hz, 1H), 7.30-7.19 (m, 2H),7.07 (d, J=8.7 Hz, 1H), 7.07-7.04 (m, 1H), 6.91-6.84 (m, 1H), 6.82 (s,1H), 5.38 (s, 2H). LCMS (M+H)⁺: 357.0 (most abundant).

Step 3.5-chloro-1-(3-chlorobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridine

A mixture of2-bromo-5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridine (1.3 g,3.3 mmol, from Step 2),1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1.1 g, 3.9 mmol, Aldrich), and Na₂CO₃ (1.7 g, 16 mmol) in1,2-dimethoxyethane (40 mL) and water (6 mL) was degassed by a stream ofnitrogen through the solution for 10 minutes.Tetrakis(triphenylphosphine)palladium(0) (0.38 g, 0.33 mmol, Strem) wasadded, and the reaction was heated to reflux for 35 minutes. Uponcooling to room temperature, the reaction was diluted with water andextracted with EtOAc three times. The combined extracts were dried oversodium sulfate, filtered, and concentrated. Flash chromatography,eluting with a gradient from 0-30% EtOAc in hexanes afforded product asa light yellow oil (0.87 g, 56%).

¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J=1.8 Hz, 1H), 7.49 (dd, J=8.6, 0.8Hz, 1H), 7.25-7.14 (m, 2H), 7.17 (d, J=8.6 Hz, 1H), 6.97 (d, J=0.8 Hz,1H), 6.86-6.81 (m, 1H), 6.74 (dt, J=7.1, 1.5 Hz, 1H), 6.31 (d, J=1.8 Hz,1H), 5.32 (d, J=17.0 Hz, 1H), 5.26 (d, J=17.0 Hz, 1H), 5.21 (dd, J=10.5,2.3 Hz, 1H), 4.08-4.01 (m, 1H), 3.53 (td, J=11.8, 2.2 Hz, 1H), 2.59-2.41(m, 1H), 2.10-1.43 (m, 5H). LCMS (M+H)⁺: 426.9, 428.1.

Step 4. di-tert-butyl1-{1-(3-chlorobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate

5-Chloro-1-(3-chlorobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridine(0.87 g, 1.8 mmol, from Step 3), di-tert-butylhydrazine-1,2-dicarboxylate (0.64 g, 2.7 mmol, Aldrich) and Cs₂CO₃ (0.90g, 2.7 mmol, Aldrich) were combined in toluene (16 mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.14 g, 0.18 mmol, Aldrich) was added. The mixture was degassedby a stream of nitrogen through the solution for 10 minutes. Thereaction was heated in a sealed vial to 130° C. for 55 minutes, then at135° C. for 40 minutes. Additional di-tert-butylhydrazine-1,2-dicarboxylate (0.32 g, 1.4 mmol), Cs₂CO₃ (0.45 g, 1.4mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.10 g, 0.13 mmol) were added. The mixture was again degassed,then sealed and heated to 140° C. for 40 minutes. After cooling to roomtemperature, the mixture was diluted with DCM, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-50%EtOAc in hexanes afforded product as a white solid (0.51 g, 40%). LCMS(M+H)⁺: 623.3.

Step 5.6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of di-tert-butyl1-{1-(3-chlorobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(0.50 g, 0.72 mmol, from Step 4) in AcOH (20 mL) and was heated in themicrowave to a temperature of 180 OC for 8 minutes. The AcOH was removedin vacuo and the product was purified via preparative HPLC-MS (C18eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield (78mg, 30%).

¹H NMR (400 MHz, d₆-DMSO) δ 13.13 (br s, 1H), 7.87 (s, 1H), 7.63 (d,J=9.7 Hz, 1H), 7.39 (s, 1H), 7.32 (d, J=9.7 Hz, 1H), 7.30-7.22 (m, 2H),7.12 (s, 1H), 6.94 (d, J=5.6 Hz, 1H), 6.86 (s, 1H), 6.09 (s, 2H), 2.95(s, 3H). LCMS (M+H)⁺: 362.7.

Step 6.3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid

Methyl acrylate (19 μL, 0.21 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (10. L, 0.069 mmol, Aldrich) wereadded to a mixture of6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.069 mmol, from Step 5) in acetonitrile (0.90 mL). After areaction time of 70 minutes, the product was purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)to afford 31 mg of adduct. This was stirred with 1.0 M NaOH in water(0.45 mL, 0.45 mmol) in THF (0.45 mL) for 25 minutes, then pH wasadjusted to the range of 3-4 by the addition of 1N HCl and the productprecipitated as white solid which was isolated by filtration, rinsedwith water, and air dried (21 mg, 70%).

¹H NMR (400 MHz, d₆-DMSO) δ 12.41 (s, 1H), 7.83 (d, J=2.3 Hz, 1H), 7.71(d, J=10.0 Hz, 1H), 7.35 (s, 1H), 7.34 (d, J=9.7 Hz, 1H), 7.27-7.23 (m,2H), 7.15 (br m, 1H), 7.01-6.90 (m, 1H), 6.78 (d, J=2.3 Hz, 1H), 6.04(s, 2H), 4.34 (t, J=6.7 Hz, 2H), 2.94 (s, 3H), 2.78 (t, J=6.7 Hz, 2H).LCMS (M+H)⁺: 434.6.

Step 7.3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N,N-dimethylpropanamide

To a solution of3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid (8.0 mg, 0.018 mmol, from Step 6) in DMF (0.25 mL) was addedN,N-diisopropylethylamine (13 μL, 0.074 mmol, Aldrich) followed byN,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate (12 mg, 0.033 mmol, Aldrich). After 2 minutes, 2.0 Mdimethylamine in THF (0.074 mL, 0.15 mmol, Aldrich) was added. After 15minutes, the reaction was diluted with MeOH and purified via preparativeHPLC-MS (C18 eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH).

Yield: (5.5 mg, 65%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.82 (d, J=2.3 Hz, 1H), 7.69 (d, J=9.8 Hz,1H), 7.35 (s, 1H), 7.33 (d, J=9.7 Hz, 1H), 7.30-7.24 (m, 2H), 7.15 (s,1H), 6.99-6.93 (m, 1H), 6.78 (d, J=2.3 Hz, 1H), 6.05 (s, 2H), 4.33 (t,J=6.8 Hz, 2H), 2.94 (s, 3H), 2.81 (t, J=6.7 Hz, 2H), 2.80 (s, 3H), 2.75(s, 3H). LCMS (M+H)⁺: 462.1.

Example 104:7-[1-(3-azetidin-1-yl-3-oxopropyl)-1H-pyrazol-3-yl]-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Prepared in the manner of Example 103, using azetidine (4.0 μL, 0.060mmol, Aldrich). Yield: (4.0 mg, 56%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.80 (d, J=2.3 Hz, 1H), 7.68 (d, J=9.5 Hz,1H), 7.36 (s, 1H), 7.33 (d, J=9.7 Hz, 1H), 7.31-7.25 (m, 2H), 7.18-7.13(m, 1H), 7.02-6.91 (m, 1H), 6.80 (d, J=2.3 Hz, 1H), 6.07 (s, 2H), 4.32(t, J=6.7 Hz, 2H), 3.83 (t, J=7.6 Hz, 2H), 3.74 (t, J=7.7 Hz, 2H), 2.94(s, 3H), 2.52 (t, J=6.7 Hz, 2H), 2.04 (p, J=7.7 Hz, 2H). LCMS: (M+H)⁺:474.1.

Example 105:6-(3-chlorobenzyl)-1-methyl-7-{1-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]-1H-pyrazol-3-yl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Prepared in the manner of Example 103, using piperazine, 1-methyl- (6.6μL, 0.060 mmol, Aldrich). Yield: (4.0 mg, 52%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.82 (d, J=2.3 Hz, 1H), 7.70 (d, J=9.7 Hz,1H), 7.35 (s, 1H), 7.33 (d, J=9.7 Hz, 1H), 7.30-7.24 (m, 2H), 7.18-7.13(m, 1H), 7.01-6.93 (m, 1H), 6.78 (d, J=2.3 Hz, 1H), 6.05 (s, 2H), 4.34(t, J=6.8 Hz, 2H), 3.41-3.35 (m, 2H), 3.30-3.20 (m, 2H), 2.94 (s, 3H),2.83 (t, J=6.9 Hz, 2H), 2.15 (q, J=4.9 Hz, 4H), 2.11 (s, 3H). LCMS(M+H)⁺: 517.3.

Example 106:(1-acetyl-3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile

Step 1.(3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile

6-(3-Chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.069 mmol, from Example 103, Step 5) in acetonitrile (0.90 mL),was treated with tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate(27 mg, 0.14 mmol, prepared as described in WO 2009114512) and1,8-diazabicyclo[5.4.0]undec-7-ene (10. L, 0.069 mmol, Aldrich). After70 minutes, 4.0 M hydrogen chloride in dioxane (0.23 mL, 0.90 mmol) wasadded into the reaction. After 30 minutes, the reaction was diluted withmethanol, and adjusted to pH ˜10 by the addition of a small amount ofaqueous ammonia. Purification via preparative HPLC-MS (C18 eluting witha gradient of MeCN/H₂O containing 0.15% NH₄OH) afforded product (23 mg,73%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.12 (d, J=2.5 Hz, 1H), 7.77 (d, J=9.8 Hz,1H), 7.44 (s, 1H), 7.37 (d, J=9.7 Hz, 1H), 7.29-7.21 (m, 2H), 7.19-7.12(m, 1H), 6.96 (d, J=2.5 Hz, 1H), 6.97-6.92 (m, 1H), 6.03 (s, 2H), 3.86(d, J=9.0 Hz, 2H), 3.58 (d, J=9.3 Hz, 2H), 3.45 (s, 2H), 2.95 (s, 3H).LCMS (M+H)⁺: 456.6.

Step 2.(1-acetyl-3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile

Acetyl chloride (1.1 μL, 0.016 mmol, Aldrich) in DCM (0.35 mL) was addedto(3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile(6.0 mg, 0.013 mmol, from Step 1). Triethylamine (3.7 μL, 0.026 mmol)was then added and the reaction was stirred for 10 minutes. Purificationvia preparative HPLC-MS (C18 eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) afforded product (4.0 mg, 61%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.21 (d, J=2.5 Hz, 1H), 7.76 (d, J=9.8 Hz,1H), 7.47 (s, 1H), 7.38 (d, J=9.8 Hz, 1H), 7.29-7.23 (m, 2H), 7.17-7.11(m, 1H), 7.01 (d, J=2.5 Hz, 1H), 6.97-6.90 (m, 1H), 6.03 (s, 2H), 4.52(d, J=9.4 Hz, 1H), 4.40 (d, J=9.4 Hz, 1H), 4.24 (d, J=10.4 Hz, 1H), 4.11(d, J=10.4 Hz, 1H), 3.55 (s, 2H), 2.95 (s, 3H), 1.78 (s, 3H). LCMS(M+H)⁺: 499.1.

Example 107:[3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile

To(3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile(6.0 mg, 0.013 mmol, from Example 106, Step 1) was added methanesulfonylchloride (1.2 μL, 0.016 mmol, Aldrich) in DCM (0.46 mL), followed bytriethylamine (3.7 μL, 0.026 mmol). After 10 minutes, the product waspurified via preparative HPLC-MS (C18 eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH).

Yield: (4.6 mg, 65%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.25 (d, J=2.6 Hz, 1H), 7.75 (d, J=9.8 Hz,1H), 7.48 (s, 1H), 7.38 (d, J=9.8 Hz, 1H), 7.30-7.21 (m, 2H), 7.19-7.10(m, 1H), 7.03 (d, J=2.5 Hz, 1H), 6.99-6.92 (m, 1H), 6.05 (s, 2H), 4.38(d, J=9.4 Hz, 2H), 4.20 (d, J=9.4 Hz, 2H), 3.54 (s, 2H), 3.03 (s, 3H),2.95 (s, 3H). LCMS (M+H)⁺: 535.1.

Example 108:7-[1-(1-acetylazetidin-3-yl)-1H-pyrazol-3-yl]-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Step 1.7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

6-(3-Chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.069 mmol, from Example 103, Step 5) in DMF (1.5 mL) wastreated with Cs₂CO₃ (34 mg, 0.10 mmol, Aldrich) and tert-butyl3-[(methylsulfonyl)oxy]azetidine-1-carboxylate (26 mg, 0.10 mmol,prepared as in WO 2012004703). The mixture was heated at 70° C. for 14hours. After cooling to room temperature, the mixture was diluted withwater and extracted with three portions of EtOAc. The combined extractswere washed twice with brine, then were dried over sodium sulfate,filtered, and concentrated. The residue, dissolved in acetonitrile (1.0mL) was treated with 4.0 M HCl in dioxane (0.40 mL, 1.6 mmol). After 20minutes, the solvent and excess HCl were removed in vacuo. The residuewas re-dissolved in methanol and pH was made basic by the addition of afew drops of NH₄OH solution. Purification via preparative HPLC-MS (C18eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH) affordedclean product (13.2 mg, 46%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.93 (d, J=2.3 Hz, 1H), 7.75 (d, J=9.8 Hz,1H), 7.39 (s, 1H), 7.36 (d, J=9.7 Hz, 1H), 7.32-7.22 (m, 2H), 7.21-7.15(m, 1H), 7.02-6.93 (m, 1H), 6.84 (d, J=2.4 Hz, 1H), 6.09 (s, 2H), 5.20(p, J=7.5 Hz, 1H), 3.87 (t, J=7.7 Hz, 2H), 3.69 (t, J=8.0 Hz, 2H), 2.95(s, 3H). LCMS (M+H)⁺: 418.2.

Step 2.7-[1-(1-acetylazetidin-3-yl)-1H-pyrazol-3-yl]-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(6.0 mg, 0.014 mmol, from Step 1) was added acetyl chloride (1.2 μL,0.017 mmol, Aldrich) in DCM (0.38 mL). Triethylamine (4.0 μL, 0.029mmol) was then added and the reaction was complete in 2 minutes.Purification via preparative HPLC-MS (C18 eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) afforded clean product (4.6 mg, 70%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.98 (d, J=2.4 Hz, 1H), 7.74 (d, J=9.8 Hz,1H), 7.43 (s, 1H), 7.37 (d, J=9.7 Hz, 1H), 7.30-7.22 (m, 2H), 7.11-7.05(m, 1H), 7.03-6.94 (m, 1H), 6.89 (d, J=2.4 Hz, 1H), 6.09 (d, J=16.5 Hz,1H), 6.02 (d, J=16.7 Hz, 1H), 5.26 (tt, J=8.0, 5.3 Hz, 1H), 4.52 (t,J=8.3 Hz, 1H), 4.32-4.19 (m, 2H), 4.04 (dd, J=9.9, 5.3 Hz, 1H), 2.95 (s,3H), 1.76 (s, 3H). LCMS (M+H)⁺: 460.2.

Example 109:6-(3-chlorobenzyl)-1-methyl-7-{1-[1-(methylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(6.0 mg, 0.014 mmol, from Example 108, Step 1) was added methanesulfonylchloride (1.3 μL, 0.017 mmol, Aldrich) in DCM (0.50 mL). This wasfollowed by triethylamine (4.0 μL, 0.029 mmol) and the reaction wasstirred for 2 minutes. Purification via preparative HPLC-MS (C18 elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH) afforded cleanproduct (4.7 mg, 66%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.98 (d, J=2.4 Hz, 1H), 7.69 (d, J=9.9 Hz,1H), 7.45 (s, 1H), 7.36 (d, J=9.7 Hz, 1H), 7.32-7.24 (m, 2H), 7.16-7.11(m, 1H), 7.06-6.98 (m, 1H), 6.92 (d, J=2.4 Hz, 1H), 6.10 (s, 2H), 5.33(p, J=7.1 Hz, 1H), 4.28-4.20 (m, 4H), 2.95 (s, 3H), 2.93 (s, 3H). LCMS(M+H)⁺: 496.2.

Example 110:{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-ethylazetidin-3-yl}acetonitrile

Prepared by the method of Example 93, using{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile(8.5 mg, 0.020 mmol, from Example 90) in DCM (0.4 mL), and acetaldehyde(5.6 μL, 0.10 mmol, Aldrich), followed by sodium triacetoxyborohydride(13 mg, 0.060 mmol). Yield: (6.7 mg, 74%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.12 (d, J=2.5 Hz, 1H), 7.73 (d, J=9.7 Hz,1H), 7.41 (s, 1H), 7.34 (d, J=9.7 Hz, 1H), 7.27-7.13 (m, 3H), 7.10-7.00(m, 2H), 6.93 (d, J=2.5 Hz, 1H), 6.03 (s, 2H), 3.46 (d, J=8.0 Hz, 2H),3.44 (d, J=8.0 Hz, 2H), 3.41 (s, 2H), 2.94 (s, 3H), 2.44 (q, J=7.1 Hz,2H), 0.86 (t, J=7.1 Hz, 3H). LCMS (M+H)⁺: 451.0.

Example 111:{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-isopropylazetidin-3-yl}acetonitrile

Prepared by the method of Example 110, using acetone (7.4 μL, 0.10 mmol,EMD). Yield: (5.0 mg, 53%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.12 (d, J=2.5 Hz, 1H), 7.73 (d, J=9.8 Hz,1H), 7.41 (s, 1H), 7.34 (d, J=9.7 Hz, 1H), 7.28-7.12 (m, 3H), 7.10-6.97(m, 2H), 6.93 (d, J=2.5 Hz, 1H), 6.03 (s, 2H), 3.47 (d, J=8.2 Hz, 2H),3.42 (d, J=8.2 Hz, 2H), 3.39 (s, 2H), 2.94 (s, 3H), 2.35 (hept, J=6.1Hz, 1H), 0.84 (d, J=6.2 Hz, 6H). LCMS (M+H)⁺: 465.0.

Example 112:6-benzyl-1-methyl-6H-pyrazolo[3,4-e][1,2,4]triazolo[4,3-a]pyridine

Step 1. 1-benzyl-5-chloro-1H-pyrazolo[4,3-b]pyridine and2-benzyl-5-chloro-2H-pyrazolo[4,3-b]pyridine

To a suspension of sodium hydride (94 mg, 2.3 mmol, 60% in mineral oil)in DMF (4.0 mL) was added dropwise a solution of5-chloro-1H-pyrazolo[4,3-b]pyridine (0.30 g, 2.0 mmol, J&W Pharmlab) inDMF (1.0 mL). The mixture was stirred for 10 minutes, then benzylbromide (0.244 mL, 2.05 mmol, Aldrich) was added. After 70 minutes, themixture was quenched by the addition of water and the product wasextracted with EtOAc. The combined extracts were washed with water,followed by brine, dried over sodium sulfate, filtered, andconcentrated. Flash chromatography, eluting with a gradient from 0-20%EtOAc in hexanes afforded two isomeric products: Peak 1 (first to elute,1-benzyl-5-chloro-1H-pyrazolo[4,3-b]pyridine): 0.21 g, 44% yield. Peak 2(second to elute, 2-benzyl-5-chloro-2H-pyrazolo[4,3-b]pyridine): 0.10 g,21% yield.

Peak 1 (first to elute, 1-benzyl-5-chloro-1H-pyrazolo[4,3-b]pyridine):¹H NMR (500 MHz, CDCl₃) δ 8.19 (d, J=0.8 Hz, 1H), 7.56 (dd, J=8.8, 0.7Hz, 1H), 7.38-7.27 (m, 3H), 7.22 (d, J=8.8 Hz, 1H), 7.18 (dd, J=7.7, 1.5Hz, 2H), 5.59 (s, 2H); LCMS (M+H)⁺: 244.1, 246.1.

Peak 2 (second to elute, 2-benzyl-5-chloro-2H-pyrazolo[4,3-b]pyridine):¹H NMR (500 MHz, CDCl₃) δ 8.07 (d, J=0.8 Hz, 1H), 8.00 (dd, J=9.0, 0.8Hz, 1H), 7.41-7.33 (m, 3H), 7.29 (dd, J=7.6, 1.7 Hz, 2H), 7.19 (d, J=9.0Hz, 1H), 5.60 (s, 2H); LCMS (M+H)⁺: 244.1, 246.1.

Step 2. di-tert-butyl1-(1-benzyl-1H-pyrazolo[4,3-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

A reaction vial was charged with1-benzyl-5-chloro-1H-pyrazolo[4,3-b]pyridine (0.210 g, 0.862 mmol) (Peak1 from Step 1), di-tert-butyl hydrazine-1,2-dicarboxylate (0.22 g, 0.96mmol, Aldrich), cesium carbonate (0.281 g, 0.862 mmol, Aldrich) andtoluene (2 mL, 20 mmol).Dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.068 g, 0.086 mmol, Aldrich) was added and the mixture wasdegassed by a stream of nitrogen through the solution for 15 minutes.The reaction vial was sealed and heated to 110° C. for 2 hours, then wasstirred at room temperature for 3 days. The reaction mixture waspartitioned between ethyl acetate and water and the aqueous wasextracted with two further portions of EtOAc. The combined extracts weredried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanesafforded product (0.19 g, 50%).

¹H NMR (300 MHz, CD₃OD) δ 8.12 (s, 1H), 7.97 (d, J=9.1 Hz, 1H), 7.63 (d,J=9.1 Hz, 1H), 7.34-7.14 (m, 5H), 5.63 (s, 2H), 1.50 (s, 9H), 1.49 (s,9H); LCMS (M+H)⁺: 440.0.

Step 3. 6-benzyl-1-methyl-6H-pyrazolo[3,4-e][1,2,4]triazolo[4,3-a]pyridine

di-tert-Butyl1-(1-benzyl-1H-pyrazolo[4,3-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate(0.030 g, 0.068 mmol, from Step 2) in AcOH (3 mL) was heated in themicrowave to 180° C. for 5 minutes. The AcOH was removed in vacuo, theresidue was reconstituted in MeOH, and purified via preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH) to afford product (8 mg, 40%).

¹H NMR (300 MHz, CDCl₃) δ 8.12 (d, J=0.8 Hz, 1H), 7.55 (d, J=9.9 Hz,1H), 7.39-7.17 (m, 6H), 5.63 (s, 2H), 2.98 (s, 3H); LCMS (M+H)⁺: 264.1.

Example 113:6-(3-Chlorobenzyl)-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

To a suspension of6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.023 g, 0.067 mmol, prepared as in Example 99, Step 4) in DMF(1.5 mL) was added N,N-diisopropylethylamine (0.035 mL, 0.20 mmol)followed by HATU (0.0385 g, 0.101 mmol) and ethylamine (2.0 M in THF,0.17 mL, 0.34 mmol, Aldrich). After stirring overnight, the reaction wasdiluted with MeCN and purified by preparative HPLC-MS (Waters SunFireC18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield:(0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.27 (d, J=9.8 Hz, 1H), 7.77 (d, J=0.5 Hz,1H), 7.65 (d, J=9.7 Hz, 1H), 7.30-7.21 (m, 2H), 7.15-7.11 (m, 1H), 7.08(dt, J=6.8, 1.9 Hz, 1H), 6.06 (s, 2H), 3.42 (q, J=7.3 Hz, 2H), 3.10 (s,3H), 1.23 (t, J=7.3 Hz, 3H); LCMS (M+H)⁺: 368.2.

Example 114:6-(3-Chlorobenzyl)-N-(cyclopropylmethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 113using 1-cyclopropylmethanamine hydrochloride (0.014 g, 0.13 mmol,Aldrich). Yield: (0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.33 (d, J=9.7 Hz, 1H), 7.81 (d, J=0.5 Hz,1H), 7.67 (d, J=9.7 Hz, 1H), 7.30-7.21 (m, 2H), 7.16-7.11 (m, 1H), 7.09(dt, J=6.7, 1.9 Hz, 1H), 6.07 (s, 2H), 3.25 (d, J=7.0 Hz, 2H), 3.12 (s,3H), 1.14-1.03 (m, 1H), 0.71-0.38 (m, 2H), 0.38-0.07 (m, 2H); LCMS(M+H)⁺: 394.2.

Example 115.6-(3-Chlorobenzyl)-N-[2-(dimethylamino)ethyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 113using N,N-dimethyl-1,2-ethanediamine (0.022 mL, 0.20 mmol, Aldrich).Yield: (0.01 g, 20%).

¹H NMR (400 MHz, CD₃OD) δ 8.12 (d, J=9.7 Hz, 1H), 7.80 (d, J=0.5 Hz,1H), 7.63 (d, J=9.8 Hz, 1H), 7.32-7.23 (m, 2H), 7.15-7.10 (m, 1H),7.09-7.04 (m, 1H), 6.08 (s, 2H), 3.78 (t, J=6.0 Hz, 2H), 3.38 (t, J=6.0Hz, 2H), 3.09 (s, 3H), 2.98 (s, 6H); LCMS (M+H)⁺: 411.3.

Example 116:6-(3-Chlorobenzyl)-1-methyl-7-(morpholin-4-ylcarbonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 113using morpholine (0.018 mL, 0.20 mmol, Aldrich). Yield: (0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.44 (d, J=9.7 Hz, 1H), 7.69 (d, J=9.7 Hz,1H), 7.43 (d, J=0.6 Hz, 1H), 7.36-7.29 (m, 2H), 7.20-7.16 (m, 1H),7.14-7.07 (m, 1H), 5.73 (s, 2H), 3.80-3.20 (br m, 8H), 3.09 (s, 3H);LCMS (M+H)⁺: 410.2.

Example 117:6-(3-Chlorobenzyl)-N-(2-hydroxyethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 113using ethanolamine (0.012 mL, 0.20 mmol, Aldrich). Yield: (0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.27 (d, J=9.8 Hz, 1H), 7.85 (d, J=0.6 Hz,1H), 7.65 (d, J=9.7 Hz, 1H), 7.31-7.21 (m, 2H), 7.17-7.13 (m, 1H), 7.09(dt, J=6.9, 1.9 Hz, 1H), 6.07 (s, 2H), 3.72 (t, J=5.7 Hz, 2H), 3.52 (t,J=5.7 Hz, 2H), 3.11 (s, 3H); LCMS (M+H)⁺: 384.0.

Example 118:6-(3-Chlorobenzyl)-1-methyl-N-(1-methylazetidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 113using 1-methylazetidin-3-amine (0.017 g, 0.20 mmol, Synthonix). Yield:(0.01 g, 20%).

¹H NMR (400 MHz, CD₃OD) δ 8.21 (d, J=9.8 Hz, 1H), 7.89 (d, J=5.3 Hz,1H), 7.67 (d, J=9.8 Hz, 1H), 7.31-7.21 (m, 2H), 7.16-7.10 (m, 1H),7.10-7.02 (m, 1H), 6.10 (s, 1H, rotamers), 6.06 (s, 1H, rotamers),4.88-4.53 (m, 3H), 4.34 (t, J=9.8 Hz, 1H), 4.26 (t, J=9.7 Hz, 1H), 3.11(s, 3H), 3.04 (s, 1.5H, rotamers), 2.98 (s, 1.5H, rotamers); LCMS(M+H)⁺: 409.1.

Example 119:6-(3-Chlorobenzyl)-1-methyl-N-(2-morpholin-4-ylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 113,using6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.050 g, 0.15 mmol), N,N-diisopropylethylamine (0.077 mL, 0.44mmol), HATU (0.084 g, 0.22 mmol) and N-(2-aminoethyl)morpholine (0.057g, 0.44 mmol, Aldrich) in N,N-dimethylformamide (3.3 mL). The reactiontime was 1 hour. Yield: (8 mg, 10%).

¹H NMR (300 MHz, d₆-DMSO) δ 9.93 (br s, 1H), 9.05 (t, J=5.8 Hz, 1H),7.93 (d, J=9.9 Hz, 1H), 7.81 (s, 1H), 7.62 (d, J=9.8 Hz, 1H), 7.38-7.28(m, 2H), 7.20 (s, 1H), 7.10-7.01 (m, 1H), 6.04 (s, 2H), 3.98 (br m, 2H),3.77-3.42 (m, 6H), 3.32 (t, J=6.1 Hz, 2H), 3.18 (br m, 2H), 2.96 (s,3H); LCMS (M+H)⁺: 453.1.

Example 120:N-(tert-Butyl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 113,using6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.050 g, 0.15 mmol), N,N-diisopropylethylamine (0.077 mL, 0.44mmol), HATU (0.084 g, 0.22 mmol) and tert-butylamine (0.032 g, 0.44mmol, Aldrich) in N,N-dimethylformamide (3.3 mL). The reaction time was1 hour. Yield: (8 mg, 10%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.05 (d, J=9.7 Hz, 1H), 8.05 (s, 1H), 7.69(s, 1H), 7.59 (d, J=9.8 Hz, 1H), 7.35-7.26 (m, 2H), 7.20 (s, 1H),7.10-7.00 (m, 1H), 5.98 (s, 2H), 2.96 (s, 3H), 1.38 (s, 9H); LCMS(M+H)⁺: 396.1.

Example 121:6-[3-(Azetidin-1-ylmethyl)benzyl]-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

Step 1. [3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)phenyl]methanol

To a solution of 1,3-phenylenedimethanol (10.00 g, 72.38 mmol, Aldrich)in DCM (200 mL) was added 1H-imidazole (5.17 g, 76.0 mmol, Aldrich),followed by the addition of tert-butylchlorodiphenylsilane (19.8 mL,76.0 mmol, Aldrich) and 4-dimethylaminopyridine (0.88 g, 7.2 mmol,Aldrich). After stirring overnight, the reaction was partitioned betweenDCM and water, the organic layer was dried over sodium sulfate, filteredand concentrated. The product was purified by flash chromatography(gradient elution, 0 to 20% EtOAc/hexanes). Yield: (7.9 g, 29%).

¹H NMR (300 MHz, CDCl₃) δ 7.73-7.63 (m, 4H), 7.48-7.21 (m, 10H), 4.77(s, 2H), 4.68 (d, J=5.8 Hz, 2H), 1.09 (s, 9H); LCMS (M+OH+H)⁺: 394.2.

Step 2. tert-Butyl{[3-(chloromethyl)benzyl]oxy}diphenylsilane

To a solution of[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)phenyl]methanol (7.9 g, 21mmol, from Step 1) in methylene chloride (100 mL) at 0° C. was addedtriethylamine (5.85 mL, 42.0 mmol), followed by the addition ofmethanesulfonyl chloride (1.62 mL, 21.0 mmol, Aldrich). The reaction wasstirred at 0° C. for 30 minutes, after which time the reaction wasallowed to warm to room temperature for 1 hour. Water was added and thelayers were separated. The aqueous layer was extracted with anotherportion of DCM. The combined organic extracts were washed sequentiallywith water and brine, dried over sodium sulfate, filtered andconcentrated. The product was isolated by flash chromatography (gradientelution, 0 to 25% EtOAc/hexanes). The product was used further in Step3. Yield: (3.9 g, 47%).

¹H NMR (300 MHz, CDCl₃) δ 7.73-7.64 (m, 4H), 7.48-7.23 (m, 10H), 4.77(s, 2H), 4.59 (s, 2H), 1.10 (s, 9H).

Step 3. 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)benzyl1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.803 g, 4.08mmol, from Example 99, Step 1) in DMF (20 mL) was treated with Cs₂CO₃(4.0 g, 12 mmol), followed by the addition oftert-butyl{[3-(chloromethyl)benzyl]oxy}diphenylsilane (3.9 g, 9.9 mmol,from Step 2). After stirring overnight, the crude reaction mixture waspartitioned between water and ethyl acetate and the aqueous layer wasextracted with an additional two portions of ethyl acetate. The combinedorganic extracts were washed sequentially with water and brine, driedover sodium sulfate, filtered and concentrated. The product was purifiedby flash chromatography, eluting with a slow gradient from 0-20%EtOAc/hexanes. Yield: (2.18 g, 58%).

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.64 (m, 4H), 7.62-7.55 (m, 5H), 7.46 (d,J=0.7 Hz, 1H), 7.44-7.10 (m, 19H), 6.97 (s, 1H), 6.94 (d, J=7.5 Hz, 1H),5.82 (s, 2H), 5.32 (s, 2H), 4.76 (s, 2H), 4.64 (s, 2H), 1.08 (s, 9H),0.98 (s, 9H); LCMS (M+H)⁺: 913.1.

Step 4. Di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-2-({[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)benzyl1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(2.18 g, 2.38 mmol, from Step 3) and di-tert-butylhydrazine-1,2-dicarboxylate (0.71 g, 3.1 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.22 g, 0.28 mmol, Aldrich) and Cs₂CO₃ (0.91 g, 2.8 mmol) werecombined in toluene (27 mL) and the mixture was degassed by a stream ofnitrogen bubbled through the solution for 10 minutes. The reactionvessel was sealed and heated at 110° C. for 3 hours. The reactionmixture was partitioned between water and ethyl acetate, the aqueouslayer was extracted three times and the combined organic extracts weredried over sodium sulfate, filtered and concentrated. The product waspurified by flash chromatography, eluting with a gradient from 0-25%EtOAc/hexanes. Yield: (1.31 g, 50%).

LCMS (M+H)⁺: 1109.3.

Step 5. 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)benzyl6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate

Di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-2-({[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(1.30 g, 1.18 mmol, from Step 4) in acetic acid (17 mL) was divided intothree equal portions and each was heated in the microwave to 180° C. for5 minutes. The batches were recombined and acetic acid was removed invacuo. The crude residue was partitioned between an additional NaHCO₃solution and EtOAc. The aqueous layer was extracted further with twoportions of EtOAc. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. The product was used without furtherpurification. Yield: (900. mg, 87%).

¹H NMR (400 MHz, CDCl₃) δ 7.73-7.66 (m, 4H), 7.63-7.56 (m, 4H), 7.52 (d,J=9.9 Hz, 1H), 7.49 (s, 1H), 7.44-7.20 (m, 18H), 7.18-7.13 (m, 1H),7.03-6.96 (m, 2H), 5.94 (s, 2H), 5.34 (s, 2H), 4.80 (s, 2H), 4.67 (s,2H), 2.90 (s, 3H), 1.10 (s, 9H), 0.95 (s, 9H); LCMS (M+H)⁺: 933.2.

Step 6. 3-(Azetidin-1-ylmethyl)benzyl6-[3-(azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylatetris(trifluoroacetate) salt

3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)benzyl6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.890 g, 0.954 mmol, from Step 5) was dissolved in 1,4-dioxane (20 mL)and 4.0 M solution of HCl in dioxane (20 mL, 80 mmol) was added. Thereaction was stirred for 1 h at 110° C. Three additional portions of 4.0M HCl in dioxane (10 mL, 40 mmol) were added periodically over thecourse of 6.5 hours at 110° C. After the third addition, the reactionmixture was heated at 110° C. in a sealed vessel for 48 hours. When thereaction was complete, the dioxane was evaporated and the residue wasneutralized by the addition of saturated NaHCO₃ solution. The productwas extracted with three portions of EtOAc. The combined organicextracts were dried over sodium sulfate, filtered and concentrated.Flash chromatography, eluting with a gradient from 0-10% MeOH/DCM wasused to isolate 3-(chloromethyl)benzyl6-[3-(hydroxymethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate,which was used in the displacement reaction that follows.

To 3-(chloromethyl)benzyl6-[3-(hydroxymethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.26 g, 0.53 mmol) in N,N-dimethylformamide (5 mL) was added K₂CO₃(0.29 g, 2.1 mmol) and N,N-diisopropylethylamine (0.28 mL, 1.6 mmol).Azetidine (0.14 mL, 2.1 mmol, Aldrich) was added and the reaction wasstirred at 60° C. for 5 hours. The reaction mixture was cooled andpartitioned between water and ethyl acetate. The aqueous layer wasextracted with three portions of EtOAc. The extracts were dried oversodium sulfate, filtered and concentrated. The product was purified bypreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA). Yield: (0.15 g, 29%).

¹H NMR (400 MHz, CD₃OD) δ 8.30 (d, J=9.8 Hz, 1H), 7.87 (s, 1H), 7.76 (d,J=9.8 Hz, 1H), 7.60-7.32 (m, 6H), 7.22 (s, 1H), 7.17-7.10 (m, 1H), 6.13(s, 2H), 5.42 (s, 2H), 4.38 (s, 2H), 4.28 (s, 2H), 4.24-3.93 (m, 8H),3.12 (s, 3H), 2.62-2.30 (m, 4H); LCMS (M+H)⁺: 535.3.

Step 7.6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

3-(Azetidin-1-ylmethyl)benzyl6-[3-(azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylatetris(trifluoroacetate) (0.15 g, 0.17 mmol, from Step 6) was dissolved intetrahydrofuran (5 mL) and 1.0 M NaOH (5 mL, 5 mmol) was added. Thereaction was stirred for 1 hour. The product was purified by preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH) Yield: (0.033 g, 51%).

LCMS (M+H)⁺: 535.3.

Step 8.6-[3-(Azetidin-1-ylmethyl)benzyl]-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

To a solution of6-[3-(azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.017 g, 0.045 mmol, from Step 7) in N-methylpyrrolidinone (1 mL)was added N,N-diisopropylethylamine (0.032 mL, 0.18 mmol) and ethylamine(0.010 g, 0.018 mmol, Aldrich), followed by the addition of HATU (0.022g, 0.059 mmol). When the reaction was complete as determined by LCMS,the reaction was diluted with MeCN, and TFA was added to aid insolubility. The product was purified via preparative HPLC-MS (WatersSunFire C18, 5 m 30×100 mm, (H₂O, 0.1% TFA)/MeOH, flow rate: 60 mL/min).

Yield: (10 mg, 35%).

¹H NMR (400 MHz, CD₃OD) δ 8.16 (d, J=9.6 Hz, 1H), 7.79 (s, 1H), 7.62 (d,J=9.7 Hz, 1H), 7.42-7.31 (m, 2H), 7.29-7.26 (m, 1H), 7.19-7.14 (m, 1H),6.08 (s, 2H), 4.29 (s, 2H), 4.18-3.94 (m, 4H), 3.40 (q, J=7.3 Hz, 2H),3.10 (s, 3H), 2.60-2.46 (m, 1H), 2.46-2.31 (m, 1H), 1.22 (t, J=7.3 Hz,3H); LCMS (M+H)⁺: 403.2.

Example 122:6-[3-(Azetidin-1-ylmethyl)benzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 121,Step 8, using methylamine hydrochloride (0.0053 g, 0.078 mmol, AlfaAesar). Yield: (10 mg, 35%).

¹H NMR (400 MHz, CD₃OD) δ 8.11 (d, J=9.8 Hz, 1H), 7.75 (s, 1H), 7.60 (d,J=9.8 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.26 (m, 1H), 7.20-7.13 (m, 1H),6.09 (s, 2H), 4.29 (s, 2H), 4.21-3.97 (m, 4H), 3.09 (s, 3H), 2.92 (s,3H), 2.60-2.47 (m, 1H), 2.47-2.34 (m, 1H); LCMS (M+H)⁺: 389.1.

Example 123:6-Benzyl-N-(3-hydroxypropyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

To a suspension of6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.01 g, 0.04 mmol, from Example 100, Step 3) inN,N-dimethylformamide (1.0 mL) was added N,N-diisopropylethylamine(0.024 mL, 0.13 mmol), followed by the addition of HATU (0.0257 g,0.0675 mmol) and 3-amino-1-propanol (0.010 g, 0.13 mmol, Aldrich). Whenthe reaction was complete, the reaction mixture was diluted with MeCNand the product was purified by preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (8 mg,40%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.75 (t, J=5.6 Hz, 1H), 8.20 (d, J=9.6 Hz,1H), 7.84 (s, 1H), 7.66 (d, J=9.8 Hz, 1H), 7.31-7.25 (m, 2H), 7.25-7.20(m, 1H), 7.14-7.09 (m, 2H), 6.10 (s, 2H), 3.47 (t, J=6.3 Hz, 2H), 3.35(q, J=6.7 Hz, 2H), 3.01 (s, 3H), 1.70 (p, J=6.5 Hz, 2H); LCMS (M+H)⁺:364.2.

Example 124:N-(Azetidin-3-ylmethyl)-6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 123,using tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (0.025 g, 0.13mmol, Astatech) in the coupling step. After completing an aqueousworkup, the Boc protecting group was removed from the product bystirring with 1:1 TFA:DCM for 1 hour. Solvents were evaporated in vacuo.The final purification was performed according to the methods of Example123. Yield: (6 mg, 20%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.92 (t, J=5.8 Hz, 1H), 8.65 (br d, 2H),7.98 (d, J=9.8 Hz, 1H), 7.77 (s, 1H), 7.60 (d, J=9.8 Hz, 1H), 7.31-7.26(m, 2H), 7.26-7.20 (m, 1H), 7.14-7.03 (m, 2H), 6.05 (s, 2H), 4.02-3.89(m, 2H), 3.83-3.72 (m, 2H), 3.51 (t, J=6.3 Hz, 2H), 3.07-2.98 (m, 1H),2.97 (s, 3H); LCMS (M+H)⁺: 375.2.

Example 125:6-Benzyl-N-isobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate

The title compound was prepared according to the methods of Example 123,using 2-methyl-1-propanamine (9.9 mg, 0.13 mmol, Aldrich). Yield: (4 mg,20%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.73 (t, J=5.9 Hz, 1H), 8.14 (d, J=9.8 Hz,1H), 7.82 (s, 1H), 7.63 (d, J=9.8 Hz, 1H), 7.30-7.24 (m, 2H), 7.24-7.18(m, 1H), 7.14-7.03 (m, 2H), 6.08 (s, 2H), 3.11 (t, J=6.5 Hz, 2H), 3.00(s, 3H), 1.90-1.75 (m, 1H), 0.89 (d, J=6.7 Hz, 6H); LCMS (M+H)⁺: 362.2.

Example 126:6-Benzyl-1-methyl-N-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 123,using 4-(aminomethyl)pyridine (0.014 g, 0.13 mmol, Aldrich). Yield: (9mg, 30%).

¹H NMR (500 MHz, d₆-DMSO) δ 9.48 (t, J=5.9 Hz, 1H), 8.71 (d, J=6.3 Hz,2H), 8.05 (d, J=9.8 Hz, 1H), 7.93 (s, 1H), 7.68-7.59 (m, 3H), 7.32-7.20(m, 3H), 7.10-7.02 (m, 2H), 6.05 (s, 2H), 4.67 (d, J=5.9 Hz, 2H), 2.99(s, 3H); LCMS (M+H)⁺: 397.2.

Example 127:6-(3-Chlorobenzyl)-N-(3-hydroxypropyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

To a suspension of6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.004 g, 0.01 mmol, from Example 99, Step 4) in DMF (0.5 mL) wasadded N,N-diisopropylethylamine (0.014 mL, 0.078 mmol), followed by theaddition of HATU (0.010 g, 0.026 mmol). After 1 minute,3-amino-1-propanol (5.9 mg, 0.078 mmol, Aldrich) was added to thereaction mixture. The reaction mixture was diluted with MeCN andpurified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (4.8 mg, 70%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.75 (t, J=5.7 Hz, 1H), 8.12 (d, J=9.8 Hz,1H), 7.84 (s, 1H), 7.65 (d, J=9.8 Hz, 1H), 7.35-7.27 (m, 2H), 7.19 (s,1H), 7.09-7.01 (m, 1H), 6.07 (s, 2H), 3.47 (t, J=6.3 Hz, 2H), 3.34 (appq, J=6.6 Hz, 2H), 2.99 (s, 3H), 1.70 (app p, J=6.5 Hz, 2H); LCMS (M+H)⁺:398.1.

Example 128:N-(Azetidin-3-ylmethyl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared as in Example 127, using tert-butyl3-(aminomethyl)azetidine-1-carboxylate (14 mg, 0.078 mmol, Astatech).After the coupling step was complete, the crude reaction mixture wasdiluted with water and the product was extracted with EtOAc. Thecombined organic layers were dried over sodium sulfate, filtered, andthe solvent removed in vacuo. The crude residue was dissolved in 1:1mixture of TFA:DCM and the resultant reaction mixture was stirred for 1hour until the Boc group was removed. The title product was purifiedaccording to the methods of Example 127. Yield: (5.4 mg, 60%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.93 (t, J=5.8 Hz, 1H), 8.63 (br s, 2H),7.95 (d, J=9.9 Hz, 1H), 7.79 (s, 1H), 7.60 (d, J=9.8 Hz, 1H), 7.37-7.26(m, 2H), 7.19 (s, 1H), 7.09-6.97 (m, 1H), 6.03 (s, 2H), 4.03-3.92 (m,2H), 3.83-3.73 (m, 2H), 3.52 (t, J=6.3 Hz, 2H), 3.07-2.98 (m, 1H), 2.96(s, 3H); LCMS (M+H)⁺: 409.2.

Example 129:6-(3-Chlorobenzyl)-N-isobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 127,using 2-methyl-1-propanamine (5.7 mg, 0.078 mmol, Aldrich). Yield: (4.3mg, 60%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.76 (t, J=5.9 Hz, 1H), 8.19 (d, J=9.8 Hz,1H), 7.85 (s, 1H), 7.67 (d, J=9.8 Hz, 1H), 7.35-7.27 (m, 2H), 7.17 (s,1H), 7.09-7.02 (m, 1H), 6.07 (s, 2H), 3.11 (t, J=6.4 Hz, 2H), 3.01 (s,3H), 1.84 (dp, J=13.3, 6.7 Hz, 1H), 0.89 (d, J=6.7 Hz, 6H); LCMS (M+H)⁺:396.1.

Example 130:6-(3-Chlorobenzyl)-1-methyl-N-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 127,using 4-(aminomethyl)pyridine (8.5 mg, 0.078 mmol, Aldrich). Yield: (4.2mg, 50%).

¹H NMR (500 MHz, d₆-DMSO) δ 9.49 (t, J=5.9 Hz, 1H), 8.70 (d, J=6.3 Hz,2H), 8.03 (d, J=9.8 Hz, 1H), 7.95 (s, 1H), 7.67-7.60 (m, 3H), 7.34-7.28(m, 2H), 7.14 (s, 1H), 7.03-6.98 (m, 1H), 6.04 (s, 2H), 4.66 (d, J=5.9Hz, 2H), 2.99 (s, 3H); LCMS (M+H)⁺: 431.1.

Example 131:6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

Step 1. Methyl 3-chloro-5-(hydroxymethyl)benzoate

To a solution of dimethyl 5-chloroisophthalate (10.0 g, 43.7 mmol,Astatech) in methanol (50 mL) and methylene chloride (50 mL) at 0° C.was added sodium borohydride (5.5 g, 140 mmol, Aldrich). The reactionwas allowed to gradually reach room temperature and stir for 1 hour.Additional portions of sodium borohydride (0.50 g, 13 mmol) were addedat 2 hours and 3 hours. The reaction mixture was cooled to 0° C. and thereaction was quenched with water. The layers were separated and theaqueous layer was extracted with three portions of DCM. The combinedorganic extracts were dried over sodium sulfate, filtered andconcentrated. The product was purified by flash chromatography, elutingwith a gradient from 0-25% EtOAc in hexanes.

Yield: (4.51 g, 51%).

¹H NMR (400 MHz, CDCl₃) δ 7.92-7.90 (m, 1H), 7.90-7.88 (m, 1H),7.57-7.55 (m, 1H), 4.73 (s, 2H), 3.92 (s, 3H); LCMS (M+H)⁺: 201.1/203.1.

Step 2.[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorophenyl]methanol

To a solution of methyl 3-chloro-5-(hydroxymethyl)benzoate (4.51 g, 22.5mmol, from Step 1) in methylene chloride (60 mL) was added 1H-imidazole(1.61 g, 23.6 mmol), followed by the addition oftert-butylchlorodiphenylsilane (6.14 mL, 23.6 mmol) and4-dimethylaminopyridine (0.27 g, 2.2 mmol). The reaction mixture wasstirred for 3 hours, transferred to a separatory funnel and washed withwater. The aqueous layer was extracted with three portions of EtOAc andthe extracts were combined with the original DCM layer. The combinedorganic extracts were washed with water, followed by brine, dried oversodium sulfate, filtered and concentrated. The intermediate ester wasused without further purification in the following reduction reaction.

The intermediate ester was dissolved in toluene (60 mL) and DCM (20 mL)and the reaction mixture was cooled to −40° C. 1.0 M solution ofdiisobutylaluminum hydride in toluene (45 mL, 45 mmol, Aldrich) wasadded dropwise. After complete addition, cooling bath was removed andthe reaction was allowed to warm to room temperature. The reaction wascooled again to −40° C. and additional 1.0 M diisobutylaluminum hydridein DCM (45 mL, 45 mmol) was added. Upon completion of the secondaddition, the cooling bath was removed and the reaction was allowed towarm to room temperature. The reaction was quenched by the addition of asolution of Rochelle's salt and the resulting mixture was stirredovernight. The layers were separated, and the aqueous layer wasextracted with two further portions of DCM. The combined organicextracts were dried over sodium sulfate, filtered and concentrated. Theproduct was purified by flash chromatography, eluting with a gradientfrom 0-50% EtOAc in hexanes. Yield: (7.86 g, 85%).

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.64 (m, 4H), 7.47-7.35 (m, 6H),7.28-7.26 (m, 1H), 7.26-7.23 (m, 1H), 7.15-7.12 (m, 1H), 4.72 (s, 2H),4.65 (d, J=5.9 Hz, 2H), 1.09 (s, 9H); LCMS (M+Na)+: 433.3.

Step 3. 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzylmethanesulfonate

Triethylamine (7.8 mL, 56 mmol) and methanesulfonyl chloride (2.9 mL, 37mmol) were added to a solution of[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorophenyl]methanol(7.65 g, 18.6 mmol, from Step 2) in DCM (50 mL) at 0° C. The coolingbath was removed and after reaction mixture warmed to room temperature,the reaction mixture was diluted with DCM and washed with water. Theaqueous layer was extracted with two further portions of DCM. Thecombined organic extracts were washed with brine, dried over sodiumsulfate, filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-40% EtOAc/hexanes. Yield:(6.8 g, 75%).

¹H NMR (400 MHz, CDCl₃) δ 7.69-7.64 (m, 4H), 7.47-7.36 (m, 6H),7.36-7.34 (m, 1H), 7.29-7.27 (m, 1H), 7.22-7.20 (m, 1H), 5.17 (s, 2H),4.73 (s, 2H), 2.96 (s, 3H), 1.10 (s, 9H).

Step 4. 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.645 g, 3.28mmol, from Example 99, Step 1) and Cs₂CO₃ (3.2 g, 9.8 mmol) were addedto a solution of3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzylmethanesulfonate (3.88 g, 7.93 mmol, from Step 3) in DMF (13 mL).Concurrently, a separate batch of5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.558 g, 2.81mmol) was treated with the same reagents under the same conditions.After stirring each reaction overnight, the reactions were combined,diluted with water and extracted with three portions of EtOAc. Thecombined organic extracts were washed sequentially with water and brine,dried over sodium sulfate, filtered and concentrated. The product waspurified by flash chromatography, eluting with a gradient from 0-50%EtOAc in hexanes. Yield: (3.11 g, 52%).

¹H NMR (400 MHz, CDCl₃) δ 7.69-7.62 (m, 4H), 7.60-7.53 (m, 5H),7.50-7.18 (m, 16H), 7.18-7.15 (m, 1H), 7.15-7.10 (m, 1H), 6.96-6.92 (m,1H), 6.81-6.79 (m, 1H), 5.77 (s, 2H), 5.27 (s, 2H), 4.71 (s, 2H), 4.59(s, 2H), 1.08 (s, 9H), 0.98 (s, 9H); LCMS (M+H)⁺: 983.3.

Step 5. Di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-({[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A degassed mixture of3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(3.11 g, 3.16 mmol, from Step 4), di-tert-butylhydrazine-1,2-dicarboxylate (0.81 g, 3.5 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.29 g, 0.37 mmol, Aldrich) and Cs₂CO₃ (1.1 g, 3.5 mmol) intoluene (36 mL) was sealed and heated at 110° C. for 4 hours. Thereaction mixture was partitioned between water and ethyl acetate and theaqueous was extracted three times. The combined organic extracts weredried over sodium sulfate, filtered and concentrated. The product waspurified by flash chromatography, eluting with a gradient from 0-25%EtOAc in hexanes.

Yield: (1.19 g, 32%).

LCMS (M+H)⁺: 1179.2.

Step 6. 3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate

A solution of di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-({[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(1.19 g, 1.01 mmol, from Step 5) in acetic acid (40 mL) was partitionedequally into four microwavable vials. Each was heated to 180° C. in themicrowave for 5 minutes. The batches were combined and the acetic acidwas removed in vacuo. An additional NaHCO₃ solution was added and theproduct was extracted with EtOAc. The combined organic extracts weredried over sodium sulfate, filtered and concentrated. The product wasused without further purification. Yield: (0.75 g, 74%).

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.24 (m, 25H), 7.23-7.20 (m, 1H),7.15-7.12 (m, 1H), 6.98-6.94 (m, 1H), 6.83-6.79 (m, 1H), 5.87 (s, 2H),5.28 (s, 2H), 4.73 (s, 2H), 4.61 (s, 2H), 2.93 (s, 3H), 1.08 (s, 9H),0.94 (s, 9H); LCMS (M+H)⁺: 1001.1/1003.1.

Step 7. 3-Chloro-5-formylbenzyl6-(3-chloro-5-formylbenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate

Acetic acid (0.041 mL, 0.72 mmol) and 1.0 M solution of TBAF in THF(0.79 mL, 0.79 mmol, Aldrich) were added to a solution of3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.36 g, 0.36 mmol, from Step 1) in THF (20 mL). After stirring for 3hours, the reaction was poured into pH7 buffer and extracted with threeportions of EtOAc. The combined organic extracts were dried over Na₂SO₄,filtered and concentrated.

Manganese (IV) oxide (0.2 g, 2 mmol, Aldrich) was added to a DCM (20 mL)solution of the bis-alcohol intermediate. After stirring overnight,additional manganese (IV) oxide was added (total of 1.3 g, 15 mmol, inthree portions over 4.5 hours) to drive the reaction to completion. Thereaction mixture was diluted with further DCM, and Celite was added intothe reaction, which was then swirled and allowed to settle. The mixturewas filtered through a well-packed pad of Celite and rinsed with severalportions of DCM. The filtrate was dried over sodium sulfate, andfiltered, and the solvent was removed in vacuo. The product was purifiedby flash chromatography, eluting with a gradient from 0-10% MeOH in DCM.Yield: (70 mg, 37%).

¹H NMR (400 MHz, CDCl₃) δ 9.98 (s, 1H), 9.88 (s, 1H), 7.85-7.83 (m, 1H),7.82-7.79 (m, 1H), 7.76-7.73 (m, 1H), 7.66-7.64 (m, 1H), 7.62 (d, J=9.9Hz, 1H), 7.58 (d, J=0.5 Hz, 1H), 7.42-7.39 (m, 1H), 7.30 (dd, J=9.9, 0.5Hz, 1H), 7.25-7.22 (m, 1H), 5.94 (s, 2H), 5.38 (s, 2H), 3.03 (s, 3H);LCMS (M+H)⁺: 521.0/523.0.

Step 8. 3-(Azetidin-1-ylmethyl)-5-chlorobenzyl6-[3-(azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylatetris(trifluoroacetate) salt

Sodium triacetoxyborohydride (0.2 g, 1 mmol, Aldrich) was added to amixture of 3-chloro-5-formylbenzyl6-(3-chloro-5-formylbenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.070 g, 0.13 mmol, from Step 7) and azetidine (0.08 mL, 1 mmol,Aldrich) in DCM (4 mL). After 2 hours, additional azetidine (0.020 mL,0.30 mmol) and sodium triacetoxyborohydride (0.050 g, 0.24 mmol) wereadded and the reaction was continued for 30 minutes. Solvent was removedin vacuo, the crude residue was dissolved in MeCN and water, filteredand purified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (80 mg, 63%).

¹H NMR (400 MHz, CD₃OD) δ 8.30 (d, J=9.8 Hz, 1H), 7.92 (s, 1H), 7.78 (d,J=9.8 Hz, 1H), 7.58-7.54 (m, 1H), 7.54-7.49 (m, 2H), 7.45-7.38 (m, 1H),7.17-7.11 (m, 2H), 6.09 (s, 2H), 5.41 (s, 2H), 4.39 (s, 2H), 4.28 (s,2H), 4.24-3.97 (m, 8H), 3.13 (s, 3H), 2.64-2.33 (m, 4H); LCMS (M+H)⁺:603.3.

Step 9.6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

3-(Azetidin-1-ylmethyl)-5-chlorobenzyl6-[3-(azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylatetrifluoroacetate salt (0.080 g, 0.085 mmol, from Step 8) in THF (2 mL)was treated with 1.0 M solution of NaOH in water (2 mL, 2 mmol). After 1hour, MeCN and MeOH were added to make the reaction monophasic, and theproduct was purified by preparative HPLC-MS (Waters XBridge C18, elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (35 mg,100%).

LCMS (M+H)⁺: 410.2.

Step 10.6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

To a solution of6-[3-(azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.035 g, 0.085 mmol, from Step 9) in NMP (2 mL) was addedN,N-diisopropylethylamine (0.059 mL, 0.34 mmol), methylaminehydrochloride (9.9 mg, 0.15 mmol, Alfa Aesar) and HATU (0.042 g, 0.11mmol). After 30 minutes, the reaction was complete, and the reactionmixture was diluted with MeCN and a small amount of TFA. The product waspurified by preparative HPLC-MS (Waters SunFire C18, 5 um 30×100 mm, H₂O(0.1% TFA)/MeOH @ 60 mL/min). Yield: (0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.04 (d, J=9.6 Hz, 1H), 7.76 (s, 1H), 7.59 (d,J=9.7 Hz, 1H), 7.43-7.39 (m, 1H), 7.22-7.19 (m, 1H), 7.19-7.16 (m, 1H),6.06 (s, 2H), 4.29 (s, 2H), 4.19-4.00 (m, 4H), 3.08 (s, 3H), 2.92 (s,3H), 2.61-2.32 (m, 2H); LCMS (M+H)⁺: 423.2.

Example 132:6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide2.5×(trifluoroacetate) salt

Step 1.6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

3-Chloro-5-formylbenzyl6-(3-chloro-5-formylbenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylate(0.035 g, 0.067 mmol, from Example 131, Step 7) was suspended in DCM (4mL) and pyrrolidine (0.03 g, 0.4 mmol, Aldrich) and sodiumtriacetoxyborohydride (0.2 g, 0.8 mmol, Aldrich) were added. Afterstirring overnight, the reaction mixture was made basic by the additionof 1N solution of NaOH, and the product was extracted with EtOAc. Theorganic extract was dried over sodium sulfate, filtered andconcentrated. The crude product was stirred with 1.0 M solution of NaOH(2 mL, 2 mmol) and THF (2 mL) for 1.5 hours. The product was purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (5 mg, 18%).

LCMS (M+H)⁺: 424.2.

Step 2.6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide2.5×(trifluoroacetate) salt

N,N-Diisopropylethylamine (0.025 mL, 0.14 mmol), methylaminehydrochloride (0.0071 g, 0.10 mmol, Alfa Aesar) and HATU (0.011 g, 0.028mmol) were added to a solution of6-[3-chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.006 g, 0.01 mmol, from Step 1) in NMP (2 mL). The reactionmixture was stirred for 30 min and was diluted with MeCN. The productwas purified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (7 mg, 100%).

¹H NMR (300 MHz, CD₃OD) δ 8.09 (d, J=9.8 Hz, 1H), 7.77 (s, 1H), 7.61 (d,J=9.8 Hz, 1H), 7.49-7.44 (m, 1H), 7.26-7.22 (m, 1H), 7.22-7.16 (m, 1H),6.07 (s, 2H), 4.31 (s, 2H), 3.52-3.35 (m, 2H), 3.18-3.02 (m, 2H), 3.08(s, 3H), 2.91 (s, 3H), 2.25-1.88 (m, 4H); LCMS (M+H)⁺: 437.1.

Example 133:6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 132,Step 2, using6-[3-chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.015 g, 0.035 mmol, from Example 132, Step 1),N,N-diisopropylethylamine (0.031 mL, 0.18 mmol), ethylaminehydrochloride (0.014 g, 0.18 mmol, Aldrich), HATU (0.014 g, 0.037 mmol),and NMP (3 mL). Yield: (6 mg, 25%).

¹H NMR (400 MHz, CD₃OD) δ 8.07 (d, J=9.8 Hz, 1H), 7.79 (s, 1H), 7.60 (d,J=9.8 Hz, 1H), 7.49-7.46 (m, 1H), 7.29-7.26 (m, 1H), 7.19-7.14 (m, 1H),6.06 (s, 2H), 4.32 (s, 2H), 3.51-3.42 (br m, 2H), 3.40 (q, J=7.2 Hz,2H), 3.18-3.09 (br m, 2H), 3.09 (s, 3H), 2.22-2.07 (br m, 2H), 2.05-1.89(br m, 2H), 1.23 (t, J=7.3 Hz, 3H); LCMS (M+H)⁺: 451.3.

Example 134:6-{3-Chloro-5-[(3,3-difluoropyrrolidin-1-yl)methyl]benzyl}-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide2.4×(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 132,Steps 1 and 2, using 3,3-difluoropyrrolidine hydrochloride (55 mg, 0.38mmol, Synthonix) and N,N-diisopropylethylamine (0.067 mL, 0.38 mmol) inStep 1. Yield: (10 mg, 20% over the two steps).

¹H NMR (300 MHz, CD₃OD) δ 8.16 (d, J=9.8 Hz, 1H), 7.78 (s, 1H), 7.63 (d,J=9.8 Hz, 1H), 7.46-7.40 (m, 1H), 7.24-7.20 (m, 1H), 7.18-7.13 (m, 1H),6.07 (s, 2H), 4.19 (s, 2H), 3.54 (t, J=12.0 Hz, 2H), 3.39 (t, J=7.5 Hz,2H), 3.10 (s, 3H), 2.92 (s, 3H), 2.53 (tt, J=14.3, 7.4 Hz, 2H); ¹⁹F NMR(282 MHz, CD₃OD) δ −77.61 (s, 7.2° F.), −94.75-−97.06 (m, 2F); LCMS(M+H)⁺: 473.1.

Example 135:6-{3-Chloro-5-[(3,3-dimethylazetidin-1-yl)methyl]benzyl}-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 132,Steps 1 and 2, using 3,3-dimethylazetidine hydrochloride (0.066 g, 0.55mmol, Synthonix) and N,N-diisopropylethylamine (0.095 mL, 0.55 mmol) inStep 1. Yield: (15 mg, 23% over the two steps).

¹H NMR (400 MHz, CD₃OD) δ 8.03 (d, J=9.7 Hz, 1H), 7.75 (s, 1H), 7.59 (d,J=9.8 Hz, 1H), 7.45-7.41 (m, 1H), 7.27-7.23 (m, 1H), 7.17-7.12 (m, 1H),6.06 (s, 2H), 4.31 (s, 2H), 3.96-3.76 (m, 4H), 3.08 (s, 3H), 2.92 (s,3H), 1.36 (s, 3H), 1.31 (s, 3H); LCMS (M+H)⁺: 451.2.

Example 136:N,1-dimethyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

Step 1. 3-(Trifluoromethyl)benzyl5-chloro-1-[3-(trifluoromethyl)benzyl]-H-pyrrolo[3,2-b]pyridine-2-carboxylate

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (0.250 g, 1.27mmol, from Example 99, Step 1) in DMF (6 mL) was treated with Cs₂CO₃(1.6 g, 5.1 mmol) and 1-(bromomethyl)-3-(trifluoromethyl)benzene (0.39mL, 2.5 mmol, Aldrich). After stirring overnight, additional1-(bromomethyl)-3-(trifluoromethyl)benzene (0.21 mL, 1.4 mmol) was addedand stirring continued for an additional 24 hours. Water was added andthe product was extracted with three portions of EtOAc. The extract waswashed sequentially with water and brine, dried over sodium sulfate,filtered and concentrated. The product was used without furtherpurification in Step 2.

LCMS (M+H)⁺: 513.0/515.0.

Step 2. Di-tert-butyl1-[1-[3-(trifluoromethyl)benzyl]-2-({[3-(trifluoromethyl)benzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A degassed mixture of 3-(trifluoromethyl)benzyl5-chloro-1-[3-(trifluoromethyl)benzyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxylate(3.2 g, 6.2 mmol, prepared as in Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (1.6 g, 6.9 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.58 g, 0.74 mmol, Aldrich) and Cs₂CO₃ (2.2 g, 6.9 mmol) intoluene (71 mL) was heated at 110° C. for 2 hours. Upon cooling, waterwas added, and the layers were separated. The aqueous layer was furtherextracted with three portions of EtOAc. The combined organic extractswere dried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanes wasused to purify the product. Yield: (0.28 g, 6% over the two steps).

LCMS (M+H)⁺: 709.1.

Step 3.1-Methyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid

Di-tert-butyl1-[1-[3-(trifluoromethyl)benzyl]-2-({[3-(trifluoromethyl)benzyl]oxy}carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.28 g, 0.40 mmol, from Step 2) in acetic acid (10 mL) was heated to180° C. in the microwave for 5 minutes. The acetic acid was then removedin vacuo. The residue was dissolved in THF (10 mL) and 1.0 M NaOH (10mL, 10 mmol) was added. After stirring for 20 minutes, MeOH was added tomake the mixture monophasic and the product was purified by preparativeHPLC-MS (Waters XBridge C18, eluting with a gradient of MeCN/H₂Ocontaining 0.15% NH₄OH). Yield: 45 mg, 30%.

LCMS (M+H)⁺: 375.3.

Step 4.N,1-Dimethyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

To a solution of1-methyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (0.022 g, 0.059 mmol, from Step 3) in NMP (2 mL) was addedN,N-diisopropylethylamine (0.051 mL, 0.29 mmol), methylaminehydrochloride (0.020 g, 0.29 mmol, Alfa Aesar) followed by HATU (0.027g, 0.070 mmol). The product was purified by preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeOH/H₂O containing 0.1% TFA).Yield: 7 mg, 20%.

¹H NMR (400 MHz, CD₃OD) δ 7.99 (d, J=9.8 Hz, 1H), 7.69 (s, 1H), 7.56 (d,J=7.8 Hz, 1H), 7.54 (d, J=9.9 Hz, 1H), 7.52-7.45 (m, 2H), 7.36 (d, J=7.5Hz, 1H), 6.12 (s, −2H), 3.05 (s, 3H), 2.92 (s, 3H); LCMS (M+H)⁺: 388.1.Example 137:N-Ethyl-1-methyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 136,using ethylamine hydrochloride (0.024 g, 0.29 mmol, Aldrich). Yield:(0.01 g, 30%).

¹H NMR (400 MHz, CD₃OD) δ 8.23 (d, J=9.7 Hz, 1H), 7.77 (d, J=0.6 Hz,1H), 7.63 (d, J=9.8 Hz, 1H), 7.57 (d, J=7.9 Hz, 1H), 7.53-7.45 (m, 2H),7.39 (d, J=7.7 Hz, 1H), 6.15 (s, 2H), 3.41 (q, J=7.3 Hz, 2H), 3.10 (s,3H), 1.22 (t, J=7.3 Hz, 3H); LCMS (M+H)⁺: 402.2.

Example 138:6-Benzyl-1-methyl-7-(trifluoromethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

Step 1. tert-Butyl (6-chloro-2-methylpyridin-3-yl)carbamate

To 6-chloro-2-methylpyridin-3-amine (9.50 g, 66.6 mmol, Matrix) anddi-tert-butyldicarbonate (14 g, 67 mmol, Aldrich) in THF (280 mL) at−20° C. was added dropwise 1.0 M LHMDS (lithiumbis(trimethylsilyl)amide) in THF (67 mL, 67 mmol, Aldrich). After 45minutes, additional di-tert-butyldicarbonate (14 g, 67 mmol) and 1.0 MLHMDS in THF (67 mL, 67 mmol) were introduced. After 45 minutes,additional 1.0 M LHMDS in THF (20.0 mL, 20.0 mmol) was added and thereaction was complete after 1 hour. Water was added, the layers wereseparated, and the aqueous layer was further extracted with threeportions of ethyl acetate. The combined organic extracts were dried oversodium sulfate, filtered and concentrated. The crude product was treatedwith 1.0 M NaOH in water (200 mL, 200 mmol) in 2:1 THF/MeOH (300 mL).Additional solid NaOH (11 g, 270 mmol) was added and the reaction wasstirred overnight. Volatile solvents were removed in vacuo. The productwas extracted from the remaining aqueous mixture using EtOAc. Thecombined organic extracts were washed sequentially with water and brine,dried over sodium sulfate, filtered and concentrated. The product waspurified via flash chromatography, eluting with a gradient from 0-50%EtOAc in hexanes. Yield: (15.4 g, 95%).

¹H NMR (400 MHz, CDCl₃) δ 8.16 (br s, 1H), 7.14 (d, J=8.6 Hz, 1H), 6.32(s, 1H), 2.46 (s, 3H), 1.51 (s, 6H); LCMS (M+H)⁺: 243.1/245.1.

Step 2.5-Chloro-1-(phenylsulfonyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine

To a solution of tert-butyl (6-chloro-2-methylpyridin-3-yl)carbamate(7.00 g, 28.8 mmol, from Step 1) in THF (100 mL) at −78° C. was added1.3 M sec-butyllithium in cyclohexane (46.6 mL, 60.6 mmol, Pfaltz andBauer). After 15 minutes, ethyl trifluoroacetate (4.12 mL, 34.6 mmol,Aldrich) in THF (60 mL) was introduced. After 30 min, the reaction waspoured into 1N HCl and the aqueous layer was extracted with threeportions of Et₂O. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated.

The crude trifluoromethyl ketone was stirred overnight in a mixture ofTFA (35 mL) and DCM (175 mL). Solvent was removed in vacuo. The residuewas partitioned between EtOAc and NaHCO₃ solution. The aqueous layer wasextracted further with two portions of EtOAc, and the combined organicextracts were washed with brine, dried over sodium sulfate, filtered andconcentrated.

The crude pyrrolopyridine was treated with triethylamine (6.0 mL, 43mmol), benzenesulfonyl chloride (4.0 mL, 32 mmol, Aldrich) and4-dimethylaminopyridine (0.4 g, 3 mmol, Aldrich) in DCM (100 mL). Afterstirring overnight, the reaction mixture was partitioned between waterand EtOAc. The organic layer was washed with brine, then dried oversodium sulfate, filtered and concentrated. The product was purified byflash chromatography, eluting with a gradient from 0-25% EtOAc inhexanes. Yield: (8.07 g, 77%).

¹H NMR (400 MHz, CDCl₃) δ 8.53 (dd, J=8.9, 0.7 Hz, 1H), 7.89-7.84 (m,2H), 7.67-7.60 (m, 1H), 7.53-7.46 (m, 2H), 7.43 (d, J=8.9 Hz, 1H), 7.29(s, 1H); LCMS (M+H)⁺: 361.0/363.0.

Step 3. Di-tert-butyl1-[1-(phenylsulfonyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A degassed mixture of5-chloro-1-(phenylsulfonyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine(0.500 g, 1.39 mmol, from Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (0.35 g, 1.5 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.13 g, 0.16 mmol, Aldrich) and Cs₂CO₃ (0.50 g, 1.5 mmol) intoluene (11.5 mL) was heated at 110° C. for 2 hours. After cooling toroom temperature, water was added, and the aqueous layer was extractedwith three portions of EtOAc. The combined organic extracts were driedover sodium sulfate, filtered and concentrated. The product was purifiedby flash chromatography, eluting with a gradient from 0-50% EtOAc inhexanes. (Yield: 0.66 g, 86%).

LCMS (M+H)⁺: 557.2.

Step 4. 1-Methyl-7-(trifluoromethyl)-6H-pyrrolo[2,3-e][, 2,4]triazolo[4,3-a]pyridine

A solution of di-tert-butyl1-[1-(phenylsulfonyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.66 g, 1.2 mmol, from Step 3) in acetic acid (20 mL) was heated at180° C. for 5 minutes in the microwave. The acetic acid was removed invacuo. The residue was dissolved in EtOAc and washed with an additionalNaHCO₃ solution. The organic layer was dried over sodium sulfate,filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-10% MeOH in DCM. Yield:(0.14 g, 49%).

LCMS (M+H)⁺: 241.0.

Step 5.6-Benzyl-1-methyl-7-(trifluoromethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

A solution of1-methyl-7-(trifluoromethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.020 g, 0.083 mmol, from Step 4) in DMF (0.5 mL) was treated withCs₂CO₃ (0.054 g, 0.17 mmol) and benzyl bromide (0.010 mL, 0.084 mmol,Aldrich). After stirring overnight, the reaction was diluted with waterand MeOH. The product was purified by preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (6 mg, 12%).

¹H NMR (400 MHz, CD₃OD) δ 8.12 (d, J=9.8 Hz, 1H), 7.77 (s, 1H), 7.70 (d,J=9.8 Hz, 1H), 7.35-7.25 (m, 3H), 7.08-7.02 (m, 2H), 5.79 (s, 2H), 3.11(s, 3H); LCMS (M+H)⁺: 331.0.

Example 139:1-(3-Chloro-5-{[1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)azetidin-3-ol

Step 1. 5-Chloro-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

To 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (2.00 g, 10.2mmol, from Example 99, Step 1) in THF (40 mL) at 0° C. was added4-methylmorpholine (1.3 mL, 12 mmol, Aldrich) and isobutyl chloroformate(1.38 mL, 10.7 mmol, Aldrich). After 20 minutes, hydrazine hydrate (3.0mL, 61 mmol, Aldrich) was added. Cooling was discontinued and thereaction was stirred overnight. The reaction mixture was diluted withEtOAc and washed sequentially with an additional NaHCO₃ and brine. Theaqueous layer was extracted with EtOAc. Insoluble material at theinterface of the layers was collected by filtration. The combinedorganic extracts were dried over sodium sulfate, filtered andconcentrated. The product from the extracts and the solid from thefiltration were combined and dissolved in trimethylorthoformate (35 mL,Aldrich). p-Toluenesulfonic acid (150 mg, 0.87 mmol, Aldrich) was addedand the mixture was heated to 90° C. for 2 hours. Trimethylorthoformatewas removed from the filtrate in vacuo to yield a crude product whichwas used in step 2 without purification.

LCMS (M+H)⁺: 221.0/223.0.

Step 2.1-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

Triethylamine (0.71 mL, 5.1 mmol) and methanesulfonyl chloride (0.29 mL,3.7 mmol, Aldrich) were added to a solution of[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorophenyl]methanol(1.40 g, 3.40 mmol, from Example 131, Step 2) in DCM (10 mL) at 0° C.After 1 hour, the reaction mixture was diluted with DCM, washedsequentially with water and brine, dried over sodium sulfate, filteredand concentrated to afford the crude mesylate.

5-Chloro-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine (0.750 g,3.40 mmol, from Step 1) in N,N-dimethylformamide (10 mL) was treatedwith Cs₂CO₃ (3.3 g, 10. mmol) followed by a solution of the crudemesylate generated above as a solution in DMF (5 mL). After 1.5 hours,the mixture was diluted with water and the aqueous layer was extractedthree times with EtOAc. The combined organic extracts were dried oversodium sulfate, filtered and concentrated. The product was purified byflash chromatography, eluting with a gradient from 0-50% EtOAc inhexanes. Yield: (1.0 g, 48%).

¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 7.59 (dd, J=8.7, 0.8 Hz, 1H),7.57-7.52 (m, 4H), 7.45-7.38 (m, 3H), 7.37-7.30 (m, 4H), 7.21 (d, J=8.7Hz, 1H), 7.16-7.11 (m, 1H), 7.01-6.97 (m, 1H), 6.85-6.81 (m, 1H), 6.03(s, 2H), 4.59 (s, 2H), 0.97 (s, 9H); LCMS (M+H)⁺: 613.0/615.0.

Step 3. Di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A degassed mixture of1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine(0.500 g, 0.815 mmol, from Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (0.21 g, 0.90 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.076 g, 0.096 mmol, Aldrich) and Cs₂CO₃ (0.29 g, 0.90 mmol) intoluene (7 mL) was heated at 110° C. for 4 h. Additional di-tert-butylhydrazine-1,2-dicarboxylate (0.1 g, 0.43 mmol), Cs₂CO₃ (0.15 g, 0.46mmol), anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.050 g, 0.063 mmol) were added and heating was continued for 5h. Upon cooling, the reaction mixture was diluted with water andextracted with three portions of EtOAc. The combined organic extractswere dried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanes wasused to purify product. Yield: (0.26 g, 39%).

¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 7.66-7.29 (m, 13H), 7.20-7.15(m, 1H), 6.97-6.93 (m, 1H), 6.91-6.84 (m, 1H), 6.00 (s, 2H), 4.61 (s,2H), 1.49 (s, 9H), 1.47 (s, 9H), 1.00 (s, 9H); LCMS (M+H)⁺: 809.2.

Step 4.(3-Chloro-5-{[1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}phenyl)methanol

A solution of di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.26 g, 0.32 mmol, from Step 3) in acetic acid (15 mL) was heated at180° C. for 5 minutes in the microwave. Acetic acid was removed invacuo. The residue was partitioned between an additional NaHCO₃ andEtOAc. The aqueous layer was further extracted with two portions ofEtOAc. The combined organic layers were dried over sodium sulfate,decanted and concentrated. The product was dissolved in THF (5 mL) andwas treated with 1.0 M TBAF in THF (0.64 mL, 0.64 mmol, Aldrich). Whenthe reaction was complete as determined by LCMS, the reaction mixturewas poured into pH 7 buffer and extracted with three portions of EtOAc.The combined organics were dried over sodium sulfate, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-10%MeOH in DCM was used to purify the product. Yield: (0.045 g, 35%).

LCMS (M+H)⁺: 395.1/397.1.

Step 5.1-(3-Chloro-5-{[1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)azetidin-3-ol

Triethylamine (49 μL, 0.35 mmol) and methanesulfonyl chloride (22 μL,0.28 mmol, Aldrich) were added to a mixture of(3-chloro-5-{[1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}phenyl)methanol(0.033 g, 0.084 mmol, from Step 4) in DCM (4.9 mL). After 30 minutes,additional triethylamine (49 μL, 0.35 mmol) and methanesulfonyl chloride(22 μL, 0.28 mmol) were added. After 30 additional minutes, the mixturewas briefly heated to reflux and then cooled. The solvent was removed invacuo. The crude mesylate was reconstituted in THF (1.9 mL) and Methanol(1.9 mL). Half of this solution was added to azetidin-3-ol hydrochloride(37 mg, 0.33 mmol, Aldrich) and triethylamine (46 μL, 0.33 mmol) in THF(0.2 mL). [The other half of the mesylate solution was used in Example140]. After 20 minutes, additional azetidin-3-ol hydrochloride (125 mg,1.12 mmol, Aldrich) and triethylamine (156 μL, 1.12 mmol) were added andthe mixture was stirred overnight. Sequential preparative HPLC-MS runswere used to purify the product (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA, followed by Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield:(5 mg, 10%).

¹H NMR (500 MHz, DMSO) δ 9.43 (s, 1H), 7.78 (d, J=9.9 Hz, 1H), 7.74 (s,1H), 7.59 (d, J=9.8 Hz, 1H), 7.18-7.16 (m, 1H), 7.00-6.98 (m, 1H),6.97-6.94 (m, 1H), 6.11 (s, 2H), 5.23 (d, J=6.4 Hz, 1H), 4.11 (h, J=6.1Hz, 1H), 3.45 (s, 2H), 3.40-3.35 (m, 2H), 2.98 (s, 3H), 2.68-2.63 (m,2H); LCMS (M+H)⁺: 450.2.

Example 140:6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

The remaining mesylate solution prepared in Example 139, Step 5 wastreated with the solution of azetidine (0.023 mL, 0.33 mmol, Aldrich) inTHF (0.2 mL). After 20 minutes, additional azetidine (0.078 mL, 1.1mmol, Aldrich) was added and the reaction was stirred overnight. Theproduct was isolated by preparative HPLC-MS (Waters XBridge C18, elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (5 mg, 10%).

¹H NMR (400 MHz, CD₃OD) δ 9.07 (s, 1H), 7.81-7.77 (m, 2H), 7.54 (d,J⁼10.0 Hz, 1H), 7.21-7.18 (m, 1H), 7.09-7.06 (m, 1H), 6.93-6.90 (m, 1H),6.16 (s, 2H), 3.48 (s, 2H), 3.17 (t, J=7.2 Hz, 4H), 3.06 (s, 3H), 2.04(p, J=7.1 Hz, 2H); LCMS (M+H)⁺: 434.2.

Example 141:6-(3-Chlorobenzyl)-1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

Step 1.5-Chloro-1-(3-chlorobenzyl)-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

5-Chloro-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine (0.060 g,0.27 mmol, from Example 139, Step 1) in DMF (5 mL) was treated withCs₂CO₃ (0.222 g, 0.681 mmol) and 1-(bromomethyl)-3-chloro-benzene (0.046mL, 0.35 mmol). After 1 hour, additional1-(bromomethyl)-3-chloro-benzene (0.040 mL, 0.30 mmol, Aldrich) wasadded and stirring continued for 1 hour. Water was added, and thesolution was extracted with three portions of EtOAc. The combinedorganic extracts were washed sequentially with water and brine, driedover sodium sulfate, filtered and concentrated. Flash chromatography,eluting with a gradient from 0-40% EtOAc in hexanes afforded purifiedproduct. Yield: (67 mg, 71%).

LCMS (M+H)⁺: 345.0/346.9.

Step 2.6-(3-chlorobenzyl)-1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

A degassed mixture of5-chloro-1-(3-chlorobenzyl)-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridine(0.067 g, 0.19 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.050 g, 0.21 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.018 g, 0.023 mmol, Aldrich) and Cs₂CO₃ (0.070 g, 0.21 mmol) intoluene (3 mL) was heated at 110° C. for 5.5 h. After cooling to roomtemperature, water was added, and the layers were separated. The aqueouslayer was further extracted with three portions of EtOAc. The combinedorganic extracts were dried over sodium sulfate, filtered andconcentrated. The intermediate di-tert-butyl1-(1-(3-chlorobenzyl)-2-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylatewas purified by flash chromatography, eluting with a gradient from 0-50%EtOAc. The intermediate product was dissolved in acetic acid (5 mL) andheated at 180° C. for 5 minutes in the microwave, and the title productwas purified by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (6 mg, 7%).

¹H NMR (500 MHz, DMSO) δ 9.44 (s, 1H), 7.91 (d, J=9.8 Hz, 1H), 7.79 (s,1H), 7.64 (d, J=9.8 Hz, 1H), 7.36-7.28 (m, 2H), 7.23-7.18 (m, 1H),7.02-6.94 (m, 1H), 6.15 (s, 2H), 3.00 (s, 3H); LCMS (M+H)⁺: 365.1.

Example 142:N-{6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl}-N′-methylureabis(trifluoroacetate) salt

Step 1.4-Bromo-1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1,7-Dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(4.00 g, 12.2 mmol, from Example 2, Step 4) in 1,2-dichloroethane (100mL) was treated with N-bromosuccinimide (2.18 g, 12.2 mmol, Aldrich) at60° C. for 1 hour. Additional N-bromosuccinimide (1.08 g, 6.07 mmol) wasadded and heating continued for 1 hour. The reaction mixture was cooledto room temperature and diluted with DCM, then washed sequentially withan additional NaHCO₃ and brine, dried over sodium sulfate, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-10%MeOH in DCM, afforded purified product.

Yield: (1.57 g, 31%).

LCMS (M+H)⁺: 405.0/407.0.

Step 2.4-Bromo-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

1.0 M NaOH in water (15 mL, 15 mmol) was added to4-bromo-1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(1.57 g, 3.87 mmol, from Step 1) in THF (15 mL) and EtOH (15 mL). Thereaction was continued for 1 hour, and a precipitate formed. The solidproduct was isolated by filtration. The solid was then suspended inEt₂O, filtered and air dried. Yield: (0.86 g, 84%).

¹H NMR (400 MHz, d₆-DMSO): δ 11.83 (s, 1H), 7.78 (d, J=0.7 Hz, 1H), 6.69(s, 1H), 2.86 (s, 3H), 2.42 (s, 3H); LCMS (M+H)⁺: 265.0/267.0.

Step 3.4-Bromo-6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

Triethylamine (0.68 mL, 4.9 mmol) and methanesulfonyl chloride (0.301mL, 3.89 mmol, Aldrich) were added to[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorophenyl]methanol(1.47 g, 3.57 mmol, from Example 131, Step 2) in DCM (10 mL) at 0° C.After 1 hour, the reaction mixture was diluted with DCM, and was washedsequentially with water and brine, dried over sodium sulfate, filteredand concentrated to afford a crude intermediate. The crude intermediatewas dissolved in DMF (5 mL) and added to a mixture of4-bromo-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.86 g, 3.2 mmol, from Step 2) and Cs₂CO₃ (3.2 g, 9.7 mmol) in DMF (10mL). After 2 hours, the reaction mixture was diluted with water andextracted with three portions of EtOAc. The combined organic extractswere dried over sodium sulfate, filtered and concentrated. The productwas purified by flash chromatography, eluting first with a gradient of0-100% EtOAc in hexanes, and then eluting with a gradient from 5-10%MeOH in DCM.

LCMS (M+H)⁺: 659.2.

Step 4.{3-[(4-Bromo-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-5-chlorophenyl}methanol

4-Bromo-6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(2.1 g, 3.2 mmol, from Step 3) in THF (30 mL) was treated with 1.0 MTBAF in THF (6.4 mL, 6.4 mmol, Aldrich) for 1 hour. The reaction mixturewas diluted with water and extracted with three portions of EtOAc. Thecombined organic extracts were washed with brine, dried over sodiumsulfate, filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-10% MeOH.

Yield: (0.722 g, 54% over the two steps).

LCMS (M+H)⁺: 419.0/421.0.

Step 5.4-Bromo-6-[3-chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of{3-[(4-bromo-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-5-chlorophenyl}methanol(0.360 g, 0.858 mmol, from Step 4) in DCM (50. mL) was treated withtriethylamine (510 μL, 3.6 mmol) and methanesulfonyl chloride (220 μL,2.9 mmol, Aldrich). After 30 minutes, the solvent was removed in vacuo,and the residue was dissolved in a mixture of THF (20. mL) and methanol(20. mL). The solution was added to a mixture of pyrrolidine (0.42 mL, 5mmol, aldrich) and triethylamine (0.61 mL, 4.3 mmol) in THF (10 mL). Thereaction was stirred for 1 hour, and then the solvent was removed invacuo. The residue was partitioned between water and DCM. The organiclayer was dried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-10% MeOH in DCM, was usedto purify product. Yield: (0.30 g, 74%).

¹H NMR (400 MHz, CD₃OD) δ 7.84 (s, 1H), 7.28-7.24 (m, 1H), 6.94-6.90 (m,1H), 6.84-6.81 (m, 1H), 6.76 (s, 1H), 5.43 (s, 2H), 3.55 (s, 2H), 2.92(s, 3H), 2.51-2.41 (m, 4H), 2.39 (s, 3H), 1.79-1.68 (m, 4H); LCMS(M+H)⁺: 472.1/474.1.

Step 6.N-{6-[3-chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl}-N′-methylureabis(trifluoroacetate) salt

A degased suspension of4-bromo-6-[3-chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(110.0 mg, 0.2326 mmol, from Step 5), tBuBrettPhos Pd G3(tert-BuBrettPhos-Pd-G3,[(2-Di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II)methanesulfonate) (24 mg, 0.028 mmol, Aldrich), N-methylurea (25 mg,0.33 mmol, Aldrich), Water (0.082 mL, 4.6 mmol), and Cs₂CO₃ (116.7 mg,0.3583 mmol) in N-Methylpyrrolidinone (1 mL) was heated at 80° C. for 1hour, then at 90° C. for 1 hour. The reaction mixture was diluted withwater and MeCN and was purified by preparative HPLC-MS (Waters SunFireC18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Thepurest fractions were collected, eluent removed in vacuo and the productrepurified by HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeOH/H₂O containing 0.1% TFA). Yield: (5 mg, 3%).

¹H NMR (400 MHz, CD₃OD) δ 8.15 (s, 1H), 7.52-7.50 (m, 1H), 7.15-7.12 (m,2H), 7.07-7.03 (m, 1H), 5.62 (s, 2H), 4.31 (s, 2H), 3.54-3.38 (br m,2H), 3.16-3.03 (br m, 2H), 3.09 (s, 3H), 2.80 (s, 3H), 2.54 (s, 3H),2.21-2.06 (br m, 2H), 2.06-1.89 (br m, 2H); LCMS (M+H)⁺: 466.2.

Example 143:6-benzyl-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

Step 1.5-chloro-2-(1,3-oxazol-2-yl)-1-(phenylsulfonyl)-H-pyrrolo[3,2-b]pyridine

A degassed mixture of2-bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (4.3 g, 12mmol, prepared by the procedure of Example 62, Step 1 but purified byflash chromatography to afford the free base),2-(tributylstannyl)-1,3-oxazole (5.0 g, 14 mmol, Aldrich), andTetrakis(triphenylphosphine)palladium(0) (1.3 g, 1.2 mmol, Strem) intoluene (69 mL) was heated to 110° C. for 14 hours. Solvent was removedin vacuo, and the residue was purified by flash chromatography, elutingwith a gradient from 0-100% EtOAc in hexanes.

Yield: (2.09 g, 50%).

LCMS (M+H)⁺: 360.0/362.0.

Step 2. 5-chloro-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

A solution of5-chloro-2-(1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine(2.09 g, 5.81 mmol, from Step 2) in THF (30 mL) and EtOH (10 mL) wastreated with 1.0 M NaOH in water (30 mL, 30 mmol). After stirring for 1hour, the reaction mixture was diluted with water, and the volatilecomponents were removed in vacuo. The aqueous mixture was extracted withthree portions of EtOAc. The combined organic extracts were washed withbrine, dried over sodium sulfate, filtered and concentrated. The productwas triturated in EtOAc/DCM/MeOH, and the yellow solid was isolated byfiltration and air dried. Yield: (0.78 g, 61%).

¹H NMR (300 MHz, CD₃OD) δ 8.05 (s, 1H), 7.88 (d, J=8.6 Hz, 1H), 7.37 (s,1H), 7.27 (d, J=8.6 Hz, 1H), 7.13 (s, 1H); LCMS (M+H)⁺: 220.0/222.0.

Step 3. 1-benzyl-5-chloro-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridine

To a well stirred mixture of5-chloro-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridine (0.39 g, 1.8mmol, from Step 2) in DMF (8 mL) was added Cs₂CO₃ (1.7 g, 5.3 mmol) andbenzyl bromide (0.21 mL, 1.8 mmol, Aldrich). After stirring overnight,the reaction mixture was partitioned between water and ethyl acetate.The aqueous layer was extracted with an additional two portions ofEtOAc. The combined organic extracts were dried over sodium sulfate,filtered and concentrated. The resulting light yellow crystalline solidwas used directly in Step 4.

LCMS (M+H)⁺: 310.1/312.1.

Step 4. di-tert-butyl1-[1-benzyl-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A degassed mixture of1-benzyl-5-chloro-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridine (0.55 g,1.8 mmol, from Step 3), di-tert-butyl hydrazine-1,2-dicarboxylate (0.50g, 2.2 mmol, Aldrich), Cs₂CO₃ (0.70 g, 2.2 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.18 g, 0.24 mmol, Aldrich) in toluene (16.8 mL) was heated to110° C. for 4 hours. Upon cooling, the reaction was partitioned betweenwater and EtOAc. The aqueous layer was extracted with an additional twoportions of EtOAc. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. Flash chromatography, eluting with25% then 40% EtOAc in hexanes afforded purified product.

Yield: (0.59 g, 65%).

LCMS (M+H)⁺: 506.2.

Step 5.6-benzyl-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine,trifluoroacetate salt

A solution of di-tert-butyl1-[1-benzyl-2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(0.59 g, 1.2 mmol, from Step 4) in acetic acid (20 mL) was prepared. Thesolution was partitioned equally into three microwavable vials and eachwas heated in the microwave at 180° C. for 5 minutes. The acetic acidwas removed in vacuo from the combined batches. The residue wasdissolved in EtOAc and washed with saturated solution of NaHCO₃. Theaqueous layer was extracted with two further portions of EtOAc. Thecombined organic extracts were dried over sodium sulfate, filtered andconcentrated. The product was purified via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (0.15 g, 39%).

¹H NMR (400 MHz, CD₃OD) δ 8.31 (dd, J=0.6, 9.7 Hz, 1H), 8.10 (d, J=0.7Hz, 1H), 7.86 (d, J=0.6 Hz, 1H), 7.64 (d, J=9.7 Hz, 1H), 7.41 (d, J=0.7Hz, 1H), 7.30-7.18 (m, 3H), 7.15-7.06 (m, 2H), 6.32 (s, 2H), 3.16 (s,3H); LCMS (M+H)⁺: 330.1.

Example 144:6-benzyl-1,7-dimethyl-N-(1-methylpiperidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(racemic)

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25.0 mg, 0.0804 mmol, Example 228, Step 7), 1-methylpiperidin-3-amine(37 mg, 0.32 mmol, racemic, ChemBridge), Sodium tert-butoxide (15 mg,0.16 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (9.3 mg, 0.016mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (7.4 mg,0.0080 mmol, Aldrich) in toluene (1.2 mL) was heated at 100° C.overnight. Additional 1-methylpiperidin-3-amine (37 mg, 0.32 mmol),sodium tert-butoxide (15 mg, 0.16 mmol),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (46 mg, 0.080mmol) and tris(dibenzylideneacetone)dipalladium(0) (44 mg, 0.040 mmol),were added, the mixture was again degassed and heating at 100° C. wascontinued for 3 hours. The reaction mixture was partitioned betweenwater and EtOAc. The aqueous layer was extracted with two furtherportions of EtOAc. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. The product was purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeOH/H₂O containing 0.1% TFA), followed by repurification using HPLC-MS(Waters SunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1%TFA), again followed by a final purification using HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)to afford product as the free base. Yield: (3 mg, 10%).

¹H NMR (500 MHz, CD₃OD) δ 7.32-7.26 (m, 2H), 7.26-7.20 (m, 1H), 7.00 (d,J=7.4 Hz, 2H), 6.66 (s, 1H), 6.55 (s, 1H), 5.47-5.37 (m, 2H), 3.62-3.51(m, 1H), 3.08-2.98 (m, 1H), 2.93 (s, 3H), 2.84-2.73 (m, 1H), 2.38 (s,3H), 2.29 (s, 3H), 2.23-2.07 (m, 1H), 2.06-1.91 (m, 2H), 1.87-1.76 (m,1H), 1.75-1.60 (m, 1H), 1.42-1.24 (m, 1H); LCMS (M+H)⁺: 389.2.

Example 145:6-benzyl-1,7-dimethyl-N-(1-methylpyrrolidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminebis(trifluoroacetate) salt (racemic)

Prepared by the procedure of Example 144, using1-methylpyrrolidin-3-amine (0.032 g, 0.32 mmol, racemic, ChemBridge),and purified via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: 2 mg, 4%.

¹H NMR (500 MHz, CD₃OD) δ 7.32-7.27 (m, 2H), 7.27-7.22 (m, 1H), 7.00 (d,J=7.2 Hz, 2H), 6.71 (s, 1H), 6.62 (s, 1H), 5.46 (s, 2H), 4.39 (br m,1H), 4.07-1.21 (m, 15H); LCMS (M+H)⁺: 375.2.

Example 146:6-benzyl-1,7-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25.0 mg, 0.0804 mmol, Example 228, Step 7), tetrahydro-2H-pyran-4-amine(32 mg, 0.32 mmol, CombiBlocks), sodium tert-butoxide (23 mg, 0.24 mmol,Aldrich), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (9.3mg, 0.016 mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0)(7.4 mg, 0.0080 mmol, Aldrich) in toluene (1.2 mL) was heated at 100° C.overnight. Toluene was removed in vacuo and the crude mixture wasdissolved in MeOH/H₂O/MeCN and purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH). Yield: (3 mg, 10%).

¹H NMR (500 MHz, CD₃OD) δ 7.31-7.24 (m, 2H), 7.24-7.19 (m, 1H), 6.99 (d,J=7.3 Hz, 2H), 6.59 (s, 1H), 6.47 (s, 1H), 5.37 (s, 2H), 3.93 (dt,J=11.8, 3.6 Hz, 2H), 3.60 (tt, J=10.0, 4.0 Hz, 1H), 3.52 (td, J=11.5,2.1 Hz, 2H), 2.90 (s, 3H), 2.37 (s, 3H), 2.01-1.90 (m, 2H), 1.51 (dtd,J=14.3, 10.7, 4.2 Hz, 2H); LCMS (M+H)⁺: 376.2.

Example 147:6-benzyl-1,7-dimethyl-N-[(3R)-tetrahydrofuran-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

The title compound was prepared according to the methods of Example 146,using (3R)-tetrahydrofuran-3-amine 4-methylbenzenesulfonate (40 mg, 0.15mmol, Advanced Chem Blocks). Yield: (3 mg, 10%).

¹H NMR (500 MHz, CD₃OD) δ 7.31-7.26 (m, 2H), 7.26-7.20 (m, 1H), 7.02 (d,J=7.4 Hz, 2H), 6.65 (s, 1H), 6.46 (s, 1H), 5.41 (s, 2H), 4.16 (ddt,J=8.8, 6.8, 3.2 Hz, 1H), 4.00-3.88 (m, 2H), 3.82 (td, J=8.4, 5.3 Hz,1H), 3.69 (dd, J=9.1, 3.2 Hz, 1H), 2.93 (s, 3H), 2.39 (s, 3H), 2.26 (dq,J=13.0, 7.4 Hz, 1H), 1.91 (dddd, J=12.6, 7.8, 5.0, 3.3 Hz, 1H); LCMS(M+H)⁺: 362.1.

Example 148:6-benzyl-1,7-dimethyl-N-[(3S)-tetrahydrofuran-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

The title compound was prepared according to the methods of Example 146,using (3S)-tetrahydrofuran-3-amine hydrochloride (20 mg, 0.16 mmol,Advanced Chem Blocks). Yield: 3 mg, 10%.

¹H NMR (500 MHz, CD₃OD) δ 7.31-7.26 (m, 2H), 7.26-7.21 (m, 1H), 7.01 (d,J=7.3 Hz, 2H), 6.64 (s, 1H), 6.45 (s, 1H), 5.41 (s, 2H), 4.16 (dp,J=8.9, 3.3 Hz, 1H), 3.98-3.89 (m, 2H), 3.82 (td, J=8.4, 5.3 Hz, 1H),3.69 (dd, J=9.1, 3.2 Hz, 1H), 2.92 (s, 3H), 2.39 (s, 3H), 2.26 (dq,J=13.0, 7.5 Hz, 1H), 1.94-1.87 (m, 1H); LCMS (M+H)⁺: 362.1.

Example 149: tert-butyl(3R)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(200.0 mg, 0.6435 mmol, Example 228, Step 7), tert-butyl(3R)-3-aminopyrrolidine-1-carboxylate (0.40 mL, 2.3 mmol, Aldrich),sodium tert-butoxide (190 mg, 1.98 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (93 mg, 0.16mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (74 mg,0.080 mmol, Aldrich) in toluene (12 mL) was heated at 100° C. for 3.5hours, then at 125° C. for 2 hours. The reaction mixture was partitionedbetween water and ethyl acetate, and the aqueous layer was extractedfurther with two portions of EtOAc. The combined organic extracts werewashed with brine, dried over sodium sulfate, decanted and concentrated.The product was purified by flash chromatography, eluting first with agradient from 0-100% EtOAc in hexanes, then eluting with 5% MeOH in DCM.Yield: (190 mg, 64%). A portion of this material was then purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) to provide a pure title compound.

¹H NMR (400 MHz, d₆-DMSO) δ 7.34-7.27 (m, 2H), 7.27-7.19 (m, 1H), 7.02(d, J=7.4 Hz, 2H), 6.67 (d, J=4.3 Hz, 1H), 6.62 (s, 1H), 5.88-5.80 (m,1H), 5.45 (s, 2H), 4.24-3.97 (m, 1H), 3.67-3.50 (m, 1H), 3.46-3.37 (m,1H), 3.31-3.21 (m, 1H), 3.15 (td, J=10.8, 5.1 Hz, 1H), 2.83 (s, 3H),2.31 (s, 1.5H, rotamers), 2.30 (s, 1.5H, rotamers), 2.20-2.06 (m, 1H),2.04-1.84 (m, 1H), 1.39 (s, 4.5H, rotamers), 1.35 (s, 4.5H, rotamers);LCMS (M+H)⁺: 461.2.

Example 150: tert-butyl(3S)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate

The title compound was prepared according to the methods of Example 149,using tert-butyl (3S)-3-aminopyrrolidine-1-carboxylate (0.40 mL, 2.3mmol, Aldrich). The product was purified by flash chromatography,eluting with a gradient from 0-10% MeOH in DCM. Yield: (190 mg, 64%). Aportion of this material was then purified by preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH) to afford the pure title compound.

¹H NMR (400 MHz, d₆-DMSO) δ 7.34-7.27 (m, 2H), 7.27-7.20 (m, 1H), 7.02(d, J=7.5 Hz, 2H), 6.67 (d, J=4.4 Hz, 1H), 6.62 (s, 1H), 5.88-5.80 (m,1H), 5.44 (s, 2H), 4.23-4.03 (m, 1H), 3.66-3.51 (m, 1H), 3.48-3.37 (m,1H), 3.32-3.20 (m, 1H), 3.20-3.08 (m, 1H), 2.83 (s, 3H), 2.31 (s, 1.5H,rotamers), 2.30 (s, 1.5H, rotamers), 2.20-2.05 (m, 1H), 2.05-1.88 (m,1H), 1.39 (s, 4.5H, rotamers), 1.35 (s, 4.5H, rotamers); LCMS (M+H)⁺:461.2.

Example 151:6-benzyl-1,7-dimethyl-N-[(3R)-pyrrolidin-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminebis(trifluoroacetate) salt

tert-Butyl(3R)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate(0.175 g, 0.380 mmol, from Example 149) in 1,4-dioxane (10 mL) wastreated with 4.0 M solution of HCl in dioxane (4 mL, 20 mmol), and thereaction was stirred for 1 hour. Solvent and excess reagents wereremoved in vacuo. The product was purified by preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH) and was then repurified by preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA) toyield the title product.

LCMS (M+H)⁺: 361.2.

Example 152:6-benzyl-1,7-dimethyl-N-[(3S)-pyrrolidin-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 151,using tert-butyl(3S)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate(Example 150).

LCMS (M+H)⁺: 361.2.

Example 153:1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

Step 1.4-chloro-1,7-dimethyl-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To 4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.150 g, 0.680 mmol, from Example 228, Step 6) and Cs₂CO₃ (0.88 g, 2.7mmol) in DMF (2.10 mL) was added 2-(chloromethyl)pyridine hydrochloride(0.139 g, 0.850 mmol, Aldrich). The reaction was stirred overnight, thendiluted with water and extracted with three portions of 5% iPrOH in DCM.The combined organic extracts were dried over sodium sulfate, filteredand concentrated. The product was purified by flash chromatography,eluting with a gradient from 0-10% MeOH in DCM. Yield: (206 mg, 97%).

LCMS (M+H)⁺: 312.1/314.1.

Step 2.1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed mixture of4-chloro-1,7-dimethyl-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50.0 mg, 0.160 mmol, from Step 1), 1-methylpiperidin-4-amine (0.072 mg,0.48 mmol, Matrix), Sodium tert-butoxide (77 mg, 0.80 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (23 mg, 0.040mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (18 mg,0.020 mmol, Aldrich) in toluene (3.1 mL) was heated at 125° C. for 2.5hours. The product was purified via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield:(10 mg, 16%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.52 (d, J=4.4 Hz, 1H), 7.71 (td, J=7.7, 1.7Hz, 1H), 7.27 (dd, J=7.1, 5.0 Hz, 1H), 6.85 (d, J=7.9 Hz, 1H), 6.60 (s,1H), 6.57 (s, 1H), 5.49 (s, 2H), 5.24 (d, J=8.6 Hz, 1H), 3.42-3.32 (m,1H), 2.82 (s, 3H), 2.75-2.63 (m, 2H), 2.34 (s, 3H), 2.17 (s, 3H),2.07-1.97 (m, 2H), 1.91-1.78 (m, 2H), 1.55-1.42 (m, 2H); LCMS (M+H)⁺:390.3.

Example 154:1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6-(pyridin-3-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

Prepared as in Example 153, using 3-(chloromethyl)pyridine hydrochloride(0.139 g, 0.850 mmol, Aldrich) in Step 1. Yield (Step 1): (136 mg, 64%).Yield (Step 2): (10 mg, 16%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.45 (dd, J=2.8, 3.7 Hz, 1H), 8.38-8.35 (m,1H), 7.33-7.31 (m, 2H), 6.61 (s, 1H), 6.58 (s, 1H), 5.48 (s, 2H), 5.28(d, J=8.7 Hz, 1H), 3.44-3.34 (m, 1H), 2.82 (s, 3H), 2.74-2.64 (m, 2H),2.33 (s, 3H), 2.17 (s, 3H), 2.02 (dd, J=1.9, 11.5 Hz, 2H), 1.91-1.82 (m,2H), 1.56-1.43 (m, 2H); LCMS (M+H)⁺: 390.3.

Example 155:6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 103,Step 5, with the exception of the purification step. Title compound waspurified via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA).

¹H NMR (400 MHz, d₆-DMSO) δ 13.31 (s, 1H), 8.19 (d, J=9.5 Hz, 1H), 7.95(d, J=2.2 Hz, 1H), 7.65 (s, 1H), 7.55 (d, J=9.6 Hz, 1H), 7.34-7.24 (m,2H), 7.17-7.10 (m, 1H), 7.04-6.94 (m, 2H), 6.21 (s, 2H), 3.06 (s, 3H);LCMS (M+H)⁺: 363.1.

Example 156:7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

Tert-Butyl-3-hydroxyazetidine-1-carboxylate (0.20 g, 1.2 mmol, Aldrich)in THF (10 mL) at 0° C. was treated with triethylamine (0.32 mL, 2.3mmol) and methanesulfonyl chloride (0.11 mL, 1.4 mmol, Aldrich). After1.5 hours, water was added, and the aqueous mixture was extracted withEtOAc. The combined organic extracts were washed with brine, dried overNa₂SO₄, filtered and concentrated to afford crude tert-butyl3-[(methylsulfonyl)oxy]azetidine-1-carboxylate, which was used infurther step without purification.

To6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(30. mg, 0.083 mmol, prepared according to the methods of Example 103,Step 5) in DMF (1.8 mL) was added Cs₂CO₃ (40. mg, 0.12 mmol), followedby tert-butyl 3-[(methylsulfonyl)oxy]azetidine-1-carboxylate (42 mg,0.16 mmol, prepared above). The mixture was heated at 50° C. for 2 days.The reaction mixture was diluted with water and the product wasextracted with three portions of EtOAc. The combined organic extractswere washed twice with brine, dried over sodium sulfate, filtered andconcentrated. The residue was dissolved in MeCN (1.2 mL) and treatedwith 4.0 M HCl in dioxane (0.48 mL, 1.9 mmol) and stirred for 45minutes. The reaction mixture was concentrated in vacuo. The titleproduct was purified via preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (23 mg,43%).

Pure7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinewas obtained by preparative HPLC-MS using the following conditions:Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH.

¹H NMR (300 MHz, d₆-DMSO) δ 7.94 (d, J=2.3 Hz, 1H), 7.76 (d, J=9.8 Hz,1H), 7.40 (s, 1H), 7.37 (d, J=9.7 Hz, 1H), 7.34-7.22 (m, 2H), 7.22-7.15(m, 1H), 7.03-6.95 (m, 1H), 6.85 (d, J=2.4 Hz, 1H), 6.10 (s, 2H), 5.21(p, J=7.1 Hz, 1H), 3.88 (t, J=7.7 Hz, 2H), 3.70 (t, J=8.0 Hz, 2H), 2.96(s, 3H); LCMS (M+H)⁺: 418.2.

Example 157:(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrilebis(trifluoroacetate) salt

6-(3-Chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.069 mmol, prepared according to the methods of Example 103,Step 5) in acetonitrile (0.90 mL) was treated with tert-butyl3-(cyanomethylene)azetidine-1-carboxylate (27 mg, 0.14 mmol, prepared asin WO2009/114512) and 1,8-diazabicyclo[5.4.0]undec-7-ene (10. pL, 0.069mmol, Aldrich) for 70 minutes, after which time 4.0 M HCl in dioxane(0.23 mL, 0.90 mmol) was added to the reaction mixture. After 30minutes, solvent was removed in vacuo and the residue was dissolved inMeOH and made basic by the addition of aq. NH₄OH. This solution waspurified via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (23 mg, 73%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.13 (d, J=2.5 Hz, 1H), 7.78 (d, J=9.8 Hz,1H), 7.45 (s, 1H), 7.38 (d, J=9.7 Hz, 1H), 7.29-7.23 (m, 2H), 7.19-7.15(m, 1H), 6.97 (d, J=2.5 Hz, 1H), 6.96-6.93 (m, 1H), 6.04 (s, 2H), 3.87(d, J=9.1 Hz, 2H), 3.59 (d, J=9.3 Hz, 2H), 3.46 (s, 2H), 2.96 (s, 3H);LCMS (M+H)⁺: 456.6.

A portion of this product (2.5 mg, 0.0055 mmol) was purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA) to afford product as thebis(trifluoroacetate) salt. Yield: (3.0 mg, 80%).

LCMS (M+H)⁺: 457.1.

Example 158:(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-1-ethylazetidin-3-yl)acetonitrilebis(trifluoroacetate) salt

A solution of(3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile(5.5 mg, 0.012 mmol, from Example 157 as the free base) in MeOH (0.23mL) was treated with acetaldehyde (3.4 μL, 0.060 mmol, Aldrich) andsodium triacetoxyborohydride (7.6 mg, 0.036 mmol, Aldrich). After 10minutes, the product was purified via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (5.5 mg, 64%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (br s, 1H), 8.12 (d, J=9.5 Hz, 1H),7.68 (s, 1H), 7.58 (d, J=9.7 Hz, 1H), 7.35-7.26 (m, 2H), 7.22-7.15 (m,2H), 7.03-6.95 (m, 1H), 6.15 (s, 2H), 4.56 (br m, 8H), 3.04 (s, 3H),1.13-0.86 (m, 3H); LCMS (M+H)⁺: 485.3.

Example 159:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanamidetrifluoroacetate salt

Step 1.3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid

6-(3-Chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.069 mmol, from Example 103, Step 5) in acetonitrile (0.90 mL)was treated with methyl acrylate (19 μL, 0.21 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (10. pL, 0.069 mmol, Aldrich) andstirred for 70 minutes. Purification via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)followed by evaporation of eluent afforded methyl3-(3-(6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl)propanoate.The ester intermediate was dissolved in THF (0.45 mL) and was treatedwith 1.0 M NaOH in water (0.45 mL, 0.45 mmol). After 25 minutes, thereaction was acidified to pH 3-4 by the addition of 1 N HCl. Water wasadded (3 mL), and the precipitated product was isolated by filtrationand air dried. Yield: (21 mg, 70%).

¹H NMR (400 MHz, d₆-DMSO) δ 12.42 (s, 1H), 7.84 (d, J=2.3 Hz, 1H), 7.72(d, J=10.0 Hz, 1H), 7.39-7.31 (m, 2H), 7.29-7.24 (m, 2H), 7.18-7.13 (m,1H), 7.00-6.94 (m, 1H), 6.79 (d, J=2.3 Hz, 1H), 6.05 (s, 2H), 4.35 (t,J=6.7 Hz, 2H), 2.95 (s, 3H), 2.79 (t, J=6.7 Hz, 2H); LCMS (M+H)⁺: 434.6.

Step 2.3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanamidetrifluoroacetate salt

A solution of3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid (10. mg, 0.023 mmol, from Step 1) in DMF (0.46 mL) was treated withN,N-diisopropylethylamine (16 μL, 0.092 mmol) and HATU (16 mg, 0.041mmol). After two minutes, ammonia (gas, Aldrich) was bubbled through themixture for 30 seconds), and the reaction vessel was sealed and stirredfor 15 minutes. The reaction mixture was diluted with MeOH, and thetitle product was purified via preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (10.2mg, 81%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.33 (d, J=9.6 Hz, 1H), 7.87 (d, J=2.3 Hz,1H), 7.63 (s, 1H), 7.60 (d, J=9.6 Hz, 1H), 7.40 (br s, 1H), 7.34-7.25(m, 2H), 7.18 (br s, 1H), 7.06-6.99 (m, 1H), 6.94 (br s, 1H), 6.93 (d,J=2.3 Hz, 1H), 6.19 (s, 2H), 4.37 (t, J=6.9 Hz, 2H), 3.06 (s, 3H), 2.65(t, J=6.9 Hz, 2H); LCMS (M+H)⁺: 434.2.

Example 160:6-(3-Chlorobenzyl)-7-[1-(1-ethylazetidin-3-yl)-1H-pyrazol-3-yl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

A solution of7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt (10.1 mg, 0.0156 mmol, prepared as in Example156) in methanol (0.30 mL) was treated with triethylamine (8.7 μL, 0.062mmol), acetaldehyde (4.4 μL, 0.078 mmol, Aldrich) and sodiumtriacetoxyborohydride (9.9 mg, 0.047 mmol, Aldrich). The reaction wascomplete in about 10 minutes, and the product was purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA). Yield: (8.0 mg, 76%).

LCMS (M+H)⁺: 446.1.

Example 161:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N,N-dimethylazetidine-1-sulfonamidebis(trifluoroacetate) salt

A solution of7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt (10.2 mg, 0.0158 mmol, prepared as in Example156) in DCM (0.56 mL) was treated with triethylamine (11 μL, 0.079 mmol)and dimethylsulfamoyl chloride (2.5 μL, 0.024 mmol, Aldrich) and stirredfor 35 minutes. Additional triethylamine (4.4 μL, 0.032 mmol) anddimethylsulfamoyl chloride (1.0 μL, 0.0093 mmol) were added. When thereaction was complete as determined by HPLC-MS, the product was purifiedvia preparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA). Yield: (6.3 mg, 90%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.26 (d, J=9.7 Hz, 1H), 7.98 (d, J=2.4 Hz,1H), 7.70 (s, 1H), 7.60 (d, J=9.6 Hz, 1H), 7.32-7.22 (m, 2H), 7.15-7.11(m, 1H), 7.04 (d, J=2.4 Hz, 1H), 7.04-7.00 (m, 1H), 6.30 (s, 2H),5.42-5.22 (m, 1H), 4.35-4.05 (m, 4H), 3.06 (s, 3H), 2.74 (s, 6H); LCMS(M+H)⁺: 525.3.

Example 162:2-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)-N,N-dimethyl-2-oxoethanaminebis(trifluoroacetate) salt

A solution of7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5.0 mg, 0.012 mmol, prepared as in Example 156, isolated as the freebase) in DCM (0.50 mL) was treated with dimethylaminoacetyl chloridehydrochloride (2.8 mg, 0.018 mmol, Aldrich) and triethylamine (5.0 μL,0.036 mmol). The reaction was complete within a few minutes and theproduct was purified via preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (6.7mg, 76%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.83 (s, 1H), 8.23 (d, J=9.8 Hz, 1H), 8.06(d, J=2.4 Hz, 1H), 7.66 (s, 1H), 7.59 (d, J=9.7 Hz, 1H), 7.33-7.24 (m,2H), 7.12-7.08 (m, 1H), 7.06-7.01 (m, 1H), 7.02 (d, J=2.4 Hz, 1H), 6.21(d, J=16.5 Hz, 1H), 6.11 (d, J=16.5 Hz, 1H), 5.40 (ddd, J=13.5, 8.1, 5.4Hz, 1H), 4.62 (t, J=8.8 Hz, 1H), 4.50-4.38 (m, 2H), 4.17 (dd, J=10.3,5.3 Hz, 1H), 4.07 (d, J=16.2 Hz, 1H), 3.99 (d, J=15.6 Hz, 1H), 3.04 (s,3H), 2.81 (s, 6H); LCMS (M+H)⁺: 503.2.

Example 163:6-(3-Chlorobenzyl)-1-methyl-7-[1-(1-propionylazetidin-3-yl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 162,using propanoyl chloride (1.6 μL, 0.018 mmol, Aldrich). A drop ofaqueous ammonia and MeOH (0.5 mL) were added to the reaction mixturebefore purification. Yield: (4.2 mg, 60%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.27 (d, J=9.6 Hz, 1H), 8.05 (d, J=2.4 Hz,1H), 7.69 (s, 1H), 7.59 (d, J=9.6 Hz, 1H), 7.32-7.25 (m, 2H), 7.13-7.08(m, 1H), 7.07-7.00 (m, 1H), 7.03 (d, J=2.4 Hz, 1H), 6.21 (d, J=16.5 Hz,1H), 6.13 (d, J=16.4 Hz, 1H), 5.31 (tt, J=8.1, 5.3 Hz, 1H), 4.54 (t,J=8.4 Hz, 1H), 4.32-4.23 (m, 2H), 4.06 (dd, J=10.1, 5.5 Hz, 1H), 3.06(s, 3H), 2.05 (dq, J=11.1, 7.8 Hz, 2H), 0.96 (t, J=7.5 Hz, 3H); LCMS(M+H)⁺: 474.2.

Example 164:6-(3-Chlorobenzyl)-7-{1-[1-(cyclopropylcarbonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 162,using cyclopropanecarbonyl chloride (1.6 μL, 0.018 mmol. Aldrich).Yield: (5.0 mg, 70%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.33 (d, J=9.6 Hz, 1H), 8.06 (d, J=2.4 Hz,1H), 7.71 (s, 1H), 7.62 (d, J=9.6 Hz, 1H), 7.31-7.26 (m, 2H), 7.09-7.05(m, 2H), 7.04 (d, J=2.4 Hz, 1H), 6.22 (d, J=16.4 Hz, 1H), 6.15 (d,J=16.1 Hz, 1H), 5.36 (tt, J=7.8, 5.1 Hz, 1H), 4.70 (t, J=8.3 Hz, 1H),4.43 (dd, J=8.8, 5.2 Hz, 1H), 4.31 (t, J=9.1 Hz, 1H), 4.10 (dd, J=9.9,5.2 Hz, 1H), 3.07 (s, 3H), 1.59-1.51 (m, 1H), 0.79-0.67 (m, 4H); LCMS(M+H)⁺: 486.2.

Example 165:6-(3-Chlorobenzyl)-7-{1-[1-(cyclopropylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 162,using cyclopropanesulfonyl chloride (1.8 μL, 0.018 mmol, Aldrich).Yield: (4.8 mg, 63%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.19 (d, J=9.7 Hz, 1H), 8.02 (d, J=2.4 Hz,1H), 7.68 (s, 1H), 7.58 (d, J=9.6 Hz, 1H), 7.35-7.25 (m, 2H), 7.17-7.12(m, 1H), 7.08-7.03 (m, 2H), 6.24 (s, 2H), 5.44-5.34 (m, 1H), 4.33 (dd,J=8.5, 6.7 Hz, 2H), 4.26 (t, J=8.3 Hz, 2H), 3.05 (s, 3H), 2.66-2.58 (m,1H), 0.97-0.89 (m, 4H); LCMS (M+H)⁺: 522.1.

Example 166:6-(3-Chlorobenzyl)-7-{1-[1-(ethylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 162,using ethanesulfonyl chloride (1.7 μL, 0.018 mmol, Aldrich). Yield: (5.3mg, 71%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.48 (d, J=9.6 Hz, 1H), 8.03 (d, J=2.4 Hz,1H), 7.80 (s, 1H), 7.69 (d, J=9.6 Hz, 1H), 7.34-7.24 (m, 2H), 7.19-7.13(m, 1H), 7.13-7.06 (m, 2H), 6.29 (s, 2H), 5.38 (p, J=7.0 Hz, 1H),4.33-4.21 (m, 4H), 3.11 (q, J=7.3 Hz, 2H), 3.10 (s, 3H), 1.20 (t, J=7.3Hz, 3H); LCMS (M+H)⁺: 510.2.

Example 167: Ethyl3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidine-1-carboxylatetrifluoroacetate salt

The title compound was prepared according to the methods of Example 162using ethyl chloroformate (1.7 μL, 0.018 mmol, Alfa Aesar). Yield: (5.2mg, 72%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.30 (d, J=9.5 Hz, 1H), 8.03 (d, J=2.4 Hz,1H), 7.69 (s, 1H), 7.61 (d, J=9.6 Hz, 1H), 7.32-7.25 (m, 2H), 7.13-7.09(m, 1H), 7.05 (ddd, J=4.7, 3.4, 1.6 Hz, 1H), 7.02 (d, J=2.4 Hz, 1H),6.18 (s, 2H), 5.30 (tt, J=8.0, 5.1 Hz, 1H), 4.41-4.28 (m, 2H), 4.14 (dd,J=8.6, 4.8 Hz, 2H), 4.02 (q, J=7.0 Hz, 2H), 3.06 (s, 3H), 1.17 (t, J=7.1Hz, 3H); LCMS (M+H)⁺: 490.3.

Example 168:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-oxetan-3-ylpropanamidetrifluoroacetate salt

A solution of3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid (5.0 mg, 0.011 mmol, prepared as in Example 159, Step 1) in DMF(0.23 mL) was treated with N,N-diisopropylethylamine (8.0 μL, 0.046mmol) and HATU (7.9 mg, 0.021 mmol), followed by oxetan-3-amine (2.4 μL,0.034 mmol, Synthonix). After 15 minutes, the reaction mixture wasdiluted with MeOH, and the product was isolated by preparative HPLC-MS(Waters SunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1%TFA). Yield: (4.3 mg, 62%).

¹H NMR (400 MHz, d₆-DMSO, rotamers) 6 8.69 (d, J=6.5 Hz, 0.5H), 8.19 (d,J=9.7 Hz, 0.5H), 8.09 (d, J=9.7 Hz, 0.5H), 8.05-7.96 (m, 1H), 7.89 (d,J=2.4 Hz, 0.5H), 7.83 (d, J=2.3 Hz, 0.5H), 7.58-7.48 (m, 2H), 7.31-7.22(m, 2H), 7.18-7.12 (m, 1H), 7.02-6.93 (m, 1H), 6.90 (d, J=2.3 Hz, 0.5H),6.88 (d, J=2.3 Hz, 0.5H), 6.14 (s, 1H), 6.11 (s, 1H), 4.74-4.66 (m,0.5H), 4.63 (t, J=6.7 Hz, 1H), 4.43 (t, J=6.7 Hz, 1H), 4.37 (t, J=6.7Hz, 1H), 4.30 (t, J=6.3 Hz, 1H), 4.17-4.05 (m, 1H), 3.57 (dd, J=11.4,4.7 Hz, 0.5H), 3.49 (dd, J=11.5, 5.8 Hz, 0.5H), 3.38-3.29 (m, 0.5H),3.01 (s, 1.5H), 3.01 (s, 1.5H), 2.92 (t, J=6.7 Hz, 1H), 2.68 (t, J=6.8Hz, 1H); LCMS (M+H)⁺: 490.2.

Example 169:6-(3-Chlorobenzyl)-1-methyl-7-[1-(3-morpholin-4-yl-3-oxopropyl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

The title compound was prepared according to the methods of Example 168,using morpholine (3.0 μL, 0.034 mmol, Aldrich). Yield: (2.8 mg, 39%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.27 (d, J=9.7 Hz, 1H), 7.90 (d, J=2.3 Hz,1H), 7.63 (s, 1H), 7.58 (d, J=9.6 Hz, 1H), 7.33-7.26 (m, 2H), 7.20-7.15(m, 1H), 7.04-6.97 (m, 1H), 6.94 (d, J=2.3 Hz, 1H), 6.18 (s, 2H), 4.40(t, J=6.8 Hz, 2H), 3.50-3.41 (m, 4H), 3.38 (dd, J=5.6, 4.0 Hz, 2H),3.30-3.23 (m, 2H), 3.05 (s, 3H), 2.87 (t, J=6.8 Hz, 2H); LCMS (M+H)⁺:504.3.

Example 170:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-(tetrahydro-2H-pyran-4-yl)propanamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 168,using tetrahydro-2H-pyran-4-amine (3.5 mg, 0.034 mmol, Combi-Blocks).Yield: (3.3 mg, 45%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.19 (d, J=9.5 Hz, 1H), 7.91 (d, J=7.5 Hz,1H), 7.84 (d, J=2.3 Hz, 1H), 7.59-7.52 (m, 2H), 7.33-7.25 (m, 2H),7.22-7.16 (m, 1H), 7.04-6.96 (m, 1H), 6.90 (d, J=2.3 Hz, 1H), 6.16 (s,2H), 4.39 (t, J=6.8 Hz, 2H), 3.76 (dt, J=11.7, 3.5 Hz, 2H), 3.69 (ddd,J=14.7, 7.2, 3.6 Hz, 1H), 3.29 (td, J=11.5, 2.1 Hz, 2H), 3.04 (s, 3H),2.65 (t, J=6.8 Hz, 2H), 1.64-1.54 (m, 2H), 1.35-1.22 (m, 2H); LCMS(M+H)⁺: 518.3.

Example 171:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-(1-methylazetidin-3-yl)propanamidebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 168,using 1-methylazetidin-3-amine (3.0 mg, 0.034 mmol, Synthonix). Yield:(4.0 mg, 48%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.75 (br s, 1H), 8.74-8.64 (m, 1H), 8.20 (d,J=9.5 Hz, 1H), 7.94-7.77 (m, 1H), 7.64-7.48 (m, 2H), 7.35-7.25 (m, 2H),7.21-7.16 (m, 1H), 7.08-6.95 (m, 1H), 6.92 (d, J=2.3 Hz, 1H), 6.16 (s,2H), 4.58-3.74 (m, 7H), 3.04 (s, 3H), 2.89-2.78 (m, 3H), 2.76-2.63 (m,2H); LCMS (M+H)⁺: 503.3.

Example 172:6-(3-Chlorobenzyl)-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

Step 1.5-Chloro-1-(3-chlorobenzyl)-2-(1-trityl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridine

A mixture of2-bromo-5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridine (0.59 g,1.7 mmol, prepared as in Example 103, Step 2) and4-(tributylstannyl)-1-trityl-1H-imidazole (1.0 g, 1.7 mmol, Synthonix)in toluene (32 mL) was degassed.Tetrakis(triphenylphosphine)palladium(0) (0.19 g, 0.17 mmol, Strem) wasadded, and the mixture was heated at 110° C. for 17 hours. Solvent wasremoved in vacuo, and the product was purified by flash chromatography,eluting with a gradient from 0-35% EtOAc in hexanes. Yield: (0.61 g,62%).

¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J=1.4 Hz, 1H), 7.41 (dd, J=8.5, 0.7Hz, 1H), 7.38-7.30 (m, 9H), 7.18 (ddd, J=1.4, 1.9, 8.0 Hz, 1H),7.15-7.08 (m, 7H), 7.06 (d, J=1.4 Hz, 1H), 7.01 (d, J=8.5 Hz, 1H), 6.97(t, J=1.5 Hz, 1H), 6.79 (dt, J=7.5, 1.3 Hz, 1H), 6.75 (d, J=0.7 Hz, 1H),5.76 (s, 2H); LCMS (M+H)⁺: 585.2.

Step 2.6-(3-Chlorobenzyl)-7-(H-imidazol-4-yl)-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

A degassed mixture of5-chloro-1-(3-chlorobenzyl)-2-(1-trityl-1H-imidazol-4-yl)-1H-pyrrolo[3,2-b]pyridine(0.61 g, 1.0 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (0.36 g, 1.6 mmol, Aldrich), Cs₂CO₃ (0.51 g,1.6 mmol, Aldrich) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (82 mg, 0.10 mmol, Aldrich) in toluene (21 mL) heated at 130° C.for 18 hours. The mixture was cooled to room temperature, diluted withDCM, and filtered. Solvent was removed in vacuo. The intermediatederivative of di-tert-butyl hydrazine-1,2-dicarboxylate was purified byflash chromatography, eluting with a gradient from 0-50% EtOAc inhexanes. The intermediate derivative of di-tert-butylhydrazine-1,2-dicarboxylate was dissolved in acetic acid (20 mL) andevenly divided between two microwavable vials. Each vial was heated at180° C. in the microwave for 8 minutes. The batches were combined, andacetic acid was removed in vacuo. The product was isolated bypreparative HPLC-MS, sequential runs: first (Waters XBridge C18, elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH), followed by (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).

¹H NMR (400 MHz, d₆-DMSO) δ 12.49 (br s, 1H), 7.82 (s, 1H), 7.71 (br s,1H), 7.63 (d, J=9.7 Hz, 1H), 7.32-7.21 (m, 4H), 7.14 (s, 1H), 6.97 (d,J=5.1 Hz, 1H), 6.12 (s, 2H), 2.94 (s, 3H); LCMS (M+H)⁺: 363.2.

Example 173:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propan-1-oltrifluoroacetate salt

6-(3-Chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(10. mg, 0.028 mmol, prepared as in Example 103, Step 5) in acetonitrile(0.36 mL) was treated with methyl acrylate (7.4 μL, 0.083 mmol, Aldrich)and 1,8-diazabicyclo[5.4.0]undec-7-ene (4.1 μL, 0.028 mmol, Aldrich).After 15 minutes, the solvent was removed in vacuo and replaced with THF(1.0 mL). 1.0 M LiAlH₄ in THF (55 μL, 0.055 mmol, Aldrich) was added tothe reaction mixture. After 20 minutes, the reaction was quenched by theaddition of a small amount of water, and the reaction mixture wasdiluted with acetonitrile and methanol. After stirring for 5 minutes,the mixture was filtered and the product was isolated via preparativeHPLC-MS (Waters SunFire C18, eluting with a gradient of MeCN/H₂Ocontaining 0.1% TFA). Yield: (6.2 mg, 42%).

¹H NMR (300 MHz, d₆-DMSO) δ 8.21 (d, J=9.4 Hz, 1H), 7.90 (d, J=2.3 Hz,1H), 7.58 (s, 1H), 7.55 (d, J=9.8 Hz, 1H), 7.33-7.23 (m, 2H), 7.18-7.11(m, 1H), 7.04-6.95 (m, 1H), 6.92 (d, J=2.3 Hz, 1H), 6.16 (s, 2H), 4.22(t, J=6.9 Hz, 2H), 3.33 (t, J=6.0 Hz, 2H), 3.04 (s, 3H), 1.91 (p, J=6.4Hz, 2H); LCMS (M+H)⁺: 421.1.

Example 174:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-methylpropanamidetrifluoroacetate salt

A solution of3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanoicacid (5.2 mg, 0.012 mmol, from Example 159, Step 1) inN,N-dimethylformamide (0.24 mL) was treated withN,N-diisopropylethylamine (8.3 μL, 0.048 mmol), HATU (8.2 mg, 0.022mmol), and 2.0 M methylamine in THF (48 μL, 0.096 mmol, Aldrich). After15 minutes, the reaction mixture was diluted with MeOH and the productwas isolated by preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (3.5 mg, 52%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.19 (d, J=9.6 Hz, 1H), 7.90-7.82 (m, 1H),7.85 (d, J=2.3 Hz, 1H), 7.57 (s, 1H), 7.55 (d, J=9.6 Hz, 1H), 7.32-7.25(m, 2H), 7.19-7.14 (m, 1H), 7.04-6.97 (m, 1H), 6.90 (d, J=2.3 Hz, 1H),6.17 (s, 2H), 4.38 (t, J=6.8 Hz, 2H), 3.03 (s, 3H), 2.64 (t, J=6.9 Hz,2H), 2.52 (s, 3H); LCMS (M+H)⁺: 448.1.

Example 175:3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-ethylpropanamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 174,using ethylamine (7 μL, 0.12 mmol, Aldrich). Yield: (3.0 mg, 44%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.16 (d, J=9.5 Hz, 1H), 7.91 (t, J=5.4 Hz,1H), 7.84 (d, J=2.3 Hz, 1H), 7.56 (s, 1H), 7.54 (d, J=9.6 Hz, 1H),7.32-7.26 (m, 2H), 7.19-7.16 (m, 1H), 7.03-6.97 (m, 1H), 6.89 (d, J=2.3Hz, 1H), 6.16 (s, 2H), 4.37 (t, J=6.9 Hz, 2H), 3.03 (s, 3H), 3.01 (dq,J=5.4, 7.2 Hz, 2H), 2.63 (t, J=6.9 Hz, 2H), 0.94 (t, J=7.2 Hz, 3H); LCMS(M+H)⁺: 462.1.

Example 176:N-(tert-Butyl)-3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanamidetrifluoroacetate salt

The title compound was prepared according to the methods of Example 174,using tert-butylamine (10. L, 0.096 mmol, Aldrich). Yield: (3.5 mg,48%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.27 (d, J=9.6 Hz, 1H), 7.84 (d, J=2.3 Hz,1H), 7.61 (s, 1H), 7.58 (d, J=9.6 Hz, 1H), 7.51 (s, 1H), 7.32-7.25 (m,2H), 7.21-7.17 (m, 1H), 7.04-6.98 (m, 1H), 6.92 (d, J=2.2 Hz, 1H), 6.19(s, 2H), 4.35 (t, J=6.9 Hz, 2H), 3.05 (s, 3H), 2.61 (t, J=6.9 Hz, 2H),1.19 (s, 9H); LCMS (M+H)⁺: 490.1.

Example 177:6-(3-Chlorobenzyl)-1-methyl-7-(1-oxetan-3-yl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

To a solution of6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(7.1 mg, 0.020 mmol, prepared as in Example 103, Step 5) in DMF (0.10mL) was added Cs₂CO₃ (13 mg, 0.039 mmol) and 3-iodooxetane (7.2 mg,0.039 mmol, Synthonix). The mixture was heated in the microwave at 150°C. for 10 minutes. The product was isolated by preparative HPLC-MS(Waters SunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1%TFA). Yield: (2.2 mg, 21%).

¹H NMR (400 MHz, CD₃OD) δ 8.31 (d, J=9.5 Hz, 1H), 7.82 (d, J=2.4 Hz,1H), 7.64 (s, 1H), 7.54 (d, J=9.4 Hz, 1H), 7.28-7.19 (m, 2H), 7.11 (s,1H), 7.07 (d, J=6.8 Hz, 1H), 6.95 (d, J=2.4 Hz, 1H), 6.27 (s, 2H), 5.60(p, J=6.7 Hz, 1H), 5.02 (t, J=7.2 Hz, 2H), 4.98 (t, J=6.4 Hz, 2H), 3.16(s, 3H); LCMS (M+H)⁺: 419.2.

Example 178:2-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}ethanoltrifluoroacetate salt

A solution of6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(10. mg, 0.028 mmol, prepared as in Example 103, Step 5) in DMF (0.36mL, 4.7 mmol) was treated with NaH (3.3 mg, 0.14 mmol, 60% in mineraloil). After 10 minutes, methyl bromoacetate (7.8 μL, 0.083 mmol,Aldrich) was added. After 20 minutes, the reaction was quenched by theaddition of saturated ammonium hydroxide solution. The reaction mixturewas diluted with water and extracted with three portions of EtOAc. Themajority of the solvent was removed in vacuo, and DMF was removedazeotropically by repeated dissolution in and evaporation of MeCN. Thecrude intermediate ester was dissolved in THF (1.0 mL) and treated withLiAlH₄ (1.0 M in THF, 55 μL, 0.055 mmol, Aldrich). After 15 minutes, themixture was quenched by the addition of water and was diluted with MeCN(3 mL) and MeOH (0.5 mL). After stirring for 5 minutes, the solution wasfiltered and product was isolated via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (1.4 mg 9.8%).

¹H NMR (400 MHz, CD₃OD) δ 8.25 (d, J=9.5 Hz, 1H), 7.78 (d, J=2.4 Hz,1H), 7.57 (s, 1H), 7.50 (d, J=9.6 Hz, 1H), 7.28-7.18 (m, 2H), 7.13-7.08(m, 1H), 7.08-7.01 (m, 1H), 6.86 (d, J=2.4 Hz, 1H), 6.18 (s, 2H), 4.29(t, J=5.3 Hz, 2H), 3.90 (t, J=5.4 Hz, 2H), 3.15 (s, 3H); LCMS (M+H)⁺:407.1.

Example 179:2-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)ethanolbis(trifluoroacetate) salt

7-(1-Azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(5.0 mg, 0.012 mmol, prepared as in Example 156, isolated as the freebase) was treated with 2-bromoethanol (1.3 μL, 0.018 mmol, Aldrich) andK₂CO₃ (8.3 mg, 0.060 mmol) in DMF (0.20 mL) for 2 hours. The product wasisolated via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA).

Yield: (2.4 mg 29%).

¹H NMR (400 MHz, CD₃OD) δ 8.23 (d, J=8.1 Hz, 1H), 7.88 (d, J=2.5 Hz,1H), 7.71 (s, 1H), 7.56 (d, J=9.4 Hz, 1H), 7.37-7.23 (m, 2H), 7.19 (brs, 1H), 7.08 (br d, J=5.7 Hz, 1H), 7.02 (d, J=2.4 Hz, 1H), 6.24 (s, 2H),5.55-5.40 (m, 1H), 4.80-4.60 (m, 2H), 4.42-4.29 (m, 2H), 3.66-3.54 (m,2H), 3.17 (s, 3H), 3.11-2.99 (m, 2H); LCMS (M+H)⁺: 462.2.

Example 180:6-(3-Chlorobenzyl)-1-methyl-7-[1-(1-methylazetidin-3-yl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

To a mixture of7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt (20. mg, 0.026 mmol, prepared as in Example 156)and formaldehyde solution (37 wt % in water, 11 mg, 0.13 mmol, Aldrich)in DCM (0.50 mL) was added Na(OAc)₃BH (17 mg, 0.079 mmol, Aldrich), andthe reaction was stirred for 20 minutes. THF (0.50 mL) was added, andafter additional stirring for 20 minutes, the reaction was quenched bythe addition of water. The product was isolated via preparative HPLC-MS(Waters SunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1%TFA). Yield: (12.9 mg, 74%).

LCMS (M+H)⁺: 432.1.

Example 181.3-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)propanenitrilebis(trifluoroacetate) salt

7-(1-Azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt (19 mg, 0.025 mmol, prepared as in Example 156) inMeCN (1.0 mL) was treated with K₂CO₃ (34 mg, 0.25 mmol) and2-propenenitrile (3.3 L, 0.050 mmol, Aldrich). The reaction was stirredat room temperature for 2 hours and then was heated at 40° C. for 2hours. The reaction mixture was allowed to cool to room temperature andadditional 2-propenenitrile (3.3 μL, 0.050 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (3.7 μL, 0.025 mmol, Aldrich) wereadded. After stirring at room temperature for 3 days, the reaction wasdiluted with MeOH (2 mL) and MeCN (2 mL) and was purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA).

¹H NMR (400 MHz, d₆-DMSO) δ 8.24 (d, J=9.7 Hz, 1H), 8.04 (d, J=2.5 Hz,1H), 7.70 (s, 1H), 7.61 (d, J=9.7 Hz, 1H), 7.36-7.26 (m, 2H), 7.17-7.10(m, 1H), 7.06 (d, J=2.4 Hz, 1H), 7.01 (dt, J=6.6, 1.9 Hz, 1H), 6.24 (s,2H), 5.41 (p, J=7.4 Hz, 1H), 4.61-4.50 (m, 2H), 4.43-4.15 (br m, 2H),3.56-3.29 (br m, 2H), 3.06 (s, 3H), 2.92-2.83 (m, 2H); LCMS (M+H)⁺:471.1.

Example 182:6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroaceate) salt

Step 1.3-[(2-Bromo-5-chloro-1H-pyrrolo[3,2-b]pyridin-1-yl)methyl]benzonitrile

2-Bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (2.0 g, 8.6 mmol, prepared asin Example 103, Step 1) in DMF (20. mL) was treated with K₂CO₃ (1.8 g,13 mmol) and m-cyanobenzyl bromide (1.9 g, 9.5 mmol, Aldrich) overnight.The reaction mixture was diluted with EtOAc and washed sequentially withwater and brine. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. The solid obtained was trituratedwith hexanes/diethyl ether and isolated by filtration. Yield: (2.3 g,77%).

¹H NMR (300 MHz, CDCl₃) δ 7.59 (d, J=7.7 Hz, 1H), 7.49-7.32 (m, 3H),7.21 (d, J=7.8 Hz, 1H), 7.10 (d, J=8.6 Hz, 1H), 6.85 (s, 1H), 5.44 (s,2H); LCMS (M+H)⁺: 347.9, 345.9.

Step 2.3-({5-Chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-1-yl}methyl)benzonitrile

A mixture of3-[(2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridin-1-yl)methyl]benzonitrile(2.24 g, 6.46 mmol, from Step 1),1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(2.88 g, 10.3 mmol, Aldrich) and Na₂CO₃ (3.4 g, 32 mmol) in1,2-dimethoxyethane (70 mL) and H₂O (10 mL) was degassed.

Tetrakis(triphenylphosphine)palladium(0) (0.75 g, 0.65 mmol, Strem) wasadded, and the reaction mixture was heated at reflux for 1 hour.Additional1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(2.0 g, 7.2 mmol, Aldrich) and Tetrakis(triphenylphosphine)palladium(0)(0.50 g, 0.43 mmol, Strem) were added, and the reaction mixture washeated for an additional 35 minutes. After cooling to room temperature,the reaction was diluted with water, and the aqueous layer was extractedwith three portions of EtOAc. The combined organic extracts were driedover sodium sulfate, filtered and concentrated. The product was purifiedby flash chromatography, eluting with a gradient from 0-40% EtOAc inhexanes. Yield: (1.3 g, 48%).

¹H NMR (300 MHz, CDCl₃) δ 7.64 (d, J=1.8 Hz, 1H), 7.55 (d, J=7.7 Hz,1H), 7.46 (d, J=8.6 Hz, 1H), 7.39 (t, J=7.8 Hz, 1H), 7.21-7.14 (m, 2H),7.09 (d, J=7.9 Hz, 1H), 6.97 (s, 1H), 6.27 (d, J=1.8 Hz, 1H), 5.35 (d,J=17.1 Hz, 1H), 5.34 (d, J=17.1 Hz, 1H), 5.23 (dd, J=10.4, 2.3 Hz, 1H),4.04 (ddt, J=11.5, 3.9, 1.8 Hz, 1H), 3.52 (td, J=11.6, 2.2 Hz, 1H), 2.50(tdd, J=12.8, 10.8, 4.2 Hz, 1H), 2.13-1.42 (m, 5H); LCMS (M+H)⁺: 418.1.

Step 3. Di-tert-butyl1-{1-(3-cyanobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate

3-({5-Chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-1-yl}methyl)benzonitrile(1.3 g, 3.1 mmol, from Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (1.4 g, 6.2 mmol, Aldrich) and Cs₂CO₃ (2.0g, 6.2 mmol) were combined in toluene (20. mL) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.24 g, 0.31 mmol, Aldrich) was added. The mixture was degassedand heated at 140° C. for 70 minutes. After cooling to room temperature,the mixture was diluted with DCM, filtered, and concentrated. Flashchromatography, eluting with a gradient from 0-60% EtOAc in hexanes,afforded purified product. Yield: (1.2 g, 63%).

¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J=1.7 Hz, 1H), 7.60-7.45 (m, 3H),7.37 (t, J=7.8 Hz, 1H), 7.18 (s, 1H), 7.13-7.05 (m, 2H), 6.93 (s, 1H),6.25 (d, J=1.8 Hz, 1H), 5.35 (d, J=17.5 Hz, 1H), 5.30 (d, J=16.9 Hz,1H), 5.25 (dd, J=10.2, 1.9 Hz, 1H), 4.07-4.00 (m, 1H), 3.52 (td, J=11.7,1.9 Hz, 1H), 2.58-2.40 (m, 1H), 2.08-1.42 (m, 5H), 1.52 (s, 9H), 1.48(s, 9H).

LCMS (M+H)⁺: 614.3.

Step 4.3-{[1-Methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzonitrile

4.0 M HCl in dioxane (2.9 mL, 12 mmol) was added to a solution ofdi-tert-butyl1-{1-(3-cyanobenzyl)-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridin-5-yl}hydrazine-1,2-dicarboxylate(1.2 g, 2.0 mmol, from Step 3) in DCM (50 mL) at 0° C. After 15 minutes,the reaction was quenched by the addition of aqueous ammonia and the pHwas adjusted to 10. The mixture was diluted with water, and the aqueoussolution was extracted with three portions of EtOAc. The combinedorganic extracts were washed with water followed by brine, dried oversodium sulfate, filtered and concentrated. The product was purified viaflash chromatography, eluting with a gradient from 0-60% EtOAc inhexanes, to afford 0.83 g of deprotected pyrazole. LCMS (M+H)⁺: 530.4.

The resulting solid was dissolved in acetic acid (35 mL) and heated in asealed vessel at 130° C. for 40 minutes. Acetic acid was removed invacuo to afford a yellow solid. The solid was suspended in a mixture ofMeOH/MeCN containing aqueous ammonia (5 mL). After stirring for 10minutes, the mixture was diluted with water, and the aqueous solutionwas extracted with 10% iPrOH in CHCl₃. The organic extract was driedover sodium sulfate, filtered and concentrated. The product was isolatedby flash chromatography, eluting with a gradient from 0-10% MeOH in DCM.Yield: (0.36 g, 52%).

¹H NMR (400 MHz, d₆-DMSO) δ 13.13 (s, 1H), 7.89 (d, J=1.9 Hz, 1H), 7.70(d, J=7.7 Hz, 1H), 7.66 (d, J=9.9 Hz, 1H), 7.58-7.54 (m, 1H), 7.47 (t,J=7.8 Hz, 1H), 7.42 (s, 1H), 7.33 (d, J=9.7 Hz, 1H), 7.28 (d, J=7.0 Hz,1H), 6.89 (d, J=1.9 Hz, 1H), 6.14 (s, 2H), 2.96 (s, 3H); LCMS (M+H)⁺:354.2.

Step 5.3-{[1-Methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzoicacid

A mixture of3-{[1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzonitrile(0.29 g, 0.82 mmol, from Step 4) and KOH (0.46 g, 8.2 mmol) in EtOH (29mL) was heated at 80° C. overnight in a sealed tube. Thereafter, thereaction was heated at 120-135° C. for 37 hours. Solvent was removed invacuo. The reaction mixture was diluted with water, and the pH wasadjusted to pH 4 by the addition of 1 N HCl. The brown solid that formedwas isolated by filtration. The filtrate was saturated with solid NaCl,the pH was lowered to pH 3 by the addition of 1 N HCl and additionalproduct was obtained by extraction with five portions of 10% iPrOH inCHCl₃. The extract was dried over sodium sulfate, filtered andconcentrated. The solid obtained was combined with the solid that wasisolated by filtration above. The 0.4 g of material containing crudeproduct was used without further purification in Step 6.

LCMS (M+H)⁺: 373.2.

Step 6.(3-((1-Methyl-7-(H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)phenyl)methanol

A mixture of3-{[1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzoicacid (0.40 g, from Step 5) in THF (40. mL) at 0° C. was treated with 1.0M borane in THF (1.7 mL, 1.7 mmol, Aldrich) dropwise. The mixture wasstirred for 1.5 hours, with warming to room temperature. Additional 1.0M borane in THF (45 mL, 45 mmol) was added portionwise to the reactionmixture at room temperature over the course of 48 hours. The reactionmixture was cooled to 0° C. and cautiously quenched by the dropwiseaddition of water, followed by the addition of 1N HCl (55 mL). Themixture was then neutralized by the addition of solid NaHCO₃, and theproduct was extracted with 10% iPrOH in CHCl₃. Precipitate was dissolvedin MeOH and combined with the organic extracts. The resulting solutionwas dried over sodium sulfate, filtered and concentrated. The productwas purified by flash chromatography, eluting with a gradient from 0-10%MeOH in DCM. Yield: (0.12 g, 31%).

¹H NMR (400 MHz, d₆-DMSO) δ 13.11 (s, 1H), 7.88 (dd, J=1.5, 2.1 Hz, 1H),7.57 (d, J=9.8 Hz, 1H), 7.36 (s, 1H), 7.29 (d, J=9.7 Hz, 1H), 7.19 (t,J=7.6 Hz, 1H), 7.16-7.11 (m, 1H), 7.09-7.04 (m, 1H), 6.85 (t, J=2.1 Hz,1H), 6.84-6.81 (m, 1H), 6.10 (s, 2H), 5.12 (t, J=5.7 Hz, 1H), 4.37 (d,J=5.7 Hz, 2H), 2.96 (s, 3H); LCMS (M+H)⁺: 359.3.

Step 7.3-{[1-Methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzaldehyde

(3-((1-Methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)phenyl)methanol(0.12 g, 0.27 mmol, from Step 6) was treated with manganese(IV) oxide(0.23 g, 2.7 mmol, Aldrich) in CHCl₃ (24 mL). After stirring at roomtemperature for 80 minutes, the mixture was heated at 40° C. for 75minutes and then at 50° C. for 2.5 hours. The mixture was filteredthrough Celite and rinsed with acetonitrile. Solvent was removed fromthe filtrate in vacuo to afford aldehyde, which was used in further stepwithout purification. Yield: (75 mg, 63%).

¹H NMR (300 MHz, d₆-DMSO) δ 13.11 (s, 1H), 9.90 (s, 1H), 7.91-7.83 (m,1H), 7.77 (d, J=7.4 Hz, 1H), 7.63 (d, J=9.8 Hz, 1H), 7.58 (s, 1H), 7.52(t, J=7.6 Hz, 1H), 7.41 (s, 1H), 7.38-7.26 (m, 2H), 6.92-6.84 (m, 1H),6.20 (s, 2H), 2.97 (s, 3H); LCMS (M+H)⁺: 357.1.

Step 8.6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

A solution of3-{[1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzaldehyde(30. mg, 0.067 mmol, from Step 7) in 1,2-dichloroethane (5.0 mL) wastreated with azetidine (40 μL, 0.7 mmol, Aldrich) and acetic acid (57μL, 1.0 mmol). The mixture was stirred for 15 minutes, followed by theaddition of Na(OAc)₃BH (0.21 g, 1.0 mmol, Aldrich). After stirringovernight, the reaction was quenched with water, and the volatilecomponents were removed in vacuo. The product was purified viapreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH).

Yield: (15.4 mg, 58%).

The title compound was obtained via preparative HPLC-MS (Waters SunFireC18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).

¹H NMR (300 MHz, d₆-DMSO) δ 13.12 (s, 1H), 7.88 (s, 1H), 7.60 (d, J=9.7Hz, 1H), 7.36 (s, 1H), 7.30 (d, J=9.8 Hz, 1H), 7.16 (t, J=7.5 Hz, 1H),7.05 (d, J=7.8 Hz, 1H), 7.00 (s, 1H), 6.92-6.68 (m, 2H), 6.07 (s, 2H),3.38 (s, 2H), 3.05-2.85 (m, 4H), 2.96 (s, 3H), 1.89 (p, J=6.8 Hz, 2H);LCMS (M+H)⁺: 398.3.

Example 183:3-(3-{6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrazol-1-yl)propanenitrilebis(trifluoroacetate) salt

6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(7.0 mg, 0.018 mmol, from Example 182) in MeCN (0.23 mL) was treatedwith 2-propenenitrile (2.3 μL, 0.035 mmol, Aldrich) and1,8-diazabicyclo[5.4.0]undec-7-ene (2.6 μL, 0.018 mmol, Aldrich) for 8minutes. The product was purified via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (9.8 mg, 82%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.93 (s, 1H), 8.01-7.91 (m, 2H), 7.55 (s,1H), 7.48 (d, J=9.7 Hz, 1H), 7.33 (t, J=7.6 Hz, 1H), 7.30-7.25 (m, 1H),7.20-7.15 (m, 1H), 7.13-7.06 (m, 1H), 6.93 (d, J=2.3 Hz, 1H), 6.16 (s,2H), 4.44 (t, J=6.3 Hz, 2H), 4.24 (d, J=6.0 Hz, 2H), 4.03-3.82 (m, 4H),3.06 (t, J=6.3 Hz, 2H), 3.02 (s, 3H), 2.40-2.16 (m, 2H); LCMS (M+H)⁺:451.3.

Example 184:6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

Step 1.3-{[1-Methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzonitrile

3-{[1-Methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzonitrile(50. mg, 0.14 mmol, from Example 182, Step 4) in DMF (3.0 mL) wastreated with NaH (60% in mineral oil, 34 mg, 0.85 mmol). After 10minutes, Mel (26 μL, 0.42 mmol, Aldrich) was introduced. After 10minutes, the reaction was quenched by the addition of water. The productwas isolated via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (30 mg, 58%).

¹H NMR (400 MHz, CDCl₃) δ 7.54 (dt, J=7.8, 1.2 Hz, 1H), 7.43-7.34 (m,4H), 7.30-7.26 (m, 1H), 7.20 (dd, J=9.7, 0.4 Hz, 1H), 7.05 (s, 1H), 6.52(d, J=2.3 Hz, 1H), 5.95 (s, 2H), 3.92 (s, 3H), 3.05 (s, 3H); LCMS(M+H)⁺: 368.3

Step 2.6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

3-{[1-Methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzonitrile(24 mg, 0.065 mmol, from Step 1) was treated with KOH (37 mg, 0.65 mmol)in EtOH (2.3 mL) and the resultant reaction mixture was heated in asealed vessel at 140° C. for 2 hours. The mixture was cooled to roomtemperature and acidified to pH 4 by the addition of 1 N HCl. Most ofthe solvent was removed in vacuo, and the crude carboxylic acid wasisolated by filtration. LCMS (M+H)⁺: 387.2.

Triethylamine (91 μL, 0.65 mmol) and isobutyl chloroformate (42 μL, 0.33mmol, Aldrich) were added to the crude carboxylic acid in DCM (2.0 mL)and THF (3.0 mL) at 0° C. After 30 minutes, the reaction mixture wasfiltered through a short pad of Celite into a flask containing NaBH₄ (25mg, 0.65 mmol, Aldrich) in H₂O (2.0 mL) at 0° C. The Celite was rinsedwith THF (6 mL). The mixture was allowed to warm to room temperature andstirred for 30 minutes. The reaction was quenched by the addition of 1 NHCl and was neutralized by the addition of aqueous ammonia. The aqueousmixture was extracted with two portions of DCM, and the combined organicextracts were dried over sodium sulfate, filtered and concentrated.

The crude alcohol was dissolved in DCM (2.0 mL) and treated withN,N-diisopropylethylamine (57 μL, 0.33 mmol) and methanesulfonicanhydride (34 mg, 0.20 mmol, Aldrich). After 10 minutes, the mixture wasconcentrated, and the crude mesylate was dissolved in a mixture of THF(1.0 mL) and methanol (1.0 mL) and treated with azetidine (44 μL, 0.65mmol, Aldrich). After a reaction time of 10 minutes, the product wasisolated via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA).

Yield: (4.4 mg, 10%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.01 (br s, 1H), 7.95 (d, J=9.8 Hz, 1H),7.85 (d, J=2.3 Hz, 1H), 7.52 (s, 1H), 7.47 (d, J=9.7 Hz, 1H), 7.37-7.26(m, 2H), 7.24-7.19 (m, 1H), 7.06-7.01 (m, 1H), 6.88 (d, J=2.3 Hz, 1H),6.15 (s, 2H), 4.26 (d, J=6.0 Hz, 2H), 4.07-3.82 (m, 4H), 3.89 (s, 3H),3.02 (s, 3H), 2.42-2.17 (m, 2H); LCMS (M+H)⁺: 412.3.

Example 185:6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

Step 1.2-Bromo-1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine

To 2-bromo-5-chloro-1H-pyrrolo[3,2-b]pyridine (1.6 g, 6.7 mmol, preparedas in Example 103, Step 1) in DMF (50. mL) was added K₂CO₃ (1.4 g, 10.mmol) and 3-{[tert-butyl(diphenyl)silyl]oxy}-5-chlorobenzylmethanesulfonate (3.7 g, 7.8 mmol, prepared as in Example 131, Step1-3), and the reaction mixture was stirred overnight. The mixture wasdiluted with EtOAc, washed sequentially with water and brine, then driedover sodium sulfate, filtered and concentrated. The product was purifiedby flash chromatography, eluting with a gradient from 0-10% EtOAc inhexanes. Yield: (3.6 g, 86%).

¹H NMR (400 MHz, CDCl₃) δ 7.60-7.55 (m, 4H), 7.45-7.32 (m, 7H),7.19-7.15 (m, 1H), 7.05 (d, J=8.6 Hz, 1H), 7.00-6.98 (m, 1H), 6.86-6.83(m, 1H), 6.81 (d, J=0.6 Hz, 1H), 5.36 (s, 2H), 4.62 (s, 2H), 1.01 (s,9H); LCMS (M+H)⁺: 625.2.

Step 2.1-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridine

Tetrakis(triphenylphosphine)palladium(0) (0.65 g, 0.56 mmol, Strem) wasadded to a degassed mixture of2-bromo-1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-1H-pyrrolo[3,2-b]pyridine(3.5 g, 5.6 mmol, from Step 1),1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(2.5 g, 9.0 mmol, Aldrich) and Na₂CO₃ (3.0 g, 28 mmol) in1,2-dimethoxyethane (60 mL) and Water (10 mL). The mixture was heated atreflux for 2 hours. Additional1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.50 g, 1.8 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.32 g,0.28 mmol) were added, and the reaction mixture was heated at refluxuntil LCMS indicated that the reaction was complete. After cooling toroom temperature, the reaction was diluted with water, and the aqueousmixture was extracted with three portions of EtOAc. The combined organicextracts were washed with water, followed by brine, dried over Na₂SO₄,filtered and concentrated. Flash chromatography, eluting with a gradientfrom 0-20% EtOAc in hexanes afforded product as a light yellow oil.Yield: (2.73 g, 70%).

¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J=1.8 Hz, 1H), 7.58-7.52 (m, 4H),7.47 (d, J=8.6 Hz, 1H), 7.41 (dq, J=6.5, 2.0 Hz, 2H), 7.38-7.31 (m, 4H),7.18-7.15 (m, 1H), 7.13 (d, J=8.6 Hz, 1H), 6.96 (s, 1H), 6.76-6.71 (m,2H), 6.28 (d, J=1.8 Hz, 1H), 5.27 (d, J=4.4 Hz, 2H), 5.21 (dd, J=10.4,2.2 Hz, 1H), 4.60 (s, 2H), 4.08-3.98 (m, 1H), 3.52 (td, J=11.8, 2.1 Hz,1H), 2.50 (tdd, J=13.1, 10.7, 4.3 Hz, 1H), 2.10-1.93 (m, 1H), 1.79-1.63(m, 2H), 1.55-1.44 (m, 2H), 0.98 (s, 9H); LCMS (M+H)⁺: 695.4.

Step 3. Di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-(1H-pyrazol-3-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A mixture of1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-5-chloro-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-1H-pyrrolo[3,2-b]pyridine(2.7 g, 3.9 mmol, from Step 2), di-tert-butylhydrazine-1,2-dicarboxylate (0.99 g, 4.3 mmol, Aldrich), Cs₂CO₃ (2.5 g,7.8 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.30 g, 0.39 mmol, Aldrich) in toluene (25 mL) was degassed andheated at 140° C. for 3 hours. Additional di-tert-butylhydrazine-1,2-dicarboxylate (0.50 g, 2.2 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.30 g, 0.38 mmol) were added and heating was continued for 1hour. After addition of more di-tert-butyl hydrazine-1,2-dicarboxylate(0.20 g, 0.86 mmol) and heating for another 40 minutes, the mixture wascooled to room temperature and diluted with DCM, filtered andconcentrated. The intermediate thus obtained was isolated by flashchromatography, eluting with a gradient from 0-25% EtOAc in hexanes (2.5g). A solution of the intermediate in DCM (80 mL) at 0° C. was treatedwith 4.0 M HCl in dioxane (3.9 mL, 16 mmol). After stirring for 15minutes, the reaction was quenched with aqueous ammonia. The reactionmixture was diluted with water, and the aqueous solution was extractedwith three portions of EtOAc. The combined organic extracts were washedsequentially with water and brine, dried over sodium sulfate, filteredand concentrated. The title product was purified by flashchromatography, eluting with a gradient from 0-50% EtOAc in hexanes.Yield: (1.1 g, 35%).

LCMS (M+H)⁺: M+H 807.4.

Step 4.6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of di-tert-butyl1-[1-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-2-(1H-pyrazol-3-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(1.1 g, 1.4 mmol, from Step 3) in acetic acid (28 mL) was heated at 130°C. for 1.5 hours. Acetic acid was removed in vacuo, and the residue wasdissolved in DCM and washed with saturated NaHCO₃. The aqueous layer wasextracted with DCM. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-10% MeOH in DCM. Yield:(0.66 g, 54%).

¹H NMR (300 MHz, CDCl₃) δ 7.63 (d, J=2.4 Hz, 1H), 7.60-7.51 (m, 4H),7.45-7.18 (m, 8H), 7.18-7.10 (m, 1H), 7.05 (s, 1H), 7.02-6.98 (m, 1H),6.92-6.84 (m, 1H), 6.58 (d, J=2.4 Hz, 1H), 5.87 (s, 2H), 4.60 (s, 2H),3.01 (s, 3H), 0.94 (s, 9H); LCMS (M+H)⁺: 631.3.

Step 5.6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.20 g, 0.22 mmol, from Step 4) in DMF (4.7 mL) was treated with NaH(60% in mineral oil, 27 mg, 0.66 mmol). After 10 minutes, Mel (41 μL,0.66 mmol, Aldrich) was added to the reaction mixture. After 10 minutes,the reaction was quenched by the addition of water, and the product waspurified via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (50 mg, 30%).

¹H NMR (400 MHz, CDCl₃) δ 7.58-7.53 (m, 4H), 7.42-7.28 (m, 8H), 7.21 (d,J=9.7 Hz, 1H), 7.17-7.13 (m, 1H), 7.01 (s, 1H), 7.01-6.96 (m, 1H),6.87-6.83 (m, 1H), 6.45 (d, J=2.3 Hz, 1H), 5.85 (s, 2H), 4.60 (s, 2H),3.93 (s, 3H), 3.01 (s, 3H), 0.94 (s, 9H); LCMS (M+H)⁺: 645.0.

Step 6.6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

A solution of6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(47 mg, 0.073 mmol, from Step 5) in THF (4 mL) was treated with 1.0 MTBAF in THF (87 μL, 0.087 mmol, Aldrich) for 35 minutes. Upon completeconversion to the deprotected alcohol, DCM (5.0 mL), triethylamine (51μL, 0.36 mmol) and methanesulfonyl chloride (22 μL, 0.29 mmol, Aldrich)were added. After 10 minutes, the solvent was removed in vacuo, and theresidue was dissolved in a mixture of 1:1 THF:MeOH (4.0 mL). Azetidine(49 μL, 0.73 mmol, Aldrich) was added. After 35 minutes, the product wasisolated from the reaction mixture via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH), followed by additional purification (Waters SunFire C18, elutingwith a gradient of MeCN/H₂O containing 0.1% TFA) to afford the titleproduct as the TFA salt. Yield: (28.6 mg, 50%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.01 (s, 1H), 7.97 (d, J=9.4 Hz, 1H), 7.86(d, J=2.3 Hz, 1H), 7.55 (s, 1H), 7.49 (d, J=9.7 Hz, 1H), 7.44-7.39 (m,1H), 7.17-7.12 (m, 2H), 6.90 (d, J=2.3 Hz, 1H), 6.14 (s, 2H), 4.26 (d,J=5.6 Hz, 2H), 4.03-3.83 (m, 4H), 3.89 (s, 3H), 3.03 (s, 3H), 2.40-2.18(m, 2H); LCMS (M+H)⁺: 446.2.

Example 186:6-Benzyl-1-methyl-7-pyrrolidin-3-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt (racemic)

Step 1. tert-Butyl3-[5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]-2,5-dihydro-1H-pyrrole-1-carboxylate

Tetrakis(triphenylphosphine)palladium(0) (0.13 g, 0.11 mmol, Strem) wasadded to a degassed mixture of2-bromo-5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridine (0.50 g,1.1 mmol, prepared as in Example 103, Step 2), tert-butyl3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate(0.414 g, 1.40 mmol, Combi-Blocks) and Na₂CO₃ (0.60 g, 5.6 mmol) in1,2-dimethoxyethane (10 mL) and water (2 mL), and the sealed reactionmixture was heated at 106° C. for two hours. Additional tert-butyl3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate(0.33 g, 1.1 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.13 g,0.11 mmol) were added, and heating was continued for additional twohours. Upon cooling to room temperature, the reaction mixture wasdiluted with water, and the aqueous layer was extracted with threeportions of EtOAc. The combined organic extracts were dried over sodiumsulfate, filtered and concentrated. The product was purified by flashchromatography, eluting with a gradient from 0-30% EtOAc in hexanes.Yield: (0.12 g, 24%).

LCMS (M+H)⁺: 444.2.

Step 2.6-Benzyl-1-methyl-7-pyrrolidin-3-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt (racemic)

A degassed mixture of tert-butyl3-[5-chloro-1-(3-chlorobenzyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]-2,5-dihydro-1H-pyrrole-1-carboxylate(0.12 g, 0.27 mmol, from Stepl), di-tert-butylhydrazine-1,2-dicarboxylate (94 mg, 0.40 mmol, Aldrich), Cs₂CO₃ (0.18 g,0.54 mmol) anddicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (21 mg, 0.027 mmol, Aldrich) in toluene (2.0 mL) was heated in asealed vial at 140° C. for 70 minutes. Upon cooling to room temperature,the reaction mixture was diluted with DCM and filtered. The filtrate wasconcentrated, and the residue was purified by flash chromatography,eluting with a gradient from 0-40% EtOAc in hexanes. Yield: (29 mg).LCMS (M+H)⁺: 640.3. The derivative of di-tert-butylhydrazine-1,2-dicarboxylate this obtained was then hydrogenated (1 atmH₂) over Pd (10% on carbon, 8.6 mg, 0.0081 mmol) in MeOH (4.0 mL) for 3days. The reaction mixture was filtered, and the filtrate wasconcentrated in vacuo. The intermediate pyrrolidine as a solution inacetic acid (1.0 mL) was heated in the microwave at 180° C. for 5minutes. The product was isolated via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (2.4 mg, 2%).

¹H NMR (400 MHz, CD₃OD) δ 8.29 (d, J=9.5 Hz, 1H), 7.55 (d, J=9.6 Hz,1H), 7.39-7.26 (m, 4H), 7.05-6.97 (m, 2H), 5.77 (s, 2H), 3.92 (p, J=8.8Hz, 1H), 3.63-3.52 (m, 2H), 3.46-3.33 (m, 2H), 3.13 (s, 3H), 2.47-2.33(m, 1H), 2.20 (dq, J=13.0, 8.9 Hz, 1H); LCMS (M+H)⁺: 331.9.

Example 187:7-(1-Acetylpyrrolidin-3-yl)-6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt (racemic)

The title compound was obtained as a byproduct in Example 186, Step 2.The title product was isolated via preparative HPLC-MS (Waters SunFireC18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield:(2.7 mg, 2%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.26 (d, J=9.2 Hz, 1H), 7.56 (d, J=9.6 Hz,0.5 H, rotamers), 7.55 (d, J=9.6 Hz, 0.5 H, rotamers), 7.37-7.23 (m,3H), 7.30 (s, 1H), 7.04-6.94 (m, 2H), 5.79 (s, 2H), 3.83-3.20 (m, 5H),3.02 (s, 3H), 2.23-1.98 (m, 2H), 1.96 (s, 1.5 H, rotamers), 1.90 (s, 1.5H, rotamers); LCMS (M+H)⁺: 373.8.

Example 188:6-(3-(Azetidin-1-ylmethyl)-5-chlorobenzyl)-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

Step 1.6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of6-[3-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.10 g, 0.11 mmol, from Example 185, Step 4) in DMF (2.3 mL) wastreated with NaH (60% in mineral oil, 13 mg, 0.33 mmol). After 10minutes, iodoethane (27 μL, 0.33 mmol, Sigma-Aldrich) was added. After10 minutes, the reaction was quenched with water. The product waspurified via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH).

Yield: (14 mg, 19%).

LCMS (M+H)⁺: 659.3.

Step 2.6-(3-(Azetidin-1-ylmethyl)-5-chlorobenzyl)-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(7.0 mg, 0.011 mmol, from Step 1) in THF (0.5 mL) was treated with 1.0 MTBAF in THF (12 μL, 0.012 mmol, Aldrich), and the reaction mixture wasstirred for 35 minutes. The reaction mixture was then diluted with DCM(0.7 mL) and treated with triethylamine (7.4 μL, 0.053 mmol) andmethanesulfonyl chloride (3.3 L, 0.042 mmol, Aldrich). After 10 minutes,the solvents were removed in vacuo and the residue was dissolved in THF(0.3 mL) and MeOH (0.3 mL). Azetidine (3.6 μL, 0.053 mmol, Aldrich) wasadded, and the reaction was stirred for 35 minutes. Solvent was removedin vacuo, and the residue was dissolved in MeOH and the title productwas isolated via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of MeCN/H₂O containing 0.1% TFA). Yield: (5.8 mg, 71%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.10 (s, 1H), 8.09 (d, J=9.4 Hz, 1H), 7.91(d, J=2.2 Hz, 1H), 7.58 (s, 1H), 7.54 (d, J=9.4 Hz, 1H), 7.44-7.39 (m,1H), 7.21-7.17 (m, 1H), 7.16-7.13 (m, 1H), 6.91 (d, J=2.2 Hz, 1H), 6.15(s, 2H), 4.25 (d, J=5.3 Hz, 2H), 4.17 (q, J=7.2 Hz, 2H), 4.05-3.82 (m,4H), 3.04 (s, 3H), 2.41-2.14 (m, 2H), 1.35 (t, J=7.3 Hz, 3H); LCMS(M+H)⁺: 460.2.

Example 189:6-(3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl)-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetris(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 188,using pyrrolidine (4.4 μL, 0.053 mmol, Aldrich) in Step 2. Yield: (5.6mg, 68%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.89 (s, 1H), 8.13 (d, J=9.8 Hz, 1H), 7.91(d, J=2.3 Hz, 1H), 7.60 (s, 1H), 7.55 (d, J=9.6 Hz, 1H), 7.52-7.47 (m,1H), 7.21-7.18 (m, 1H), 7.18-7.16 (m, 1H), 6.92 (d, J=2.3 Hz, 1H), 6.16(s, 2H), 4.26 (d, J=5.4 Hz, 2H), 4.17 (q, J=7.3 Hz, 2H), 3.34-3.17 (m,2H), 3.05 (s, 3H), 3.01-2.89 (m, 2H), 2.03-1.89 (m, 2H), 1.88-1.72 (m,2H), 1.35 (t, J=7.3 Hz, 3H); LCMS (M+H)⁺: 474.2.

Example 190:6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 185,using pyrrolidine in Step 6. Yield: (4.8 mg, 45%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.99 (s, 1H), 8.06 (d, J=9.5 Hz, 1H), 7.86(d, J=2.3 Hz, 1H), 7.57 (s, 1H), 7.55-7.48 (m, 2H), 7.23-7.19 (m, 1H),7.14-7.10 (m, 1H), 6.91 (d, J=2.3 Hz, 1H), 6.16 (s, 2H), 4.28 (d, J=4.0Hz, 2H), 3.89 (s, 3H), 3.34-3.21 (m, 2H), 3.04 (s, 3H), 3.02-2.89 (m,2H), 2.04-1.91 (m, 2H), 1.88-1.74 (m, 2H); LCMS (M+H)⁺: 460.2.

Example 191:1-(3-Chloro-5-{[1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}phenyl)-N,N-dimethylmethanaminebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 185,using 2.0 M dimethylamine (Aldrich) in THF in Step 6. Yield: (3.2 mg,31%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.86 (s, 1H), 8.10 (d, J=9.7 Hz, 1H), 7.86(d, J=2.3 Hz, 1H), 7.59 (s, 1H), 7.53 (d, J=9.6 Hz, 1H), 7.51-7.47 (m,1H), 7.18-7.14 (m, 2H), 6.92 (d, J=2.3 Hz, 1H), 6.16 (s, 2H), 4.19 (s,2H), 3.89 (s, 3H), 3.05 (s, 3H), 2.65 (s, 6H); LCMS (M+H)⁺: 434.2.

Example 192:6-[3-Chloro-5-(morpholin-4-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 185,using morpholine (Aldrich) in Step 6. Yield: (4.7 mg, 43%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.09 (d, J=9.5 Hz, 1H), 7.87 (d, J=2.3 Hz,1H), 7.60 (s, 1H), 7.54 (d, J=9.6 Hz, 1H), 7.51-7.46 (m, 1H), 7.19-7.14(m, 1H), 7.14-7.11 (m, 1H), 3.18-2.92 (m, 4H), 6.92 (d, J=2.3 Hz, 1H),6.17 (s, 2H), 4.23 (s, 2H), 3.89 (s, 3H), 3.99-3.50 (m, 4H), 3.05 (s,3H); LCMS (M+H)⁺: 476.2.

Example 193:6-(3-Chlorobenzyl)-7-(4,5-dihydro-1,3-oxazol-2-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a solution of6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxylicacid (29 mg, 0.085 mmol, prepared as in Example 99, Step 4) in DMF (0.90mL) was added N,N-diisopropylethylamine (30 μL, 0.17 mmol), followed byHATU (48 mg, 0.13 mmol). After stirring for 15 minutes, ethanolamine(10. L, 0.17 mmol, Aldrich) was added to the reaction mixture. Afterstirring for 15 minutes, the intermediate amide was purified viapreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH) to afford a white solid (15 mg). Theintermediate amide was treated with triethylamine (47 μL, 0.34 mmol) andmethanesulfonic anhydride (37 mg, 0.21 mmol, Aldrich) in THF (2.0 mL)for 30 minutes at room temperature, and the reaction mixture was thenheated at 50° C. for 1.5 hours. The title product was purified viapreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (9.2 mg, 30%).

¹H NMR (300 MHz, CDCl₃) δ 7.48 (d, J=8.7 Hz, 1H), 7.41-7.15 (m, 4H),7.09-7.00 (m, 1H), 6.96-6.82 (m, 1H), 6.06 (s, 2H), 4.39 (t, J=8.6 Hz,2H), 4.10 (t, J=8.4 Hz, 2H), 3.01 (s, 3H); LCMS (M+H)⁺: 366.0.

Example 194:6-(3-Chlorobenzyl)-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

Step 1.5-Chloro-2-(1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

Tetrakis(triphenylphosphine)palladium(0) (0.31 g, 0.27 mmol) was addedto a degassed mixture of2-bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (1.0 g,2.7 mmol, prepared as in Example 62, Step 1, isolated as the free base)and 2-(tributylstannyl)-1,3-oxazole (1.2 g, 3.4 mmol, Aldrich) intoluene (16 mL). The reaction was heated at 110° C. overnight. Uponcooling, solvent was removed in vacuo. The product was purified by flashchromatography, eluting with a gradient from 0-40% EtOAc in hexanes.Yield: (0.80 g, 83%).

¹H NMR (400 MHz, CDCl₃) δ 8.41 (dd, J=8.8, 0.7 Hz, 1H), 7.91 (d, J=0.7Hz, 1H), 7.88-7.82 (m, 2H), 7.62-7.55 (m, 1H), 7.50-7.43 (m, 2H), 7.39(d, J=0.7 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H), 7.19 (d, J=0.7 Hz, 1H); LCMS(M+H)⁺: 360.1.

Step 2.2-(1-Methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7yl)oxazole

A degassed mixture of5-chloro-2-(1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine(0.80 g, 2.2 mmol, from Step 1), di-tert-butylhydrazine-1,2-dicarboxylate (1.0 g, 4.4 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (0.17 g, 0.22 mmol, Aldrich), and Cs₂CO₃ (1.1 g, 3.3 mmol,Aldrich) in toluene (10. mL) was heated at 140° C. for 2 hours. Themixture was cooled to room temperature, diluted with DCM, filtered andconcentrated. Flash chromatography, eluting with a gradient from 0-50%EtOAc in hexanes afforded di-tert-butyl1-[2-(1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(yield: 0.18 g, 14%; LCMS (M+H)⁺: 556.2) and also di-tert-butyl1-[2-(1,3-oxazol-2-yl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(yield: 0.12 g, 13%; LCMS (M+H)⁺: 416.2). Each of these products wasdissolved separately in acetic acid (5.0 mL) and heated in the microwaveat 180° C. for 5 minutes. Both reaction mixtures were combined, and theacetic acid was removed in vacuo. The residue thus obtained wasdissolved in THF (20 mL) and treated with 2.8 M NaOH in water (10 mL, 28mmol) for 40 minutes, after which time the reaction mixture was treatedwith 1 N HCl to achieve pH˜10, and then saturated with solid NaCl. Theaqueous solution was extracted with 15% iPrOH in CHCl₃. The organicextract was dried over sodium sulfate, filtered and concentrated. Theproduct was purified by flash chromatoagraphy, eluting with a gradientfrom 0-10% MeOH in DCM. Yield: (76 mg, 9%).

¹H NMR (300 MHz, d₆-DMSO) δ 12.94 (s, 1H), 8.29 (s, 1H), 7.52 (d, J=9.7Hz, 1H), 7.48-7.41 (m, 3H), 2.94 (s, 3H); LCMS (M+H)⁺: 240.1.

Step 3.6-(3-Chlorobenzyl)-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinetrifluoroacetate salt

A mixture of2-(1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7yl)oxazole(10. mg, 0.042 mmol, from Step 2) in DMF (0.50 mL) was treated withK₂CO₃ (17 mg, 0.12 mmol) and 1-(bromomethyl)-3-chlorobenzene (17 mg,0.084 mmol, Aldrich), and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with MeCN,filtered and purified via preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (5.7mg, 28%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (d, J=0.6 Hz, 1H), 8.01 (d, J=9.6 Hz,1H), 7.73 (s, 1H), 7.63 (d, J=9.6 Hz, 1H), 7.50 (d, J=0.6 Hz, 1H),7.35-7.27 (m, 2H), 7.22-7.16 (m, 1H), 7.00-6.93 (m, 1H), 6.22 (s, 2H),3.02 (s, 3H); LCMS (M+H)⁺: 364.2.

Example 195:6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

Step 1.6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A solution of2-(1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7yl)oxazole(20. mg, 0.084 mmol, Example 194, Step 2) in DMF (10.0 mL) was treatedwith K₂CO₃ (58 mg, 0.42 mmol) and3-{[tert-butyl(diphenyl)silyl]oxy}-5-chlorobenzyl methanesulfonate (44mg, 0.092 mmol, prepared as in Example 131, Step 1-3) and stirred for 3days. The reaction mixture was diluted with EtOAc and washed with water,followed by brine. The organic layer was dried over sodium sulfate,filtered and concentrated to afford a light yellow solid, which was usedwithout further purification in Step 2. Yield: (51 mg, 96%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.30 (d, J=0.7 Hz, 1H), 7.74 (d, J=9.9 Hz,1H), 7.59 (s, 1H), 7.51 (d, J=9.8 Hz, 1H), 7.44 (d, J=0.7 Hz, 1H),7.43-7.36 (m, 6H), 7.36-7.33 (m, 1H), 7.32-7.26 (m, 4H), 7.14-7.12 (m,1H), 6.80-6.75 (m, 1H), 6.22 (s, 2H), 4.58 (s, 2H), 2.90 (s, 3H), 0.68(s, 9H); LCMS (M+H)⁺: 632.3.

Step 2.6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

6-[3-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-5-chlorobenzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(48 mg, 0.076 mmol, from Step 1) in THF (4 mL) was treated with 1.0 MTBAF in THF (84 μL, 0.084 mmol, Aldrich). After 30 minutes, DCM (5.2mL), triethylamine (53 μL, 0.38 mmol), and methanesulfonyl chloride (24μL, 0.30 mmol, Aldrich) were added. After 30 minutes, the solvents wereremoved in vacuo. The residue was dissolved in THF (2.1 mL) and MeOH(2.1 mL), and azetidine (51 μL, 0.76 mmol, Aldrich) was added to thereaction mixture. After 40 minutes, the solvent was removed in vacuo andthe crude reaction mixture was dissolved in MeOH and purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA). Yield: (24.2 mg, 48%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.98 (s, 1H), 8.35 (d, J=0.8 Hz, 1H), 7.88(d, J=9.7 Hz, 1H), 7.73 (s, 1H), 7.61 (d, J=9.8 Hz, 1H), 7.47 (d, J=0.8Hz, 1H), 7.45-7.42 (m, 1H), 7.26-7.21 (m, 1H), 7.10-7.05 (m, 1H), 6.21(s, 2H), 4.25 (d, J=6.0 Hz, 2H), 4.05-3.76 (m, 4H), 3.02 (s, 3H),2.41-2.09 (m, 2H); LCMS (M+H)⁺: 433.2.

Example 196:6-{3-Chloro-5-[(3,3-dimethylazetidin-1-yl)methyl]benzyl}-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 195,Step 2, using 3,3-dimethylazetidine hydrochloride (Synthonix) andtriethylamine in the displacement step. The reaction time was 3 hours.Yield: (5.4 mg, 29%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.13 (s, 1H), 8.34 (d, J=0.8 Hz, 1H), 7.82(d, J=9.8 Hz, 1H), 7.70 (s, 1H), 7.59 (d, J=9.8 Hz, 1H), 7.47 (d, J=0.8Hz, 1H), 7.46-7.43 (m, 1H), 7.23-7.19 (m, 1H), 7.11-7.07 (m, 1H), 6.21(s, 2H), 4.28 (d, J=5.8 Hz, 2H), 3.82-3.74 (m, 2H), 3.65-3.58 (m, 2H),3.00 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H); LCMS (M+H)⁺: 461.2.

Example 197:6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridinebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 195,using pyrrolidine (Aldrich) in Step 2. Yield: (8.7 mg, 48%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.72 (s, 1H), 8.33 (s, 1H), 7.82 (d, J=9.8Hz, 1H), 7.70 (s, 1H), 7.58 (d, J=9.8 Hz, 1H), 7.54-7.50 (m, 1H), 7.46(d, J=0.6 Hz, 1H), 7.24-7.20 (m, 1H), 7.15-7.10 (m, 1H), 6.21 (s, 2H),4.27 (d, J=5.7 Hz, 2H), 3.31-3.21 (m, 2H), 3.00 (s, 3H), 2.99-2.89 (m,2H), 2.01-1.88 (m, 2H), 1.87-1.73 (m, 2H); LCMS (M+H)⁺: 447.2.

Example 198:1-(3-Chloro-5-{[1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)azetidin-3-olbis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 195,Step 2, using azetidin-3-ol hydrochloride (Aldrich) and triethylamine inthe displacement reaction.

Yield: (6.4 mg, 40%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.27 (br s, 0.3H), 9.89 (br s, 0.7H), 8.35(d, J=0.8 Hz, 1H), 7.91 (dd, J=9.8, 3.6 Hz, 1H), 7.74 (s, 1H), 7.62 (d,J=9.8 Hz, 1H), 7.47 (d, J=0.6 Hz, 1H), 7.47-7.43 (m, 1H), 7.25-7.22 (m,1H), 7.14-7.08 (m, 1H), 6.21 (s, 2H), 4.57-4.48 (m, 0.3H), 4.39 (p,J=6.8 Hz, 0.7H), 4.30-4.22 (m, 2H), 4.18-4.03 (m, 2H), 3.84-3.69 (m,2H), 3.02 (s, 3H); LCMS (M+H)⁺: 449.0.

Example 199:1-(3-Chloro-5-{[1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)pyrrolidin-3-olbis(trifluoroacetate) salt (racemic)

The title compound was prepared according to the methods of Example 195,using 3-pyrrolidinol (Aldrich) in Step 2. Yield: (8.3 mg, 51%).

¹H NMR (400 MHz, d₆-DMSO) δ 10.23 (br s, 0.6H), 9.97 (br s, 0.4H), 8.34(d, J=0.6 Hz, 1H), 7.93-7.86 (m, 1H), 7.73 (s, 1H), 7.61 (d, J=9.8 Hz,1H), 7.55-7.51 (m, 1H), 7.47 (d, J=0.5 Hz, 1H), 7.25-7.20 (m, 1H),7.20-7.13 (m, 1H), 6.21 (s, 2H), 4.43-4.18 (m, 3H), 3.51-3.03 (m, 4H),3.02 (s, 3H), 2.27-1.69 (m, 2H); LCMS (M+H)⁺: 463.0.

Example 200:6-Benzyl-1,7-dimethyl-N-1H-pyrazol-3-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminetris(trifluoroacetate) salt

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.080 mmol, from Example 228, Step 7), 1H-pyrazol-3-amine (20.mg, 0.24 mmol, Aldrich), tBuBrettPhos Pd G3 (6.9 mg, 0.0080 mmol,Aldrich) and NaO^(t)Bu (15 mg, 0.16 mmol, Aldrich) in tert-butyl alcohol(1.0 mL) was heated at 50° C. for 1 hour and then at 80° C. for 7minutes. The product was isolated via preparative HPLC-MS (WatersSunFire C18, eluting with a gradient of MeCN/H₂O containing 0.1% TFA).Yield: (11 mg, 20%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.74 (s, 1H), 8.31 (s, 1H), 7.60 (d, J=2.2Hz, 1H), 7.37-7.29 (m, 2H), 7.29-7.22 (m, 1H), 7.09-7.01 (m, 2H), 6.84(s, 1H), 6.04 (d, J=2.2 Hz, 1H), 5.44 (s, 2H), 2.96 (s, 3H), 2.40 (s,3H); LCMS (M+H)⁺: 358.1.

Example 201:6-Benzyl-1,7-dimethyl-N-pyrimidin-2-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminetris(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 200,using 2-amino-pyrimidine (Aldrich) at 80° C. for 10 minutes. Yield: (13mg, 30%).

¹H NMR (400 MHz, d₆-DMSO) δ 9.44 (s, 1H), 8.47-8.41 (m, 3H), 7.37-7.30(m, 2H), 7.30-7.23 (m, 1H), 7.10-7.03 (m, 3H), 6.90 (t, J=4.8 Hz, 1H),5.62 (s, 2H), 3.01 (s, 3H), 2.49 (s, 3H); LCMS (M+H)⁺: 370.1.

Example 202:6-Benzyl-1,7-dimethyl-N-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminetris(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 200,using 1-methyl-1H-pyrazol-3-amine (Combi-Blocks) at 80° C. for 10minutes. Yield: 9.6 mg, 21%). 1H NMR (400 MHz, d₆-DMSO) δ 8.70 (s, 1H),8.24 (s, 1H), 7.52 (d, J=2.1 Hz, 1H), 7.37-7.30 (m, 2H), 7.29-7.22 (m,1H), 7.20-7.13 (m, 2H), 6.77 (s, 1H), 5.98 (d, J=2.1 Hz, 1H), 5.41 (s,2H), 3.77 (s, 3H), 2.92 (s, 3H), 2.46 (s, 3H); LCMS (M+H)⁺: 371.9.

Example 203:N-1,3-Benzoxazol-2-yl-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminebis(trifluoroacetate) salt

The title compound was prepared according to the methods of Example 200,using 1,3-benzoxazol-2-amine (Matrix) at 80° C. for 10 minutes. Yield:(6.8 mg, 12%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.47 (s, 1H), 7.48 (d, J=7.7 Hz, 1H),7.41-7.30 (m, 3H), 7.30-7.25 (m, 1H), 7.22 (td, J=7.7, 1.1 Hz, 1H),7.16-7.09 (m, 3H), 6.95 (s, 1H), 5.56 (s, 2H), 2.97 (s, 3H), 2.47 (s,3H); LCMS (M+H)⁺: 409.2.

Example 204:6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-oltrifluoroacetate salt

The title compound was obtained as a byproduct in Example 200. The titleproduct was isolated via preparative HPLC-MS (Waters SunFire C18,eluting with a gradient of MeCN/H₂O containing 0.1% TFA). Yield: (5.0mg, 26%).

¹H NMR (400 MHz, d₆-DMSO) δ 11.13 (br s, 1H), 7.36-7.29 (m, 3H),7.29-7.23 (m, 1H), 7.03-6.97 (m, 2H), 6.92 (s, 1H), 5.53 (s, 2H), 2.95(s, 3H), 2.43 (s, 3H); LCMS (M+H)⁺: 293.0.

Example 205:N-1H-Benzimidazol-2-yl-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-aminetrifluoroacetate salt

The title compound was prepared according to the methods of Example 200,using 2-aminobenzimidazole (Aldrich) at 80° C. for 30 minutes. Yield:(5.0 mg, 10%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.15 (s, 1H), 7.42-7.25 (m, 7H), 7.07-7.03(m, 2H), 7.00 (s, 1H), 5.58 (s, 2H), 2.97 (s, 3H), 2.45 (s, 3H); LCMS(M+H)⁺: 408.2.

Example 206:6-Benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(80. mg, 0.26 mmol, from Example 228, Step 7), tert-butyl4-aminopiperidine-1-carboxylate (210 mg, 1.0 mmol, Combi-Blocks),NaO^(t)Bu (49 mg, 0.51 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (30. mg, 0.051mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (24 mg,0.026 mmol, Aldrich) in toluene (4.0 mL) was heated at 100° C.overnight. After cooling, the reaction mixture was diluted with EtOAcand washed sequentially with water and brine. The organic layer wasdried over sodium sulfate, filtered and concentrated. The crude productwas dissolved in DCM (5.0 mL) and was treated with 4.0 M HCl in dioxane(2.0 mL, 8.0 mmol) for 1 hour. The reaction mixture was concentrated invacuo. The product was purified via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield:(40 mg, 38%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.32-7.25 (m, 2H), 7.24-7.17 (m, 1H),7.03-6.97 (m, 2H), 6.57 (s, 1H), 6.53 (s, 1H), 5.40 (s, 2H), 5.20 (d,J=8.6 Hz, 1H), 2.95-2.84 (m, 2H), 2.80 (s, 3H), 2.57-2.47 (m, 2H), 2.29(s, 3H), 1.87-1.75 (m, 2H), 1.32-1.21 (m, 2H); LCMS (M+H)⁺: 375.2.

Example 207:6-Benzyl-1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

To a mixture of6-benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(50. mg, 0.13 mmol, from Example 206) and formaldehyde (37 wt % solutionin water, 12 mg, 0.15 mmol, Aldrich) in DCM (2.6 mL) was addedNa(OAc)₃BH (42 mg, 0.20 mmol, Aldrich). After 25 minutes, volatilesolvent was removed in vacuo. The mixture was diluted with water andmethanol, and the product was purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH). Yield: (24.8 mg, 49%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.32-7.25 (m, 2H), 7.24-7.18 (m, 1H),7.03-6.96 (m, 2H), 6.58 (s, 1H), 6.54 (s, 1H), 5.40 (s, 2H), 5.27 (d,J=8.7 Hz, 1H), 3.40-3.29 (m, 1H), 2.81 (s, 3H), 2.72-2.61 (m, 2H), 2.29(s, 3H), 2.14 (s, 3H), 2.03-1.94 (m, 2H), 1.87-1.79 (m, 2H), 1.52-1.40(m, 2H); LCMS (M+H)⁺: 389.3.

Example 208:6-Benzyl-1,7-dimethyl-N-(2-morpholin-4-ylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25 mg, 0.080 mmol, from Example 228, Step 7),N-(2-aminoethyl)morpholine (42 μL, 0.32 mmol, Aldrich), NaO^(t)Bu (15mg, 0.16 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (9.3 mg, 0.016mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (7.4 mg,0.0080 mmol, Aldrich) in toluene (1.2 mL) was heated at 100° C.overnight. Upon cooling, the reaction mixture was diluted with MeCN,filtered and purified via preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (4.8mg, 15%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.35-7.19 (m, 3H), 7.04-6.93 (m, 2H), 6.62(s, 1H), 6.56 (s, 1H), 5.57 (t, J=6.6 Hz, 1H), 5.43 (s, 2H), 3.61-3.53(m, 4H), 3.25 (app q, J=6.3 Hz, 2H), 2.83 (s, 3H), 2.57 (t, J=6.3 Hz,2H), 2.43-2.34 (m, 4H), 2.30 (s, 3H); LCMS (M+H)⁺: 405.3.

Example 209.6-Benzyl-N-(2-methoxyethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

The title compound was prepared according to the methods of Example 208,using 2-methoxyethylamine (28 μL, 0.32 mmol, Aldrich). Yield: (3.3 mg,12%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.35-7.18 (m, 3H), 7.05-6.96 (m, 2H), 6.61(s, 1H), 6.61 (s, 1H), 5.53 (t, J=5.8 Hz, 1H), 5.42 (s, 2H), 3.55 (t,J=5.6 Hz, 2H), 3.32 (t, J=5.8 Hz, 2H), 3.26 (s, 3H), 2.83 (s, 3H), 2.30(s, 3H); LCMS (M+H)⁺: 350.1.

Example 210:2-[(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]ethanol

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(25.0 mg, 0.0804 mmol, Example 228, Step 7), ethanolamine (44 mg, 0.72mmol, Aldrich), Cs₂CO₃ (79 mg, 0.24 mmol, Aldrich) and tBuBrettPhos PdG3 (8.2 mg, 0.0096 mmol, Aldrich) in NMP (1 mL) and Water (38 μL) washeated at 100° C. overnight. Upon cooling, the reaction mixture wasdiluted with MeCN, filtered and purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH). Yield: (5.9 mg, 22%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.36-7.19 (m, 3H), 7.05-6.93 (m, 2H), 6.61(s, 1H), 6.57 (s, 1H), 5.59 (t, J=5.6 Hz, 1H), 5.42 (s, 2H), 4.85 (t,J=5.5 Hz, 1H), 3.64 (app q, J=5.6 Hz, 2H), 3.22 (app q, J=5.7 Hz, 2H),2.84 (s, 3H), 2.30 (s, 3H); LCMS (M+H)⁺: 336.2.

Example 211:6-Benzyl-1,7-dimethyl-N-[1-(methylsulfonyl)piperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

To6-benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(7.0 mg, 0.019 mmol, from Example 206) in DCM (2.4 mL) was addedmethanesulfonyl chloride (1.6 μL, 0.020 mmol, Aldrich) and triethylamine(5.2 μL, 0.037 mmol). After 25 minutes, the solvent was removed invacuo, and the product was purified via preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH). Yield: (4.2 mg, 50%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.34-7.28 (m, 2H), 7.27-7.21 (m, 1H),7.05-6.98 (m, 2H), 6.62 (s, 1H), 6.61 (s, 1H), 5.59 (d, J=8.9 Hz, 1H),5.43 (s, 2H), 3.62-3.44 (m, 3H), 2.89 (s, 3H), 2.91-2.85 (m, 2H), 2.83(s, 3H), 2.30 (s, 3H), 2.03-1.93 (m, 2H), 1.64-1.50 (m, 2H); LCMS(M+H)⁺: 453.2.

Example 212:6-Benzyl-N-(1-ethylpiperidin-4-yl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A mixture of6-benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(7.0 mg, 0.019 mmol, from Example 206) and acetaldehyde (5.2 μL, 0.093mmol, Aldrich) in DCM (2.4 mL) was treated with Na(OAc)₃BH (5.2 mg,0.024 mmol, Aldrich). After 8 minutes, the solvent was removed in vacuo,and the product was purified via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield:(2.0 mg, 26%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.33-7.27 (m, 2H), 7.26-7.21 (m, 1H),7.04-6.99 (m, 2H), 6.60 (s, 1H), 6.56 (s, 1H), 5.42 (s, 2H), 5.30 (d,J=8.7 Hz, 1H), 3.43-3.29 (m, 1H), 2.82 (s, 3H), 2.85-2.74 (m, 2H), 2.32(q, J=7.2 Hz, 2H), 2.31 (s, 3H), 2.05-1.95 (m, 2H), 1.92-1.83 (m, 2H),1.52-1.39 (m, 2H), 0.99 (t, J=7.2 Hz, 3H); LCMS (M+H)⁺: 403.3.

Example 213:6-Benzyl-N-(1-isopropylpiperidin-4-yl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

The title compound was prepared according to the methods of Example 212,using acetone (12 μL, 0.228 mmol) and Na(OAc)₃BH (9.2 mg, 0.043 mmol,Aldrich) with stirring overnight. Yield: (2.9 mg, 37%).

¹H NMR (400 MHz, d₆-DMSO) δ 7.34-7.27 (m, 2H), 7.27-7.20 (m, 1H),7.04-6.98 (m, 2H), 6.60 (s, 1H), 6.57 (s, 1H), 5.43 (s, 2H), 5.27 (d,J=8.7 Hz, 1H), 3.41-3.29 (m, 1H), 2.82 (s, 3H), 2.78-2.63 (m, 3H), 2.30(s, 3H), 2.28-2.18 (m, 2H), 1.95-1.84 (m, 2H), 1.48-1.33 (m, 2H), 0.96(d, J=6.6 Hz, 6H); LCMS (M+H)⁺: 417.3.

Example 214: tert-Butyl4-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]piperidine-1-carboxylate

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(200. mg, 0.644 mmol, Example 228, Step 7), tert-butyl4-aminopiperidine-1-carboxylate (520 mg, 2.6 mmol, Combi-Blocks),NaO^(t)Bu (180 mg, 1.9 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (93 mg, 0.16mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (71 mg,0.077 mmol, Aldrich) in toluene (10. mL) was heated at 120° C. for 4hours. Upon cooling, the reaction mixture was diluted with EtOAc andwashed sequentially with water and brine. The organic layer was driedover sodium sulfate, filtered and concentrated. Flash chromatography,eluting with a gradient from 0-5% MeOH in DCM afforded product as alight yellow solid (0.15 g, 49%). A portion (11 mg) of this solid waspurified via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (7.1 mg, 65%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.27 (m, 3H), 7.01-6.93 (m, 2H), 6.50 (s,1H), 6.16 (s, 1H), 5.29 (s, 2H), 4.16-3.82 (m, 2H), 3.47-3.35 (m, 1H),2.99-2.82 (m, 2H), 2.96 (s, 3H), 2.39 (s, 3H), 1.99-1.87 (m, 2H),1.53-1.43 (m, 2H), 1.46 (s, 9H); LCMS (M+H)⁺: 475.3.

Example 215 a and 215 b:4-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]cyclohexanecarbonitriletrifluoroacetate salt, Trans-(215 a) and Cis-(215 b) Isomers Isolated

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50. mg, 0.16 mmol, Example 228, Step 7), 4-aminocyclohexanecarbonitrilehydrochloride (78 mg, 0.48 mmol, J&W Pharmlab, mixture of cis- andtrans-isomers), NaO^(t)Bu (93 mg, 0.96 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (23 mg, 0.040mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (18 mg,0.019 mmol, Aldrich) in toluene (2.5 mL) was heated at 120° C. for 4hours. Upon cooling, the mixture was diluted with acetonitrile, filteredand purified via preparative HPLC-MS (Waters SunFire C18, eluting with agradient of 24-42% MeCN/H₂O, 0.1% TFA, flow rate 60 mL/min, separationtime 12 min). Partial separation of the isomers was possible and purestfractions were collected for each peak. First eluting peak (peak 1) wasthe trans-isomer, 215 a. Yield: (4.4 mg, 5%). Second eluting peak (peak2) was the cis-isomer, 215 b. Yield: (7.9 mg, 10%).

Peak 1 (trans-; 215 a): ¹H NMR (400 MHz, d₆-DMSO) δ 7.34-7.28 (m, 2H),7.28-7.22 (m, 1H), 7.17 (s, 1H), 7.07-7.01 (m, 2H), 6.83 (s, 1H), 5.53(s, 2H), 3.60-3.50 (m, 1H), 3.17-3.10 (m, 1H), 2.94 (s, 3H), 2.37 (s,3H), 1.98-1.87 (m, 4H), 1.80-1.65 (m, 2H), 1.57-1.44 (m, 2H).

LCMS (M+H)⁺: 399.2.

Peak 2 (cis-; 215 b): ¹H NMR (400 MHz, d₆-DMSO) δ 7.36-7.29 (m, 2H),7.29-7.21 (m, 1H), 7.11-7.01 (m, 3H), 6.79 (s, 1H), 5.52 (s, 2H),3.56-3.42 (m, 1H), 2.92 (s, 3H), 2.74 (tt, J=11.5, 3.4 Hz, 1H), 2.37 (s,3H), 2.12-2.02 (m, 2H), 2.02-1.92 (m, 2H), 1.65 (qd, J=12.7, 3.1 Hz,2H), 1.37-1.19 (m, 2H); LCMS (M+H)⁺: 399.2.

Example 216:N-(1-Acetylpiperidin-4-yl)-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

To6-benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(10. mg, 0.027 mmol, from Example 206) in DCM (1.0 mL) was added acetylchloride (2.3 μL, 0.032 mmol, Aldrich), followed by the addition oftriethylamine (7.4 μL, 0.053 mmol). After 15 minutes, volatiles wereremoved in vacuo. The mixture was diluted with water and MeOH, and theproduct was isolated via preparative HPLC-MS (Waters XBridge C18,eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (7.6mg, 68%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.28 (m, 3H), 7.00-6.95 (m, 2H), 6.50 (s,1H), 6.13 (s, 1H), 5.35-5.21 (m, 2H), 4.38-4.28 (m, 1H), 3.87-3.76 (m,1H), 3.57-3.45 (m, 1H), 3.25-3.17 (m, 1H), 2.95 (s, 3H), 2.97-2.87 (m,1H), 2.39 (s, 3H), 2.11 (s, 3H), 2.07-1.89 (m, 2H), 1.80-1.32 (m, 2H);LCMS (M+H)⁺: 417.3.

Example 217:trans-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.150 g, 0.483 mmol, Example 228, Step 7), tert-butyl(trans-4-aminocyclohexyl)carbamate (0.41 g, 1.9 mmol, Combi-Blocks),NaO^(t)Bu (0.14 g, 1.4 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (70. mg, 0.12mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (53 mg,0.058 mmol, Aldrich) in toluene (7.5 mL) was heated at 120° C. for 2hours. After cooling to room temperature, the reaction mixture wasdiluted with EtOAc and washed with water, followed by brine. The organiclayer was dried over sodium sulfate, filtered and concentrated. Theresidue was dissolved in 1,4-dioxane (4.0 mL) and treated with 4.0 M HClin dioxane (1.0 mL, 4.0 mmol). After stirring for one hour, solvent wasremoved in vacuo, and the product was purified via preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH). Yield: (31 mg, 16%).

¹H NMR (300 MHz, CDCl₃) δ 7.35-7.24 (m, 3H), 7.03-6.93 (m, 2H), 6.46 (s,1H), 6.07 (s, 1H), 5.27 (s, 2H), 4.81 (d, J=7.1 Hz, 1H), 3.34-3.13 (m,1H), 2.93 (s, 3H), 2.35 (s, 3H), 2.19-1.98 (m, 4H), 1.48-1.14 (m, 4H),3.03-2.83 (m, 1H); LCMS (M+H)⁺: 389.2.

Example 218:cis-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine

The title compound was prepared according to the methods of Example 217,using tert-butyl (cis-4-aminocyclohexyl)carbamate (0.41 g, 1.9 mmol,Matrix). Yield: (58 mg, 31%).

¹H NMR (300 MHz, CDCl₃) δ 7.34-7.22 (m, 3H), 7.00-6.92 (m, 2H), 6.46 (s,1H), 6.08 (s, 1H), 5.25 (s, 2H), 5.07 (d, J=7.3 Hz, 1H), 3.59-3.44 (m,1H), 3.01-2.85 (m, 1H), 2.93 (s, 3H), 2.35 (s, 3H), 2.11-1.50 (m, 8H);LCMS (M+H)⁺: 389.3.

Example 219:trans-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N′-methylcyclohexane-1,4-diamine

Sodium triacetoxyborohydride (11 mg, 0.053 mmol) was added to a mixtureoftrans-N-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine(10. mg, 0.027 mmol, from Example 217) and formaldehyde solution (37 wt% in water, 3.2 mg, 0.040 mmol, Aldrich) in DCM (0.5 mL). After 30minutes, both monomethylated and dimethylated products were observed byLCMS. Purification via preparative HPLC-MS (Waters XBridge C18, elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH) affordedmonomethylated product. (Yield: 0.8 mg, 7%).

LCMS (M+H)⁺: 403.3.

Example 220:trans-N′-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N,N-dimethylcyclohexane-1,4-diamine

The title compound was isolated from the reaction mixture given inExample 219. The purification via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)afforded dimethylated product. Yield: (5.9 mg, 53%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.27 (m, 3H), 7.00-6.95 (m, 2H), 6.46 (s,1H), 6.07 (s, 1H), 5.27 (s, 2H), 4.84 (d, J=8.0 Hz, 1H), 3.25-3.14 (m,1H), 2.93 (s, 3H), 2.36 (s, 3H), 2.32 (s, 6H), 2.29-2.19 (m, 1H),2.18-2.11 (m, 2H), 1.99-1.93 (m, 2H), 1.41-1.13 (m, 4H); LCMS (M+H)⁺:417.2.

Example 221:cis-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N′-methylcyclohexane-1,4-diamine

The title compound was prepared according to the methods of Example 219,usingcis-N-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine(10. mg, 0.027 mmol, from Example 218) as a starting material.Purification via preparative HPLC-MS (Waters XBridge C18, eluting with agradient of MeCN/H₂O containing 0.15% NH₄OH) afforded monomethylatedproduct. Yield: (1.2 mg, 11%).

LCMS (M+H)⁺: 403.3.

Example 222:cis-N′-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N,N-dimethylcyclohexane-1,4-diamine

The title compound was isolated from the reaction mixture given inExample 221. The purification via preparative HPLC-MS (Waters XBridgeC18, eluting with a gradient of MeCN/H₂O containing 0.15% NH₄OH)afforded dimethylated product. Yield: (4.2 mg, 38%).

¹H NMR (400 MHz, CDCl₃) δ 7.33-7.26 (m, 3H), 6.99-6.95 (m, 2H), 6.46 (s,1H), 6.08 (s, 1H), 5.25 (s, 2H), 5.08 (d, J=7.2 Hz, 1H), 3.62-3.56 (m,1H), 2.93 (s, 3H), 2.35 (s, 3H), 2.33 (s, 6H), 2.43-1.49 (m, 9H).

LCMS (M+H)⁺: 417.3.

Example 223: 3-Benzyl-2,8-dimethyl-N-(1-methylpiperidin-4-yl)-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridin-5-amine

Step 1.3-Benzyl-5-chloro-2,8-dimethyl-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridine

A suspension of 3-benzyl-2,8-dimethyl-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridine (0.50 g, 1.8 mmol, Example 55) andN-chlorosuccinimide (0.29 g, 2.2 mmol, Aldrich) in DCE (9 mL) was heatedat 60° C. for 2 hours. Upon cooling to room temperature, the mixture wasdiluted with DCM. The solution was washed with saturated NaHCO₃,followed by water, and finally, brine. The organic layer was dried oversodium sulfate, filtered and concentrated. Flash chromatography, elutingwith a gradient from 0-2.5% MeOH in DCM, afforded product as a lightyellow solid. Yield: (0.21 g, 37%).

¹H NMR (400 MHz, CDCl₃) δ 7.40-7.33 (m, 3H), 7.29 (s, 1H), 7.06-7.01 (m,2H), 5.35 (s, 2H), 3.17 (s, 3H), 2.61 (s, 3H); LCMS (M+H)⁺: 312.1.

Step 2.3-Benzyl-2,8-dimethyl-N-(1-methylpiperidin-4-yl)-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridin-5-amine

A degassed mixture of3-benzyl-5-chloro-2,8-dimethyl-3H-imidazo[4,5-e][1,2,4]triazolo[4,3-a]pyridine(37 mg, 0.12 mmol, from Step 1), 1-methylpiperidin-4-amine hydrochloride(54 mg, 0.36 mmol, Matrix), NaO^(t)Bu (57 mg, 0.59 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (17 mg, 0.030mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (13 mg,0.014 mmol, Aldrich) in toluene (1.8 mL) was heated at 125° C. for 80minutes. After cooling to room temperature, the mixture was diluted withacetonitrile, filtered and concentrated. The product was isolated viapreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (9.8 mg, 21%).

¹H NMR (400 MHz, CDCl₃) δ 7.39-7.31 (m, 3H), 7.09-7.04 (m, 2H), 5.95 (s,1H), 5.29 (s, 2H), 5.11 (d, J=7.4 Hz, 1H), 3.42-3.30 (m, 1H), 3.12 (s,3H), 2.91-2.77 (m, 2H), 2.53 (s, 3H), 2.35 (s, 3H), 2.41-1.41 (m, 6H);LCMS (M+H)⁺: 390.2.

Example 224.6-Benzyl-N-[(2S,4S)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amineand6-Benzyl-N-[(2R,4R)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(Racemic Mixture Prepared)

Step 1.6-Benzyl-1,7-dimethyl-N-[(2S,4S)-2-methylpiperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amineand6-Benzyl-1,7-dimethyl-N-[(2R,4R)-2-methylpiperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(Racemic Mixture Prepared)

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.10 g, 0.32 mmol, Example 228, Step 7), tert-butylcis-4-amino-2-methylpiperidine-1-carboxylate hydrochloride (0.24 g, 0.96mmol, Chembridge), NaO^(t)Bu (0.15 g, 1.6 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (46 mg, 0.080mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (35 mg,0.039 mmol, Aldrich) in toluene (5.0 mL) was heated at 125° C. for 2hours. Upon cooling, the mixture was diluted with EtOAc and washed withwater, followed by brine. The organic layer was dried over sodiumsulfate, filtered and concentrated. The residue was dissolved in1,4-dioxane (3.0 mL) and treated with 4.0 M HCl in dioxane (1.0 mL, 4.0mmol). After 1 hour, the product was purified via preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH). Yield: (38 mg, 31%).

LCMS (M+H)⁺: 389.3.

Step 2.6-Benzyl-N-[(2S,4S)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amineand 6-Benzyl-N-[(2R,4R)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(Racemic Mixture Prepared)

To a mixture of6-benzyl-1,7-dimethyl-N-[(2S,4S)-2-methylpiperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amineand6-benzyl-1,7-dimethyl-N-[(2R,4R)-2-methylpiperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(15 mg, 0.031 mmol, from Step 1) in DCM (0.6 mL) was added formaldehyde(37 wt % in water, 2.5 mg, 0.031 mmol, Aldrich), followed by theaddition of Na(OAc)₃BH (9.8 mg, 0.046 mmol, Aldrich). After 25 minutes,volatile solvent was removed in vacuo. The mixture was diluted withwater and MeOH, and the product was purified via preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH). Yield: (9.7 mg, 78%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.27 (m, 3H), 7.02-6.94 (m, 2H), 6.47 (s,1H), 6.07 (s, 1H), 5.27 (s, 2H), 4.85 (d, J=8.4 Hz, 1H), 3.41-3.29 (m,1H), 3.02-2.94 (m, 1H), 2.93 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H),2.26-1.21 (m, 6H), 1.13 (d, J=6.1 Hz, 3H); LCMS (M+H)⁺: 403.2.

Example 225:6-Benzyl-N-[(2R,4S)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amineand6-Benzyl-N-[(2S,4R)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(Racemic Mixture Prepared)

The title compounds were prepared according to the methods of Example224, using tert-butyl trans-4-amino-2-methylpiperidine-1-carboxylate(0.21 g, 0.96 mmol, Chembridge).

Yield: (8.9 mg, 72%).

¹H NMR (400 MHz, CDCl₃) δ 7.33-7.27 (m, 3H), 6.97 (d, J=6.7 Hz, 2H),6.47 (s, 1H), 6.06 (s, 1H), 5.26 (s, 2H), 5.10 (d, J=6.8 Hz, 1H),3.76-3.67 (m, 1H), 2.94 (s, 3H), 2.78-2.66 (m, 1H), 2.63-2.45 (m, 2H),2.37 (s, 3H), 2.35 (s, 3H), 2.06-1.50 (m, 4H), 1.10 (d, J=6.2 Hz, 3H);LCMS (M+H)⁺: 403.2.

Example 226:6-Benzyl-1,7-dimethyl-N-((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed mixture of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(50. mg, 0.16 mmol),(1R,3r,SS)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (68 mg, 0.48 mmol,Synthonix), NaO^(t)Bu (46 mg, 0.48 mmol, Aldrich),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (23 mg, 0.040mmol, Aldrich) and tris(dibenzylideneacetone)dipalladium(0) (18 mg,0.019 mmol, Aldrich) in toluene (2.5 mL) was heated at 125° C. for 1.5hours. Upon cooling to room temperature, the reaction was diluted withacetonitrile, filtered and concentrated. The product was purified viapreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (3.3 mg, 5%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.26 (m, 3H), 6.97 (d, J=6.7 Hz, 2H),6.46 (s, 1H), 5.96 (s, 1H), 5.25 (s, 2H), 5.28-5.21 (m, 1H), 3.62 (q,J=6.2 Hz, 1H), 3.20 (br s, 2H), 2.93 (s, 3H), 2.36 (s, 3H), 2.33 (s,3H), 1.91 (br m, 8H); LCMS (M+H)⁺: 415.3.

Example 227:6-Benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carbonitriletrifluoroacetate salt

Step 1.5-Chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile

A degassed mixture of2-bromo-5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (3.0 g,8.1 mmol, prepared as in Example 62, Step 1, isolated as the free base),zinc cyanide (9.5 g, 81 mmol, Aldrich) andtetrakis(triphenylphosphine)palladium(0) (1.6 g, 1.4 mmol, Strem) in DMF(51 mL) was heated at 120° C. for 3 hours. Upon cooling to roomtemperature, the mixture was diluted with EtOAc and washed sequentiallywith diluted aqueous ammonia, water, and brine. The organic layer wasdried over sodium sulfate, filtered and concentrated. Flashchromatography, eluting with a gradient from 0-20% EtOAc in hexanes, wasused to purify the product. Yield: (1.2 g. 47%).

LCMS (M+H)⁺: 318.0.

Step 2. 5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile

5-Chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile(0.50 g, 1.6 mmol, from Step 1) in THF (10. mL) was treated with 1.0 MNaOH (10. mL, 10. mmol) until removal of phenylsulfonyl protecting groupwas complete as determined by LCMS. The reaction mixture was extractedwith three portions of EtOAc. The combined organic extracts were driedover sodium sulfate, filtered and concentrated until solid productprecipitated. The solid was collected via filtration and triturated withEtOAc. Yield: (0.21 g, 75%).

¹H NMR (300 MHz, d₆-DMSO) δ 7.98 (d, J=8.7 Hz, 1H), 7.44 (s, 1H), 7.35(d, J=8.7 Hz, 1H); LCMS (M+H)⁺: 178.1.

Step 3. 1-Benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile

5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile (0.10 g, 0.56 mmol,from Step 2) in DMF (1.3 mL) was treated with K₂CO₃ (0.12 g, 0.84 mmol)and benzyl bromide (74 μL, 0.62 mmol, Aldrich) overnight. The reactionmixture was diluted with EtOAc and washed three times with water andonce with brine. The organic layer was dried over sodium sulfate,filtered and concentrated. Flash chromatography, eluting with a gradientfrom 0-20% EtOAc in hexanes afforded purified product. Yield: (0.12 g,80%).

¹H NMR (400 MHz, CDCl₃) δ 7.58 (dd, J=8.8, 0.8 Hz, 1H), 7.37-7.29 (m,4H), 7.25 (d, J=8.8 Hz, 1H), 7.15-7.11 (m, 2H), 5.49 (s, 2H); LCMS(M+H)⁺: 268.1.

Step 4. Di-tert-butyl1-(1-benzyl-2-cyano-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate

A degassed mixture of1-benzyl-5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carbonitrile (0.12 g, 0.45mmol, from Step 3), di-tert-butyl hydrazine-1,2-dicarboxylate (0.12 g,0.54 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (35 mg, 0.045 mmol, Aldrich) and Cs₂CO₃ (0.18 g, 0.54 mmol,Aldrich) in toluene (2.5 mL) was heated at 100° C. for 3 hours. Uponcooling to room temperature, the reaction mixture was diluted with DCM,filtered to remove solids, and the solvent was removed in vacuo. Flashchromatography, eluting with a gradient from 0-20% EtOAc in hexanesafforded purified product. Yield: (0.14 g, 67%).

¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J=9.1 Hz, 1H), 7.61 (d, J=8.5 Hz,1H), 7.36-7.28 (m, 4H), 7.18-7.06 (m, 3H), 5.47 (s, 2H), 1.50 (s, 9H),1.47 (s, 9H); LCMS (M+H)⁺: 463.3.

Step 5.6-Benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carbonitriletrifluoroacetate salt

Di-tert-butyl1-(1-benzyl-2-cyano-1H-pyrrolo[3,2-b]pyridin-5-yl)hydrazine-1,2-dicarboxylate(0.14 g, 0.30 mmol, from Step 4) was dissolved in acetic acid (6.0 mL)and heated at 130° C. for 1.5 hours. Acetic acid was removed in vacuo,and the residue was dissolved in EtOAc/DCM and washed with saturatedNaHCO₃ solution. The aqueous layer was extracted with EtOAc/DCM, and thecombined organic extracts were dried over sodium sulfate, filtered andconcentrated to afford product as an off-white solid. Yield: (76 mg,88%). A small portion of the product was further purified viapreparative HPLC-MS (Waters SunFire C18, eluting with a gradient ofMeCN/H₂O containing 0.1% TFA) to afford product as the trifluoroacetatesalt.

¹H NMR (400 MHz, d₆-DMSO) δ 7.96 (s, 1H), 7.89 (d, J=9.9 Hz, 1H), 7.68(d, J=9.9 Hz, 1H), 7.40-7.27 (m, 3H), 7.21-7.14 (m, 2H), 5.72 (s, 2H),2.88 (s, 3H); LCMS (M+H)⁺: 288.2.

Example 228:6-Benzyl-N-(cyclopropylmethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

Step 1. 5-Chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

To a suspension of 5-chloro-1H-pyrrolo[3,2-b]pyridine (20. g, 130 mmol,Adesis) in DCM (200 mL) was added benzenesulfonyl chloride (20. mL, 160mmol, Aldrich), triethylamine (27 mL, 200 mmol) and4-dimethylaminopyridine (0.80 g, 6.6 mmol, Aldrich). The reactionmixture was stirred overnight. Water was added and the mixture wasstirred for 4h.

Layers were separated and the organic phase was washed sequentially with1 N HCl, water, saturated solution of NaHCO₃, and brine. The organiclayer was dried over sodium sulfate, filtered and concentrated to givean orange solid, which was triturated with MeOH (100 mL). The solid wasfiltered, washed with MeOH, and dried at 40° C. under high vacuumovernight. Additional product was obtained by flash chromatography ofthe filtrate (eluting with a gradient from 0-60% EtOAc in hexanes).Yield: (26.8 g, 95%).

¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J=8.7 Hz, 1H), 7.88-7.86 (m, 2H),7.80 (d, J=3.8 Hz, 1H), 7.65-7.56 (m, 1H), 7.49 (t, J=7.8 Hz, 2H),7.32-7.22 (m, 1H), 6.81 (d, J=3.7 Hz, 1H).

LCMS (M+H)⁺: 293.

Step 2. 5-Chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

To N,N-diisopropylamine (13 mL, 93 mmol, Aldrich) in tetrahydrofuran(200 mL) at −78° C. was added 1.6 M n-butyllithium in hexanes (55 mL, 88mmol, Aldrich). The reaction mixture was warmed to 0° C., and themixture was stirred for 30 minutes. The reaction mixture was cooled to−78° C., and 5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (17.1g, 58.4 mmol, from Step 1) in tetrahydrofuran (86 mL) was added dropwiseover 30 minutes. The reaction mixture was then stirred for 1 hour at−78° C., and methyl iodide (7.3 mL, 120 mmol, Aldrich) was addeddropwise over 5 minutes. The reaction was allowed to warm to 5° C. over3 hours, then cooled to −20° C. and quenched by the addition of 1 N HCl.EtOAc was added, and the solution was stirred for 15 minutes and left atambient temperature overnight. The layers were separated and the organiclayer was washed sequentially with water and brine, dried over sodiumsulfate, filtered and concentrated in vacuo to give a wet orange solidthat was then triturated with MeOH (18 mL). The solid was isolated byfiltration, washed and dried at 40° C. under high vacuum for 2.2 h togive 14.4 g of product. Additional amount of product was obtained byflash chromatography of the filtrate (eluting with a gradient from 0-40%EtOAc in hexanes) afforded 1.87 g. (Yield: 16.3 g, 91%).

¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 7.75 (d, J=7.8 Hz, 2H), 7.61 (t,J=7.3 Hz, 1H), 7.57-7.38 (m, 2H), 7.34-7.09 (m, 1H), 6.49 (s, 1H), 2.62(s, 3H). LCMS (M+H)⁺: 307.

Step 3. Di-tert-butyl1-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate

A mixture of5-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine (16.29 g,53.10 mmol, from Step 2), di-tert-butyl hydrazine-1,2-dicarboxylate (12g, 53 mmol, Aldrich),dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine-(2′-aminobiphenyl-2-yl)(chloro)palladium(1:1) (4.2 g, 5.3 mmol, Aldrich), and Cs₂CO₃ (17.3 g, 53.1 mmol) intoluene (170 mL) was degassed and heated at 100° C. overnight. Uponcooling to room temperature, the solid product was isolated byfiltration and washed with several portions of DCM. The solid was thentriturated with DCM, and again isolated by filtration, and dried at 40°C. under vacuum (19.5 g). Flash chromatography of the filtrate (elutingwith a gradient from 0-40% EtOAc in hexanes) afforded an additional 2.5g of product. Yield: (22 g, 82%).

¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.76 (dd, J=8.5, 1.2 Hz, 2H),7.64-7.55 (m, 2H), 7.50-7.43 (m, 2H), 7.18 (s, 1H), 6.50 (s, 1H), 2.62(d, J=0.9 Hz, 3H), 1.50 (s, 9H), 1.46 (s, 9H). LCMS (M+H)⁺: 503.

Step 4. 1,7-Dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A mixture of di-tert-butyl1-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]hydrazine-1,2-dicarboxylate(19.53 g, 38.86 mmol, from Step 3) in acetic acid (200 mL) was heated at120° C. overnight. Precipitate was filtered off, and the filtrate wasconcentrated in vacuo. Dichloroethane (15 mL) was added, and thesuspension was heated at reflux for 15 minutes. Upon cooling to 0° C.,the solid product was isolated by filtration and dried at 40° C. undervacuum to give an off-white solid (5.94 g). Solvent was removed from thefiltrate in vacuo and the above procedure was repeated using DCE (6 mL)to afford additional solid (3.6 g). Additional product was obtained byflash chromatography of the filtrate, (eluting with a gradient of 0-1%MeOH/DCM containing 1% NH₄OH). The chromatography afforded product as aglass, which was recrystallized from MeOH (6 mL). Uponrecrystallization, product was isolated as white crystals and air dried(2.19 g). Yield: (11.7 g, 92%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.08 (d, 1H), 7.94 (d, J=7.7 Hz, 2H), 7.74(t, J=7.4 Hz, 1H), 7.68-7.55 (m, 2H), 7.50 (d, J=10.0 Hz, 1H), 7.17 (s,1H), 2.82 (s, 3H), 2.64 (s, 3H). LCMS (M+H)⁺: 327.

Step 5.4-Chloro-1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A suspension of1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(2.0 g, 6.1 mmol, from Step 4) and N-chlorosuccinimide (0.91 g, 6.8mmol, Aldrich) in 1,2-dichloroethane (40 mL) was heated at 60° C.overnight. Flash chromatography, eluting with a gradient from 0-5%MeOH/DCM (0.5% NH₄OH), afforded an orange solid which was refluxed in 10mL MeOH for 15 minutes. The product was isolated by filtration. Yield:(2.2 g, 80%). ¹H NMR (500 MHz, d₆-DMSO) δ 8.23 (s, 1H), 8.01-7.96 (m,2H), 7.80-7.74 (m, 1H), 7.68-7.61 (m, 2H), 7.22 (s, 1H), 2.86 (s, 3H),2.62 (s, 3H); LCMS (M+H)⁺: 361.

Step 6.4-Chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a suspension of4-chloro-1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(2.34 g, 6.48 mmol, from Step 5) in tetrahydrofuran (15 mL) and ethanol(15 mL) was added 10% (w/w) KOH in water (16.0 mL, 28.5 mmol). Afterstirring for 1.5 hours, the reaction mixture was diluted with DCM andwater and stirred for 3 hours. The solid product was isolated byfiltration and dried at 40° C. under vacuum overnight. Yield: (1.33 g,93%).

¹H NMR (400 MHz, d₆-DMSO): δ 11.83 (s, 1H), 7.62 (d, J=0.6 Hz, 1H), 6.65(s, 1H), 2.84 (s, 3H), 2.40 (s, 3H). LCMS (M+H)⁺: 221.

Step 7.6-Benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a suspension of4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(1.0 g, 4.5 mmol, from Step 6) in N,N-dimethylformamide (20 mL) at 0° C.was added NaH (60% in mineral oil, 0.246 g, 6.14 mmol). After stirringfor 1 h, benzyl bromide (0.65 mL, 5.4 mmol, Aldrich) was added. Thereaction mixture was allowed to warm to room temperature and was stirredovernight. The mixture was cooled in an ice bath, and water (50 mL) andethyl acetate (50 mL) were added. The mixture was stirred for 5.5 h. Theproduct was isolated by filtration and was washed with ethyl acetate andwater. The solid was dried at 40° C. vacuum overnight. Yield: (1.12 g,80%).

¹H NMR (400 MHz, d₆-DMSO) δ 8.01 (s, 1H), 7.33-7.27 (m, 2H), 7.27-7.22(m, 1H), 6.96 (d, J=7.2 Hz, 2H), 6.83 (s, 1H), 5.56 (s, 2H), 2.87 (s,3H), 2.35 (s, 3H). LCMS (M+H)⁺: 311.

Step 8. 6-Benzyl-N-(cyclopropylmethyl)-1, 7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A suspension of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(20.0 mg, 0.0644 mmol, from Step 7), cyclopropylmethylamine (51 μL, 0.60mmol, Aldrich), tBuBrettPhos Pd G3 (6.5 mg, 0.0076 mmol, Aldrich) andCs₂CO₃ (0.045 g, 0.14 mmol) in N-methylpyrrolidinone (0.3 mL) and water(0.030 g) was degassed and heated at 100° C. for 4.5 h, after which timethe reaction mixture was filtered and the product was purified bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (10.5 mg, 47%).

¹H NMR (400 MHz, CDCl₃) δ 7.36-7.28 (m, 3H), 6.96-6.89 (m, 2H), 6.58 (s,1H), 6.52 (s, 1H), 5.34 (s, 2H), 3.02 (s, 3H), 3.02 (d, J=6.6 Hz, 2H),2.42 (s, 3H), 1.17-1.03 (m, 1H), 0.58-0.51 (m, 2H), 0.28-0.21 (m, 2H);LCMS (M+H)⁺: 346.

Examples 229-260: The Examples in Table 1 were Made by ProceduresAnalogous to Those Used to Prepare Example 228

TABLE 1 MS Ex Name Structure Salt [M + H]⁺ 2291-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3- methylurea

n/a 349 230 1-(1,7-Dimethyl-6-(3-(trifluoromethyl)benzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea

n/a 403 231 1-(6-(3-Chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 369 232 6-Benzyl-N-cyclohexyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-amine

n/a 374 233 1-(6-(3,5-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 371 234 1-(6-(3,4-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 371 235 1-(6-(3-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 353 236 1-(6-(2,4-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 371 237 1-(6-(2,3-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 371 238 1-(6-(2-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 353 239 1-(6-(4-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

n/a 353 240 6-benzyl-1,7-Dimethyl-N-(pyridin-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3- a]pyridin-4-amine

n/a 369 241 6-Benzyl-N-(cyclobutylmethyl)-1,7- dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

n/a 360 242 tert-Butyl 4-((6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)methyl)piperidine-1-carboxylate

n/a 489 243 tert-Butyl 3-((6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)methyl)azetidine-1-carboxylate

n/a 461 244 tert-Butyl 3-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)azetidine-1-carboxylate

n/a 447 245 N1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N3,N3-dimethylpropane-1,3-diamine

n/a 377 246 N1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N2,N2-dimethylethane-1,2-diamine

n/a 363 247 trans-3-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-ylamino)cyclobutanol

n/a 362 248 tert-Butyl 6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-ylcarbamate

n/a 392 249 1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3- ethylurea

n/a 363 250 1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3- isopropylurea

n/a 377 251 3-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-1,1- dimethylurea

n/a 363 252 1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea

n/a 335 253 6-Benzyl-N-(1H-imidazol-2-yl)-1,7- dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

TFA 358 254 1-(6-(2,6-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)urea

TFA 371 255 6-Benzyl-1,7-dimethyl-N-(pyridin-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3- a]pyridin-4-amine

3× TFA 369 256 6-Benzyl-1,7-dimethyl-N-(pyridin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3- a]pyridin-4-amine

3× TFA 369 257 N1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-yl)propane-1,3-diamine

3× TFA 349 258 N1-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)ethane- 1,2-diamine

3× TFA 335 259 6-Benzyl-N-ethyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-amine

2× TFA 320 260 6-Benzyl-1,7-dimethyl-N-phenyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-amine

2× TFA 368

TABLE 1a ¹H NMR data for examples 229-260 Example # ¹H NMR Spectrum 229¹H NMR (500 MHz, d₆-DMSO) δ 8.74 (s, 1H), 8.21 (s, 1H), 7.31 (t, J = 7.4Hz, 2H), 7.25 (t, J = 7.3 Hz, 1H), 6.99 (d, J = 7.3 Hz, 2H), 6.84 (s,1H), 6.77 (s, 1H), 5.45 (s, 2H), 2.93 (s, 3H), 2.65 (s, 3H), 2.40 (s,3H). 230 ¹H NMR (400 MHz, d₆-DMSO) δ 8.80 (s, 1H), 8.10 (s, 1H),7.66-7.60 (m, 1H), 7.56-7.49 (m, 1H), 7.46 (s, 1H), 7.08 (d, J = 7.8 Hz,1H), 6.75 (s, 1H), 6.40 (s, 2H), 5.51 (s, 2H), 2.87 (s, 3H), 2.34 (s,3H). 231 ¹H NMR (300 MHz, CDCl₃) δ 8.16 (s, 1H), 7.22-7.18 (m, 2H),6.88-6.85 (m, 1H), 6.84-6.78 (m, 1H), 6.54 (s, 1H), 5.30 (s, 2H), 2.94(s, 3H), 2.34 (s, 3H). 232 ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.24 (m, 3H),6.99 (d, J = 6.8 Hz, 2H), 6.46 (s, 1H), 6.08 (s, 1H), 5.26 (s, 2H), 4.90(d, J = 7.8 Hz, 1H), 3.32-3.19 (m, 1H), 2.93 (s, 3H), 2.35 (s, 3H),2.06-1.92 (m, 2H), 1.81-1.71 (m, 2H), 1.41-1.12 (m, 6H). 233 ¹H NMR (400MHz, d₆-DMSO) δ 8.81 (s, 1H), 8.07 (s, 1H), 7.16 (tt, J = 9.4, 2.3 Hz,1H), 6.74 (s, 1H), 6.68-6.60 (m, 2H), 6.40 (s, 2H), 5.43 (s, 2H), 2.86(s, 3H), 2.34 (s, 3H). 234 ¹H NMR (400 MHz, d₆-DMSO) δ 8.80 (s, 1H),8.09 (s, 1H), 7.38 (dt, J = 10.7, 8.5 Hz, 1H), 7.09 (ddd, J = 11.3, 7.7,2.1 Hz, 1H), 6.79-6.66 (m, 2H), 6.40 (s, 2H), 5.38 (s, 2H), 2.86 (s,3H), 2.34 (s, 3H). 235 ¹H NMR (400 MHz, d₆-DMSO) δ 8.79 (s, 1H), 8.10(s, 1H), 7.34 (td, J = 8.0, 6.1 Hz, 1H), 7.08 (td, J = 8.3, 2.2 Hz, 1H),6.84-6.70 (m, 3H), 6.39 (s, 2H), 5.41 (s, 2H), 2.86 (s, 3H), 2.34 (s,3H). 236 ¹H NMR (400 MHz, d₆-DMSO) δ 8.80 (s, 1H), 8.12 (s, 1H), 7.33(ddd, J = 10.8, 9.3, 2.6 Hz, 1H), 6.98 (td, J = 8.7, 2.4 Hz, 1H), 6.73(s, 1H), 6.64 (td, J = 8.7, 6.7 Hz, 1H), 6.39 (br s, 2H), 5.39 (s, 2H),2.85 (s, 3H), 2.35 (s, 3H). 237 ¹H NMR (400 MHz, d₆-DMSO) δ 8.75 (s,1H), 8.07 (s, 1H), 7.50-7.17 (m, 1H), 7.10-6.96 (m, 1H), 6.69 (s, 1H),6.47-6.17 (m, 3H), 5.44 (s, 2H), 2.81 (s, 3H), 2.30 (s, 3H). 238 ¹H NMR(400 MHz, CDCl₃) δ 8.27 (s, 1H), 7.24-7.16 (m, 1H), 7.10-7.00 (m, 1H),6.95 (td, J = 7.6, 0.9 Hz, 1H), 6.56 (s, 1H), 6.54-6.47 (m, 1H), 5.37(s, 2H), 2.93 (s, 3H), 2.37 (s, 3H). 239 ¹H NMR (400 MHz, d₆-DMSO) δ8.80 (s, 1H), 8.12 (s, 1H), 7.20-7.09 (m, 2H), 7.07-6.90 (m, 2H), 6.71(s, 1H), 6.40 (s, 2H), 5.37 (s, 2H), 2.86 (s, 3H), 2.33 (s, 3H). 240 ¹HNMR (400 MHz, CDCl₃) δ 8.72 (s, 1H), 8.24 (dd, J = 4.8, 1.4 Hz, 1H),8.04 (br s, 1H), 7.52 (ddd, J = 8.6, 7.3, 1.9 Hz, 1H), 7.34-7.27 (m,3H), 7.09-7.04 (m, 2H), 6.88 (d, J = 8.2 Hz, 1H), 6.77 (dd, J = 6.7, 5.4Hz, 1H), 6.53 (s, 1H), 5.36 (s, 2H), 2.98 (s, 3H), 2.40 (s, 3H). 241 ¹HNMR (300 MHz, CDCl₃) δ 7.27-7.18 (m, 3H), 7.15-6.60 (m, 2H), 6.40 (s,1H), 6.07 (s, 1H), 5.20 (s, 2H), 5.15 (br s, 1H), 3.09 (d, J = 6.6 Hz,2H), 2.87 (s, 3H), 2.67 (app hept, J = 7.3 Hz, 1H), 2.27 (s, 3H),2.12-2.00 (m, 2H), 1.90-1.75 (m, 2H), 1.74-1.62 (m, 2H). 242 ¹H NMR (400MHz, CDCl₃) δ 7.33-7.26 (m, 3H), 6.98-6.93 (m, 2H), 6.46 (s, 1H), 6.06(s, 1H), 5.27 (s, 2H), 5.04 (t, J = 4.9 Hz, 1H), 4.08 (br s, 2H),3.10-2.98 (m, 2H), 2.93 (s, 3H), 2.72-2.50 (m, 2H), 2.35 (s, 3H),2.02-1.64 (m, 3H), 1.44 (s, 9H), 1.23-1.07 (m, 2H). 243 ¹H NMR (400 MHz,CDCl₃) δ 7.35-7.27 (m, 3H), 6.97-6.91 (m, 2H), 6.52 (s, 1H), 6.29 (s,1H), 5.31 (s, 2H), 4.05 (t, J = 8.5 Hz, 2H), 3.64 (dd, J = 8.3, 4.7 Hz,2H), 3.35 (d, J = 7.6 Hz, 2H), 2.95 (s, 3H), 2.91-2.78 (m, 1H), 2.38 (s,3H), 1.41 (s, 9H). 244 ¹H NMR (400 MHz, CDCl₃) δ 7.34-7.26 (m, 3H),6.98-6.92 (m, 2H), 6.48 (s, 1H), 5.88 (s, 1H), 5.32 (d, J = 4.5 Hz, 1H),5.25 (s, 2H), 4.24-4.17 (m, 3H), 3.83-3.74 (m, 2H), 2.94 (s, 3H), 2.38(s, 3H), 1.43 (s, 9H). 245 ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.24 (m, 3H),6.98-6.91 (m, 2H), 6.47 (s, 1H), 6.16 (s, 1H), 5.27 (s, 2H), 5.13 (br s,1H), 3.23 (t, J = 6.9 Hz, 2H), 2.94 (s, 3H), 2.42 (t, J = 6.9 Hz, 2H),2.33 (s, 3H), 2.23 (s, 6H), 1.86 (t, J = 6.9 Hz, 2H). 246 ¹H NMR (400MHz, CDCl₃) δ 7.33-7.24 (m, 3H), 6.98-6.93 (m, 2H), 6.47 (s, 1H), 6.13(s, 1H), 5.35 (t, J = 5.2 Hz, 1H), 5.27 (s, 2H), 3.23 (app q, J = 6.0Hz, 2H), 2.94 (s, 3H), 2.60 (t, J = 6.3 Hz, 2H), 2.34 (s, 3H), 2.25 (s,6H). 247 ¹H NMR (300 MHz, CDCl₃) δ 7.34-7.25 (m, 3H), 6.99-6.93 (m, 2H),6.48 (s, 1H), 6.13 (s, 1H), 5.27 (s, 2H), 4.10 (p, J = 7.3 Hz, 1H), 3.48(p, J = 7.5 Hz, 1H), 2.93 (s, 3H), 2.87 (ddd, J = 12.8, 6.9, 2.9 Hz,2H), 2.38 (s, 3H), 2.11 (ddd, J = 12.5, 10.4, 7.9 Hz, 2H). 248 1H NMR(300 MHz, CDCl3) δ 8.02 (s, 1H), 7.85 (s, 1H), 7.35-7.19 (m, 3H),6.99-6.86 (m, 2H), 6.54 (s, 1H), 5.33 (s, 2H), 2.97 (s, 3H), 2.34 (s,3H), 1.51 (s, 9H). 249 ¹H NMR (400 MHz, CDCl₃) δ 8.17 (s, 1H), 7.23-7.12(m, 3H), 6.90-6.83 (m, 2H), 6.48 (s, 1H), 6.38 (t, J = 4.9 Hz, 1H), 5.28(s, 2H), 3.21 (qd, J = 7.2, 5.5 Hz, 2H), 2.88 (s, 3H), 2.30 (s, 3H),1.10 (t, J = 7.2 Hz, 3H). 250 ¹H NMR (400 MHz, CDCl₃) δ 9.15 (s, 1H),8.27 (s, 1H), 7.30-7.20 (m, 3H), 7.15 (d, J = 5.8 Hz, 1H), 6.96-6.90 (m,2H), 6.52 (s, 1H), 5.34 (s, 2H), 4.09-4.00 (m, 1H), 2.96 (s, 3H), 2.34(s, 3H), 1.23 (d, J = 6.5 Hz, 6H). 251 ¹H NMR (400 MHz, CDCl₃) δ 8.23(s, 1H), 7.75 (s, 1H), 7.32-7.17 (m, 3H), 6.96-6.87 (m, 2H), 6.53 (s,1H), 5.33 (s, 2H), 3.10 (s, 6H), 2.97 (s, 3H), 2.35 (s, 3H). 252 ¹H NMR(400 MHz, d₆-DMSO) δ 8.80 (s, 1H), 8.23 (s, 1H), 7.35-7.29 (m, 2H),7.29-7.22 (m, 1H), 7.04-6.93 (m, 2H), 6.87 (s, 1H), 6.39 (s, 2H), 5.48(s, 2H), 2.94 (s, 3H), 2.40 (s, 3H). 253 ¹H NMR (400 MHz, CDCl₃) δ 7.49(s, 1H), 7.33-7.23 (m, 3H), 7.04-6.98 (m, 2H), 6.74 (s, 2H), 6.62 (s,1H), 5.40 (s, 2H), 3.01 (s, 3H), 2.47 (s, 3H). 254 ¹H NMR (400 MHz,d₆-DMSO) δ 8.78 (s, 1H), 8.31 (s, 1H), 7.51-7.38 (m, 1H), 7.18-7.04 (m,2H), 6.79 (s, 1H), 6.38 (s, 2H), 5.49 (s, 2H), 2.90 (s, 3H), 2.45 (s,3H). 255 ¹H NMR (400 MHz, d₆-DMSO) δ 10.70 (s, 1H), 8.28 (d, J = 6.9 Hz,2H), 8.00 (s, 1H), 7.36-7.30 (m, 2H), 7.30-7.24 (m, 1H), 7.07-7.00 (m,4H), 5.58 (s, 2H), 2.95 (s, 3H), 2.45 (s, 3H). 256 ¹H NMR (400 MHz,CDCl₃) δ 10.67 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.12 (dd, J = 8.5, 1.9Hz, 1H), 8.09 (d, J = 5.2 Hz, 1H), 7.93 (s, 1H), 7.64 (dd, J = 8.6, 5.3Hz, 1H), 7.34-7.22 (m, 3H), 6.92-6.88 (m, 2H), 6.80 (s, 1H), 5.67 (s,2H), 3.10 (s, 3H), 2.55 (s, 3H). 257 ¹H NMR (400 MHz, d₆-DMSO) δ 7.83(s, 1H), 7.74 (s, 2H), 7.33-7.27 (m, 2H), 7.26-7.21 (m, 1H), 7.02-6.92(m, 2H), 6.88 (s, 1H), 6.73 (s, 1H), 5.47 (s, 2H), 3.27 (t, J = 6.6 Hz,2H), 2.93-2.83 (m, 2H), 2.90 (s, 3H), 2.29 (s, 3H), 1.87 (app p, J = 6.8Hz, 2H). 258 ¹H NMR (400 MHz, CDCl₃) δ 7.28-7.19 (m, 3H), 7.05 (s, 1H),6.92-6.86 (m, 2H), 6.60 (s, 1H), 5.43 (s, 2H), 3.57 (t, J = 5.8 Hz, 2H),3.23 (t, J = 5.8 Hz, 2H), 2.99 (s, 3H), 2.39 (s, 3H). 259 ¹H NMR (400MHz, CDCl₃) δ 7.36-7.27 (m, 3H), 6.98-6.92 (m, 2H), 6.59 (s, 1H), 6.53(s, 1H), 5.34 (s, 2H), 3.19 (q, J = 7.2 Hz, 2H), 3.01 (s, 3H), 2.43 (s,3H), 1.31 (t, J = 7.2 Hz, 3H). 260 ¹H NMR (400 MHz, d₆-DMSO) δ 8.27 (brs, 1H), 7.79 (s, 1H), 7.37-7.31 (m, 2H), 7.31-7.24 (m, 1H), 7.22-7.14(m, 2H), 7.06-7.00 (m, 2H), 6.96 (s, 1H), 6.92 (d, J = 7.9 Hz, 2H),6.86-6.80 (m, 1H), 5.55 (s, 2H), 2.97 (s, 3H), 2.48 (s, 3H).

Example 261:6-Benzyl-N,1,7-trimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

To a solution of tert-butyl(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)carbamate(9.0 mg, 0.023 mmol, Example 248) in tetrahydrofuran (1 mL) at 0° C. wasadded NaH (60% in mineral oil, 2.4 mg, 0.060 mmol). After 30 mintues, asolution of methyl iodide (2.9 μL, 0.046 mmol, Aldrich) in THF (95 μL)was added to the reaction mixture, and the reaction mixture was stirredovernight, after which time additional NaH (60% in mineral oil, 8.3 mg,0.21 mmol) and a solution of methyl iodide (5.8 μL in 0.19 mL THF, 0.092mmol) were added. After 4 hours, water and ethyl acetate were added.Layers were separated, and the organic phase was washed with brine,dried over sodium sulfate, filtered and concentrated. The crudetert-butyl(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)(methyl)carbamatewas treated with Trifluoroacetic Acid (2.0 mL, 26 mmol) for 1 hour. Thesolvent was removed in vacuo, and the title product was isolated bypreparative HPLC-MS (Waters XBridge C18, eluting with a gradient ofMeCN/H₂O containing 0.15% NH₄OH). Yield: (2.5 mg, 36%).

¹H NMR (500 MHz, CDCl₃) δ 7.42-7.20 (m, 3H), 7.00-6.95 (m, 2H), 6.45 (s,1H), 6.07 (s, 1H), 5.26 (s, 2H), 5.02 (s, 1H), 2.92 (s, 3H), 2.90 (s,3H), 2.32 (s, 3H). LCMS (M+H)⁺: 306.

Example 262:6-Benzyl-N-propyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

The title compound was prepared according to the methods of Example 261using 1-iodopropane (Aldrich).

¹H NMR (400 MHz, CDCl₃) δ 7.36-7.24 (m, 3H), 7.00-6.92 (m, 2H), 6.47 (s,1H), 6.10 (s, 1H), 5.27 (s, 2H), 4.99-4.89 (m, 1H), 3.12 (app q, J=6.8Hz, 2H), 2.94 (s, 3H), 2.34 (s, 3H), 1.71 (app h, J=7.4 Hz, 2H), 1.01(t, J=7.4 Hz, 3H); LCMS (M+H)⁺: 334.

Example 263:6-Benzyl-N-isopropyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

To a suspension of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(20.0 mg, 0.0644 mmol, from Example 228, Step 7), 2-propanamine (51 μL,0.60 mmol, Aldrich) and tBuXPhos Pd G1 (7.1 mg, 0.0096 mmol, Aldrich) intetrahydrofuran (0.3 mL) was added 1.0 M LHMDS in THF (0.19 mL, 0.19mmol, Aldrich). The reaction was stirred for 3 days, after which timeadditional amounts of tBuXPhos Pd G1 (6 mg, 0.008 mmol), 2-propanamine(51 uL, 0.60 mmol), THF (0.3 mL) and 1.0 M LHMDS in THF (0.2 mL, 0.2mmol) were added and the mixture was heated at 100° C. for 2.5 hours.After cooling to room temperature, MeOH was added, and the mixture wasfiltered. The product was purified by preparative HPLC-MS (WatersXBridge C18, eluting with a gradient of MeCN/H₂O containing 0.15%NH₄OH). Yield: (0.2 mg, 1%).

¹H NMR (400 MHz, CDCl₃) δ 7.35-7.26 (m, 3H), 7.02-6.89 (m, 2H), 6.48 (s,1H), 6.14 (s, 1H), 5.27 (s, 2H), 3.69-3.52 (m, 1H), 2.95 (s, 3H), 2.36(s, 3H), 1.24 (d, J=6.4 Hz, 6H); LCMS (M+H)⁺: 334.

Example 264:6-Benzyl-4-methoxy-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

A suspension of6-benzyl-4-chloro-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(10.0 mg, 0.0322 mmol, from Example 228, Step 7) in 25 wt % solution ofNaOMe in MeOH (1.3 mL, 5.6 mmol, Aldrich) was heated at 150° C. in themicrowave for 3 hours. The reaction was purified by preparative HPLC-MS(Waters XBridge C18, eluting with a gradient of MeCN/H₂O containing0.15% NH₄OH). Yield: (0.7 mg, 7%).

¹H NMR (400 MHz, CDCl₃) δ 7.36-7.26 (m, 3H), 7.21 (s, 1H), 6.97-6.89 (m,2H), 6.61 (s, 1H), 5.35 (s, 2H), 5.01 (s, 3H), 2.99 (s, 3H), 2.41 (s,3H); LCMS (M+H)⁺: 307.

Example 266:N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)acetamide

Step 1. 1,7-Dimethyl-4-nitro-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a solution of1,7-dimethyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(1.0 g, 3.1 mmol, from Example 228, Step 4) in 1,2-dichloroethane (20mL) was added nitronium tetrafluoroborate (0.57 g, 4.3 mmol, Aldrich).The reaction mixture was stirred overnight, filtered and washed withDCE, and air-dried overnight. To a suspension of the nitrated product inMethanol (7 mL) was added 10% (w/w) KOH in water (7 mL, 10 mmol) and thereaction mixture was stirred for 3 hours, after which time the reactionmixture was diluted with DCM and water. 2.0 M solution of HCl in water(4.0 mL, 8.0 mmol) was added to adjust pH ˜10 and the mixture wasstirred for 2 hours. The precipitated solid was isolated by filtration,washed with DCM and water, and then dried at 50° C. under high vacuumfor 2 hours. Yield: (0.30 g, 40%).

LCMS (M+H)⁺: 231.

Step 2.6-Benzyl-1,7-dimethyl-4-nitro-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine

To a suspension of1,7-dimethyl-4-nitro-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.30 g, 1.3 mmol, from Step 1) in N,N-dimethylformamide (5 mL) wasadded Cs₂CO₃ (0.51 g, 1.6 mmol). After stirring for 1 hour, benzylbromide (0.18 mL, 1.6 mmol, Aldrich) was added, and the reaction mixturewas stirred overnight, after which time water was added, and thereaction mixture was stirred for 5 minutes. Ethyl acetate was added, andthe mixture was stirred overnight. The product, which had precipitated,was isolated by filtration. The product was washed sequentially withethyl acetate, water, and again with ethyl acetate. Yield: (0.20 g,48%).

LCMS (M+H)⁺: 322.

Step 3.6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine

A degassed suspension of6-benzyl-1,7-dimethyl-4-nitro-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine(0.20 g, 0.62 mmol, from Step 2) in methanol (20 mL) and tetrahydrofuran(20 mL) was hydrogenated over Palladium (10% on carbon (Degussa type,Aldrich), 0.066 g, 0.062 mmol) under 1 atm H₂ overnight. The reactionmixture was filtered, and the solvent was removed in vacuo. The productwas purified by flash chromatography, eluting with 7% MeOH/DCM (0.7%NH₄OH). The product thus obtained (190 mg) was triturated in 2.5 mL MTBEand 0.25 mL DCM. The solid title product od step 3 was isolated byfiltration and dried at 40° C. under vacuum overnight. Yield: (0.13 g,69%).

LCMS (M+H)⁺: 292.

Step 4.N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)acetamide

To a suspension of6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine(32.0 mg, 0.110 mmol, from Step 3) in tetrahydrofuran (1 mL) was addedacetyl chloride (15.1 μL, 0.213 mmol, Aldrich) andN,N-diisopropylethylamine (76 μL, 0.44 mmol). After 3.5 hours, theproduct was purified by preparative HPLC-MS (Waters XBridge C18, elutingwith a gradient of MeCN/H₂O containing 0.15% NH₄OH). Yield: (19 mg,52%).

¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 8.41 (s, 1H), 7.33-7.21 (m, 3H),7.00-6.91 (m, 2H), 6.55 (s, 1H), 5.33 (s, 2H), 2.97 (s, 3H), 2.39 (s,3H), 2.26 (s, 3H); LCMS (M+H)⁺: 334.

Examples 267-272: The Examples in Table 2 were Made by ProceduresAnalogous to Those Used to Prepare Example 266

TABLE 2 MS Ex Name Structure Salt [M + H]⁺ 267N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4- yl)butyramide

n/a 362 268 N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4- yl)propionamide

3× TFA 348 269 N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4- yl)cyclopropanecarboxamide

n/a 360 270 N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4- yl)isobutyramide

n/a 362 271 N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4- yl)methanesulfonamide

n/a 370 272 Methyl 6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-ylcarbamate

n/a 350

TABLE 2a ¹H NMR data for Examples 267-272 Example # ¹H NMR Spectrum 267¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 8.47 (s, 1H), 7.33-7.20 (m, 3H),6.94 (d, J = 6.8 Hz, 2H), 6.56 (s, 1H), 5.33 (s, 2H), 2.98 (s, 3H), 2.45(t, J = 7.5 Hz, 2H), 2.38 (s, 3H), 1.77 (app h, J = 7.4 Hz, 2H), 1.00(t, J = 7.4 Hz, 3H). *268  N/A 269 ¹H NMR (300 MHz, d₆-DMSO) δ 10.36 (s,1H), 8.23 (s, 1H), 7.35-7.20 (m, 3H), 7.00-6.93 (m, 2H), 6.79 (s, 1H),5.41 (s, 2H), 2.86 (s, 3H), 2.37 (s, 3H), 2.32-2.22 (m, 1H), 0.82-0.73(m, 4H). 270 N/A 271 ¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, 1H), 7.35-7.26(m, 3H), 6.99-6.93 (m, 2H), 6.59 (s, 1H), 5.35 (s, 2H), 2.98 (s, 3H),2.98 (s, 3H), 2.43 (s, 3H). 272 ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H),7.95 (s, 1H), 7.33-7.26 (m, 3H), 6.98-6.92 (m, 2H), 6.55 (s, 1H), 5.34(s, 2H), 3.79 (s, 3H), 2.97 (s, 3H), 2.38 (s, 3H).

Example A1: BRD4 AlphaScreen™ Assay

BRD4-BD1 and BRD4-BD2 assays were conducted in white 384-wellpolystyrene plate in a final volume of 20 μL for BD1 and 40 μL for BD2.Inhibitors were first serially diluted in DMSO and added to the platewells before the addition of other reaction components. The finalconcentration of DMSO in the assay was 1.25% (BD1) and 0.83% (BD2). Theassays were carried out at room temperature for 75 min. in the assaybuffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% CHAPS, 0.01% BSA),containing 50 nM Biotin-labeled tetra-acetylated histone H4 peptide(H4Ac4), 3.8 nM (BRD4-BD1, BPS Bioscience #31040) or 20 nM (BRD4-BD2,BPS Bioscience #31041). The reaction followed by the addition of 20 μLof assay buffer supplemented with Streptavidin donor beads (PerkinElmer6760002) and GSH Acceptor beads (PerkinElmer-AL109C) at 4 μg/mL underreduced light. After plate sealing, the plate was incubated in the darkat room temperature for 75 min. before reading on a PHERAstar FS platereader (BMG Labtech). IC₅₀ determination was performed by fitting thecurve of percent control activity versus the log of the inhibitorconcentration using the GraphPad Prism 5.0 software. IC₅₀ data for theExamples is presented in Table 3 as determined by Assay A1.

TABLE 3 BRD4 BD-1 BRD4 BD-2 enzyme IC₅₀ enzyme IC₅₀ Example No.* (nM)**(nM)**  1 ++ +  2 + +  2a + ++  3 ++ ++  4 (rac) ++ +  5 (enant) ++ +  6++ ++  7 ++ ++  8 ++ +  9 + +  10 + +  11 ++ ++  12 ++ ++  13 ++ + 14 + +  15 + +  16 + +  17 + +  18 + +  19 + +  20 ++ +  21 ++ +  22++ +  23 + +  24 (rac) ++ ++  25 ++ +  26 + +  27 + +  28 + +  29 (rac)++ ++  30 ++ +  31 ++ +  32 ++ +  33 ++ +  34 + +  35 + +  36 + +  37++ +  38 ++ +  39 ++ +  40 + +  41 + +  42 + +  43 ++ +  44 ++ +  45 + + 46 + +  47 ++ +  48 ++ +  49 ++ +  50 + +  51 ++ ++  52 ++ ++  53 ++ ++ 54 ++ +  55 ++ +  56 ++ +  57 +++ ++  58 + +  59 + +  60 ++ +  61 +++++  62 + +  63 + +  64 + +  65 + +  66 + +  67 + +  68 ++ +  69 ++ + 70 + +  71 ++ +++  72 + +  73 ++ +  74 + +  75 + +  76 + +  77 + + 78 + +  79 + +  80 + +  81 + +  82 + +  83 + +  84 ++ ++  85 + +  86 ++++  87 (rac) + +  88 (rac) + +  89 ++ +  90 + +  91 + +  92 + +  93 + + 94 ++ ++  95 + +  96 + +  97 + +  98 + +  99 + + 100 + + 101 ++ ++102 + + 103 + + 104 + + 105 + + 106 + + 107 + + 108 + + 109 + + 110 + +111 + + 112 ++ ++ 113 + + 114 + + 115 ++ ++ 116 +++ +++ 117 + + 118 ++++ 119 + + 120 ++ ++ 121 + + 122 + + 123 ++ + 124 +++ +++ 125 ++ ++ 126++ ++ 127 + + 128 ++ ++ 129 + + 130 + + 131 + + 132 + + 133 + + 134 + +135 + + 136 + + 137 + + 138 ++ ++ 139 + + 140 + + 141 + + 142 + +143 + + 144 (rac) + + 145 (rac) + + 146 + + 147 (enant) + + 148(enant) + + 149 (enant) ++ + 150 (enant) + + 151 (enant) + + 152(enant) + + 153 + + 154 + + 155 + + 156 + + 157 + + 158 + + 159 + +160 + + 161 + + 162 + + 163 + + 164 + + 165 + + 166 + + 167 + + 168 + +169 + + 170 + + 171 + + 172 + + 173 + + 174 + + 175 + + 176 + + 177 + +178 + + 179 + + 180 + + 181 + + 182 + + 183 + + 184 + + 185 + + 186(rac) +++ ++ 187 (rac) +++ +++ 188 + + 189 + + 190 + + 191 + + 192 + +193 + + 194 + + 195 + + 196 + + 197 + + 198 + + 199 (rac) + + 200 + +201 + + 202 + + 203 + + 204 + + 205 + + 206 + + 207 + + 208 + + 209 + +210 + + 211 + + 212 + + 213 + + 214 ++ + 215 a (trans) ++ + 215 b(cis) + + 216 + + 217 + + 218 + + 219 + + 220 + + 221 + + 222 + +223 + + 224 (rac) + + 225 (rac) + + 226 (enant) ++ + 227 + + 228 + +229 + + 230 + + 231 + + 232 ++ ++ 233 + + 234 + + 235 + + 236 + +237 + + 238 + + 239 + + 240 + + 241 ++ + 242 ++ + 243 ++ + 244 + +245 + + 246 + + 247 + + 248 ++ + 249 + + 250 + + 251 ++ + 252 + +253 + + 254 + + 255 ++ + 256 + + 257 + + 258 + + 259 + + 260 + + 261 + +262 + + 263 + + 264 ++ ++ 266 + + 267 ++ + 268 + + 269 + + 270 + + 271++ + 272 + + *“rac” refer to racemic; “enant” refers to the more potentenantiomer **column symbols: + refers to ≦100 nM; ++ refers to >100 nMand ≦1000 nM; +++ refers to >1000 nM and ≦10,000 nM.

Example B1: KMS.12.BM Cell Viability Assay

KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka,Japan) and maintained in RPMI with 10% FBS culture medium. To measurethe cytotoxic activity of the compounds through ATP quantitation, theKMS.12.BM cells are plated in the RPMI culture medium at 5000cells/well/per 100 μL into a 96-well polystyrene clear black tissueculture plate (Greiner-bio-one through VWR, NJ), in the presence orabsence of a concentration range of test compounds. After 3 days, 100 mLCell Titer-GLO Luminescent (Promega, Madison, Wis.) cell culture agentis added to each well for 10 minutes at room temperature to stabilizethe luminescent signal. This determines the number of viable cells inculture based on quantitation of the ATP present, which signals thepresence of metabolically active cells. Luminescence is measured withthe Top Count 384 (Packard Bioscience through Perkin Elmer, Boston,Mass.).

Compound inhibition is determined relative to cells cultured with nodrug and the IC₅₀ is reported as the compound concentration required for50% cell death. IC₅₀ data for the Examples is presented in Table 4 asdetermined by Assay B1.

TABLE 4 Example No.* KMS cellular IC₅₀ (nM)*  1 ++  2 +  2a ++  3 ++  4(rac) ++  5 (enant) ++  6 ++  7 ++  8 +  9 +  10 +  11 ++  12 NA  13 ++ 14 +  15 +  16 +  17 +  18 +  19 +  20 +  21 +  22 +  23 +  24 (rac) ++ 25 +  26 +  27 +  28 +  29 (rac) NA  30 ++  31 ++  32 +  33 +  34 + 35 +  36 +  37 +  38 +  39 +  40 +  41 +  42 +  43 ++  44 ++  45 + 46 +  47 ++  48 ++  49 +  50 ++  51 NA  52 ++  53 ++  54 +  55 +  56 ++ 57 ++  58 +  59 +  60 +  61 ++  62 +  63 +  64 +  65 +  66 +  67 + 68 +  69 +  70 +  71 NA  72 +  73 +  74 +  75 +  76 +  77 +  78 +  79 + 80 +  81 +  82 +  83 +  84 NA  85 +  86 NA  87 (rac) +  88 (rac) + 89 +  90 +  91 +  92 +  93 +  94 NA  95 +  96 +  97 +  98 +  99 + 100++ 101 ++ 102 + 103 + 104 + 105 + 106 + 107 + 108 + 109 + 110 + 111 +112 NA 113 + 114 + 115 NA 116 NA 117 + 118 NA 119 + 120 NA 121 + 122 ++123 + 124 NA 125 + 126 + 127 + 128 NA 129 + 130 + 131 + 132 + 133 +134 + 135 + 136 + 137 + 138 NA 139 ++ 140 + 141 + 142 + 143 + 144 (rac)++ 145 (rac) + 146 ++ 147 (enant) ++ 148 (enant) ++ 149 (enant) ++ 150(enant) ++ 151 (enant) + 152 (enant) + 153 + 154 + 155 + 156 + 157 +158 + 159 + 160 + 161 + 162 + 163 + 164 + 165 + 166 + 167 + 168 + 169 +170 + 171 + 172 + 173 + 174 + 175 + 176 + 177 + 178 + 179 + 180 + 181 +182 + 183 + 184 + 185 + 186 (rac) NA 187 (rac) NA 188 + 189 + 190 +191 + 192 + 193 + 194 + 195 + 196 + 197 + 198 + 199 (rac) + 200 + 201 +202 + 203 + 204 ++ 205 + 206 + 207 + 208 ++ 209 ++ 210 ++ 211 + 212 +213 + 214 ++ 215 a (trans) NA 215 b (cis) ++ 216 ++ 217 + 218 ++ 219 +220 ++ 221 ++ 222 ++ 223 + 224 (rac) + 225 (rac) + 226 (enant) NA 227 +228 ++ 229 + 230 + 231 + 232 NA 233 + 234 + 235 + 236 + 237 + 238 ++239 + 240 ++ 241 ++ 242 NA 243 ++ 244 + 245 + 246 + 247 + 248 + 249 +250 + 251 + 252 + 253 + 254 + 255 + 256 + 257 + 258 + 259 + 260 ++ 261 +262 ++ 263 ++ 264 NA 266 + 267 + 268 + 269 + 270 + 271 + 272 + *“rac”refer to racemic; “enant” refers to the more potent enantiomer **columnsymbols: + refers to ≦1000 nM; ++ refers to >1000 nM and ≦10,000 nM; NAindicates that data was not available

Example C1: KMS.12.BM C-Myc ELISA Assay

KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka,Japan) and maintained in RPMI with 10% FBS culture medium. To measurethe C-myc inhibitory activity of the compounds, the KMS.12.BM cells areplated in the RPMI culture medium at 75000 cells/well/per 200 μL into a96-well flat bottom polystyrene tissue culture plate (Corning throughVWR, NJ), in the presence or absence of a concentration range of testcompounds. After 2 hours, cell are pelleted and lysed with CellExtraction Buffer (BioSource, Carlsbad, Calif.) in the presence ofprotease inhibitors (Life Technologies, Grand Island, N.Y. and Sigma, StLouis, Mo.). Clarified lyses are tested in a C-myc commercial ELISA(Life Technologies, Grand Island, N.Y.). Compound inhibition isdetermined relative to cells cultured with no drug and the IC₅₀ isreported as the compound concentration required for 50% C-mycinhibition.

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the appended claims. Each reference, including all patent,patent applications, and publications, cited in the present applicationis incorporated herein by reference in its entirety.

1-41. (canceled)
 42. A method of treating a proliferative disordercomprising administering to a patient in need of such treatment atherapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein: X is CR⁴; Y isCR⁵; L is C₁₋₆ alkylene wherein each alkylene moiety of any of theaforementioned L groups is optionally substituted by 1, 2, or 3substituents independently selected from F, Cl, OH, C₁₋₄ alkoxy, CF₃,and CN; Cy is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, each of which is optionally substitutedby 1, 2, or 3 R^(Cy); R¹ is H, C₁₋₆ alkyl, cyclopropyl, cyclobutyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, or C₁₋₆ hydroxyalkyl; R² and R³are each independently selected from H, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a), SR^(a), C(O)R^(b),C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b), OC(O)NR^(c)R^(d), NR^(c)R^(d),NR^(c)C(O)R^(b), NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d),C(═NR^(e))R^(b), C(═NR^(e))NR^(c)R^(d), NR^(c)C(═NR^(e))NR^(c)R^(d),NR^(c)S(O)R^(b), NR^(c)S(O)₂R^(b), NR^(c)S(O)₂NR^(c)R^(d), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), and S(O)₂NR^(c)R^(d); wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from halo, CN,NO₂, OR^(a), SR^(a), C(O)R^(b), C(O)NR^(c)R^(d), C(O)OR^(a), OC(O)R^(b),OC(O)NR^(c)R^(d), C(═NR^(e))NR^(c)R^(d), NR^(c)C(═NR^(e))NR^(c)R^(d),NR^(c)R^(d), NR^(c)C(O)R^(b), NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d),NR^(c)S(O)R^(b), NR^(c)S(O)₂R^(b), NR^(c)S(O)₂NR^(c)R^(d), S(O)R^(b),S(O)NR^(c)R^(d), S(O)₂R^(b), and S(O)₂NR^(c)R^(d); R⁴ is H, halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C₆₋₁₀aryl-C₁₋₄alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, (5-10 memberedheteroaryl)-C₁₋₄ alkyl, (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl, CN,NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1),OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1), NR^(c1)C(O)R^(b1),NR^(c1)C(O)OR^(a1), NR^(c1)C(O)NR^(c1)R^(d1), C(═NR^(e1))R^(b1),C(═NR^(e1))NR^(c1)R^(d1), NR^(c1)C(═NR^(e1))NR^(c1)R^(d1),NR^(c1)S(O)R^(b1), NR^(c1)S(O)₂R^(b1), NR^(c1)S(O)₂NR^(c1)R^(d1),S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1), and S(O)₂NR^(c1)R^(d1);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, (5-10 memberedheteroaryl)-C₁₋₄ alkyl, and (4-10 membered heterocycloalkyl)-C₁₋₄ alkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from R^(A); R⁵ is H, halo, C₁₋₄ alkyl, C₂₋₄alkenyl, C₁₋₄ haloalkyl, OR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),or S(O)₂NR^(c2)R^(d2); each R^(Cy) is independently selected from halo,C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl,C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10 memberedheterocycloalkyl, C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,(5-10 membered heteroaryl)-C₁₋₄ alkyl, (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3),NR^(c3)C(O)NR^(c3)R^(d3), C(═NR^(e3))R^(b3), C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3),NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3),and S(O)₂NR^(c3)R^(d3); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₄ alkyl, C₃₋₁₀ cycloalkyl-C₁₋₄alkyl, (5-10 membered heteroaryl)-C₁₋₄ alkyl, and (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl are each optionally substituted with 1, 2,3, 4, or 5 substituents independently selected from halo, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c4)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); each R^(A) isindependently selected from Cy¹, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4),C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4),NR^(c4)R^(d4), NR^(c4)C(O)R^(b4), NR^(c4)C(O)OR^(a4),NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4), C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4),NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4),and S(O)₂NR^(c4)R^(d4); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl are each optionally substituted with 1, 2, 3, 4, or 5substituents independently selected from Cy¹, halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4)SR^(a4),C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4),NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4),S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4); each Cy¹ isindependently selected from C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, and 4-10 membered heterocycloalkyl, each of which isoptionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, CN, NO₂, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(c5)R^(d5),C(═NR^(e5))R^(b5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)S(O)R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5), S(O)₂R^(b5),and S(O)₂NR^(c5)R^(d5); wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆alkynyl are each optionally substituted with 1, 2, 3, 4, or 5substituents independently selected from halo, C₁₋₆ haloalkyl, CN, NO₂,OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)OR^(a5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)S(O)R^(b5),NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), and S(O)₂NR^(c5)R^(d5); each R^(a),R^(b), R^(c), R^(d), R^(a1), R^(b1), R^(c1), R^(d1), R^(a2), R^(b2),R^(c2), R^(d2), R^(a3), R^(b3), R^(c3), R^(d3), R^(a4), R^(b4), R^(c4),R^(d4), R^(a5), R^(b5), R^(c5), and R^(d5) is independently selectedfrom H, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10 memberedheterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀ cycloalky-C₁₋₆ alkyl,(5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10 memberedheterocycloalkyl)-C₁₋₆ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl is optionally substituted with 1,2, 3, 4, or 5 substituents independently selected from C₁₋₄ alkyl, C₁₋₄haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c) andR^(d) together with the N atom to which they are attached form a 4-, 5-,6-, or 7-membered heterocycloalkyl group optionally substituted with 1,2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c1) andR^(d1) together with the N atom to which they are attached form a 4-,5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with1, 2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c2) andR^(d2) together with the N atom to which they are attached form a 4-,5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with1, 2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c3) andR^(d3) together with the N atom to which they are attached form a 4-,5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with1, 2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c4) andR^(d4) together with the N atom to which they are attached form a 4-,5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with1, 2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); or any R^(c5) andR^(d5) together with the N atom to which they are attached form a 4-,5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with1, 2, or 3 substituents independently selected from C₁₋₆ alkyl, C₃₋₇cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 memberedheteroaryl, C₁₋₆ haloalkyl, halo, CN, OR^(a6), SR^(a6), C(O)R^(b6),C(O)NR^(c6)R^(d6), C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6),NR^(c6)R^(d6), NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6),NR^(c6)C(O)OR^(a6), C(═NR^(e6))NR^(c6)R^(d6),NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6), S(O)NR^(c6)R^(d6),S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6), NR^(c6)S(O)₂NR^(c6)R^(d6), andS(O)₂NR^(c6)R^(d6), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a6), SR^(a6), C(O)R^(b6), C(O)NR^(c6)R^(d6),C(O)OR^(a6), OC(O)R^(b6), OC(O)NR^(c6)R^(d6), NR^(c6)R^(d6),NR^(c6)C(O)R^(b6), NR^(c6)C(O)NR^(c6)R^(d6), NR^(c6)C(O)OR^(a6),C(═NR^(e6))NR^(c6)R^(d6), NR^(c6)C(═NR^(e6))NR^(c6)R^(d6), S(O)R^(b6),S(O)NR^(c6)R^(d6), S(O)₂R^(b6), NR^(c6)S(O)₂R^(b6),NR^(c6)S(O)₂NR^(c6)R^(d6), and S(O)₂NR^(c6)R^(d6); each R^(e), R^(e1),R^(e3), R^(e4), and R^(e5) is independently selected from H, C₁₋₄ alkyl,CN, OR^(a6), SR^(b6), S(O)₂R^(b6), C(O)R^(b6), S(O)₂NR^(c6)R^(d6), andC(O)NR^(c6)R^(d6); each R^(a6), R^(b6), R^(c6), and R^(d6) isindependently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl,and C₂₋₄ alkynyl, wherein said C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄alkynyl, is optionally substituted with 1, 2, or 3 substituentsindependently selected from OH, CN, amino, halo, C₁₋₄ alkyl, C₁₋₄alkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄haloalkyl, and C₁₋₄ haloalkoxy; or any R^(c6) and R^(d6) together withthe N atom to which they are attached form a 4-, 5-, 6-, or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3substituents independently selected from OH, CN, amino, halo, C₁₋₄alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy; each R^(e6) isindependently selected from H, C₁₋₄ alkyl, and CN; n is 0 or 1; and m is0 or
 1. 43. The method of claim 42, wherein the proliferative disorderis cancer.
 44. The method of claim 43, wherein the cancer isadenocarcinoma, adult T-cell leukemia/lymphoma, bladder cancer,blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloidsarcoma, cervical cancer, colorectal cancer, esophageal cancer,gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladdercancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma,non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngealcancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lungcancer, non-small cell lung cancer, mesothelioma, multiple myeloma,ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitarytumor, primary central nervous system lymphoma, prostate cancer,pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectalcancer, sarcoma, skin cancer, spinal tumor, small intestine cancer,stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer,throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer,vaginal cancer, or Wilms' tumor. 45-50. (canceled)
 51. The method ofclaim 42, wherein L is CH₂, S(═O)₂, —CH(CH₂OH)—, or —CH((CH₂)₃CH₃)—. 52.The method of claim 42, wherein L is CH₂ or S(═O)₂.
 53. The method ofclaim 42, wherein L is CH₂.
 54. The method of claim 42, wherein Cy isC₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, or 5-10 membered heteroaryl, each of whichis optionally substituted by 1, 2, or 3 R^(Cy).
 55. The method of claim42, wherein Cy is phenyl, cyclopentyl, quinolinyl, or pyridyl, each ofwhich is optionally substituted by 1, 2, or 3 R^(Cy).
 56. The method ofclaim 42, wherein Cy is phenyl or pyridyl, each of which is optionallysubstituted by 1, 2, or 3 R^(Cy).
 57. The method of claim 42, wherein Cyis phenyl optionally substituted by 1, 2, or 3 R^(Cy).
 58. The method ofclaim 42, wherein each R^(Cy) is independently selected from halo, C₁₋₆alkyl, C₁₋₄ haloalkyl, (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl, CN,OR^(a3), C(O)NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), andNR^(c3)C(O)NR^(c3)R^(d3) wherein said C₁₋₆ alkyl and (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl are each optionally substituted with 1, 2,or 3 substituents independently selected from halo, C₁₋₆ alkyl, OR^(a3),and NR^(c3)R^(d3).
 59. The method of claim 42, wherein each R^(Cy) isindependently selected from halo, C₁₋₆ alkyl, (4-10 memberedheterocycloalkyl)-C₁₋₄ alkyl, CN, OR^(a3), C(O)NR^(c3)R^(d3),NR^(c3)C(O)R^(b3), and NR^(c3)C(O)NR^(c3)R^(d3) wherein said C₁₋₆ alkyland (4-10 membered heterocycloalkyl)-C₁₋₄ alkyl are each optionallysubstituted with 1, 2, or 3 substituents independently selected fromC₁₋₆ alkyl, OR^(a3), and NR^(c3)R^(d3).
 60. The method of claim 42,wherein each R^(Cy) is independently selected from fluoro, chloro,methyl, cyano, hydroxy, methoxy, aminocarbonyl, methylcarbonylamino,methylaminocarbonyl, ethylaminocarbonyl, azetidinylmethyl,pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl,morpholinomethyl, ureido, and ethylureido, wherein said methyl,azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl,piperazinylmethyl, and morpholinomethyl are each optionally substitutedwith 1, 2, or 3 substituents independently selected from fluoro, methyl,hydroxy, methoxy, methylamino, ethylamino, dimethylamino,hydroxycyclobutylamino, hydroxyethyl(methyl)amino, andhydroxyethylamino.
 61. The method of claim 42, wherein R¹ is H or C₁₋₆alkyl.
 62. The method of claim 42, wherein R¹ is C₁₋₆ alkyl.
 63. Themethod of claim 42, wherein R¹ is methyl.
 64. The method of claim 42,wherein R² and R³ are both H.
 65. The method of claim 42, wherein R³ isH.
 66. The method of claim 42, wherein R² is H, OR^(a), NR^(c)R^(d),NR^(c)C(O)R^(b), NR^(c)C(O)OR^(a), NR^(c)C(O)NR^(c)R^(d), orNR^(c)S(O)₂R^(b).
 67. The method of claim 42, wherein R² is H, —OH,—NHC(═O)OCH₃, —NHC(═O)CH₃, —NHC(═O)CH₂CH₃, —NHC(═O)CH₂CH₂CH₃,—NHC(═O)CH(CH₃)₂, —NHS(═O)₂CH₃, —OCH₃, —NHCH₃, —NHCH₂CH₃, —NHCH(CH₃)₂,—NHCH₂CH₂CH₃, —NH-(phenyl), —NH-(imidazolyl), —NH-(pyridyl),—NHCH₂CH₂NH₂, —NHCH₂CH₂CH₂NH₂, —NHC(═O)NH₂, —NHC(═O)NH(CH₃),—NHC(═O)N(CH₃)₂, —NHC(═O)NHCH(CH₃)₂, —NHC(═O)NHCH₂CH₃,—NHC(═O)O-(t-butyl), —NH-(hydroxycyclobutyl), —NHCH₂CH₂N(CH₃)₂,—NHCH₂CH₂CH₂N(CH₃)₂, —NH-(t-butyloxycarbonylazetidinyl),—NH-(t-butyloxycarbonylazetidinylmethyl),—NH-(t-butyloxycarbonylpiperidinylmethyl), —NH-(cyclobutylmethyl),—NH-(cyclohexyl), —NH-(cyclopropylmethyl),—NH-(8-azabicyclo[3,2,1]octan-3-yl), —NH-(dimethylpiperidinyl),—NH-(methylpiperidinyl), —NH-(piperidinyl), —NH-(methylpiperidinyl),—NH-(dimethylaminocyclohexyl), —NH-(methylaminocyclohexyl),—NH-(aminocyclohexyl), —NH-(acetylpiperidinyl), —NH-(cyanocyclohexyl),—NH-(t-butyloxycarbonylpiperidinyl), —NH-(2-propylpiperidinyl),—NH-(ethylpiperidinyl), —NH-(methylsulfonylpiperidinyl), —NHCH₂CH₂OH,—NHCH₂CH₂OCH₃, —NH-(morpholinoethyl), —NH-(benzimidazolyl),—NH-(benzoxazolyl), —NH-(methylpyrazolyl), —NH-(pyrimidinyl),—NH-(pyrazolyl), —NH-(pyrrolidinyl), —NH-(methylpyrrolidinyl),—NH-(t-butyloxycarbonylpyrrolidinyl), —NH-(tetrahydrofuranyl), or—NH-(tetrahydropyranyl).
 68. The method of claim 42, wherein R⁴ is H,CN, C₁₋₆ alkyl, C₁₋₄ haloalkyl, 5-10 membered heteroaryl, (5-10 memberedheteroaryl)-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl,C(O)NR^(c1)R^(d1), C(O)OR^(a1), or NR^(c1)R^(d1); wherein said C₁₋₆alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and(5-10 membered heteroaryl)-C₁₋₄ alkyl are each optionally substitutedwith 1, 2, 3, 4, or 5 substituents independently selected from R^(A).69. The method of claim 42, wherein R⁴ is H, C₁₋₆ alkyl, 5-10 memberedheteroaryl, (5-10 membered heteroaryl)-C₁₋₄ alkyl, C(O)NR^(c1)R^(d1),C(O)OR^(a1), or NR^(c1)R^(d1); wherein said C₁₋₆ alkyl, 5-10 memberedheteroaryl, and (5-10 membered heteroaryl)-C₁₋₄ alkyl are eachoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from R^(A).
 70. The method of claim 42, wherein R⁴ is H, C₁₋₄alkyl, 5 to 6-membered heteroaryl, (5-membered heteroaryl)-C₁₋₄ alkyl,C(O)NR^(c1)R^(d1), C(O)OR^(a1), or NR^(c1)R^(d1); wherein said C₁₋₄alkyl, 5 to 6-membered heteroaryl, and (5-membered heteroaryl)-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from R^(A).
 71. The method of claim 42, whereinR⁴ is H, C₁₋₄ alkyl, pyrazolyl, imidazolyl, thienyl, thiazolyl, pyridyl,imidazolylmethyl, C(O)NR^(c1)R^(d1), C(O)OR^(a)l, or NR^(c1)R^(d1);wherein said C₁₋₄ alkyl, pyrazolyl, imidazolyl, thienyl, thiazolyl,pyridyl, and imidazolylmethyl, are each optionally substituted with 1,2, or 3 substituents independently selected from R^(A).
 72. The methodof claim 42, wherein R⁴ is H, CN, methyl, ethyl, pyrazolyl, imidazolyl,thienyl, thiazolyl, pyridyl, imidazolylmethyl, oxadiazolyl, oxazolyl,dihydrooxazolyl, pyrrolidinyl, —C(═O)NH-(methyl), —C(═O)NH-(ethyl),—C(═O)—NH-(t-butyl), —C(═O)—NH-(s-butyl), —C(═O)NH-(pyridylmethyl),—C(═O)NH-(isopropyl), —C(═O)NH-(hydroxypropyl),—C(═O)NH-(azetidinylmethyl), —C(═O)NH-(morpholinoethyl),—C(═O)-(methylazetidinyl), —C(═O)NH-(hydroxyethyl), —C(═O)-(morpholino),—C(═O)NH-(dimethylaminoethyl), —C(═O)NH-(cyclopropylmethyl),—C(═O)NH-(cyclobutyl), —C(═O)NH-(cyanocyclobutyl), —C(═O)NH₂,—C(═O)N(CH₃)₂, —C(═O)NH-(2,2,2-trifluoro-1-methylethyl), or—C(═O)-(cyanoazetidinyl), wherein said methyl, ethyl, pyrazolyl,imidazolyl, thienyl, thiazolyl, pyridyl, imidazolylmethyl, oxadiazolyl,oxazolyl, dihydrooxazolyl, and pyrrolidinyl are each optionallysubstituted with 1, 2, or 3 substituents independently selected fromR^(A).
 73. The method of claim 42, wherein each R^(A) is independentlyselected from Cy¹, C(O)R^(b4), and C₁₋₆ alkyl, wherein said C₁₋₆ alkylis optionally substituted with 1, 2, or 3 substituents independentlyselected from Cy¹, CN, OR^(a4), C(O)NR^(c4)R^(d4), and NR^(c4)R^(d4).74. The method of claim 42, wherein each R^(A) is independently selectedfrom Cy¹ and C₁₋₆ alkyl, wherein said C₁₋₆ alkyl is optionallysubstituted with 1, 2, or 3 substituents independently selected fromCy¹, CN, C(O)NR^(c4)R^(d4), and NR^(c4)R^(d4).
 75. The method of claim42, wherein R⁵ is H.
 76. The method of claim 42, wherein the compound isa compound of Formula III:


77. The method of claim 42, wherein the compound is a compound ofFormula IVa, IVb, or IVc:


78. The method of claim 42, wherein the compound is selected from:6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1-methyl-6-(phenylsulfonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1-methyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;(S)-1,7-dimethyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;(R)-1,7-dimethyl-6-(1-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-(2-phenylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(2-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(4-chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine1,7-dimethyl-6-(pyridin-3-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine1,7-dimethyl-6-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(cyclopentylmethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(2-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine6-(3-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(4-fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-(2-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-(3-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-(4-methylbenzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-6-yl)methyl]benzonitrile;1,7-dimethyl-6-(quinolin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenol;1,7-dimethyl-6-(1-phenylpentyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}acetamide;{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl)}methanol;1-(3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzyl)azetidin-3-ol;6-[3-(azetidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;2-(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-phenylethanol;3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzamide;3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-N-methylbenzamide;3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]-N-ethylbenzamide;6-(4-methoxybenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenol;2-({3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl)}amino)ethanol;2-[{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}(methyl)amino]ethanol;1,7-dimethyl-6-[3-(morpholin-4-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;(1r,3r)-3-((3-((1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl)benzyl)amino)cyclobutanol;1-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N,N-dimethylmethanamine;1-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N-methylmethanamine;N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl)}ethanamine;N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N′-ethylurea;N-{3-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}urea;1,7-dimethyl-6-[3-(pyrrolidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-[3-(piperidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-{3-[(4-methylpiperazin-1-yl)methyl]benzyl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-[3-(piperazin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}methanol;6-[4-(azetidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1,7-dimethyl-6-[4-(pyrrolidin-1-ylmethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;1-{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]benzyl}azetidin-3-ol;1-{4-[(1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl)methyl]phenyl}-N,N-dimethylmethanamine;6-{3-[(3-methoxyazetidin-1-yl)methyl]benzyl}-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)methanol;6-benzyl-7-(1H-imidazol-1-ylmethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide6-benzyl-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;1-[(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)carbonyl]azetidine-3-carbonitrile;2-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)ethanol;6-benzyl-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1H-pyrazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;[4-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]acetonitrile;[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]acetonitrile;6-benzyl-1-methyl-7-(1,3-thiazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1,3-thiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-pyridin-2-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1,3-thiazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1-methyl-1H-imidazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(3-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(2-thienyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-[1-(2-morpholin-4-ylethyl)-1H-imidazol-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-1-methyl-7-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanenitrile;6-benzyl-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-benzyl-7-(1-ethyl-1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;3-[4-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-imidazol-1-yl]propanenitrile;6-benzyl-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-1-methyl-N-propyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-N-isopropyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-N-cyclobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-1-methyl-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]butanenitrile;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-2-methylpropanenitrile;2-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N,N-dimethylethanamine;{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;{1-acetyl-3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;[3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-methylazetidin-3-yl}acetonitrile;6-benzyl-N,N,1-trimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N,N-dimethylpropanamide;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N-ethylpropanamide;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-N-methylpropanamide;3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]propanamide;6-(3-chlorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-N-(trans-3-cyanocyclobutyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-benzyl-N-(cis-3-cyanocyclobutyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-fluorobenzyl)-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N,N-dimethylpropanamide;7-[1-(3-azetidin-1-yl-3-oxopropyl)-1H-pyrazol-3-yl]-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-chlorobenzyl)-1-methyl-7-{1-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]-1H-pyrazol-3-yl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;(1-acetyl-3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile;[3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-1-(methylsulfonyl)azetidin-3-yl]acetonitrile;7-[1-(1-acetylazetidin-3-yl)-1H-pyrazol-3-yl]-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-chlorobenzyl)-1-methyl-7-{1-[1-(methylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-ethylazetidin-3-yl}acetonitrile;and{3-[3-(6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl]-1-isopropylazetidin-3-yl}acetonitrile;or a pharmaceutically acceptable salt of any of the aforementioned. 79.The method of claim 42, wherein the compound is selected from:(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-1-ethylazetidin-3-yl)acetonitrile;(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-3-yl)acetonitrile;1-(1,7-Dimethyl-6-(3-(trifluoromethyl)benzyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(3-Chloro-5-{[1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)azetidin-3-ol;1-(3-Chloro-5-{[1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)azetidin-3-ol;1-(3-Chloro-5-{[1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}benzyl)pyrrolidin-3-ol;1-(3-Chloro-5-{[1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-6-yl]methyl}phenyl)-N,N-dimethylmethanamine;1-(6-(2,3-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(2,4-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(2,6-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(2-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(3,4-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(3,5-Difluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(3-Chlorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(3-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-(4-Fluorobenzyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3-ethylurea;1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3-isopropylurea;1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-3-methylurea;1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)urea;1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6-(pyridin-2-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6-(pyridin-3-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;2-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)ethanol;2-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)-N,N-dimethyl-2-oxoethanamine;2-[(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]ethanol;2-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}ethanol;3-(3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidin-1-yl)propanenitrile;3-(3-{6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrazol-1-yl)propanenitrile;3-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-1,1-dimethylurea;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-(1-methylazetidin-3-yl)propanamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-(tetrahydro-2H-pyran-4-yl)propanamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N,N-dimethylazetidine-1-sulfonamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-ethylpropanamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-methylpropanamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}-N-oxetan-3-ylpropanamide;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propan-1-ol;3-{3-[6-(3-Chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanamide;6-(3-(Azetidin-1-ylmethyl)-5-chlorobenzyl)-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl)-7-(1-ethyl-1H-pyrazol-3-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-chlorobenzyl)-1-methyl-7-(1H-pyrazol-5-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-(1-oxetan-3-yl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-(morpholin-4-ylcarbonyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-[1-(1-methylazetidin-3-yl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-[1-(1-propionylazetidin-3-yl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-7-[1-(3-morpholin-4-yl-3-oxopropyl)-1H-pyrazol-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-1-methyl-N-(1-methylazetidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-1-methyl-N-(2-morpholin-4-ylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-1-methyl-N-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-7-(1H-imidazol-4-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-7-(4,5-dihydro-1,3-oxazol-2-yl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-7-[1-(1-ethylazetidin-3-yl)-1H-pyrazol-3-yl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-7-{1-[1-(cyclopropylcarbonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-7-{1-[1-(cyclopropylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-7-{1-[1-(ethylsulfonyl)azetidin-3-yl]-1H-pyrazol-3-yl}-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-(3-Chlorobenzyl)-N-(2-hydroxyethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-N-(3-hydroxypropyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-N-(cyclopropylmethyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-N-[2-(dimethylamino)ethyl]-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-(3-Chlorobenzyl)-N-isobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1,3,4-oxadiazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-(Azetidin-1-ylmethyl)-5-chlorobenzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-(Azetidin-1-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-(Azetidin-1-ylmethyl)benzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-[3-(Azetidin-1-ylmethyl)benzyl]-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-[3-Chloro-5-(morpholin-4-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1-methyl-7-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-N-ethyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-{3-Chloro-5-[(3,3-difluoropyrrolidin-1-yl)methyl]benzyl}-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-{3-Chloro-5-[(3,3-dimethylazetidin-1-yl)methyl]benzyl}-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-{3-Chloro-5-[(3,3-dimethylazetidin-1-yl)methyl]benzyl}-N,1-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ol;6-Benzyl-1,7-dimethyl-N-((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-(1-methyl-1H-pyrazol-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-(1-methylpiperidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-(1-methylpiperidin-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-(1-methylpyrrolidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-(2-morpholin-4-ylethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-Dimethyl-N-(pyridin-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-(pyridin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-(pyridin-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-[(3R)-pyrrolidin-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-[(3R)-tetrahydrofuran-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-[(3S)-pyrrolidin-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-benzyl-1,7-dimethyl-N-[(3S)-tetrahydrofuran-3-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-[1-(methylsulfonyl)piperidin-4-yl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-1H-pyrazol-3-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-phenyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-piperidin-4-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1,7-dimethyl-N-pyrimidin-2-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carbonitrile;6-benzyl-1-methyl-7-(1,3-oxazol-2-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-Benzyl-1-methyl-7-(trifluoromethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-Benzyl-1-methyl-7-pyrrolidin-3-yl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-Benzyl-1-methyl-N-(pyridin-4-ylmethyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-Benzyl-4-methoxy-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;6-Benzyl-N-(1-ethylpiperidin-4-yl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-(1H-imidazol-2-yl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-(1-isopropylpiperidin-4-yl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-(2-methoxyethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-(3-hydroxypropyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-Benzyl-N-(cyclobutylmethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-(cyclopropylmethyl)-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N,1,7-trimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-[(2R,4R)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-[(2R,4S)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-[(2S,4R)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-[(2S,4S)-1,2-dimethylpiperidin-4-yl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-cyclohexyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-ethyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-isobutyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;6-Benzyl-N-isopropyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;6-Benzyl-N-propyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;7-(1-Acetylpyrrolidin-3-yl)-6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;7-(1-azetidin-3-yl-1H-pyrazol-3-yl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine;cis-4-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]cyclohexanecarbonitrile;cis-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine;cis-N′-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N,N-dimethylcyclohexane-1,4-diamine;cis-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N′-methylcyclohexane-1,4-diamine;Ethyl3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}azetidine-1-carboxylate;Methyl6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylcarbamate;N-(1-Acetylpiperidin-4-yl)-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)acetamide;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)butyramide;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclopropanecarboxamide;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)isobutyramide;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)methanesulfonamide;N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)propionamide;N-(Azetidin-3-ylmethyl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;N-(Azetidin-3-ylmethyl)-6-benzyl-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;N-(tert-Butyl)-3-{3-[6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-7-yl]-1H-pyrazol-1-yl}propanamide;N-(tert-Butyl)-6-(3-chlorobenzyl)-1-methyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;N,1-dimethyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;N-{6-[3-Chloro-5-(pyrrolidin-1-ylmethyl)benzyl]-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl}-N′-methylurea;N1-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)ethane-1,2-diamine;N1i-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N2,N2-dimethylethane-1,2-diamine;N1-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N3,N3-dimethylpropane-1,3-diamine;N1i-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)propane-1,3-diamine;N-1,3-Benzoxazol-2-yl-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;N-1H-Benzimidazol-2-yl-6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-amine;N-Ethyl-1-methyl-6-[3-(trifluoromethyl)benzyl]-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;tert-butyl(3R)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate;tert-butyl (3S)-3-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]pyrrolidine-1-carboxylate;tert-Butyl3-((6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)methyl)azetidine-1-carboxylate;tert-Butyl3-(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)azetidine-1-carboxylate;tert-Butyl4-((6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)methyl)piperidine-1-carboxylate;tert-Butyl4-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]piperidine-1-carboxylate;tert-Butyl6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylcarbamate;trans-3-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-ylamino)cyclobutanol;trans-4-[(6-benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)amino]cyclohexanecarbonitrile;trans-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)cyclohexane-1,4-diamine;trans-N′-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N,N-dimethylcyclohexane-1,4-diamine;andtrans-N-(6-Benzyl-1,7-dimethyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin-4-yl)-N′-methylcyclohexane-1,4-diamine;or a pharmaceutically acceptable salt of any of the aforementioned.